

Disclaimer

The following report(s) provides findings from an FDA-initiated query using Sentinel. While Sentinel queries may be undertaken to assess potential medical product safety risks, they may also be initiated for various other reasons. Some examples include determining a rate or count of an identified health outcome of interest, examining medical product use, exploring the feasibility of future, more detailed analyses within Sentinel, and seeking to better understand Sentinel capabilities.

Data obtained through Sentinel are intended to complement other types of evidence such as preclinical studies, clinical trials, postmarket studies, and adverse event reports, all of which are used by FDA to inform regulatory decisions regarding medical product safety. The information contained in this report is provided as part of FDA's commitment to place knowledge acquired from Sentinel in the public domain as soon as possible. Any public health actions taken by FDA regarding products involved in Sentinel queries will continue to be communicated through

FDA wants to emphasize that the fact that FDA has initiated a query involving a medical product and is reporting findings related to that query does not mean that FDA is suggesting health care practitioners should change their prescribing practices for the medical product or that patients taking the medical product should stop using it. Patients who have questions about the use of an identified medical product should contact their health care

The following report contains a description of the request, request specifications, and results from the modular program run(s).

If you are using a web page screen reader and are unable to access this document, please contact the Sentinel Operations Center for assistance at info@sentinelssystem.org.

Overview for Request: cder_mpl1p_wp045

Request ID: cder_mpl1p_wp045_nsdp_v01

Request Description: In this report we examined utilization and switching patterns of mixed amphetamine salt (MAS) products among patients with attention deficit hyperactivity disorder (ADHD) and narcolepsy in the Sentinel Distributed Database (SDD). This is report 1 of 2, containing information on utilization and switching for each Abbreviated New Drug Application (ANDA) grouping of MAS products as well as each grouping of MAS products except for those of a specific ANDA. This report contains information regarding switching to or from an ANDA group other than the one on which the patient started. Report 2 contains information about the same ANDA groupings, but instead examines switching to any higher strength MAS immediate release (IR) product, regardless of ANDA group.

Sentinel Routine Querying Module: Cohort Identification and Descriptive Analysis (CIDA) module, version 10.3.2, with custom programming

Data Source: We distributed this query to five Sentinel Data Partners on November 9, 2021. These five Data Partners are a subset of the SDD and do not include patients with Medicare coverage. The study period included data from January 1, 2013 through December 31, 2019. Please see Appendix A for a list of dates of available data for each Data Partner.

Study Design: We identified individuals with prevalent use of five different groups of MAS products, grouped by ANDA Application: ANDA 202424; ANDA 040440; ANDA 040422; ANDA 040439; and ANDA 040480, as well as five groups that included all MAS products except those in a specific ANDA: Non-202424; Non-040440; Non-040422; Non-040439; and Non-040480. Patients must have had a diagnosis of either attention deficit hyperactivity disorder (ADHD) or narcolepsy. Within each cohort we identified patients who switched from a MAS product in a specific ANDA to a MAS product not in that ANDA and then back to a MAS product in the original, specific ANDA; or from a MAS product not in a specific ANDA to a MAS product in a specific ANDA and then back to a MAS product not in the original, specific ANDA. We also evaluated patients whose second switch was to the same non-ANDA, as opposed to any non-ANDA.

- ANDA ##### to Non-##### to ANDA #####
- Non-##### to ANDA ##### to Non-#####
- Non-##### to ANDA ##### to same Non-#####
- ANDA ##### to Any Higher Strength MAS regardless of ANDA

This is a Type 6 analysis in the Query Request Package (QRP) documentation.

Exposure of Interest: We identified the exposures of interest, MAS products in different ANDA groups using National Drug Codes (NDCs). All qualifying exposures were included; cohort re-entry was allowed. Please refer to Appendix C for generic names of medical products used to define exposures.

Cohort Eligibility Criteria: We required members to be enrolled in health plans with medical and drug coverage in the 183 days prior to their cohort entry (index) date in order to be included in the cohort; a gap in coverage of up to 45 days was allowed and treated as continuous enrollment. The following age groups were included in the cohort: 15-24, 25-34, 35-44, 45-54, 55-64 years. ADHD and narcolepsy diagnoses were defined using International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) diagnosis codes. Please see Appendix D for a list of codes used to define Inclusion criteria.

Switch Episodes: For the treatment episodes with switches, we required 60 days of use within an ANDA prior to being evaluated for a switch. We allowed a 99% overlap tolerance indicating a 99% percent of overlap days were allowed in between treatment episodes for index and switch exposures. Further, a gap tolerance of seven days was allowed between treatment episodes for both index and switch pattern episodes.

Overview for Request: cder_mpl1p_wp045

Baseline Characteristics: We assessed the following characteristics in the 183 days prior to and including the date of index: ADHD, narcolepsy, ADHD and narcolepsy, ADHD only, narcolepsy only, sleep disorders other than narcolepsy, mood disorders, anxiety disorders, schizophrenia, other psychotic disorders, personality disorders, substance use disorders (alcohol/drug abuse/dependence), nicotine use (including tobacco), obesity, MAS product extended release (ER), other central nervous system (CNS) stimulants, wake-promoting agents, sodium oxybate, atomoxetine, clonidine, guanfacine, any antidepressants, antidepressants used off-label to treat ADHD (e.g., bupropion, venlafaxine, tricyclic antidepressants), anxiolytics, and antipsychotics.

We assessed use of the following medications in both the 30 days prior to and 30 days immediately following the index date: MAS ER, other CNS stimulants, wake-promoting agents, sodium oxybate, atomoxetine, clonidine, guanfacine, any antidepressants, antidepressants used off-label to treat ADHD, anxiolytics, and antipsychotics. We also evaluated the daily dose of the index dispensing. Baseline characteristics were defined using ICD-9-CM codes, ICD-10-CM diagnosis codes, Healthcare Common Procedure Coding System (HCPCS) procedure codes, and NDCs. Please see Appendices E and F for a list of codes, generic and brand names, and NDCs used to define baseline characteristics. Please see Appendix G for a list of generic and brand names used to define comedications.

Please see Appendices H and I for the specifications for utilization and switching used in this request and Appendix J for the specifications for covariates in this request.

Limitations: Algorithms used to define exposures and inclusion criteria are imperfect; thus, it is possible that there may be misclassification. Therefore, data should be interpreted with this limitation in mind.

Notes: Definitions for terms used in this report can be found in the Glossary. Please contact the Sentinel Operations Center (info@sentinelssystem.org) for questions and to provide comments/suggestions for future enhancements to this document. For more information on Sentinel's routine querying modules, please refer to the documentation (<https://dev.sentinelssystem.org/projects/SENTINEL/repos/sentinel-routine-querying-tool-documentation/browse>).

Table of Contents

<u>Glossary</u>	List of Terms Found in this Report and their Definitions
<u>Table 1a</u>	Number of Overall Mixed Amphetamine Salt (MAS) Users Over Time, by Month-Year in the Sentinel Distributed Database (SDD) from January 1, 2013 to December 31, 2019
<u>Table 1b</u>	Number of Overall Mixed Amphetamine Salt (MAS) Users Over Time, by Month-Year and Sex in the Sentinel Distributed Database (SDD) from January 1, 2013 to December 31, 2019
<u>Table 1c</u>	Number of Overall Mixed Amphetamine Salt (MAS) Users Over Time, by Month-Year and Age Group in the Sentinel Distributed Database (SDD) from January 1, 2013 to December 31, 2019
<u>Table 2a</u>	Number of Overall Mixed Amphetamine Salt (MAS) Users Over Time of Episode Span, by Month-Year in the Sentinel Distributed Database (SDD) from January 1, 2013 to December 31, 2019
<u>Table 2b</u>	Number of Overall Mixed Amphetamine Salt (MAS) Users Over Time of Episode Span, by Month-Year and Sex in the Sentinel Distributed Database (SDD) from January 1, 2013 to December 31, 2019
<u>Table 2c</u>	Number of Overall Mixed Amphetamine Salt (MAS) Users Over Time of Episode Span, by Month-Year and Age Group in the Sentinel Distributed Database (SDD) from January 1, 2013 to December 31, 2019
<u>Table 3a</u>	Number of Mixed Amphetamine Salt (MAS) Dispensings Over Time, by Month-Year in the Sentinel Distributed Database (SDD) from January 1, 2013 to December 31, 2019
<u>Table 3b</u>	Number of Mixed Amphetamine Salt (MAS) Dispensings Over Time, by Month-Year and Sex in the Sentinel Distributed Database (SDD) from January 1, 2013 to December 31, 2019
<u>Table 3c</u>	Number of Mixed Amphetamine Salt (MAS) Dispensings Over Time, by Month-Year and Age Group in the Sentinel Distributed Database (SDD) from January 1, 2013 to December 31, 2019
<u>Table 4</u>	Descriptive Statistics of Days Supplied per Mixed Amphetamine Salt (MAS) Dispensing in the Sentinel Distributed Database (SDD) from January 1, 2013 to December 31, 2019
<u>Table 5</u>	Descriptive Statistics of Cumulative Exposure Duration, in Days in the Sentinel Distributed Database (SDD) from January 1, 2013 to December 31, 2019
<u>Table 6</u>	Descriptive Statistics of Treatment Exposure Duration, in Days, by Censoring Reason in the Sentinel Distributed Database (SDD) from January 1, 2013 to December 31, 2019
<u>Table 7</u>	Descriptive Statistics of Time to First Switch or Censoring, by Switch Pattern, in Days: Episode Level in the Sentinel Distributed Database (SDD) from January 1, 2013 to December 31, 2019
<u>Table 8</u>	Descriptive Statistics of Time to Second Switch or Censoring, by Switch Pattern, in Days: Episode Level in the Sentinel Distributed Database (SDD) from January 1, 2013 to December 31, 2019
<u>Table 9</u>	Descriptive Statistics of Switch Pattern Episode Duration, by Switch Pattern, in Days in the Sentinel Distributed Database (SDD) from January 1, 2013 to December 31, 2019
<u>Table 10a</u>	Frequency Distribution of Time to First Switch, by Switch Pattern, in Days in the Sentinel Distributed Database (SDD) from January 1, 2013 to December 31, 2019
<u>Table 10b</u>	Frequency Distribution of Time to First Switch, by Switch Pattern, in Days, by Year in the Sentinel Distributed Database (SDD) from January 1, 2013 to December 31, 2019
<u>Table 11a</u>	Frequency Distribution of Time to Second Switch, by Switch Pattern, in Days in the Sentinel Distributed Database (SDD) from January 1, 2013 to December 31, 2019
<u>Table 11b</u>	Frequency Distribution of Time to Second Switch, by Switch Pattern and Year, in Days, in the Sentinel Distributed Database (SDD) from January 1, 2013 to December 31, 2019
<u>Table 12a</u>	Descriptive Statistics of Time to First Switch, by Switch Pattern, in Days in the Sentinel Distributed Database (SDD) from January 1, 2013 to December 31, 2019
<u>Table 12b</u>	Descriptive Statistics of Time to First Switch, by Switch Pattern and Year, in Days, in the Sentinel Distributed Database (SDD) from January 1, 2013 to December 31, 2019
<u>Table 13a</u>	Descriptive Statistics of Time to Second Switch, by Switch Pattern, in Days in the Sentinel Distributed Database (SDD) from January 1, 2013 to December 31, 2019
<u>Table 13b</u>	Descriptive Statistics of Time to Second Switch, by Switch Pattern and Year, in Days, in the Sentinel Distributed Database (SDD) from January 1, 2013 to December 31, 2019
<u>Figure 1a</u>	Number of Overall Mixed Amphetamine Salt (MAS) Users Over Time

Table of Contents

<u>Figure 1b</u>	Number of Overall Mixed Amphetamine Salt (MAS) Users Over Time, by Sex
<u>Figure 1c</u>	Number of Overall Mixed Amphetamine Salt (MAS) Users Over Time, by Age Group
<u>Figure 2a</u>	Number of Mixed Amphetamine Salt (MAS) Dispensings Over Time, by Month-Year
<u>Figure 2b</u>	Number of Mixed Amphetamine Salt (MAS) Dispensings Over Time, by Month-Year, by Sex
<u>Figure 2c</u>	Number of Mixed Amphetamine Salt (MAS) Dispensings Over Time, by Month-Year and Age Group
<u>Figure 3.1-3.3</u>	Survival Curve for Time to First Switch, in Days
<u>Figure 4.1-4.3</u>	Survival Curve for Time to Second Switch, in Days
<u>Figure 5.1-5.15</u>	Survival Curve for Time to Censoring at First Switch Step, in Days, by Censoring Reason
<u>Figure 6.1-6.15</u>	Survival Curve for Time to Censoring at Second Switch Step, in Days, by Censoring Reason
<u>Appendix A</u>	Start and End Dates for Each Data Partner (DP) as of Request Distribution Date (November 9, 2021)
<u>Appendix B</u>	Computed Start Marketing Dates for Each Cohort at Each Data Partner (DP)
<u>Appendix C</u>	List of Generic and Brand Names for Medical Products Used to Define Exposures in this Request
<u>Appendix D</u>	List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes Used to Define Inclusions in this Request
<u>Appendix E</u>	List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes Used to Define Baseline Characteristics in this Request
<u>Appendix F</u>	List of Generic and Brand Names for Medical Products Used to Define Baseline Characteristics in this Request
<u>Appendix G</u>	List of Generic and Brand Names for Medical Products Used to Define Comedications in this Request
<u>Appendix H</u>	Specifications for Utilization in this Request
<u>Appendix I</u>	Specifications for Switching in this Request
<u>Appendix J</u>	Specifications for Covariates in this Request

**Glossary of Terms for Analyses Using
Cohort Identification and Descriptive Analysis (CIDA) Module***

Amount Supplied - number of units (pills, tablets, vials) dispensed. Net amount per NDC per dispensing.

Blackout Period - number of days at the beginning of a treatment episode that events are to be ignored. If an event occurs during the blackout period, the episode is excluded.

Care Setting - type of medical encounter or facility where the exposure, event, or condition code was recorded. Possible care settings include: Inpatient Hospital Stay (IP), Non-Acute Institutional Stay (IS), Emergency Department (ED), Ambulatory Visit (AV), and Other Ambulatory Visit (OA). For laboratory results, possible care settings include: Emergency Department (E), Home (H), Inpatient (I), Outpatient (O), or Unknown or Missing (U). The Care Setting, along with the Principal Diagnosis Indicator (PDX), forms the Care Setting/PDX parameter.

Ambulatory Visit (AV) - includes visits at outpatient clinics, same-day surgeries, urgent care visits, and other same-day ambulatory hospital encounters, but excludes emergency department encounters.

Emergency Department (ED) - includes ED encounters that become inpatient stays (in which case inpatient stays would be a separate encounter). Excludes urgent care visits.

Inpatient Hospital Stay (IP) - includes all inpatient stays, same-day hospital discharges, hospital transfers, and acute hospital care where the discharge is after the admission date.

Non-Acute Institutional Stay (IS) - includes hospice, skilled nursing facility (SNF), rehab center, nursing home, residential, overnight non-hospital dialysis and other non-hospital stays.

Other Ambulatory Visit (OA) - includes other non overnight AV encounters such as hospice visits, home health visits, skilled nursing facility visits, other non-hospital visits, as well as telemedicine, telephone and email consultations.

Charlson/Elixhauser Combined Comorbidity Score - calculated based on comorbidities observed during a requester-defined window around the exposure episode start date (e.g., in the 183 days prior to index).

Code Days - the minimum number of times the diagnosis must be found during the evaluation period in order to fulfill the algorithm to identify the corresponding patient characteristic.

Cohort Definition (drug/exposure) - indicates how the cohort will be defined: 01: Cohort includes only the first valid treatment episode during the query period; 02: Cohort includes all valid treatment episodes during the query period; 03: Cohort includes all valid treatment episodes during the query period until an event occurs.

Computed Start Marketing Date - represents the first observed dispensing date among all valid users within a GROUP (scenario) within each Data Partner site.

Days Supplied - number of days supplied for all dispensings in qualifying treatment episodes.

Eligible Members - number of members eligible for an incident treatment episode (defined by the drug/exposure and event washout periods) with drug and medical coverage during the query period.

Enrollment Gap - number of days allowed between two consecutive enrollment periods without breaking a "continuously enrolled" sequence.

Episodes - treatment episodes; length of episode is determined by days supplied in one dispensing or consecutive dispensings bridged by the episode gap.

Episode Gap - number of days allowed between two (or more) consecutive exposures (dispensings/procedures) to be considered the same treatment episode.

Event Deduplication - specifies how events are counted by the Modular Program (MP) algorithm: 0: Counts all occurrences of a health outcome of interest (HOI) during an exposure episode; 1: de-duplicates occurrences of the same HOI code and code type on the same day; 2: de-duplicates occurrences of the same HOI group on the same day (e.g., de-duplicates at the group level).

Exposure Episode Length - number of days after exposure initiation that is considered "exposed time."

Exposure Extension Period - number of days post treatment period in which the outcomes/events are counted for a treatment episode. Extensions are added after any episode gaps have been bridged.

Lookback Period - number of days wherein a member is required to have evidence of pre-existing condition (diagnosis/procedure/drug dispensing).

Maximum Episode Duration - truncates exposure episodes after a requester-specified number of exposed days. Applied after any gaps are bridged and extension days added to the length of the exposure episode.

Member-Years - sum of all days of enrollment with medical and drug coverage in the query period preceded by an exposure washout period all divided by 365.25.

Minimum Days Supplied - specifies a minimum number of days in length of the days supplied for the episode to be considered.

Minimum Episode Duration - specifies a minimum number of days in length of the episode for it to be considered. Applied after any gaps are bridged and extension days added to the length of the exposure episode.

Monitoring Period - used to define time periods of interest for both sequential analysis and simple cohort characterization requests.

Principal Diagnosis (PDX) - diagnosis or condition established to be chiefly responsible for admission of the patient to the hospital. 'P' = principal diagnosis, 'S' = secondary diagnosis, 'X' = unspecified diagnosis, '.' = blank. Along with the Care Setting values, forms the Caresetting/PDX parameter.

Query Period - period in which the modular program looks for exposures and outcomes of interest.

Switch Evaluation Step Value - value used to differentiate evaluation step. Each switch pattern can support up to 2 evaluation steps (0 = switch pattern evaluation start; 1 = first evaluation; 2 = second evaluation).

Switch Gap Inclusion Indicator - indicator for whether gaps in treatment episodes that are included in a switch episode will be counted as part of the switch episode duration.

Switch Pattern - specified sequence of drug use within the same patient. Switch patterns can characterize single switches (Drug A to Drug B), switch-backs (Drug A to Drug B to Drug A), and switch-aways (Drug A to Drug B to Drug C).

Switch Pattern Cohort - collection of treatment episodes meeting a given set of inclusion/exclusion criteria.

Switch Pattern Cohort Inclusion Date - indicates which date to use for inclusion into the switch pattern cohort of interest as well as optionally as the index date of the treatment episode initiating the switch pattern. Valid options are the product approval date, product marketing date, other requester defined date, or computed start marketing date.

Switch Pattern Cohort Inclusion Strategy - indicates how the switch pattern cohort inclusion date will be used: 01: used only as a switch cohort entry date. First treatment episode dispensing date is used as index for computing time to first switch; 02: used as switch cohort entry date and as initial switch step index date for computing time to first switch.

Switch Pattern Episode - eligible treatment episode evaluated for one of the switch patterns of interest which ended in a switch.

Treatment Episode Truncation Indicator - indicates whether the exposure episode will be truncated at the occurrence of a requester-specified code.

Washout Period (drug/exposure) - number of days a user is required to have no evidence of prior exposure (drug dispensing/procedure) and continuous drug and medical coverage prior to an incident treatment episode.

Washout Period (event/outcome) - number of days a user is required to have no evidence of a prior event (procedure/diagnosis) and continuous drug and medical coverage prior to an incident treatment episode.

Years at Risk - number of days supplied plus any episode gaps and exposure extension periods all divided by 365.25.

*all terms may not be used in this report

Table 1a. Number of Overall Mixed Amphetamine Salt (MAS) Users Over Time, by Month-Year in the Sentinel Distributed Database (SDD) from January 1, 2013 to December 31, 2019^{1,2}

Product Group	Total Overall Users	January	February	March	April	May	June	July	August	September	October	November	December
ANDA 202424	261,589												
2013	0	0	0	0	0	0	0	0	0	0	0	0	0
2014	25,511	0	0	0	130	551	792	4,341	6,220	5,253	5,591	5,708	4,586
2015	31,243	4,049	3,751	3,973	3,956	3,602	4,397	4,684	4,864	5,292	5,297	4,497	4,669
2016	41,752	4,490	4,655	6,869	5,952	5,474	5,826	6,265	7,093	6,607	6,598	6,633	5,845
2017	100,531	6,157	6,610	11,489	12,733	17,051	14,147	15,349	19,586	16,512	16,756	17,241	16,440
2018	92,830	10,718	9,449	11,774	11,989	14,353	13,249	13,277	15,985	14,430	16,424	14,274	10,609
2019	83,908	12,450	15,205	13,649	15,229	11,485	7,197	10,466	12,115	10,481	10,338	9,288	7,095
ANDA 040440	69,115												
2013	1	0	0	0	0	0	0	0	0	0	0	0	1
2014	9,518	639	937	1,111	1,086	1,013	994	1,327	1,611	1,258	1,304	1,091	966
2015	4,347	669	447	567	538	473	384	451	442	521	530	404	461
2016	4,218	450	555	581	489	333	317	420	554	540	492	499	658
2017	11,365	523	467	601	517	621	829	890	1,316	2,897	2,034	2,091	1,387
2018	22,658	1,785	2,306	2,387	2,190	2,814	2,341	2,820	3,882	2,337	2,436	1,913	2,210
2019	28,828	5,030	2,632	2,362	2,301	2,848	4,852	3,535	4,365	3,757	1,992	1,350	1,154
ANDA 040422	577,302												
2013	126,690	21,519	17,454	17,672	18,958	18,138	16,655	22,887	23,464	21,587	22,620	19,788	20,437
2014	125,755	20,212	19,470	20,748	19,456	18,774	18,575	19,589	18,867	19,608	19,670	17,166	21,144
2015	124,089	20,024	17,699	19,201	18,585	17,321	18,150	20,676	21,621	21,974	22,303	20,574	21,529
2016	126,124	20,422	19,932	22,003	18,450	16,483	16,593	18,320	22,486	20,443	19,220	18,776	18,538
2017	122,100	15,996	14,799	16,389	14,623	15,423	15,241	16,202	19,480	22,132	25,286	22,428	19,932
2018	150,049	25,216	21,850	22,166	21,320	22,757	23,235	24,276	26,460	24,416	23,151	21,344	21,638
2019	146,671	23,193	17,566	20,731	21,855	23,077	22,784	25,459	23,109	23,941	26,998	19,773	21,155
ANDA 040439	145,294												
2013	25,229	2,949	2,357	2,299	2,279	2,400	4,662	3,093	4,181	3,457	2,825	2,560	2,775
2014	20,818	3,427	2,592	2,256	2,386	2,423	2,251	2,243	2,230	2,453	2,720	2,721	2,444
2015	13,556	2,487	1,624	1,552	1,579	1,383	1,631	1,661	1,686	1,823	1,878	1,534	1,583
2016	13,577	1,473	1,767	2,964	1,807	1,629	1,706	1,737	1,452	1,497	1,652	1,407	1,356
2017	22,029	1,642	1,221	1,263	1,213	1,218	1,190	1,395	1,949	4,560	4,012	4,372	5,961
2018	43,634	5,046	3,807	4,770	2,326	966	2,191	8,247	5,923	5,806	7,828	7,199	7,130
2019	48,607	6,308	5,535	5,681	4,647	5,849	5,887	6,596	7,275	6,346	5,959	4,969	5,779
ANDA 040480	25,513												
2013	0	0	0	0	0	0	0	0	0	0	0	0	0
2014	398	0	0	9	11	16	17	28	31	46	49	100	142
2015	508	115	45	45	29	84	191	34	15	7	4	1	7

Table 1a. Number of Overall Mixed Amphetamine Salt (MAS) Users Over Time, by Month-Year in the Sentinel Distributed Database (SDD) from January 1, 2013 to December 31, 2019^{1,2}

Product Group	Total Overall Users	January	February	March	April	May	June	July	August	September	October	November	December
2016	2,588	15	62	162	143	110	141	147	423	527	436	465	548
2017	5,863	542	435	529	647	619	396	329	713	884	988	967	904
2018	10,559	1,358	2,097	993	474	352	363	251	206	141	1,797	2,382	2,192
2019	10,374	2,641	2,531	2,009	673	382	330	335	286	265	269	538	2,426
Non-202424	631,544												
2013	130,754	22,783	18,356	18,585	19,897	18,947	18,249	22,661	24,978	22,506	23,424	20,853	21,704
2014	134,797	22,280	20,853	22,018	20,961	20,188	19,927	21,313	20,933	21,560	21,971	19,324	22,872
2015	132,554	21,869	18,687	20,484	19,912	18,506	19,490	21,914	23,045	23,568	23,995	21,869	22,910
2016	135,040	21,808	21,566	24,531	19,616	17,720	18,051	19,676	23,423	21,832	20,843	20,440	20,428
2017	142,569	17,864	16,189	18,126	16,438	17,196	16,835	18,048	22,630	29,002	29,478	27,112	24,971
2018	174,425	30,060	26,553	25,984	23,454	23,981	25,706	30,845	31,278	28,283	30,180	28,287	28,825
2019	173,032	31,211	22,895	25,818	24,916	27,796	28,517	29,769	28,571	27,928	30,299	23,398	27,418
Non-040440	690,088												
2013	130,753	22,783	18,356	18,585	19,897	18,947	18,249	22,661	24,978	22,506	23,424	20,853	21,703
2014	137,817	21,955	20,544	21,629	20,729	20,205	19,951	22,674	23,073	23,546	24,055	21,461	24,134
2015	146,080	23,705	20,581	22,421	22,180	20,544	22,320	24,630	26,039	26,849	27,272	24,588	25,719
2016	156,262	24,738	24,393	28,975	23,139	21,248	22,055	23,866	28,367	26,393	25,291	24,937	23,961
2017	190,892	22,066	20,966	27,275	26,618	30,919	27,366	29,729	37,309	37,113	37,510	35,099	32,035
2018	192,377	31,798	26,804	29,319	28,884	31,480	32,097	35,557	36,854	34,234	37,552	34,577	31,459
2019	186,968	33,857	30,493	30,727	31,051	29,820	26,760	33,142	33,196	31,811	35,117	27,983	28,930
Non-040422	360,939												
2013	25,230	2,949	2,357	2,299	2,279	2,400	4,662	3,093	4,181	3,457	2,825	2,560	2,776
2014	51,104	4,059	3,503	3,332	3,522	3,897	3,939	7,701	9,729	8,584	9,225	9,140	7,724
2015	46,477	7,027	5,606	5,961	5,932	5,367	6,360	6,618	6,808	7,446	7,508	6,273	6,558
2016	57,630	6,301	6,860	10,307	8,055	7,291	7,689	8,279	9,194	8,900	8,791	8,659	7,980
2017	118,813	8,484	8,434	13,549	14,716	18,888	15,807	17,204	22,492	22,343	20,636	21,543	21,272
2018	119,104	15,599	14,015	16,020	14,284	16,281	15,756	20,777	21,086	18,681	23,600	20,505	17,531
2019	117,596	21,075	20,062	18,243	17,897	16,263	14,202	16,868	20,380	17,472	15,937	14,173	13,497
Non-040439	675,388												
2013	126,691	21,519	17,454	17,672	18,958	18,138	16,655	22,887	23,464	21,587	22,620	19,788	20,438
2014	133,465	20,543	19,803	21,179	19,986	19,501	19,363	22,101	22,624	22,611	22,982	20,494	23,270
2015	141,480	22,451	20,018	21,856	21,465	19,896	21,405	23,938	25,230	25,994	26,357	23,844	25,002
2016	153,472	24,010	23,571	27,420	22,781	20,528	21,157	23,279	28,540	26,220	24,728	24,419	23,461
2017	186,836	21,382	20,624	26,851	26,156	30,550	27,207	29,333	36,786	36,312	35,709	33,335	29,600
2018	189,951	30,841	26,561	28,346	29,437	33,442	31,953	32,856	37,337	32,778	35,474	33,168	29,999
2019	182,166	34,650	29,008	29,605	31,338	29,359	27,257	31,631	32,117	30,733	32,847	26,178	26,278

Table 1a. Number of Overall Mixed Amphetamine Salt (MAS) Users Over Time, by Month-Year in the Sentinel Distributed Database (SDD) from January 1, 2013 to December 31, 2019^{1,2}

Product Group	Total Overall Users	January	February	March	April	May	June	July	August	September	October	November	December
Non-040480	690,954												
2013	130,754	22,783	18,356	18,585	19,897	18,947	18,249	22,661	24,978	22,506	23,424	20,853	21,704
2014	139,228	22,280	20,853	22,016	21,063	20,505	20,280	23,136	23,711	23,827	24,444	21,780	24,262
2015	146,936	23,785	20,665	22,670	22,390	20,671	22,277	24,820	26,242	27,118	27,567	24,783	25,966
2016	156,384	24,994	24,642	29,155	23,255	21,295	22,052	23,966	28,393	26,346	25,340	24,958	23,984
2017	191,477	22,040	20,986	27,294	26,529	30,924	27,750	30,157	37,653	38,362	37,041	34,927	31,462
2018	191,580	31,693	26,840	30,054	29,337	32,141	32,108	35,733	37,191	33,564	36,915	33,816	31,079
2019	185,904	34,383	29,296	30,436	32,153	30,568	28,057	32,641	33,609	31,598	34,274	27,750	28,407

¹Counts of prevalent users over time are reported in year month of the valid index date.

²Multiple index dates are allowed per year.

Table 1b. Number of Overall Mixed Amphetamine Salt (MAS) Users Over Time, by Month-Year and Sex in the Sentinel Distributed Database (SDD) from January 1, 2013 to December 31, 2019¹

Product Group	Total Overall Users	January	February	March	April	May	June	July	August	September	October	November	December
ANDA 202424													
2013													
Female	0	0	0	0	0	0	0	0	0	0	0	0	0
Male	0	0	0	0	0	0	0	0	0	0	0	0	0
2014													
Female	13,898	0	0	0	64	302	449	2,330	3,380	2,877	3,002	3,191	2,529
Male	11,613	0	0	0	66	249	343	2,011	2,840	2,376	2,589	2,517	2,057
2015													
Female	16,897	2,149	2,037	2,146	2,144	1,990	2,411	2,560	2,700	2,876	2,867	2,443	2,627
Male	14,346	1,900	1,714	1,827	1,812	1,612	1,986	2,124	2,164	2,416	2,430	2,054	2,042
2016													
Female	22,994	2,393	2,577	3,812	3,298	3,071	3,214	3,487	3,885	3,681	3,566	3,709	3,241
Male	18,758	2,097	2,078	3,057	2,654	2,403	2,612	2,778	3,208	2,926	3,032	2,924	2,604
2017													
Female	54,507	3,412	3,578	6,329	6,941	9,303	7,691	8,431	10,686	9,008	9,102	9,374	8,960
Male	46,024	2,745	3,032	5,160	5,792	7,748	6,456	6,918	8,900	7,504	7,654	7,867	7,480
2018													
Female	50,138	5,686	5,100	6,319	6,554	7,732	7,311	7,224	8,576	7,827	8,891	7,717	5,768
Male	42,692	5,032	4,349	5,455	5,435	6,621	5,938	6,053	7,409	6,603	7,533	6,557	4,841
2019													
Female	45,192	6,691	8,255	7,406	8,181	6,307	3,862	5,681	6,514	5,611	5,471	4,999	3,839
Male	38,716	5,759	6,950	6,243	7,048	5,178	3,335	4,785	5,601	4,870	4,867	4,289	3,256
ANDA 040440													
2013													
Female	1	0	0	0	0	0	0	0	0	0	0	0	1
Male	0	0	0	0	0	0	0	0	0	0	0	0	0
2014													
Female	5,229	334	537	593	597	564	557	731	893	663	721	625	504
Male	4,289	305	400	518	489	449	437	596	718	595	583	466	462
2015													
Female	2,343	371	233	286	301	267	208	241	223	303	288	222	245
Male	2,004	298	214	281	237	206	176	210	219	218	242	182	216
2016													
Female	2,234	239	317	315	256	170	174	232	277	279	254	252	338
Male	1,984	211	238	266	233	163	143	188	277	261	238	247	320

Table 1b. Number of Overall Mixed Amphetamine Salt (MAS) Users Over Time, by Month-Year and Sex in the Sentinel Distributed Database (SDD) from January 1, 2013 to December 31, 2019¹

Product Group	Total Overall Users	January	February	March	April	May	June	July	August	September	October	November	December
2017													
Female	5,960	271	252	291	257	306	436	456	704	1,512	1,073	1,102	709
Male	5,405	252	215	310	260	315	393	434	612	1,385	961	989	678
2018													
Female	11,872	905	1,204	1,297	1,147	1,427	1,198	1,456	2,052	1,225	1,256	983	1,144
Male	10,786	880	1,102	1,090	1,043	1,387	1,143	1,364	1,830	1,112	1,180	930	1,066
2019													
Female	15,362	2,645	1,375	1,267	1,210	1,519	2,621	1,908	2,261	1,989	1,046	716	612
Male	13,466	2,385	1,257	1,095	1,091	1,329	2,231	1,627	2,104	1,768	946	634	542
ANDA 040422													
2013													
Female	68,494	11,606	9,435	9,675	10,456	10,014	9,185	12,499	12,962	11,813	12,346	10,921	11,236
Male	58,196	9,913	8,019	7,997	8,502	8,124	7,470	10,388	10,502	9,774	10,274	8,867	9,201
2014													
Female	68,116	10,847	10,535	11,449	10,447	10,255	10,202	10,869	10,332	10,886	10,744	9,380	11,796
Male	57,639	9,365	8,935	9,299	9,009	8,519	8,373	8,720	8,535	8,722	8,926	7,786	9,348
2015													
Female	67,404	10,854	9,696	10,551	10,071	9,606	9,993	11,450	11,780	12,048	12,186	11,305	11,854
Male	56,685	9,170	8,003	8,650	8,514	7,715	8,157	9,226	9,841	9,926	10,117	9,269	9,675
2016													
Female	69,003	11,060	10,919	12,023	10,148	9,087	9,249	10,254	12,397	11,328	10,620	10,378	10,354
Male	57,121	9,362	9,013	9,980	8,302	7,396	7,344	8,066	10,089	9,115	8,600	8,398	8,184
2017													
Female	66,547	8,714	8,137	9,083	8,003	8,445	8,402	9,030	10,734	12,088	13,858	12,301	11,014
Male	55,553	7,282	6,662	7,306	6,620	6,978	6,839	7,172	8,746	10,044	11,428	10,127	8,918
2018													
Female	81,533	13,759	11,938	12,109	11,739	12,409	12,751	13,560	14,408	13,347	12,642	11,717	11,937
Male	68,516	11,457	9,912	10,057	9,581	10,348	10,484	10,716	12,052	11,069	10,509	9,627	9,701
2019													
Female	80,035	12,540	9,608	11,441	12,066	12,823	12,608	14,213	12,713	13,236	14,690	10,970	11,588
Male	66,636	10,653	7,958	9,290	9,789	10,254	10,176	11,246	10,396	10,705	12,308	8,803	9,567
ANDA 040439													
2013													
Female	13,420	1,555	1,265	1,264	1,220	1,255	2,465	1,647	2,195	1,913	1,509	1,371	1,473

Table 1b. Number of Overall Mixed Amphetamine Salt (MAS) Users Over Time, by Month-Year and Sex in the Sentinel Distributed Database (SDD) from January 1, 2013 to December 31, 2019¹

Product Group	Total Overall Users	January	February	March	April	May	June	July	August	September	October	November	December
Male	11,809	1,394	1,092	1,035	1,059	1,145	2,197	1,446	1,986	1,544	1,316	1,189	1,302
2014													
Female	11,103	1,791	1,295	1,195	1,282	1,291	1,206	1,238	1,212	1,307	1,434	1,448	1,339
Male	9,715	1,636	1,297	1,061	1,104	1,132	1,045	1,005	1,018	1,146	1,286	1,273	1,105
2015													
Female	7,372	1,350	881	832	857	762	926	923	907	1,011	1,036	843	884
Male	6,184	1,137	743	720	722	621	705	738	779	812	842	691	699
2016													
Female	7,358	795	942	1,605	996	886	967	946	809	816	889	793	767
Male	6,219	678	825	1,359	811	743	739	791	643	681	763	614	589
2017													
Female	11,925	868	662	688	639	660	674	768	1,064	2,504	2,185	2,358	3,238
Male	10,104	774	559	575	574	558	516	627	885	2,056	1,827	2,014	2,723
2018													
Female	23,625	2,699	2,033	2,580	1,201	519	1,212	4,453	3,164	3,069	4,246	4,007	3,822
Male	20,009	2,347	1,774	2,190	1,125	447	979	3,794	2,759	2,737	3,582	3,192	3,308
2019													
Female	26,217	3,368	2,931	3,052	2,563	3,242	3,193	3,632	3,955	3,415	3,163	2,657	3,106
Male	22,390	2,940	2,604	2,629	2,084	2,607	2,694	2,964	3,320	2,931	2,796	2,312	2,673
ANDA 040480													
2013													
Female	0	0	0	0	0	0	0	0	0	0	0	0	0
Male	0	0	0	0	0	0	0	0	0	0	0	0	0
2014													
Female	203	0	0	2	8	10	9	15	21	17	23	53	71
Male	195	0	0	7	3	6	8	13	10	29	26	47	71
2015													
Female	275	66	25	23	16	50	90	22	7	6	1	1	2
Male	233	49	20	22	13	34	101	12	8	1	3	0	5
2016													
Female	1,381	7	39	91	73	58	74	85	227	279	234	232	307
Male	1,207	8	23	71	70	52	67	62	196	248	202	233	241
2017													
Female	3,103	284	237	301	312	331	222	168	379	480	526	487	495

Table 1b. Number of Overall Mixed Amphetamine Salt (MAS) Users Over Time, by Month-Year and Sex in the Sentinel Distributed Database (SDD) from January 1, 2013 to December 31, 2019¹

Product	Total Overall												
Group	Users	January	February	March	April	May	June	July	August	September	October	November	December
Male	2,760	258	198	228	335	288	174	161	334	404	462	480	409
2018													
Female	5,558	731	1,108	537	254	187	197	140	97	78	968	1,203	1,162
Male	5,001	627	989	456	220	165	166	111	109	63	829	1,179	1,030
2019													
Female	5,541	1,372	1,329	1,071	386	207	178	190	165	130	150	298	1,308
Male	4,833	1,269	1,202	938	287	175	152	145	121	135	119	240	1,118
Non-202424													
2013													
Female	70,449	12,221	9,898	10,151	10,958	10,417	10,036	12,386	13,684	12,331	12,782	11,465	11,901
Male	60,305	10,562	8,458	8,434	8,939	8,530	8,213	10,275	11,294	10,175	10,642	9,388	9,803
2014													
Female	72,852	11,890	11,237	12,135	11,255	10,997	10,946	11,839	11,469	11,906	11,983	10,553	12,714
Male	61,945	10,390	9,616	9,883	9,706	9,191	8,981	9,474	9,464	9,654	9,988	8,771	10,158
2015													
Female	71,986	11,886	10,231	11,225	10,786	10,280	10,737	12,117	12,511	12,941	13,091	12,017	12,619
Male	60,568	9,983	8,456	9,259	9,126	8,226	8,753	9,797	10,534	10,627	10,904	9,852	10,291
2016													
Female	73,759	11,804	11,804	13,399	10,810	9,753	10,080	11,002	12,924	12,068	11,504	11,290	11,395
Male	61,281	10,004	9,762	11,132	8,806	7,967	7,971	8,674	10,499	9,764	9,339	9,150	9,033
2017													
Female	77,505	9,675	8,904	10,009	8,922	9,402	9,281	10,036	12,411	15,806	16,078	14,791	13,711
Male	65,064	8,189	7,285	8,117	7,516	7,794	7,554	8,012	10,219	13,196	13,400	12,321	11,260
2018													
Female	94,500	16,321	14,414	14,194	12,823	13,068	14,101	17,077	16,924	15,371	16,387	15,502	15,781
Male	79,925	13,739	12,139	11,790	10,631	10,913	11,605	13,768	14,354	12,912	13,793	12,785	13,044
2019													
Female	94,102	16,773	12,454	14,267	13,741	15,442	15,759	16,635	15,620	15,321	16,504	12,907	15,006
Male	78,930	14,438	10,441	11,551	11,175	12,354	12,758	13,134	12,951	12,607	13,795	10,491	12,412
Non-040440													
2013													
Female	70,448	12,221	9,898	10,151	10,958	10,417	10,036	12,386	13,684	12,331	12,782	11,465	11,900
Male	60,305	10,562	8,458	8,434	8,939	8,530	8,213	10,275	11,294	10,175	10,642	9,388	9,803

Table 1b. Number of Overall Mixed Amphetamine Salt (MAS) Users Over Time, by Month-Year and Sex in the Sentinel Distributed Database (SDD) from January 1, 2013 to December 31, 2019¹

Product Group	Total Overall Users	January	February	March	April	May	June	July	August	September	October	November	December
2014													
Female	74,487	11,717	11,038	11,927	11,116	10,973	10,948	12,547	12,603	13,043	13,058	11,720	13,443
Male	63,330	10,238	9,506	9,702	9,613	9,232	9,003	10,127	10,470	10,503	10,997	9,741	10,691
2015													
Female	79,234	12,786	11,277	12,281	12,046	11,431	12,295	13,629	14,243	14,709	14,850	13,490	14,236
Male	66,846	10,919	9,304	10,140	10,134	9,113	10,025	11,001	11,796	12,140	12,422	11,098	11,483
2016													
Female	85,421	13,345	13,395	15,904	12,799	11,792	12,300	13,343	15,629	14,642	13,904	13,840	13,388
Male	70,841	11,393	10,998	13,071	10,340	9,456	9,755	10,523	12,738	11,751	11,387	11,097	10,573
2017													
Female	103,614	11,997	11,497	15,058	14,532	16,929	14,978	16,506	20,429	20,286	20,552	19,194	17,666
Male	87,278	10,069	9,469	12,217	12,086	13,990	12,388	13,223	16,880	16,827	16,958	15,905	14,369
2018													
Female	104,340	17,210	14,673	15,958	15,946	17,180	17,692	19,729	20,012	18,713	20,547	18,914	17,285
Male	88,037	14,588	12,131	13,361	12,938	14,300	14,405	15,828	16,842	15,521	17,005	15,663	14,174
2019													
Female	101,636	18,260	16,590	16,949	17,100	16,646	14,810	18,497	18,143	17,431	18,972	15,428	15,840
Male	85,332	15,597	13,903	13,778	13,951	13,174	11,950	14,645	15,053	14,380	16,145	12,555	13,090
Non-040422													
2013													
Female	13,421	1,555	1,265	1,264	1,220	1,255	2,465	1,647	2,195	1,913	1,509	1,371	1,474
Male	11,809	1,394	1,092	1,035	1,059	1,145	2,197	1,446	1,986	1,544	1,316	1,189	1,302
2014													
Female	27,649	2,123	1,816	1,773	1,902	2,098	2,158	4,179	5,296	4,651	4,963	5,037	4,211
Male	23,455	1,936	1,687	1,559	1,620	1,799	1,781	3,522	4,433	3,933	4,262	4,103	3,513
2015													
Female	25,188	3,777	3,044	3,191	3,224	2,978	3,506	3,640	3,730	4,092	4,085	3,424	3,668
Male	21,289	3,250	2,562	2,770	2,708	2,389	2,854	2,978	3,078	3,354	3,423	2,849	2,890
2016													
Female	31,525	3,360	3,774	5,679	4,443	4,052	4,258	4,601	5,021	4,912	4,735	4,819	4,426
Male	26,105	2,941	3,086	4,628	3,612	3,239	3,431	3,678	4,173	3,988	4,056	3,840	3,554
2017													
Female	64,205	4,621	4,570	7,429	7,958	10,275	8,625	9,449	12,259	12,164	11,191	11,648	11,569
Male	54,608	3,863	3,864	6,120	6,758	8,613	7,182	7,755	10,233	10,179	9,445	9,895	9,703

Table 1b. Number of Overall Mixed Amphetamine Salt (MAS) Users Over Time, by Month-Year and Sex in the Sentinel Distributed Database (SDD) from January 1, 2013 to December 31, 2019¹

Product Group	Total Overall Users	January	February	March	April	May	June	July	August	September	October	November	December
2018													
Female	64,068	8,290	7,469	8,620	7,702	8,703	8,685	11,209	11,322	10,081	12,773	11,072	9,467
Male	55,036	7,309	6,546	7,400	6,582	7,578	7,071	9,568	9,764	8,600	10,827	9,433	8,064
2019													
Female	63,419	11,292	10,826	9,920	9,711	8,936	7,661	9,291	10,942	9,355	8,445	7,653	7,323
Male	54,177	9,783	9,236	8,323	8,186	7,327	6,541	7,577	9,438	8,117	7,492	6,520	6,174
Non-040439													
2013													
Female	68,495	11,606	9,435	9,675	10,456	10,014	9,185	12,499	12,962	11,813	12,346	10,921	11,237
Male	58,196	9,913	8,019	7,997	8,502	8,124	7,470	10,388	10,502	9,774	10,274	8,867	9,201
2014													
Female	72,262	11,022	10,748	11,674	10,734	10,683	10,666	12,242	12,394	12,536	12,509	11,270	12,928
Male	61,203	9,521	9,055	9,505	9,252	8,818	8,697	9,859	10,230	10,075	10,473	9,224	10,342
2015													
Female	76,791	12,139	10,984	11,988	11,662	11,076	11,793	13,257	13,801	14,246	14,369	13,086	13,827
Male	64,689	10,312	9,034	9,868	9,803	8,820	9,612	10,681	11,429	11,748	11,988	10,758	11,175
2016													
Female	83,837	12,939	12,981	15,039	12,556	11,366	11,770	13,024	15,672	14,533	13,580	13,518	13,069
Male	69,635	11,071	10,590	12,381	10,225	9,162	9,387	10,255	12,868	11,687	11,148	10,901	10,392
2017													
Female	101,415	11,637	11,282	14,794	14,277	16,700	14,865	16,286	20,144	19,846	19,599	18,293	16,302
Male	85,421	9,745	9,342	12,057	11,879	13,850	12,342	13,047	16,642	16,466	16,110	15,042	13,298
2018													
Female	102,890	16,634	14,560	15,453	16,227	18,157	17,589	18,230	20,207	17,906	19,345	18,095	16,485
Male	87,061	14,207	12,001	12,893	13,210	15,285	14,364	14,626	17,130	14,872	16,129	15,073	13,514
2019													
Female	99,025	18,663	15,830	16,354	17,176	16,319	15,078	17,607	17,485	16,862	17,798	14,455	14,367
Male	83,141	15,987	13,178	13,251	14,162	13,040	12,179	14,024	14,632	13,871	15,049	11,723	11,911
Non-040480													
2013													
Female	70,449	12,221	9,898	10,151	10,958	10,417	10,036	12,386	13,684	12,331	12,782	11,465	11,901
Male	60,305	10,562	8,458	8,434	8,939	8,530	8,213	10,275	11,294	10,175	10,642	9,388	9,803
2014													

Table 1b. Number of Overall Mixed Amphetamine Salt (MAS) Users Over Time, by Month-Year and Sex in the Sentinel Distributed Database (SDD) from January 1, 2013 to December 31, 2019¹

Product Group	Total Overall Users	January	February	March	April	May	June	July	August	September	October	November	December
Female	75,256	11,890	11,237	12,134	11,304	11,163	11,150	12,817	12,969	13,200	13,297	11,927	13,488
Male	63,972	10,390	9,616	9,882	9,759	9,342	9,130	10,319	10,742	10,627	11,147	9,853	10,774
2015													
Female	79,728	12,852	11,337	12,418	12,163	11,509	12,292	13,729	14,332	14,869	15,014	13,601	14,371
Male	67,208	10,933	9,328	10,252	10,227	9,162	9,985	11,091	11,910	12,249	12,553	11,182	11,595
2016													
Female	85,457	13,473	13,538	15,988	12,857	11,802	12,289	13,404	15,624	14,612	13,924	13,859	13,378
Male	70,927	11,521	11,104	13,167	10,398	9,493	9,763	10,562	12,769	11,734	11,416	11,099	10,606
2017													
Female	103,855	11,975	11,504	15,020	14,496	16,926	15,176	16,741	20,631	20,963	20,282	19,115	17,317
Male	87,622	10,065	9,482	12,274	12,033	13,998	12,574	13,416	17,022	17,399	16,759	15,812	14,145
2018													
Female	103,809	17,125	14,702	16,375	16,126	17,487	17,719	19,789	20,195	18,336	20,174	18,592	17,073
Male	87,771	14,568	12,138	13,679	13,211	14,654	14,389	15,944	16,996	15,228	16,741	15,224	14,006
2019													
Female	101,067	18,557	15,971	16,797	17,612	17,060	15,545	18,285	18,330	17,328	18,572	15,298	15,552
Male	84,837	15,826	13,325	13,639	14,541	13,508	12,512	14,356	15,279	14,270	15,702	12,452	12,855

¹Counts of prevalent users over time are reported in year month of the valid index date

Table 1c. Number of Overall Mixed Amphetamine Salt (MAS) Users Over Time, by Month-Year and Age Group in the Sentinel Distributed Database (SDD) from January 1, 2013 to December 31, 2019¹

Product Group	Total Overall Users	January	February	March	April	May	June	July	August	September	October	November	December
ANDA 202424													
2013													
15-24	0	0	0	0	0	0	0	0	0	0	0	0	0
25-34	0	0	0	0	0	0	0	0	0	0	0	0	0
35-44	0	0	0	0	0	0	0	0	0	0	0	0	0
45-54	0	0	0	0	0	0	0	0	0	0	0	0	0
55-64	0	0	0	0	0	0	0	0	0	0	0	0	0
2014													
15-24	7,105	0	0	0	24	111	176	1,005	1,680	1,474	1,635	1,640	1,230
25-34	8,933	0	0	0	46	187	263	1,651	2,179	1,854	1,847	1,970	1,587
35-44	5,121	0	0	0	26	137	203	895	1,332	1,038	1,092	1,088	933
45-54	3,049	0	0	0	23	75	96	538	690	610	696	686	581
55-64	1,466	0	0	0	11	41	54	252	339	277	321	324	255
2015													
15-24	8,429	1,150	981	1,061	1,075	890	1,102	1,091	1,304	1,420	1,386	1,196	1,133
25-34	11,027	1,370	1,287	1,392	1,395	1,297	1,554	1,719	1,694	1,801	1,872	1,533	1,624
35-44	6,547	805	777	826	778	754	901	975	991	1,113	1,089	901	1,024
45-54	3,892	497	476	456	506	440	558	624	591	652	631	598	580
55-64	1,887	227	230	238	202	221	282	275	284	306	319	269	308
2016													
15-24	10,288	1,219	1,166	1,618	1,409	1,239	1,264	1,308	1,855	1,630	1,561	1,570	1,324
25-34	14,814	1,508	1,597	2,391	1,997	1,925	2,055	2,287	2,403	2,216	2,309	2,247	2,055
35-44	9,371	928	1,046	1,558	1,361	1,242	1,340	1,445	1,558	1,445	1,491	1,486	1,294
45-54	5,407	569	548	892	793	744	805	827	863	870	840	924	762
55-64	2,617	266	298	410	392	324	362	398	414	446	397	406	410
2017													
15-24	23,699	1,576	1,554	2,540	2,774	3,656	3,013	3,298	4,973	3,826	3,987	3,895	3,354
25-34	34,001	2,087	2,262	3,844	4,261	5,695	4,779	5,249	6,354	5,368	5,405	5,658	5,426
35-44	22,965	1,358	1,486	2,636	2,906	3,975	3,305	3,516	4,292	3,800	3,768	3,985	3,930
45-54	14,216	785	901	1,641	1,799	2,456	2,045	2,145	2,640	2,349	2,400	2,393	2,450
55-64	7,296	351	407	828	993	1,269	1,005	1,141	1,327	1,169	1,196	1,310	1,280
2018													
15-24	20,505	2,709	2,155	2,400	2,539	2,917	2,473	2,480	3,538	3,035	3,414	3,023	2,170
25-34	31,625	3,365	3,074	3,884	4,030	4,947	4,478	4,492	5,327	4,747	5,556	4,707	3,334
35-44	22,104	2,390	2,161	2,839	2,824	3,411	3,251	3,305	3,762	3,474	3,965	3,461	2,649
45-54	13,169	1,478	1,365	1,691	1,729	2,003	1,967	1,988	2,240	2,090	2,296	2,052	1,577
55-64	6,926	776	694	960	867	1,075	1,080	1,012	1,118	1,084	1,193	1,031	879

Table 1c. Number of Overall Mixed Amphetamine Salt (MAS) Users Over Time, by Month-Year and Age Group in the Sentinel Distributed Database (SDD) from January 1, 2013 to December 31, 2019¹

Product Group	Total Overall Users	January	February	March	April	May	June	July	August	September	October	November	December
2019													
15-24	16,518	2,592	2,814	2,662	2,833	2,146	1,318	1,715	2,231	1,963	1,935	1,740	1,375
25-34	28,048	4,083	5,121	4,494	5,152	3,769	2,342	3,564	3,956	3,374	3,293	2,960	2,193
35-44	21,432	3,117	3,853	3,379	3,855	2,924	1,875	2,711	3,056	2,705	2,710	2,374	1,768
45-54	12,414	1,748	2,252	2,007	2,239	1,727	1,089	1,596	1,890	1,548	1,534	1,428	1,096
55-64	6,792	910	1,165	1,107	1,151	919	573	880	982	891	866	786	663
ANDA 040440													
2013													
15-24	0	0	0	0	0	0	0	0	0	0	0	0	0
25-34	0	0	0	0	0	0	0	0	0	0	0	0	0
35-44	1	0	0	0	0	0	0	0	0	0	0	0	1
45-54	0	0	0	0	0	0	0	0	0	0	0	0	0
55-64	0	0	0	0	0	0	0	0	0	0	0	0	0
2014													
15-24	2,447	155	235	266	288	259	249	305	455	344	347	292	231
25-34	3,026	212	298	360	348	303	306	439	469	366	352	295	282
35-44	2,079	146	200	238	224	220	214	297	343	276	289	239	205
45-54	1,378	93	147	168	161	164	145	198	222	185	193	183	156
55-64	667	33	57	79	65	67	80	88	122	87	123	82	92
2015													
15-24	1,067	202	116	162	150	123	85	101	103	106	116	90	106
25-34	1,353	185	131	176	174	130	136	145	121	146	155	127	130
35-44	945	136	98	104	103	111	85	89	113	126	119	86	107
45-54	662	98	67	82	79	68	52	72	66	92	96	71	70
55-64	349	48	35	43	32	41	26	44	39	51	44	30	48
2016													
15-24	781	90	89	130	85	66	47	53	92	102	81	96	115
25-34	1,241	147	162	156	150	98	81	132	154	149	137	133	201
35-44	1,089	101	135	151	123	83	95	113	142	138	142	128	179
45-54	733	75	110	106	85	56	59	68	96	99	80	86	106
55-64	420	37	59	38	46	30	35	54	70	52	52	56	57
2017													
15-24	2,150	104	89	112	101	120	144	154	268	552	377	371	223
25-34	3,669	139	141	179	154	177	259	260	426	959	693	715	412
35-44	2,763	129	121	145	118	148	203	243	297	674	470	510	362
45-54	1,794	90	64	112	86	113	140	142	221	443	284	320	254
55-64	1,051	61	52	53	58	63	83	91	104	269	210	175	136

Table 1c. Number of Overall Mixed Amphetamine Salt (MAS) Users Over Time, by Month-Year and Age Group in the Sentinel Distributed Database (SDD) from January 1, 2013 to December 31, 2019¹

Product Group	Total Overall Users	January	February	March	April	May	June	July	August	September	October	November	December
2018													
15-24	3,942	315	367	429	434	494	387	477	652	400	439	337	341
25-34	7,194	576	735	734	664	887	757	857	1,157	724	726	565	669
35-44	5,866	471	612	615	540	688	556	752	1,009	594	629	497	585
45-54	3,685	270	388	393	334	466	411	460	683	368	422	325	373
55-64	2,143	153	204	216	218	279	230	274	381	251	220	189	242
2019													
15-24	4,622	780	363	403	347	454	802	534	672	560	351	215	212
25-34	9,301	1,601	784	692	727	906	1,567	1,144	1,407	1,186	619	405	351
35-44	7,659	1,385	719	631	623	750	1,268	936	1,208	983	504	368	285
45-54	4,734	843	455	408	377	475	772	578	649	643	346	226	191
55-64	2,700	421	311	228	227	263	443	343	429	385	172	136	115
ANDA 040422													
2013													
15-24	40,414	7,381	5,565	5,527	5,879	5,114	4,555	6,148	7,563	6,725	6,871	5,935	5,928
25-34	42,473	6,931	5,629	5,790	6,174	6,251	5,800	8,056	7,581	7,027	7,465	6,570	6,739
35-44	24,244	3,875	3,307	3,309	3,649	3,546	3,295	4,577	4,322	4,103	4,363	3,777	4,053
45-54	15,098	2,309	2,037	2,134	2,243	2,257	2,075	2,856	2,747	2,578	2,728	2,414	2,519
55-64	6,862	1,023	916	912	1,013	970	931	1,250	1,251	1,155	1,193	1,092	1,199
2014													
15-24	36,917	6,479	5,623	6,034	5,766	4,912	4,859	5,082	5,493	5,344	5,458	4,643	5,418
25-34	43,767	6,597	6,622	6,926	6,476	6,621	6,536	6,974	6,357	6,833	6,747	6,017	7,380
35-44	25,270	3,795	3,801	4,168	3,820	3,781	3,843	4,031	3,713	3,938	3,949	3,489	4,361
45-54	15,340	2,319	2,424	2,505	2,381	2,414	2,328	2,474	2,291	2,445	2,485	2,071	2,777
55-64	6,894	1,022	1,000	1,115	1,013	1,046	1,009	1,028	1,013	1,048	1,031	946	1,208
2015													
15-24	33,866	5,894	4,784	5,101	5,083	4,176	4,132	4,767	5,944	5,651	5,798	5,137	5,114
25-34	44,348	6,746	6,243	6,730	6,449	6,215	6,720	7,634	7,377	7,866	7,789	7,228	7,561
35-44	25,957	3,935	3,587	3,939	3,834	3,664	3,897	4,372	4,355	4,475	4,593	4,302	4,626
45-54	15,455	2,413	2,137	2,336	2,174	2,217	2,342	2,607	2,689	2,742	2,823	2,668	2,907
55-64	7,164	1,036	948	1,095	1,045	1,049	1,059	1,296	1,256	1,240	1,300	1,239	1,321
2016													
15-24	30,194	5,542	5,079	5,347	4,189	3,367	3,404	3,542	5,101	4,442	4,231	4,051	3,738
25-34	45,597	7,122	7,057	7,645	6,542	6,073	6,084	6,750	7,815	7,259	6,794	6,817	6,594
35-44	28,263	4,215	4,209	4,711	4,064	3,829	3,849	4,304	5,031	4,709	4,408	4,227	4,438
45-54	16,564	2,421	2,429	2,941	2,484	2,164	2,240	2,536	3,115	2,769	2,579	2,512	2,562
55-64	7,880	1,122	1,158	1,359	1,171	1,050	1,016	1,188	1,424	1,265	1,208	1,169	1,206

Table 1c. Number of Overall Mixed Amphetamine Salt (MAS) Users Over Time, by Month-Year and Age Group in the Sentinel Distributed Database (SDD) from January 1, 2013 to December 31, 2019¹

Product Group	Total Overall Users	January	February	March	April	May	June	July	August	September	October	November	December
2017													
15-24	26,179	3,677	3,111	3,382	3,115	3,035	2,749	2,947	4,173	4,304	5,103	4,541	3,710
25-34	43,955	5,666	5,377	5,914	5,263	5,626	5,641	5,953	6,838	7,697	8,693	7,748	6,895
35-44	29,164	3,591	3,505	3,894	3,358	3,701	3,785	3,952	4,565	5,458	6,067	5,365	4,858
45-54	16,995	2,136	1,903	2,204	1,983	2,080	2,118	2,255	2,663	3,188	3,640	3,239	3,007
55-64	8,011	926	903	995	904	981	948	1,095	1,241	1,485	1,783	1,535	1,462
2018													
15-24	31,017	5,113	4,247	4,424	4,327	4,247	4,166	4,347	5,432	4,638	4,507	4,237	4,039
25-34	52,082	8,589	7,393	7,547	7,396	7,929	8,081	8,442	8,844	8,200	7,802	7,071	7,393
35-44	36,896	6,019	5,401	5,408	5,042	5,612	5,806	6,082	6,473	6,234	5,646	5,283	5,350
45-54	21,847	3,692	3,223	3,170	3,060	3,330	3,494	3,639	3,772	3,574	3,355	3,148	3,204
55-64	11,132	1,803	1,586	1,617	1,495	1,639	1,688	1,766	1,939	1,770	1,841	1,605	1,652
2019													
15-24	27,713	4,586	3,268	3,574	3,871	3,783	3,561	4,188	4,567	4,309	4,561	3,483	3,568
25-34	50,447	7,964	5,926	7,065	7,329	7,966	7,933	8,826	7,664	7,895	8,983	6,443	6,970
35-44	38,245	5,756	4,448	5,381	5,679	6,036	6,005	6,621	5,860	6,340	7,118	5,154	5,717
45-54	21,668	3,248	2,647	3,085	3,255	3,485	3,505	3,916	3,276	3,531	4,088	2,994	3,124
55-64	11,403	1,639	1,277	1,626	1,721	1,807	1,780	1,908	1,742	1,866	2,248	1,699	1,776
ANDA 040439													
2013													
15-24	7,154	940	696	688	632	646	1,100	806	1,199	979	796	717	736
25-34	8,537	970	799	741	728	823	1,716	1,010	1,364	1,118	924	823	864
35-44	4,929	538	444	449	446	454	934	648	824	683	540	486	571
45-54	3,277	337	285	259	318	328	593	433	549	443	392	352	394
55-64	1,592	164	133	162	155	149	319	196	245	234	173	182	210
2014													
15-24	5,724	855	678	627	675	626	551	520	621	649	770	791	641
25-34	6,888	1,168	867	733	798	814	763	729	677	784	844	838	730
35-44	4,227	696	552	460	443	516	480	490	481	501	543	545	518
45-54	2,738	482	330	288	319	319	306	332	260	334	368	348	343
55-64	1,444	226	165	148	151	148	151	172	191	185	195	199	212
2015													
15-24	3,419	698	411	392	419	338	355	365	431	453	429	377	346
25-34	4,319	799	529	447	454	422	498	528	521	550	571	442	485
35-44	3,008	515	335	351	349	316	403	379	365	414	447	353	364
45-54	1,921	322	222	246	213	195	237	248	249	263	278	223	246
55-64	1,049	153	127	116	144	112	138	141	120	143	153	139	142

Table 1c. Number of Overall Mixed Amphetamine Salt (MAS) Users Over Time, by Month-Year and Age Group in the Sentinel Distributed Database (SDD) from January 1, 2013 to December 31, 2019¹

Product Group	Total Overall Users	January	February	March	April	May	June	July	August	September	October	November	December
2016													
15-24	2,960	359	390	589	399	335	350	331	376	313	329	296	292
25-34	4,151	434	556	895	532	488	476	518	397	432	459	416	382
35-44	3,287	336	407	739	447	389	414	450	326	385	419	354	336
45-54	2,141	210	270	500	276	255	280	289	215	233	287	215	240
55-64	1,184	134	144	241	153	162	186	149	138	134	158	127	106
2017													
15-24	5,168	356	253	287	278	256	239	238	507	1,107	961	1,140	1,241
25-34	7,185	542	355	332	328	337	357	433	570	1,536	1,281	1,369	1,981
35-44	5,029	387	316	313	294	325	284	339	433	999	884	913	1,410
45-54	3,185	222	194	213	188	198	209	244	291	593	586	625	872
55-64	1,660	135	103	118	125	102	101	141	148	325	300	325	457
2018													
15-24	9,192	1,217	886	999	459	224	444	1,459	1,253	1,217	1,551	1,465	1,382
25-34	14,775	1,697	1,240	1,533	712	261	749	2,976	1,865	1,924	2,620	2,393	2,444
35-44	10,454	1,059	866	1,131	553	239	520	1,964	1,463	1,370	1,949	1,764	1,741
45-54	6,378	717	527	725	401	157	305	1,189	863	841	1,123	1,047	1,041
55-64	3,328	356	288	382	201	85	173	659	479	454	585	530	522
2019													
15-24	9,779	1,435	1,072	1,120	969	1,121	1,018	1,208	1,507	1,192	1,180	998	1,163
25-34	16,302	2,024	1,821	1,806	1,550	1,950	2,012	2,224	2,321	2,080	1,933	1,697	1,966
35-44	12,044	1,478	1,343	1,427	1,115	1,460	1,493	1,681	1,794	1,605	1,409	1,154	1,378
45-54	7,128	864	819	866	662	851	895	936	1,092	946	905	727	814
55-64	3,968	507	480	462	351	467	469	547	561	523	532	393	458
ANDA 040480													
2013													
15-24	0	0	0	0	0	0	0	0	0	0	0	0	0
25-34	0	0	0	0	0	0	0	0	0	0	0	0	0
35-44	0	0	0	0	0	0	0	0	0	0	0	0	0
45-54	0	0	0	0	0	0	0	0	0	0	0	0	0
55-64	0	0	0	0	0	0	0	0	0	0	0	0	0
2014													
15-24	101	0	0	5	2	4	1	2	9	13	17	29	35
25-34	136	0	0	2	4	6	8	13	10	16	10	34	48
35-44	71	0	0	2	2	3	1	9	5	2	6	17	31
45-54	65	0	0	0	1	3	6	2	6	12	11	16	20
55-64	25	0	0	0	2	0	1	2	1	3	5	4	8

Table 1c. Number of Overall Mixed Amphetamine Salt (MAS) Users Over Time, by Month-Year and Age Group in the Sentinel Distributed Database (SDD) from January 1, 2013 to December 31, 2019¹

Product Group	Total Overall Users	January	February	March	April	May	June	July	August	September	October	November	December
2015													
15-24	128	36	17	12	6	20	41	8	7	2	0	0	0
25-34	162	34	13	15	7	30	70	7	1	1	2	0	1
35-44	118	19	9	9	10	17	47	8	2	3	1	0	4
45-54	69	15	3	6	5	14	24	7	4	1	1	1	1
55-64	33	11	3	3	1	3	9	4	1	0	0	0	1
2016													
15-24	622	1	16	40	27	34	35	33	98	127	114	102	123
25-34	766	5	12	31	50	29	37	43	138	158	116	148	146
35-44	592	7	20	44	28	21	33	32	90	116	101	96	135
45-54	420	1	9	30	30	14	20	29	73	78	66	80	91
55-64	205	1	5	17	8	12	16	10	24	48	39	39	53
2017													
15-24	1,338	127	122	126	165	153	82	77	167	196	208	198	189
25-34	1,779	182	129	158	191	160	122	92	192	273	284	295	261
35-44	1,332	113	98	123	139	139	92	79	169	199	235	220	215
45-54	950	81	58	77	101	112	63	55	121	139	156	169	160
55-64	505	39	28	45	51	55	37	26	64	77	105	85	79
2018													
15-24	2,150	278	438	246	127	91	82	66	64	34	316	447	429
25-34	3,190	405	666	290	131	99	99	66	53	40	535	695	620
35-44	2,615	341	497	223	104	70	86	52	41	30	442	605	564
45-54	1,644	213	319	150	76	53	63	46	29	24	327	371	338
55-64	1,028	121	177	84	36	39	33	21	19	13	177	264	241
2019													
15-24	2,011	498	471	426	155	82	73	79	102	82	100	112	375
25-34	3,079	788	767	596	181	106	103	109	71	51	76	148	652
35-44	2,671	669	646	503	159	98	79	73	50	63	46	141	675
45-54	1,669	426	388	307	115	64	51	48	37	43	32	87	438
55-64	1,028	260	259	177	63	32	24	26	26	26	15	50	286
Non-202424													
2013													
15-24	42,459	7,949	5,911	5,895	6,216	5,414	5,005	6,283	8,196	7,129	7,242	6,330	6,329
25-34	43,083	7,205	5,848	5,986	6,366	6,415	6,265	7,726	7,930	7,175	7,623	6,807	7,026
35-44	24,809	4,101	3,464	3,463	3,827	3,673	3,599	4,504	4,584	4,259	4,456	3,940	4,306
45-54	15,675	2,433	2,155	2,239	2,399	2,397	2,311	2,894	2,927	2,691	2,841	2,581	2,720
55-64	7,235	1,095	978	1,002	1,089	1,048	1,070	1,254	1,341	1,253	1,262	1,195	1,324

Table 1c. Number of Overall Mixed Amphetamine Salt (MAS) Users Over Time, by Month-Year and Age Group in the Sentinel Distributed Database (SDD) from January 1, 2013 to December 31, 2019¹

Product Group	Total Overall Users	January	February	March	April	May	June	July	August	September	October	November	December
2014													
15-24	40,022	7,118	6,102	6,461	6,245	5,356	5,265	5,562	6,203	5,964	6,211	5,360	5,924
25-34	46,264	7,206	7,011	7,269	6,936	6,972	6,905	7,417	6,848	7,373	7,353	6,556	7,850
35-44	26,906	4,184	4,047	4,378	4,045	4,072	4,087	4,377	4,131	4,302	4,400	3,907	4,662
45-54	16,609	2,606	2,593	2,688	2,622	2,645	2,546	2,778	2,539	2,725	2,775	2,380	3,040
55-64	7,645	1,167	1,100	1,222	1,113	1,143	1,124	1,179	1,212	1,196	1,232	1,121	1,396
2015													
15-24	36,316	6,552	5,106	5,496	5,475	4,491	4,460	5,079	6,367	6,054	6,221	5,490	5,442
25-34	46,687	7,250	6,499	7,012	6,794	6,545	7,105	7,968	7,752	8,307	8,262	7,579	7,937
35-44	27,745	4,263	3,777	4,232	4,108	3,926	4,217	4,629	4,663	4,827	4,984	4,562	4,944
45-54	16,764	2,642	2,265	2,543	2,361	2,381	2,523	2,819	2,912	3,002	3,070	2,871	3,129
55-64	7,906	1,162	1,040	1,201	1,174	1,163	1,185	1,419	1,351	1,378	1,458	1,367	1,458
2016													
15-24	32,575	5,907	5,461	5,903	4,510	3,677	3,734	3,840	5,483	4,802	4,613	4,447	4,165
25-34	48,074	7,490	7,526	8,334	6,841	6,412	6,439	7,147	8,047	7,633	7,196	7,269	7,091
35-44	30,255	4,535	4,569	5,327	4,308	4,095	4,214	4,632	5,163	5,008	4,811	4,624	4,908
45-54	18,050	2,624	2,701	3,400	2,680	2,366	2,475	2,763	3,226	3,001	2,864	2,774	2,895
55-64	8,663	1,252	1,309	1,567	1,277	1,170	1,189	1,294	1,504	1,389	1,359	1,326	1,369
2017													
15-24	31,492	4,131	3,474	3,803	3,558	3,451	3,078	3,321	4,990	5,936	6,161	5,812	4,912
25-34	50,033	6,211	5,721	6,369	5,756	6,088	6,091	6,467	7,752	9,902	9,939	9,164	8,359
35-44	33,652	4,013	3,833	4,300	3,751	4,113	4,156	4,414	5,239	6,968	6,955	6,299	5,984
45-54	20,129	2,418	2,121	2,500	2,282	2,403	2,411	2,572	3,158	4,145	4,251	3,931	3,800
55-64	9,839	1,091	1,040	1,154	1,091	1,141	1,099	1,274	1,491	2,051	2,172	1,906	1,916
2018													
15-24	37,730	6,456	5,436	5,412	4,902	4,646	4,754	5,733	6,733	5,734	6,144	5,857	5,617
25-34	59,776	10,099	8,833	8,642	7,901	8,238	8,867	10,604	10,155	9,399	10,010	9,188	9,650
35-44	42,216	6,993	6,409	6,213	5,507	5,805	6,329	7,572	7,530	7,002	7,251	6,899	7,030
45-54	25,337	4,376	3,902	3,756	3,432	3,528	3,872	4,614	4,512	4,077	4,396	4,177	4,299
55-64	13,061	2,136	1,973	1,961	1,712	1,764	1,884	2,322	2,348	2,071	2,379	2,166	2,229
2019													
15-24	34,722	6,537	4,493	4,830	4,728	4,895	4,795	5,255	6,052	5,349	5,540	4,362	4,874
25-34	58,411	10,299	7,503	8,496	8,228	9,413	9,747	10,070	9,210	9,004	9,988	7,538	8,847
35-44	44,104	7,648	5,645	6,547	6,334	7,126	7,367	7,608	7,030	7,197	7,696	5,969	7,209
45-54	25,667	4,457	3,444	3,914	3,676	4,178	4,352	4,539	4,065	4,167	4,560	3,547	4,125
55-64	13,702	2,270	1,810	2,031	1,950	2,184	2,256	2,297	2,214	2,211	2,515	1,982	2,363

Table 1c. Number of Overall Mixed Amphetamine Salt (MAS) Users Over Time, by Month-Year and Age Group in the Sentinel Distributed Database (SDD) from January 1, 2013 to December 31, 2019¹

Product Group	Total Overall Users	January	February	March	April	May	June	July	August	September	October	November	December
Non-040440													
2013													
15-24	42,459	7,949	5,911	5,895	6,216	5,414	5,005	6,283	8,196	7,129	7,242	6,330	6,329
25-34	43,083	7,205	5,848	5,986	6,366	6,415	6,265	7,726	7,930	7,175	7,623	6,807	7,026
35-44	24,808	4,101	3,464	3,463	3,827	3,673	3,599	4,504	4,584	4,259	4,456	3,940	4,305
45-54	15,675	2,433	2,155	2,239	2,399	2,397	2,311	2,894	2,927	2,691	2,841	2,581	2,720
55-64	7,235	1,095	978	1,002	1,089	1,048	1,070	1,254	1,341	1,253	1,262	1,195	1,324
2014													
15-24	41,231	7,006	5,998	6,352	6,175	5,313	5,238	5,917	6,922	6,646	6,984	6,115	6,374
25-34	47,097	7,109	6,919	7,169	6,865	7,006	6,937	7,934	7,571	7,998	7,915	7,187	8,153
35-44	27,486	4,121	3,993	4,301	4,011	4,094	4,111	4,649	4,532	4,652	4,781	4,289	4,944
45-54	16,970	2,566	2,553	2,621	2,574	2,646	2,545	2,934	2,760	2,960	3,036	2,628	3,228
55-64	7,788	1,154	1,081	1,186	1,104	1,146	1,120	1,240	1,288	1,290	1,339	1,242	1,435
2015													
15-24	40,587	7,148	5,671	6,093	6,197	5,055	5,258	5,803	7,329	7,077	7,181	6,328	6,216
25-34	51,020	7,794	7,101	7,643	7,501	7,219	8,000	8,932	8,691	9,313	9,332	8,424	8,801
35-44	30,455	4,618	4,124	4,592	4,536	4,337	4,769	5,156	5,218	5,495	5,632	5,065	5,566
45-54	18,526	2,861	2,516	2,767	2,659	2,654	2,918	3,173	3,274	3,390	3,467	3,254	3,487
55-64	8,764	1,284	1,169	1,326	1,287	1,279	1,375	1,566	1,527	1,574	1,660	1,517	1,649
2016													
15-24	38,787	6,822	6,276	7,054	5,492	4,575	4,717	4,844	6,979	6,077	5,823	5,652	5,108
25-34	55,023	8,394	8,444	9,801	7,910	7,533	7,763	8,539	9,609	9,010	8,628	8,726	8,244
35-44	34,721	5,101	5,178	6,273	5,059	4,859	5,069	5,572	6,223	5,968	5,752	5,568	5,577
45-54	20,878	3,001	3,005	4,000	3,157	2,876	3,079	3,342	3,783	3,618	3,461	3,406	3,380
55-64	10,008	1,420	1,490	1,847	1,521	1,405	1,427	1,569	1,773	1,721	1,627	1,585	1,652
2017													
15-24	45,239	5,380	4,730	5,962	5,895	6,523	5,533	6,096	9,134	8,251	8,705	8,141	6,881
25-34	65,224	7,552	7,261	9,340	9,055	10,492	9,473	10,321	12,226	12,197	12,145	11,449	10,428
35-44	43,726	4,862	4,824	6,314	6,007	7,273	6,521	6,893	8,313	8,646	8,513	7,955	7,447
45-54	27,088	2,951	2,808	3,819	3,739	4,429	3,961	4,250	5,131	5,405	5,438	5,022	4,832
55-64	13,437	1,321	1,343	1,840	1,922	2,202	1,878	2,169	2,505	2,614	2,709	2,532	2,447
2018													
15-24	44,576	7,776	6,164	6,396	6,295	6,383	6,138	6,917	8,689	7,434	8,127	7,644	6,550
25-34	64,779	10,263	8,724	9,588	9,647	10,681	10,833	12,019	11,847	11,136	12,365	11,019	10,198
35-44	45,470	7,041	6,182	6,929	6,689	7,556	7,824	8,601	8,527	8,147	8,824	8,195	7,516
45-54	27,625	4,529	3,822	4,248	4,234	4,540	4,858	5,362	5,182	5,022	5,379	5,136	4,746
55-64	14,127	2,189	1,912	2,158	2,019	2,320	2,444	2,658	2,609	2,495	2,857	2,583	2,449

Table 1c. Number of Overall Mixed Amphetamine Salt (MAS) Users Over Time, by Month-Year and Age Group in the Sentinel Distributed Database (SDD) from January 1, 2013 to December 31, 2019¹

Product Group	Total Overall Users	January	February	March	April	May	June	July	August	September	October	November	December
2019													
15-24	39,614	7,687	6,223	6,200	6,223	5,617	4,784	6,031	7,171	6,300	6,642	5,406	5,424
25-34	62,346	11,029	9,997	9,997	10,116	9,905	8,942	11,196	10,553	10,168	11,403	8,945	9,215
35-44	46,858	7,994	7,390	7,519	7,720	7,411	6,793	8,330	8,123	8,065	8,874	6,995	7,468
45-54	27,616	4,760	4,568	4,564	4,636	4,521	4,140	5,029	4,830	4,767	5,295	4,288	4,344
55-64	14,635	2,387	2,315	2,447	2,357	2,366	2,101	2,556	2,519	2,511	2,903	2,349	2,479
Non-040422													
2013													
15-24	7,154	940	696	688	632	646	1,100	806	1,199	979	796	717	736
25-34	8,537	970	799	741	728	823	1,716	1,010	1,364	1,118	924	823	864
35-44	4,930	538	444	449	446	454	934	648	824	683	540	486	572
45-54	3,277	337	285	259	318	328	593	433	549	443	392	352	394
55-64	1,592	164	133	162	155	149	319	196	245	234	173	182	210
2014													
15-24	14,153	1,010	907	887	962	980	955	1,794	2,698	2,382	2,671	2,616	2,053
25-34	17,221	1,375	1,154	1,079	1,167	1,273	1,295	2,746	3,212	2,869	2,913	2,986	2,498
35-44	10,411	842	749	691	680	851	870	1,624	2,077	1,730	1,829	1,789	1,589
45-54	6,587	573	471	452	490	547	539	1,044	1,120	1,089	1,196	1,175	1,046
55-64	3,249	259	222	223	223	246	280	493	622	514	616	574	538
2015													
15-24	12,307	2,008	1,462	1,592	1,613	1,335	1,530	1,538	1,815	1,944	1,891	1,627	1,548
25-34	15,753	2,293	1,863	1,972	1,964	1,812	2,173	2,325	2,258	2,428	2,527	2,050	2,191
35-44	9,937	1,415	1,169	1,254	1,207	1,161	1,381	1,395	1,422	1,610	1,603	1,291	1,458
45-54	6,137	895	741	763	780	693	839	910	880	982	980	874	877
55-64	3,099	416	371	380	368	366	437	450	433	482	507	431	484
2016													
15-24	13,868	1,646	1,637	2,328	1,868	1,624	1,650	1,684	2,375	2,130	2,034	2,016	1,784
25-34	19,558	2,047	2,271	3,390	2,626	2,442	2,552	2,897	2,990	2,874	2,893	2,833	2,631
35-44	13,160	1,347	1,549	2,422	1,860	1,678	1,806	1,960	2,025	2,002	2,038	1,963	1,825
45-54	7,987	835	910	1,483	1,133	1,042	1,111	1,155	1,197	1,242	1,214	1,256	1,139
55-64	4,055	426	493	684	568	505	570	583	607	652	612	592	601
2017													
15-24	28,162	2,101	1,962	3,000	3,249	4,075	3,351	3,656	5,731	5,191	4,921	5,037	4,476
25-34	39,700	2,822	2,788	4,405	4,797	6,168	5,288	5,795	7,188	7,218	6,603	6,990	6,947
35-44	27,098	1,887	1,938	3,143	3,359	4,432	3,686	3,969	4,915	5,073	4,613	4,859	5,015
45-54	17,044	1,122	1,176	1,990	2,114	2,782	2,324	2,452	3,106	3,202	2,975	3,043	3,179
55-64	8,815	552	570	1,011	1,197	1,431	1,158	1,332	1,552	1,659	1,524	1,614	1,655

Table 1c. Number of Overall Mixed Amphetamine Salt (MAS) Users Over Time, by Month-Year and Age Group in the Sentinel Distributed Database (SDD) from January 1, 2013 to December 31, 2019¹

Product Group	Total Overall Users	January	February	March	April	May	June	July	August	September	October	November	December
2018													
15-24	26,817	4,008	3,251	3,418	3,107	3,372	3,005	3,904	4,798	4,076	4,978	4,452	3,651
25-34	39,863	4,887	4,481	5,127	4,641	5,499	5,244	7,020	6,742	6,082	7,751	6,581	5,516
35-44	28,283	3,420	3,228	3,792	3,334	3,844	3,829	5,169	4,969	4,402	5,710	4,885	4,228
45-54	17,215	2,173	2,015	2,374	2,131	2,301	2,387	3,069	3,002	2,678	3,409	3,004	2,647
55-64	9,119	1,111	1,040	1,309	1,071	1,265	1,291	1,615	1,575	1,443	1,752	1,583	1,489
2019													
15-24	24,260	4,586	3,947	3,849	3,545	3,133	2,633	2,984	4,028	3,371	3,220	2,768	2,694
25-34	38,839	6,616	6,555	5,800	5,948	5,297	4,625	5,623	6,512	5,574	5,081	4,578	4,260
35-44	29,493	5,172	4,919	4,429	4,409	4,087	3,607	4,274	5,067	4,390	3,932	3,500	3,321
45-54	17,558	3,059	3,003	2,700	2,638	2,434	2,201	2,558	3,123	2,652	2,379	2,156	2,035
55-64	9,625	1,642	1,638	1,465	1,358	1,312	1,136	1,429	1,650	1,485	1,325	1,171	1,187
Non-040439													
2013													
15-24	40,414	7,381	5,565	5,527	5,879	5,114	4,555	6,148	7,563	6,725	6,871	5,935	5,928
25-34	42,473	6,931	5,629	5,790	6,174	6,251	5,800	8,056	7,581	7,027	7,465	6,570	6,739
35-44	24,245	3,875	3,307	3,309	3,649	3,546	3,295	4,577	4,322	4,103	4,363	3,777	4,054
45-54	15,098	2,309	2,037	2,134	2,243	2,257	2,075	2,856	2,747	2,578	2,728	2,414	2,519
55-64	6,862	1,023	916	912	1,013	970	931	1,250	1,251	1,155	1,193	1,092	1,199
2014													
15-24	39,692	6,591	5,733	6,155	5,901	5,108	5,082	5,779	6,809	6,420	6,630	5,783	6,124
25-34	45,920	6,698	6,723	7,040	6,652	6,810	6,754	7,804	7,402	7,663	7,587	6,902	7,950
35-44	26,754	3,858	3,858	4,253	3,913	3,950	4,009	4,516	4,437	4,474	4,588	4,098	4,758
45-54	16,370	2,361	2,470	2,576	2,479	2,539	2,442	2,817	2,745	2,835	2,902	2,535	3,098
55-64	7,406	1,035	1,019	1,155	1,041	1,094	1,076	1,185	1,231	1,219	1,275	1,176	1,340
2015													
15-24	39,260	6,745	5,481	5,957	5,988	4,893	5,026	5,615	7,069	6,850	6,954	6,117	6,061
25-34	49,790	7,431	6,978	7,535	7,333	7,025	7,784	8,755	8,463	9,041	9,078	8,244	8,605
35-44	29,400	4,360	4,030	4,426	4,380	4,193	4,520	5,008	5,066	5,311	5,394	4,903	5,390
45-54	17,838	2,716	2,423	2,655	2,572	2,562	2,784	3,062	3,154	3,283	3,356	3,150	3,373
55-64	8,347	1,199	1,106	1,283	1,192	1,223	1,291	1,498	1,478	1,509	1,575	1,430	1,573
2016													
15-24	37,779	6,601	6,054	6,726	5,314	4,399	4,484	4,663	6,836	5,979	5,668	5,516	4,967
25-34	54,297	8,207	8,191	9,366	7,869	7,345	7,551	8,389	9,679	8,991	8,480	8,569	8,137
35-44	34,239	4,954	5,000	5,907	5,002	4,704	4,873	5,425	6,332	5,947	5,644	5,445	5,483
45-54	20,458	2,910	2,905	3,722	3,123	2,759	2,929	3,260	3,884	3,599	3,349	3,346	3,261
55-64	9,786	1,338	1,421	1,699	1,473	1,321	1,320	1,542	1,809	1,705	1,587	1,543	1,613

Table 1c. Number of Overall Mixed Amphetamine Salt (MAS) Users Over Time, by Month-Year and Age Group in the Sentinel Distributed Database (SDD) from January 1, 2013 to December 31, 2019¹

Product Group	Total Overall Users	January	February	March	April	May	June	July	August	September	October	November	December
2017													
15-24	43,843	5,191	4,614	5,833	5,772	6,434	5,480	6,018	8,931	7,937	8,231	7,551	6,219
25-34	64,181	7,322	7,238	9,250	8,948	10,409	9,454	10,218	12,106	11,977	11,619	10,986	9,671
35-44	42,933	4,734	4,748	6,218	5,889	7,161	6,487	6,809	8,212	8,480	8,134	7,602	6,930
45-54	26,453	2,858	2,710	3,757	3,680	4,367	3,918	4,160	5,073	5,323	5,154	4,789	4,532
55-64	13,107	1,277	1,314	1,793	1,867	2,179	1,868	2,128	2,464	2,595	2,571	2,407	2,248
2018													
15-24	43,218	7,268	5,878	6,132	6,396	6,680	6,065	6,345	8,503	6,992	7,529	7,104	6,075
25-34	64,273	9,991	8,700	9,375	9,911	11,328	10,738	11,068	12,068	10,679	11,723	10,697	9,740
35-44	45,178	7,023	6,203	6,675	6,806	8,054	7,813	8,033	8,748	7,893	8,367	7,978	7,261
45-54	27,425	4,400	3,889	4,081	4,267	4,898	4,891	4,955	5,341	4,793	5,121	4,901	4,526
55-64	14,032	2,159	1,891	2,083	2,057	2,482	2,446	2,455	2,677	2,421	2,734	2,488	2,397
2019													
15-24	37,810	7,399	5,837	5,869	6,050	5,392	4,789	5,572	6,699	5,997	6,114	4,938	4,764
25-34	61,162	11,407	9,534	9,666	10,296	9,765	9,153	10,707	10,328	9,866	10,743	8,360	8,411
35-44	45,980	8,419	7,071	7,315	7,905	7,405	6,962	8,049	8,009	7,846	8,397	6,654	6,839
45-54	27,010	4,985	4,350	4,412	4,674	4,462	4,213	4,865	4,625	4,591	4,946	3,999	3,984
55-64	14,202	2,440	2,216	2,343	2,414	2,335	2,140	2,438	2,456	2,433	2,647	2,227	2,280
Non-040480													
2013													
15-24	42,459	7,949	5,911	5,895	6,216	5,414	5,005	6,283	8,196	7,129	7,242	6,330	6,329
25-34	43,083	7,205	5,848	5,986	6,366	6,415	6,265	7,726	7,930	7,175	7,623	6,807	7,026
35-44	24,809	4,101	3,464	3,463	3,827	3,673	3,599	4,504	4,584	4,259	4,456	3,940	4,306
45-54	15,675	2,433	2,155	2,239	2,399	2,397	2,311	2,894	2,927	2,691	2,841	2,581	2,720
55-64	7,235	1,095	978	1,002	1,089	1,048	1,070	1,254	1,341	1,253	1,262	1,195	1,324
2014													
15-24	41,785	7,118	6,102	6,460	6,265	5,422	5,358	6,070	7,187	6,788	7,128	6,222	6,431
25-34	47,433	7,206	7,011	7,269	6,973	7,064	7,007	8,047	7,674	8,020	7,984	7,232	8,169
35-44	27,759	4,184	4,047	4,377	4,067	4,156	4,172	4,724	4,656	4,708	4,862	4,353	4,934
45-54	17,166	2,606	2,593	2,688	2,640	2,698	2,592	3,018	2,849	3,003	3,082	2,695	3,263
55-64	7,882	1,167	1,100	1,222	1,118	1,165	1,151	1,277	1,345	1,308	1,388	1,278	1,465
2015													
15-24	40,864	7,214	5,697	6,195	6,264	5,097	5,246	5,845	7,390	7,144	7,260	6,381	6,284
25-34	51,235	7,802	7,123	7,693	7,558	7,232	7,998	8,985	8,729	9,363	9,407	8,485	8,868
35-44	30,591	4,613	4,147	4,633	4,578	4,372	4,741	5,190	5,272	5,555	5,687	5,090	5,613
45-54	18,683	2,873	2,526	2,800	2,693	2,670	2,911	3,212	3,305	3,452	3,521	3,293	3,530
55-64	8,848	1,283	1,172	1,349	1,297	1,300	1,381	1,588	1,546	1,604	1,692	1,534	1,671

Table 1c. Number of Overall Mixed Amphetamine Salt (MAS) Users Over Time, by Month-Year and Age Group in the Sentinel Distributed Database (SDD) from January 1, 2013 to December 31, 2019¹

Product Group	Total Overall Users	January	February	March	April	May	June	July	August	September	October	November	December
2016													
15-24	38,772	6,881	6,323	7,100	5,517	4,581	4,704	4,847	6,968	6,042	5,801	5,654	5,111
25-34	55,039	8,458	8,512	9,853	7,932	7,545	7,757	8,579	9,602	8,993	8,652	8,682	8,259
35-44	34,821	5,169	5,221	6,321	5,094	4,873	5,082	5,602	6,229	5,969	5,781	5,610	5,604
45-54	20,897	3,048	3,067	4,036	3,180	2,896	3,078	3,346	3,798	3,629	3,471	3,411	3,368
55-64	10,029	1,438	1,519	1,845	1,532	1,400	1,431	1,592	1,796	1,714	1,635	1,601	1,642
2017													
15-24	45,338	5,364	4,697	5,943	5,852	6,517	5,605	6,168	9,206	8,501	8,620	8,105	6,780
25-34	65,389	7,516	7,274	9,335	9,024	10,496	9,593	10,446	12,341	12,616	11,996	11,425	10,221
35-44	43,856	4,884	4,854	6,332	5,999	7,291	6,599	7,005	8,365	8,907	8,368	7,871	7,295
45-54	27,182	2,937	2,804	3,839	3,729	4,426	4,032	4,314	5,206	5,599	5,383	5,007	4,761
55-64	13,532	1,339	1,357	1,845	1,925	2,194	1,921	2,224	2,535	2,739	2,674	2,519	2,405
2018													
15-24	44,660	7,758	6,096	6,548	6,413	6,557	6,164	7,035	8,880	7,468	8,092	7,482	6,464
25-34	64,398	10,202	8,761	9,805	9,785	10,878	10,809	12,008	11,833	10,883	12,134	10,771	10,120
35-44	45,128	7,034	6,192	7,056	6,778	7,681	7,810	8,668	8,568	7,925	8,614	8,021	7,390
45-54	27,502	4,523	3,887	4,381	4,289	4,650	4,876	5,345	5,264	4,852	5,291	5,019	4,692
55-64	14,054	2,176	1,904	2,264	2,072	2,375	2,449	2,677	2,646	2,436	2,784	2,523	2,413
2019													
15-24	39,771	7,770	5,980	6,159	6,403	5,778	5,112	6,033	7,361	6,401	6,607	5,405	5,360
25-34	61,934	11,219	9,616	9,839	10,488	10,128	9,345	10,932	10,642	10,063	11,136	8,860	9,079
35-44	46,329	8,142	7,052	7,468	8,013	7,595	7,071	8,168	8,193	7,927	8,608	6,933	7,307
45-54	27,439	4,862	4,398	4,577	4,761	4,633	4,324	4,975	4,862	4,737	5,140	4,231	4,257
55-64	14,488	2,390	2,250	2,393	2,489	2,434	2,205	2,533	2,551	2,470	2,783	2,321	2,404

¹Counts of prevalent users over time are reported in year month of the valid index date

Table 2a. Number of Overall Mixed Amphetamine Salt (MAS) Users Over Time of Episode Span, by Month-Year in the Sentinel Distributed Database (SDD) from January 1, 2013 to December 31, 2019¹

Product Group	Total Overall Users	January	February	March	April	May	June	July	August	September	October	November	December
ANDA 202424													
2013	0	0	0	0	0	0	0	0	0	0	0	0	0
2014	25,511	0	0	0	130	676	1,307	5,225	10,512	12,623	13,481	14,109	13,385
2015	34,305	10,453	10,030	10,298	10,502	10,538	10,977	11,938	12,420	13,315	13,855	13,527	12,906
2016	44,807	11,558	12,130	14,881	16,070	15,520	15,528	16,424	17,908	18,318	18,514	18,956	18,437
2017	104,893	15,852	17,197	23,397	29,372	37,446	40,286	42,353	49,054	50,615	49,117	49,130	48,507
2018	104,863	37,476	30,416	28,938	29,382	34,102	36,398	36,898	38,933	39,571	41,104	40,995	37,244
2019	93,807	31,203	34,054	36,883	37,955	36,935	28,769	25,719	28,616	29,952	29,197	28,230	25,945
ANDA 040440													
2013	1	0	0	0	0	0	0	0	0	0	0	0	1
2014	9,519	640	1,528	2,129	2,426	2,464	2,347	2,716	3,252	3,291	3,131	2,860	2,601
2015	5,218	1,806	1,325	1,265	1,293	1,292	1,122	1,054	1,068	1,164	1,269	1,190	1,145
2016	4,552	1,079	1,236	1,381	1,322	1,095	894	919	1,118	1,250	1,317	1,332	1,485
2017	11,869	1,353	1,307	1,434	1,421	1,540	1,820	2,115	2,733	4,690	5,474	4,736	4,141
2018	23,693	3,530	4,532	5,321	5,159	5,894	5,945	6,036	7,536	7,019	5,859	5,200	5,144
2019	30,440	7,839	8,477	6,579	5,689	6,067	8,658	9,630	9,119	9,354	7,172	4,479	3,412
ANDA 040422													
2013	126,690	21,519	35,839	40,632	44,048	46,525	45,607	50,724	56,987	58,675	60,380	59,652	59,017
2014	139,387	53,331	52,963	56,147	57,332	57,290	56,075	56,713	54,862	54,050	55,288	53,511	55,469
2015	138,141	53,037	53,135	54,987	56,269	55,870	55,241	57,415	60,815	63,568	65,343	65,268	65,630
2016	143,718	59,260	59,736	61,925	59,891	53,274	50,741	52,361	57,652	59,950	59,875	59,587	59,057
2017	138,233	49,700	48,280	50,026	49,446	49,784	49,310	50,046	54,331	60,007	67,865	70,801	68,616
2018	168,137	63,616	67,983	69,083	67,859	70,525	72,150	74,566	77,243	77,228	76,724	73,114	72,759
2019	166,425	67,397	62,942	62,793	65,678	69,160	71,445	75,159	74,756	72,255	75,430	72,332	69,479
ANDA 040439													
2013	25,229	2,949	4,951	5,382	5,375	5,695	8,086	8,708	8,421	9,021	8,092	7,139	7,018
2014	22,942	7,227	7,301	6,582	6,193	6,320	6,022	5,870	5,769	6,001	6,551	6,948	6,897
2015	15,842	6,123	5,595	4,754	4,559	4,431	4,472	4,663	4,725	4,940	5,195	5,022	4,729
2016	14,926	4,176	4,560	6,110	6,116	5,118	4,950	5,099	4,651	3,963	4,067	4,178	4,135
2017	23,307	3,981	4,075	3,924	3,877	3,913	3,768	3,824	4,661	7,856	9,933	10,558	12,847
2018	47,215	12,481	10,956	10,941	8,506	5,288	4,050	10,692	14,314	13,041	15,439	17,415	17,782
2019	53,209	16,023	14,096	13,661	12,422	12,510	13,315	14,289	15,719	15,800	14,799	13,092	13,270
ANDA 040480													
2013	0	0	0	0	0	0	0	0	0	0	0	0	0
2014	398	0	0	9	20	32	36	55	64	82	106	168	264
2015	634	277	191	122	82	125	280	242	73	28	15	10	11

Table 2a. Number of Overall Mixed Amphetamine Salt (MAS) Users Over Time of Episode Span, by Month-Year in the Sentinel Distributed Database (SDD) from January 1, 2013 to December 31, 2019¹

Product Group	Total Overall Users	January	February	March	April	May	June	July	August	September	October	November	December
2016	2,594	23	78	221	308	290	305	317	594	956	1,123	1,079	1,170
2017	6,266	1,195	1,187	1,302	1,473	1,641	1,388	1,012	1,175	1,696	2,154	2,262	2,387
2018	11,588	2,725	3,932	3,620	1,807	1,128	923	732	544	398	1,995	4,104	5,200
2019	12,308	5,752	6,423	6,079	4,024	1,813	1,037	872	739	676	676	936	3,071
Non-202424													
2013	130,754	22,783	37,732	42,720	46,210	48,673	48,621	53,147	59,640	61,859	63,391	62,545	62,076
2014	148,980	56,924	57,373	60,532	61,844	62,005	60,616	61,615	60,273	59,832	61,571	60,120	61,842
2015	148,273	58,409	57,857	59,117	60,341	59,926	59,282	61,551	65,025	68,061	70,216	70,061	70,056
2016	153,700	63,316	64,197	67,703	65,520	58,313	55,612	57,120	61,770	64,030	64,502	64,646	64,460
2017	160,085	54,776	53,465	55,458	55,093	55,649	54,942	55,696	61,472	72,145	81,752	84,669	83,639
2018	195,950	78,022	82,634	83,242	79,147	78,647	79,301	85,863	92,486	91,128	92,948	93,224	94,442
2019	197,552	88,859	83,896	81,620	80,908	83,143	86,956	91,428	91,075	88,883	90,287	85,285	84,227
Non-040440													
2013	130,753	22,783	37,732	42,720	46,210	48,673	48,621	53,147	59,640	61,859	63,391	62,545	62,075
2014	151,956	56,667	56,644	59,438	60,633	61,051	60,074	62,461	64,391	66,024	68,320	67,516	68,741
2015	163,059	64,308	64,076	65,675	67,301	67,029	66,961	69,866	73,833	77,556	80,170	79,867	79,371
2016	176,893	71,691	72,881	78,404	77,320	70,163	67,830	70,079	75,902	78,466	78,962	79,444	78,563
2017	211,480	66,837	67,092	74,805	80,045	87,897	89,521	91,956	102,703	110,528	116,345	118,923	117,084
2018	222,569	101,659	98,066	97,251	95,986	99,928	102,427	108,189	113,771	113,908	118,123	119,385	117,169
2019	218,172	104,072	101,524	102,425	103,214	103,855	99,681	101,108	104,445	103,802	106,101	103,003	99,780
Non-040422													
2013	25,230	2,949	4,951	5,382	5,375	5,695	8,086	8,708	8,421	9,021	8,092	7,139	7,019
2014	53,045	7,860	8,803	8,658	8,674	9,356	9,560	13,576	19,136	21,454	22,708	23,474	22,604
2015	52,287	18,247	16,768	16,139	16,168	16,115	16,512	17,587	17,989	19,146	20,034	19,487	18,545
2016	62,110	16,641	17,751	22,205	23,395	21,676	21,296	22,344	23,789	24,048	24,482	25,017	24,606
2017	124,794	21,830	23,324	29,605	35,612	43,756	46,278	48,295	56,175	61,726	62,745	62,595	63,387
2018	133,774	51,866	44,882	43,595	40,953	43,137	43,915	49,484	54,717	54,280	57,978	60,721	59,052
2019	131,964	53,593	55,179	55,780	53,285	51,218	45,997	44,769	48,875	50,758	47,743	43,535	41,637
Non-040439													
2013	126,691	21,519	35,839	40,632	44,048	46,525	45,607	50,724	56,987	58,675	60,380	59,652	59,018
2014	146,912	53,593	53,721	57,311	58,861	59,235	58,351	60,772	63,023	64,459	66,112	64,941	65,948
2015	157,531	61,247	61,142	63,257	64,980	64,813	64,544	67,379	71,243	74,850	77,285	77,005	76,727
2016	173,340	69,353	70,394	74,971	74,081	67,196	64,707	67,097	74,013	77,222	77,462	77,575	76,639
2017	206,897	65,096	65,228	72,951	78,212	86,085	88,067	90,591	101,118	108,580	112,484	114,214	111,233
2018	218,606	95,731	93,749	93,774	93,954	101,174	104,466	106,725	110,662	110,787	112,988	112,170	109,271
2019	211,838	99,358	98,107	98,396	100,091	100,954	97,592	98,767	100,641	99,779	100,907	96,918	92,539

Table 2a. Number of Overall Mixed Amphetamine Salt (MAS) Users Over Time of Episode Span, by Month-Year in the Sentinel Distributed Database (SDD) from January 1, 2013 to December 31, 2019¹

Product Group	Total Overall Users	January	February	March	April	May	June	July	August	September	October	November	December
Non-040480													
2013	130,754	22,783	37,732	42,720	46,210	48,673	48,621	53,147	59,640	61,859	63,391	62,545	62,076
2014	153,368	56,924	57,373	60,531	61,933	62,406	61,363	63,874	66,112	67,721	69,888	68,983	69,876
2015	164,093	64,867	64,489	66,163	67,871	67,632	67,277	70,182	74,339	78,193	80,933	80,627	80,072
2016	177,191	72,380	73,608	79,093	77,906	70,636	68,106	70,340	76,156	78,555	79,033	79,587	78,696
2017	212,114	66,895	67,138	74,792	79,983	87,756	89,853	92,853	103,841	112,588	117,848	119,844	117,428
2018	222,588	101,691	98,211	98,047	97,665	102,339	104,786	110,337	116,343	116,137	119,479	119,145	115,868
2019	217,807	103,576	101,143	101,477	103,639	105,576	102,990	104,621	107,396	106,803	107,975	103,904	99,627

¹Counts of prevalent users are estimated based on the entire treatment episode so the users would be counted in each year and month of the treatment episode duration.

Table 2b. Number of Overall Mixed Amphetamine Salt (MAS) Users Over Time of Episode Span, by Month-Year and Sex in the Sentinel Distributed Database (SDD) from January 1, 2013 to December 31, 2019¹

Product Group	Total Overall Users	January	February	March	April	May	June	July	August	September	October	November	December
ANDA 202424													
2013													
Female	0	0	0	0	0	0	0	0	0	0	0	0	0
Male	0	0	0	0	0	0	0	0	0	0	0	0	0
2014													
Female	13,898	0	0	0	64	364	733	2,827	5,675	6,853	7,323	7,724	7,376
Male	11,613	0	0	0	66	312	574	2,398	4,837	5,770	6,158	6,385	6,009
2015													
Female	18,578	5,686	5,433	5,588	5,652	5,744	5,979	6,535	6,823	7,275	7,486	7,313	7,039
Male	15,727	4,767	4,597	4,710	4,850	4,794	4,998	5,403	5,597	6,040	6,369	6,214	5,867
2016													
Female	24,666	6,280	6,548	8,124	8,831	8,503	8,536	9,044	9,794	10,035	10,088	10,367	10,101
Male	20,141	5,278	5,582	6,757	7,239	7,017	6,992	7,380	8,114	8,283	8,426	8,589	8,336
2017													
Female	56,862	8,729	9,370	12,704	15,919	20,310	21,878	23,023	26,639	27,461	26,566	26,540	26,222
Male	48,031	7,123	7,827	10,693	13,453	17,136	18,408	19,330	22,415	23,154	22,551	22,590	22,285
2018													
Female	56,648	20,225	16,271	15,526	15,816	18,401	19,708	20,057	20,957	21,293	22,158	22,132	20,117
Male	48,215	17,251	14,145	13,412	13,566	15,701	16,690	16,841	17,976	18,278	18,946	18,863	17,127
2019													
Female	50,600	16,859	18,429	19,971	20,441	19,885	15,459	13,869	15,413	16,055	15,585	15,056	13,929
Male	43,207	14,344	15,625	16,912	17,514	17,050	13,310	11,850	13,203	13,897	13,612	13,174	12,016
ANDA 040440													
2013													
Female	1	0	0	0	0	0	0	0	0	0	0	0	1
Male	0	0	0	0	0	0	0	0	0	0	0	0	0
2014													
Female	5,230	335	841	1,163	1,311	1,344	1,288	1,490	1,786	1,763	1,687	1,575	1,419
Male	4,289	305	687	966	1,115	1,120	1,059	1,226	1,466	1,528	1,444	1,285	1,182
2015													
Female	2,808	957	700	654	676	706	596	549	552	626	698	644	608
Male	2,410	849	625	611	617	586	526	505	516	538	571	546	537
2016													
Female	2,409	577	678	759	713	573	481	497	571	637	662	674	761
Male	2,143	502	558	622	609	522	413	422	547	613	655	658	724

Table 2b. Number of Overall Mixed Amphetamine Salt (MAS) Users Over Time of Episode Span, by Month-Year and Sex in the Sentinel Distributed Database (SDD) from January 1, 2013 to December 31, 2019¹

Product Group	Total Overall Users	January	February	March	April	May	June	July	August	September	October	November	December
2017													
Female	6,240	704	685	733	713	766	939	1,084	1,436	2,441	2,871	2,472	2,127
Male	5,629	649	622	701	708	774	881	1,031	1,297	2,249	2,603	2,264	2,014
2018													
Female	12,387	1,784	2,327	2,821	2,707	2,999	3,009	3,111	3,903	3,680	3,033	2,637	2,639
Male	11,306	1,746	2,205	2,500	2,452	2,895	2,936	2,925	3,633	3,339	2,826	2,563	2,505
2019													
Female	16,164	4,097	4,451	3,438	2,973	3,183	4,609	5,150	4,799	4,885	3,732	2,323	1,771
Male	14,276	3,742	4,026	3,141	2,716	2,884	4,049	4,480	4,320	4,469	3,440	2,156	1,641
ANDA 040422													
2013													
Female	68,494	11,606	19,317	21,979	23,997	25,402	24,983	27,700	31,070	31,957	32,850	32,440	32,189
Male	58,196	9,913	16,522	18,653	20,051	21,123	20,624	23,024	25,917	26,718	27,530	27,212	26,828
2014													
Female	75,450	28,853	28,538	30,426	30,887	30,822	30,434	30,977	30,033	29,641	30,243	29,131	30,273
Male	63,937	24,478	24,425	25,721	26,445	26,468	25,641	25,736	24,829	24,409	25,045	24,380	25,196
2015													
Female	75,009	28,888	28,901	29,975	30,630	30,420	30,255	31,499	33,238	34,716	35,684	35,590	35,869
Male	63,132	24,149	24,234	25,012	25,639	25,450	24,986	25,916	27,577	28,852	29,659	29,678	29,761
2016													
Female	78,516	32,290	32,476	33,633	32,646	29,145	27,904	28,964	31,873	33,000	32,979	32,775	32,505
Male	65,202	26,970	27,260	28,292	27,245	24,129	22,837	23,397	25,779	26,950	26,896	26,812	26,552
2017													
Female	75,321	27,222	26,310	27,350	26,988	27,193	27,006	27,514	29,799	32,845	37,022	38,540	37,497
Male	62,912	22,478	21,970	22,676	22,458	22,591	22,304	22,532	24,532	27,162	30,843	32,261	31,119
2018													
Female	91,212	34,665	36,968	37,572	37,055	38,516	39,514	40,932	42,268	42,117	41,841	39,840	39,734
Male	76,925	28,951	31,015	31,511	30,804	32,009	32,636	33,634	34,975	35,111	34,883	33,274	33,025
2019													
Female	90,744	36,737	34,199	34,236	35,985	37,951	39,220	41,411	41,212	39,728	41,497	39,673	38,149
Male	75,681	30,660	28,743	28,557	29,693	31,209	32,225	33,748	33,544	32,527	33,933	32,659	31,330
ANDA 040439													
2013													
Female	13,420	1,555	2,626	2,916	2,873	2,988	4,276	4,617	4,449	4,832	4,338	3,825	3,752
Male	11,809	1,394	2,325	2,466	2,502	2,707	3,810	4,091	3,972	4,189	3,754	3,314	3,266

Table 2b. Number of Overall Mixed Amphetamine Salt (MAS) Users Over Time of Episode Span, by Month-Year and Sex in the Sentinel Distributed Database (SDD) from January 1, 2013 to December 31, 2019¹

Product Group	Total Overall Users	January	February	March	April	May	June	July	August	September	October	November	December
2014													
Female	12,231	3,808	3,786	3,428	3,299	3,391	3,219	3,176	3,138	3,211	3,474	3,703	3,717
Male	10,711	3,419	3,515	3,154	2,894	2,929	2,803	2,694	2,631	2,790	3,077	3,245	3,180
2015													
Female	8,600	3,324	3,025	2,558	2,464	2,424	2,492	2,625	2,631	2,724	2,891	2,780	2,595
Male	7,242	2,799	2,570	2,196	2,095	2,007	1,980	2,038	2,094	2,216	2,304	2,242	2,134
2016													
Female	8,093	2,279	2,474	3,297	3,307	2,771	2,714	2,802	2,504	2,152	2,212	2,298	2,303
Male	6,833	1,897	2,086	2,813	2,809	2,347	2,236	2,297	2,147	1,811	1,855	1,880	1,832
2017													
Female	12,603	2,156	2,187	2,095	2,072	2,088	2,056	2,083	2,534	4,275	5,424	5,742	6,921
Male	10,704	1,825	1,888	1,829	1,805	1,825	1,712	1,741	2,127	3,581	4,509	4,816	5,926
2018													
Female	25,528	6,718	5,897	5,911	4,534	2,770	2,202	5,804	7,747	6,994	8,310	9,519	9,669
Male	21,687	5,763	5,059	5,030	3,972	2,518	1,848	4,888	6,567	6,047	7,129	7,896	8,113
2019													
Female	28,722	8,660	7,547	7,305	6,722	6,854	7,263	7,771	8,598	8,552	7,916	6,949	7,039
Male	24,487	7,363	6,549	6,356	5,700	5,656	6,052	6,518	7,121	7,248	6,883	6,143	6,231
ANDA 040480													
2013													
Female	0	0	0	0	0	0	0	0	0	0	0	0	0
Male	0	0	0	0	0	0	0	0	0	0	0	0	0
2014													
Female	203	0	0	2	10	19	21	33	39	43	48	86	136
Male	195	0	0	7	10	13	15	22	25	39	58	82	128
2015													
Female	338	147	104	69	41	72	145	121	40	15	8	5	6
Male	296	130	87	53	41	53	135	121	33	13	7	5	5
2016													
Female	1,383	10	48	127	166	152	156	178	322	508	595	550	615
Male	1,211	13	30	94	142	138	149	139	272	448	528	529	555
2017													
Female	3,314	616	627	694	756	845	739	536	620	912	1,159	1,185	1,256
Male	2,952	579	560	608	717	796	649	476	555	784	995	1,077	1,131

Table 2b. Number of Overall Mixed Amphetamine Salt (MAS) Users Over Time of Episode Span, by Month-Year and Sex in the Sentinel Distributed Database (SDD) from January 1, 2013 to December 31, 2019¹

Product Group	Total Overall Users	January	February	March	April	May	June	July	August	September	October	November	December
2018													
Female	6,121	1,467	2,099	1,954	984	604	493	402	290	206	1,076	2,149	2,709
Male	5,467	1,258	1,833	1,666	823	524	430	330	254	192	919	1,955	2,491
2019													
Female	6,558	3,014	3,359	3,191	2,134	999	567	487	412	354	353	513	1,656
Male	5,750	2,738	3,064	2,888	1,890	814	470	385	327	322	323	423	1,415
Non-202424													
2013													
Female	70,449	12,221	20,258	23,045	25,069	26,487	26,525	28,978	32,358	33,576	34,410	33,923	33,759
Male	60,305	10,562	17,474	19,675	21,141	22,186	22,096	24,169	27,282	28,283	28,981	28,622	28,317
2014													
Female	80,449	30,662	30,779	32,703	33,239	33,317	32,864	33,638	32,985	32,731	33,577	32,674	33,689
Male	68,531	26,262	26,594	27,829	28,605	28,688	27,752	27,977	27,288	27,101	27,994	27,446	28,153
2015													
Female	80,419	31,780	31,449	32,199	32,814	32,662	32,511	33,814	35,552	37,178	38,378	38,224	38,278
Male	67,854	26,629	26,408	26,918	27,527	27,264	26,771	27,737	29,473	30,883	31,838	31,837	31,778
2016													
Female	83,849	34,502	34,919	36,772	35,703	31,876	30,559	31,563	34,095	35,180	35,469	35,491	35,434
Male	69,851	28,814	29,278	30,931	29,817	26,437	25,053	25,557	27,675	28,850	29,033	29,155	29,026
2017													
Female	87,017	29,899	29,074	30,222	29,941	30,261	30,015	30,525	33,615	39,363	44,478	46,004	45,458
Male	73,068	24,877	24,391	25,236	25,152	25,388	24,927	25,171	27,857	32,782	37,274	38,665	38,181
2018													
Female	105,945	42,310	44,731	45,144	43,019	42,724	43,237	46,929	50,324	49,409	50,426	50,578	51,357
Male	90,005	35,712	37,903	38,098	36,128	35,923	36,064	38,934	42,162	41,719	42,522	42,646	43,085
2019													
Female	107,281	48,153	45,322	44,237	44,091	45,511	47,646	50,234	49,967	48,565	49,394	46,515	45,991
Male	90,271	40,706	38,574	37,383	36,817	37,632	39,310	41,194	41,108	40,318	40,893	38,770	38,236
Non-040440													
2013													
Female	70,448	12,221	20,258	23,045	25,069	26,487	26,525	28,978	32,358	33,576	34,410	33,923	33,758
Male	60,305	10,562	17,474	19,675	21,141	22,186	22,096	24,169	27,282	28,283	28,981	28,622	28,317
2014													
Female	82,057	30,527	30,374	32,094	32,580	32,773	32,555	34,092	35,163	36,094	37,251	36,630	37,451
Male	69,899	26,140	26,270	27,344	28,053	28,278	27,519	28,369	29,228	29,930	31,069	30,886	31,290

Table 2b. Number of Overall Mixed Amphetamine Salt (MAS) Users Over Time of Episode Span, by Month-Year and Sex in the Sentinel Distributed Database (SDD) from January 1, 2013 to December 31, 2019¹

Product Group	Total Overall Users	January	February	March	April	May	June	July	August	September	October	November	December
2015													
Female	88,352	34,938	34,791	35,742	36,592	36,533	36,686	38,371	40,453	42,387	43,704	43,480	43,341
Male	74,707	29,370	29,285	29,933	30,709	30,496	30,275	31,495	33,380	35,169	36,466	36,387	36,030
2016													
Female	96,547	39,035	39,605	42,626	42,220	38,417	37,314	38,723	41,814	43,109	43,366	43,603	43,192
Male	80,346	32,656	33,276	35,778	35,100	31,746	30,516	31,356	34,088	35,357	35,596	35,841	35,371
2017													
Female	114,751	36,527	36,501	40,716	43,517	47,807	48,771	50,256	56,023	60,229	63,313	64,530	63,625
Male	96,729	30,310	30,591	34,089	36,528	40,090	40,750	41,700	46,680	50,299	53,032	54,393	53,459
2018													
Female	120,387	55,089	53,083	52,662	52,159	54,352	55,855	59,191	61,924	61,800	64,198	64,869	63,791
Male	102,182	46,570	44,983	44,589	43,827	45,576	46,572	48,998	51,847	52,108	53,925	54,516	53,378
2019													
Female	118,511	56,579	55,020	55,650	56,261	56,704	54,521	55,513	57,256	56,689	57,795	55,960	54,367
Male	99,661	47,493	46,504	46,775	46,953	47,151	45,160	45,595	47,189	47,113	48,306	47,043	45,413
Non-040422													
2013													
Female	13,421	1,555	2,626	2,916	2,873	2,988	4,276	4,617	4,449	4,832	4,338	3,825	3,753
Male	11,809	1,394	2,325	2,466	2,502	2,707	3,810	4,091	3,972	4,189	3,754	3,314	3,266
2014													
Female	28,671	4,142	4,610	4,566	4,636	5,032	5,176	7,362	10,373	11,585	12,247	12,736	12,334
Male	24,374	3,718	4,193	4,092	4,038	4,324	4,384	6,214	8,763	9,869	10,461	10,738	10,270
2015													
Female	28,321	9,890	9,069	8,712	8,694	8,807	9,032	9,670	9,893	10,489	10,927	10,611	10,120
Male	23,966	8,357	7,699	7,427	7,474	7,308	7,480	7,917	8,096	8,657	9,107	8,876	8,425
2016													
Female	33,958	9,040	9,608	12,099	12,799	11,815	11,673	12,300	12,945	13,102	13,278	13,620	13,464
Male	28,152	7,601	8,143	10,106	10,596	9,861	9,623	10,044	10,844	10,946	11,204	11,397	11,142
2017													
Female	67,408	11,886	12,617	15,979	19,189	23,600	25,077	26,196	30,458	33,404	33,893	33,709	34,103
Male	57,386	9,944	10,707	13,626	16,423	20,156	21,201	22,099	25,717	28,322	28,852	28,886	29,284
2018													
Female	71,946	27,874	23,905	23,348	21,918	23,070	23,661	26,714	29,381	29,100	31,151	32,668	31,791
Male	61,828	23,992	20,977	20,247	19,035	20,067	20,254	22,770	25,336	25,180	26,827	28,053	27,261

Table 2b. Number of Overall Mixed Amphetamine Salt (MAS) Users Over Time of Episode Span, by Month-Year and Sex in the Sentinel Distributed Database (SDD) from January 1, 2013 to December 31, 2019¹

Product Group	Total Overall Users	January	February	March	April	May	June	July	August	September	October	November	December
2019													
Female	71,134	28,831	29,622	29,982	28,675	27,617	24,786	24,265	26,382	27,206	25,430	23,194	22,300
Male	60,830	24,762	25,557	25,798	24,610	23,601	21,211	20,504	22,493	23,552	22,313	20,341	19,337
Non-040439													
2013													
Female	68,495	11,606	19,317	21,979	23,997	25,402	24,983	27,700	31,070	31,957	32,850	32,440	32,190
Male	58,196	9,913	16,522	18,653	20,051	21,123	20,624	23,024	25,917	26,718	27,530	27,212	26,828
2014													
Female	79,475	28,988	28,962	31,069	31,704	31,897	31,701	33,207	34,453	35,257	36,075	35,309	35,930
Male	67,437	24,605	24,759	26,242	27,157	27,338	26,650	27,565	28,570	29,202	30,037	29,632	30,018
2015													
Female	85,415	33,276	33,214	34,441	35,320	35,318	35,328	36,936	38,953	40,869	42,114	41,882	41,861
Male	72,116	27,971	27,928	28,816	29,660	29,495	29,216	30,443	32,290	33,981	35,171	35,123	34,866
2016													
Female	94,549	37,708	38,224	40,736	40,440	36,754	35,568	37,062	40,744	42,377	42,472	42,499	42,033
Male	78,791	31,645	32,170	34,235	33,641	30,442	29,139	30,035	33,269	34,845	34,990	35,076	34,606
2017													
Female	112,233	35,548	35,455	39,678	42,476	46,771	47,913	49,476	55,120	59,108	61,159	61,910	60,393
Male	94,664	29,548	29,773	33,273	35,736	39,314	40,154	41,115	45,998	49,472	51,325	52,304	50,840
2018													
Female	118,127	51,794	50,686	50,766	51,064	54,935	56,805	58,279	60,085	60,026	61,317	60,811	59,335
Male	100,479	43,937	43,063	43,008	42,890	46,239	47,661	48,446	50,577	50,761	51,671	51,359	49,936
2019													
Female	114,951	53,842	53,050	53,425	54,438	54,963	53,277	54,123	55,016	54,348	54,943	52,691	50,493
Male	96,887	45,516	45,057	44,971	45,653	45,991	44,315	44,644	45,625	45,431	45,964	44,227	42,046
Non-040480													
2013													
Female	70,449	12,221	20,258	23,045	25,069	26,487	26,525	28,978	32,358	33,576	34,410	33,923	33,759
Male	60,305	10,562	17,474	19,675	21,141	22,186	22,096	24,169	27,282	28,283	28,981	28,622	28,317
2014													
Female	82,820	30,662	30,779	32,702	33,281	33,528	33,274	34,865	36,107	37,008	38,101	37,448	38,058
Male	70,548	26,262	26,594	27,829	28,652	28,878	28,089	29,009	30,005	30,713	31,787	31,535	31,818
2015													
Female	88,921	35,237	35,028	36,012	36,895	36,875	36,872	38,554	40,704	42,730	44,136	43,893	43,707
Male	75,172	29,630	29,461	30,151	30,976	30,757	30,405	31,628	33,635	35,463	36,797	36,734	36,365

Table 2b. Number of Overall Mixed Amphetamine Salt (MAS) Users Over Time of Episode Span, by Month-Year and Sex in the Sentinel Distributed Database (SDD) from January 1, 2013 to December 31, 2019¹

Product Group	Total Overall Users	January	February	March	April	May	June	July	August	September	October	November	December
2016													
Female	96,675	39,390	39,987	42,982	42,534	38,656	37,450	38,851	41,926	43,132	43,375	43,677	43,246
Male	80,516	32,990	33,621	36,111	35,372	31,980	30,656	31,489	34,230	35,423	35,658	35,910	35,450
2017													
Female	115,017	36,557	36,517	40,667	43,453	47,713	48,934	50,708	56,620	61,293	64,047	64,960	63,708
Male	97,097	30,338	30,621	34,125	36,530	40,043	40,919	42,145	47,221	51,295	53,801	54,884	53,720
2018													
Female	120,262	54,989	53,074	53,061	52,990	55,539	57,030	60,229	63,208	62,899	64,829	64,694	63,072
Male	102,326	46,702	45,137	44,986	44,675	46,800	47,756	50,108	53,135	53,238	54,650	54,451	52,796
2019													
Female	118,255	56,256	54,777	55,106	56,412	57,577	56,316	57,423	58,782	58,223	58,806	56,439	54,264
Male	99,552	47,320	46,366	46,371	47,227	47,999	46,674	47,198	48,614	48,580	49,169	47,465	45,363

¹Counts of prevalent users are estimated based on the entire treatment episode so the users would be counted in each year and month of the treatment episode duration.

Table 2c. Number of Overall Mixed Amphetamine Salt (MAS) Users Over Time of Episode Span by Month-Year and Age Group in the Sentinel Distributed Database (SDD) from January 1, 2013 to December 31, 2019¹

Product Group	Total Overall Users	January	February	March	April	May	June	July	August	September	October	November	December
ANDA 202424													
2013													
15-24	0	0	0	0	0	0	0	0	0	0	0	0	0
25-34	0	0	0	0	0	0	0	0	0	0	0	0	0
35-44	0	0	0	0	0	0	0	0	0	0	0	0	0
45-54	0	0	0	0	0	0	0	0	0	0	0	0	0
55-64	0	0	0	0	0	0	0	0	0	0	0	0	0
2014													
15-24	7,105	0	0	0	24	134	284	1,192	2,662	3,358	3,693	3,933	3,646
25-34	8,933	0	0	0	46	232	440	1,957	3,790	4,447	4,604	4,764	4,511
35-44	5,121	0	0	0	26	163	327	1,107	2,240	2,629	2,734	2,800	2,677
45-54	3,049	0	0	0	23	95	164	644	1,215	1,473	1,647	1,727	1,691
55-64	1,466	0	0	0	11	52	92	325	608	721	812	891	869
2015													
15-24	9,337	2,788	2,599	2,653	2,752	2,707	2,690	2,779	2,990	3,347	3,503	3,412	3,169
25-34	12,046	3,477	3,378	3,515	3,576	3,640	3,780	4,186	4,327	4,538	4,753	4,612	4,374
35-44	7,207	2,173	2,114	2,165	2,165	2,173	2,350	2,586	2,665	2,842	2,927	2,870	2,791
45-54	4,304	1,348	1,274	1,296	1,342	1,340	1,409	1,578	1,612	1,720	1,760	1,741	1,679
55-64	2,109	674	668	678	676	684	762	823	840	884	921	902	902
2016													
15-24	11,059	2,829	2,986	3,529	3,710	3,547	3,348	3,362	3,964	4,263	4,181	4,307	4,124
25-34	15,919	3,917	4,111	5,082	5,468	5,295	5,377	5,782	6,190	6,187	6,311	6,429	6,253
35-44	10,120	2,546	2,658	3,370	3,685	3,572	3,630	3,844	4,130	4,222	4,292	4,380	4,245
45-54	5,817	1,478	1,556	1,927	2,133	2,084	2,139	2,312	2,419	2,415	2,481	2,577	2,550
55-64	2,846	798	828	979	1,088	1,039	1,050	1,139	1,218	1,250	1,265	1,283	1,275
2017													
15-24	24,686	3,611	3,945	5,169	6,374	7,929	8,195	8,457	10,601	11,064	10,608	10,609	9,998
25-34	35,577	5,321	5,806	7,904	9,833	12,502	13,519	14,284	16,295	16,614	15,994	15,967	15,880
35-44	24,050	3,664	3,974	5,403	6,802	8,712	9,545	10,061	11,447	11,766	11,451	11,469	11,523
45-54	14,888	2,185	2,353	3,284	4,175	5,445	5,963	6,261	7,012	7,303	7,260	7,240	7,233
55-64	7,638	1,087	1,134	1,646	2,206	2,874	3,095	3,321	3,739	3,917	3,837	3,882	3,913
2018													
15-24	23,141	7,829	6,504	6,019	5,981	6,826	6,806	6,542	7,453	7,847	8,057	8,058	7,203
25-34	35,780	12,005	9,769	9,392	9,757	11,502	12,307	12,417	13,031	13,154	13,693	13,660	12,208
35-44	25,112	8,962	7,185	6,947	7,027	8,197	8,953	9,259	9,602	9,699	10,102	10,130	9,397
45-54	15,166	5,634	4,521	4,267	4,311	4,958	5,412	5,636	5,763	5,787	6,045	5,953	5,485
55-64	7,965	3,065	2,455	2,333	2,326	2,637	2,953	3,066	3,120	3,117	3,237	3,219	2,976

Table 2c. Number of Overall Mixed Amphetamine Salt (MAS) Users Over Time of Episode Span by Month-Year and Age Group in the Sentinel Distributed Database (SDD) from January 1, 2013 to December 31, 2019¹

Product Group	Total Overall Users	January	February	March	April	May	June	July	August	September	October	November	December
2019													
15-24	18,473	5,953	6,379	6,812	6,984	6,615	4,887	4,089	4,681	5,071	5,016	4,856	4,450
25-34	31,353	10,149	11,309	12,272	12,678	12,270	9,462	8,548	9,454	9,693	9,293	8,872	8,093
35-44	24,004	7,976	8,741	9,425	9,709	9,585	7,622	6,840	7,523	7,899	7,756	7,487	6,829
45-54	13,999	4,617	4,989	5,449	5,610	5,509	4,399	4,025	4,501	4,693	4,566	4,503	4,184
55-64	7,690	2,540	2,648	2,947	3,004	2,976	2,418	2,241	2,489	2,615	2,607	2,531	2,404
ANDA 040440													
2013													
15-24	0	0	0	0	0	0	0	0	0	0	0	0	0
25-34	0	0	0	0	0	0	0	0	0	0	0	0	0
35-44	1	0	0	0	0	0	0	0	0	0	0	0	1
45-54	0	0	0	0	0	0	0	0	0	0	0	0	0
55-64	0	0	0	0	0	0	0	0	0	0	0	0	0
2014													
15-24	2,447	155	377	525	615	624	567	634	817	873	821	756	649
25-34	3,026	212	491	681	767	760	715	863	1,002	973	875	756	717
35-44	2,080	147	340	454	509	530	515	608	714	713	693	649	595
45-54	1,378	93	234	327	375	396	372	409	467	476	472	447	410
55-64	667	33	86	143	163	157	178	205	253	258	271	252	230
2015													
15-24	1,270	466	358	332	344	336	265	231	227	240	265	249	241
25-34	1,590	493	373	373	393	379	344	342	324	341	378	347	342
35-44	1,163	404	277	262	262	271	243	224	249	278	290	271	261
45-54	791	280	202	188	196	202	176	160	171	196	227	216	195
55-64	442	164	115	110	98	104	95	97	97	109	109	107	106
2016													
15-24	860	224	219	272	249	207	164	133	169	223	222	222	254
25-34	1,348	329	377	389	383	324	243	255	322	342	365	355	414
35-44	1,174	248	295	336	323	262	232	250	284	315	358	360	396
45-54	785	177	223	254	244	195	167	168	203	226	227	240	263
55-64	455	102	122	131	124	107	89	113	140	144	146	156	161
2017													
15-24	2,235	236	235	257	259	277	311	351	489	880	1,014	854	706
25-34	3,817	370	357	405	397	427	540	627	830	1,499	1,777	1,524	1,306
35-44	2,900	343	334	359	349	378	444	540	681	1,115	1,297	1,148	1,046
45-54	1,886	245	223	253	257	288	327	368	466	761	834	737	684
55-64	1,107	160	159	160	159	171	198	229	267	436	553	473	401

Table 2c. Number of Overall Mixed Amphetamine Salt (MAS) Users Over Time of Episode Span by Month-Year and Age Group in the Sentinel Distributed Database (SDD) from January 1, 2013 to December 31, 2019¹

Product Group	Total Overall Users	January	February	March	April	May	June	July	August	September	October	November	December
2018													
15-24	4,101	575	733	869	939	1,052	984	987	1,232	1,144	983	889	823
25-34	7,515	1,099	1,420	1,655	1,545	1,796	1,881	1,861	2,274	2,097	1,742	1,526	1,521
35-44	6,139	922	1,205	1,395	1,297	1,467	1,428	1,540	1,966	1,834	1,535	1,350	1,360
45-54	3,891	595	757	908	865	973	1,034	1,039	1,310	1,213	1,005	904	890
55-64	2,250	340	419	494	515	607	618	611	755	734	599	532	553
2019													
15-24	4,866	1,176	1,228	995	893	936	1,375	1,475	1,344	1,391	1,118	714	539
25-34	9,850	2,429	2,570	1,929	1,694	1,864	2,729	3,118	2,887	2,920	2,195	1,345	999
35-44	8,075	2,119	2,321	1,779	1,525	1,617	2,303	2,546	2,509	2,529	1,880	1,170	917
45-54	5,026	1,358	1,486	1,158	1,003	1,048	1,436	1,581	1,477	1,554	1,254	792	589
55-64	2,888	757	877	721	576	605	820	917	904	964	727	458	370
ANDA 040422													
2013													
15-24	40,414	7,381	11,939	12,991	13,818	14,013	12,829	13,616	16,254	17,439	17,888	17,555	17,075
25-34	42,473	6,931	11,539	13,233	14,466	15,630	15,722	17,830	19,404	19,619	20,110	19,927	19,775
35-44	24,244	3,875	6,547	7,592	8,302	8,872	8,967	10,156	11,203	11,379	11,765	11,634	11,602
45-54	15,098	2,309	4,023	4,726	5,166	5,570	5,618	6,307	6,969	7,091	7,314	7,249	7,228
55-64	6,862	1,023	1,809	2,116	2,330	2,489	2,514	2,865	3,205	3,210	3,357	3,339	3,390
2014													
15-24	41,185	15,605	15,473	16,060	16,414	15,814	14,553	14,380	14,301	14,365	14,562	14,018	14,253
25-34	48,764	17,916	17,878	19,176	19,559	19,819	19,893	20,255	19,327	18,840	19,346	18,831	19,546
35-44	28,059	10,430	10,354	11,131	11,393	11,511	11,527	11,829	11,368	11,129	11,420	11,046	11,514
45-54	17,114	6,527	6,453	6,816	6,918	7,030	7,021	7,128	6,857	6,764	6,939	6,683	7,024
55-64	7,725	2,934	2,863	3,025	3,107	3,165	3,148	3,174	3,080	2,997	3,070	2,983	3,177
2015													
15-24	37,616	13,879	13,967	14,211	14,556	14,093	12,944	13,015	14,605	15,682	16,064	15,950	15,721
25-34	49,797	18,480	18,727	19,514	19,891	19,822	20,137	21,088	21,772	22,587	23,262	23,090	23,167
35-44	29,188	11,089	11,005	11,430	11,817	11,948	12,010	12,548	13,109	13,554	13,913	13,935	14,175
45-54	17,309	6,668	6,542	6,760	6,846	6,821	6,959	7,334	7,726	8,024	8,246	8,352	8,568
55-64	7,991	2,981	2,943	3,116	3,216	3,247	3,270	3,511	3,678	3,790	3,929	3,995	4,083
2016													
15-24	34,698	14,255	14,520	14,755	13,848	11,534	10,191	10,081	11,597	12,399	12,265	12,223	11,807
25-34	52,295	20,851	21,199	21,970	21,316	19,257	18,604	19,273	20,816	21,424	21,496	21,447	21,283
35-44	32,314	12,960	12,979	13,489	13,170	12,120	11,937	12,502	13,567	14,043	14,072	13,940	13,949
45-54	18,992	7,642	7,516	8,002	7,846	7,005	6,767	7,120	7,925	8,212	8,178	8,130	8,125
55-64	9,089	3,638	3,579	3,768	3,764	3,400	3,294	3,444	3,827	3,951	3,922	3,911	3,937

Table 2c. Number of Overall Mixed Amphetamine Salt (MAS) Users Over Time of Episode Span by Month-Year and Age Group in the Sentinel Distributed Database (SDD) from January 1, 2013 to December 31, 2019¹

Product Group	Total Overall Users	January	February	March	April	May	June	July	August	September	October	November	December
2017													
15-24	29,562	10,103	9,758	9,958	9,816	9,690	8,974	8,784	10,086	11,288	12,755	13,417	12,649
25-34	50,204	17,757	17,429	18,190	17,999	18,240	18,201	18,532	19,797	21,460	23,993	24,822	24,093
35-44	33,302	11,935	11,627	12,089	11,866	12,038	12,249	12,566	13,421	14,935	16,865	17,555	17,134
45-54	19,301	6,793	6,456	6,679	6,661	6,676	6,743	6,873	7,474	8,343	9,599	10,122	9,931
55-64	9,096	3,167	3,062	3,158	3,153	3,184	3,197	3,353	3,614	4,042	4,712	4,965	4,869
2018													
15-24	34,397	11,725	12,509	12,747	12,588	12,793	12,365	12,395	13,491	13,615	13,469	12,930	12,682
25-34	59,161	22,074	23,505	23,907	23,529	24,566	25,266	26,135	26,658	26,330	26,116	24,682	24,611
35-44	41,725	15,915	17,080	17,400	16,979	17,771	18,479	19,275	19,854	19,970	19,832	18,875	18,925
45-54	24,480	9,344	9,977	10,013	9,827	10,241	10,684	11,145	11,359	11,351	11,342	10,860	10,840
55-64	12,467	4,629	4,976	5,084	4,993	5,210	5,427	5,679	5,963	6,022	6,046	5,834	5,772
2019													
15-24	31,336	11,725	10,882	10,442	10,705	10,979	10,679	11,071	11,784	11,945	12,120	11,462	10,762
25-34	57,906	22,879	21,580	21,674	22,537	23,791	24,745	26,134	25,666	24,439	25,394	24,305	23,338
35-44	43,782	17,618	16,465	16,599	17,572	18,657	19,556	20,576	20,257	19,569	20,595	19,729	19,183
45-54	24,719	9,975	9,302	9,356	9,816	10,366	10,843	11,525	11,253	10,695	11,303	10,938	10,448
55-64	13,019	5,280	4,790	4,775	5,115	5,440	5,687	5,924	5,878	5,684	6,082	5,954	5,802
ANDA 040439													
2013													
15-24	7,154	940	1,529	1,579	1,536	1,553	1,996	2,133	2,236	2,478	2,220	1,982	1,908
25-34	8,537	970	1,640	1,788	1,749	1,883	2,860	3,028	2,761	2,951	2,593	2,303	2,228
35-44	4,929	538	923	1,038	1,040	1,115	1,612	1,781	1,695	1,792	1,605	1,383	1,393
45-54	3,277	337	586	644	696	769	1,062	1,168	1,148	1,193	1,108	967	960
55-64	1,592	164	274	335	358	381	557	602	585	613	571	508	533
2014													
15-24	6,300	1,846	1,843	1,717	1,658	1,678	1,501	1,362	1,414	1,538	1,734	1,931	1,852
25-34	7,604	2,396	2,450	2,159	2,039	2,093	2,003	1,952	1,837	1,885	2,067	2,155	2,116
35-44	4,676	1,467	1,500	1,378	1,263	1,284	1,279	1,266	1,228	1,270	1,338	1,398	1,422
45-54	3,023	1,001	1,005	866	818	857	825	844	818	814	897	938	960
55-64	1,610	519	509	467	417	410	417	450	475	498	518	530	551
2015													
15-24	4,025	1,589	1,440	1,196	1,112	1,054	967	979	1,050	1,138	1,146	1,114	1,019
25-34	5,091	1,957	1,780	1,460	1,360	1,336	1,380	1,447	1,450	1,491	1,567	1,489	1,410
35-44	3,468	1,261	1,157	1,020	1,032	1,006	1,051	1,091	1,080	1,125	1,221	1,174	1,102
45-54	2,244	838	780	692	671	658	692	729	735	761	796	777	734
55-64	1,250	482	441	389	387	378	385	420	412	430	466	468	467

Table 2c. Number of Overall Mixed Amphetamine Salt (MAS) Users Over Time of Episode Span by Month-Year and Age Group in the Sentinel Distributed Database (SDD) from January 1, 2013 to December 31, 2019¹

Product Group	Total Overall Users	January	February	March	April	May	June	July	August	September	October	November	December
2016													
15-24	3,270	924	968	1,228	1,240	1,032	950	952	951	848	832	846	834
25-34	4,560	1,212	1,382	1,854	1,834	1,536	1,443	1,491	1,339	1,128	1,137	1,197	1,180
35-44	3,615	977	1,063	1,488	1,509	1,256	1,237	1,276	1,143	1,001	1,032	1,051	1,044
45-54	2,370	644	715	1,001	995	820	810	857	761	614	675	685	699
55-64	1,339	421	433	543	541	475	513	527	461	374	393	404	381
2017													
15-24	5,411	779	790	791	775	758	695	670	939	1,790	2,279	2,483	2,819
25-34	7,582	1,201	1,244	1,114	1,089	1,079	1,083	1,131	1,379	2,509	3,199	3,335	4,189
35-44	5,373	1,013	1,042	1,009	982	1,034	1,008	995	1,153	1,818	2,272	2,345	2,940
45-54	3,407	634	644	646	642	640	619	660	768	1,120	1,426	1,554	1,903
55-64	1,785	360	358	365	392	406	368	373	425	623	765	845	1,000
2018													
15-24	10,032	2,718	2,455	2,330	1,692	971	778	1,933	2,731	2,654	3,058	3,416	3,459
25-34	16,010	4,130	3,621	3,593	2,723	1,597	1,281	3,761	4,838	4,244	5,173	5,809	5,960
35-44	11,309	2,843	2,489	2,549	2,021	1,335	1,000	2,571	3,473	3,154	3,757	4,300	4,385
45-54	6,932	1,832	1,575	1,618	1,355	905	641	1,557	2,115	1,906	2,251	2,542	2,607
55-64	3,627	962	820	854	718	480	353	870	1,162	1,087	1,207	1,356	1,382
2019													
15-24	10,743	3,261	2,896	2,656	2,470	2,487	2,417	2,515	2,987	3,004	2,800	2,554	2,572
25-34	17,948	5,319	4,617	4,486	4,061	4,143	4,481	4,837	5,168	5,106	4,816	4,346	4,516
35-44	13,226	3,860	3,388	3,356	3,051	3,067	3,339	3,633	3,930	4,011	3,666	3,141	3,169
45-54	7,839	2,314	2,027	2,036	1,856	1,815	1,993	2,116	2,333	2,377	2,238	1,943	1,942
55-64	4,313	1,275	1,171	1,130	988	1,002	1,091	1,193	1,304	1,307	1,285	1,117	1,078
ANDA 040480													
2013													
15-24	0	0	0	0	0	0	0	0	0	0	0	0	0
25-34	0	0	0	0	0	0	0	0	0	0	0	0	0
35-44	0	0	0	0	0	0	0	0	0	0	0	0	0
45-54	0	0	0	0	0	0	0	0	0	0	0	0	0
55-64	0	0	0	0	0	0	0	0	0	0	0	0	0
2014													
15-24	101	0	0	5	7	9	6	5	13	22	31	48	70
25-34	136	0	0	2	6	11	17	25	24	26	29	53	90
35-44	71	0	0	2	4	6	3	11	15	9	12	24	47
45-54	65	0	0	0	1	4	9	11	9	20	26	34	44
55-64	25	0	0	0	2	2	1	3	3	5	8	9	13

Table 2c. Number of Overall Mixed Amphetamine Salt (MAS) Users Over Time of Episode Span by Month-Year and Age Group in the Sentinel Distributed Database (SDD) from January 1, 2013 to December 31, 2019¹

Product Group	Total Overall Users	January	February	March	April	May	June	July	August	September	October	November	December
2015													
15-24	163	76	57	38	19	28	61	52	18	10	4	2	0
25-34	203	92	59	37	23	41	99	81	17	2	3	2	1
35-44	143	50	30	23	21	29	65	57	12	6	4	2	5
45-54	88	40	29	15	12	20	39	36	18	7	3	3	3
55-64	41	19	16	9	7	7	16	16	8	3	1	1	2
2016													
15-24	622	1	17	55	70	75	79	72	135	228	265	251	267
25-34	766	6	17	43	83	87	88	89	185	293	321	314	329
35-44	596	11	27	61	75	58	68	74	129	210	266	249	273
45-54	421	2	10	39	54	49	41	51	106	154	181	174	199
55-64	206	3	8	23	26	21	29	31	39	72	90	91	102
2017													
15-24	1,433	262	281	316	342	391	309	210	266	383	458	446	477
25-34	1,889	358	357	383	436	466	381	285	320	488	628	656	676
35-44	1,429	270	267	298	330	355	318	238	280	396	499	536	576
45-54	1,022	202	191	203	242	288	247	185	204	281	358	400	429
55-64	546	103	91	103	123	143	133	95	106	148	212	224	229
2018													
15-24	2,334	533	787	782	431	301	229	178	148	101	366	749	938
25-34	3,502	790	1,205	1,086	498	296	252	192	126	95	581	1,192	1,510
35-44	2,852	659	970	851	429	250	207	167	120	93	486	1,035	1,338
45-54	1,843	475	617	569	279	171	146	125	94	68	363	692	851
55-64	1,141	268	353	332	173	110	89	71	58	41	199	436	566
2019													
15-24	2,348	1,023	1,111	1,120	777	368	211	196	199	207	220	247	517
25-34	3,671	1,682	1,904	1,818	1,210	527	307	262	205	167	168	256	824
35-44	3,178	1,467	1,671	1,558	1,000	441	265	216	166	148	145	219	843
45-54	1,997	948	1,041	964	638	305	161	130	116	99	93	138	542
55-64	1,259	635	698	619	400	172	93	68	53	56	50	76	345
Non-202424													
2013													
15-24	42,459	7,949	12,758	13,851	14,674	14,833	13,804	14,560	17,405	18,815	19,172	18,753	18,278
25-34	43,083	7,205	11,939	13,704	14,926	16,086	16,531	18,280	19,894	20,261	20,703	20,533	20,407
35-44	24,809	4,101	6,888	7,955	8,684	9,237	9,515	10,559	11,605	11,883	12,220	12,079	12,127
45-54	15,675	2,433	4,239	4,962	5,457	5,893	6,038	6,706	7,346	7,489	7,725	7,640	7,643
55-64	7,235	1,095	1,927	2,279	2,505	2,679	2,777	3,098	3,447	3,481	3,630	3,597	3,679

Table 2c. Number of Overall Mixed Amphetamine Salt (MAS) Users Over Time of Episode Span by Month-Year and Age Group in the Sentinel Distributed Database (SDD) from January 1, 2013 to December 31, 2019¹

Product Group	Total Overall Users	January	February	March	April	May	June	July	August	September	October	November	December
2014													
15-24	44,541	16,881	16,912	17,510	17,887	17,345	15,957	15,774	15,935	16,167	16,525	16,128	16,200
25-34	51,389	18,820	19,101	20,365	20,834	21,092	21,120	21,595	20,785	20,401	21,063	20,573	21,286
35-44	29,798	11,076	11,168	11,929	12,182	12,389	12,399	12,808	12,441	12,253	12,644	12,345	12,747
45-54	18,422	7,000	7,056	7,414	7,567	7,741	7,724	7,901	7,640	7,565	7,790	7,602	7,944
55-64	8,525	3,238	3,198	3,378	3,442	3,496	3,487	3,600	3,548	3,501	3,606	3,531	3,719
2015													
15-24	40,593	15,554	15,444	15,476	15,744	15,225	13,983	14,037	15,674	16,818	17,268	17,122	16,775
25-34	52,687	19,998	20,052	20,600	20,982	20,947	21,289	22,239	22,939	23,824	24,608	24,426	24,391
35-44	31,316	12,110	11,914	12,283	12,680	12,810	12,902	13,469	14,037	14,547	15,008	14,990	15,169
45-54	18,862	7,377	7,166	7,332	7,432	7,402	7,557	7,979	8,396	8,745	9,007	9,117	9,274
55-64	8,867	3,444	3,337	3,473	3,567	3,605	3,638	3,908	4,059	4,203	4,398	4,462	4,538
2016													
15-24	37,360	15,244	15,537	16,021	15,116	12,667	11,230	11,062	12,599	13,427	13,347	13,374	13,004
25-34	55,085	21,937	22,455	23,583	22,889	20,701	19,933	20,603	21,946	22,526	22,711	22,790	22,741
35-44	34,539	13,894	14,003	14,859	14,494	13,286	13,124	13,659	14,482	14,953	15,182	15,159	15,253
45-54	20,684	8,273	8,240	8,989	8,810	7,843	7,582	7,927	8,592	8,877	8,970	8,989	9,052
55-64	9,999	4,060	4,024	4,318	4,267	3,860	3,802	3,940	4,238	4,334	4,354	4,405	4,460
2017													
15-24	35,157	11,187	10,905	11,166	11,044	10,944	10,113	9,881	11,596	14,040	15,928	16,618	16,053
25-34	56,706	19,155	18,858	19,665	19,551	19,802	19,746	20,111	21,854	25,184	28,267	29,033	28,655
35-44	38,164	13,161	12,864	13,400	13,199	13,455	13,643	13,982	15,140	17,722	20,021	20,656	20,548
45-54	22,692	7,659	7,330	7,601	7,639	7,713	7,736	7,879	8,676	10,189	11,681	12,261	12,278
55-64	11,082	3,673	3,565	3,679	3,715	3,786	3,761	3,912	4,273	5,080	5,928	6,192	6,178
2018													
15-24	41,865	14,990	15,849	15,913	15,052	14,586	13,901	14,760	16,752	16,752	17,031	17,165	17,165
25-34	68,075	26,541	28,094	28,243	26,830	26,840	27,385	29,711	31,417	30,557	31,230	30,999	31,404
35-44	47,913	19,195	20,417	20,667	19,618	19,651	20,119	21,858	23,395	23,175	23,592	23,689	24,173
45-54	28,578	11,575	12,177	12,210	11,688	11,628	11,878	12,928	13,763	13,489	13,806	13,952	14,196
55-64	14,725	5,809	6,170	6,291	6,033	6,003	6,106	6,684	7,259	7,224	7,390	7,504	7,610
2019													
15-24	39,356	16,224	15,209	14,302	13,988	14,042	13,832	14,276	15,274	15,517	15,370	14,337	13,833
25-34	67,628	29,484	27,926	27,370	27,141	28,087	29,663	31,293	30,651	29,478	29,955	28,357	27,951
35-44	50,910	22,770	21,541	21,138	21,199	21,938	23,293	24,538	24,167	23,568	24,039	22,653	22,636
45-54	29,529	13,337	12,583	12,348	12,218	12,521	13,227	14,046	13,753	13,255	13,597	12,936	12,760
55-64	15,721	7,148	6,735	6,526	6,447	6,644	7,029	7,372	7,338	7,161	7,413	7,077	7,118

Table 2c. Number of Overall Mixed Amphetamine Salt (MAS) Users Over Time of Episode Span by Month-Year and Age Group in the Sentinel Distributed Database (SDD) from January 1, 2013 to December 31, 2019¹

Product Group	Total Overall Users	January	February	March	April	May	June	July	August	September	October	November	December
Non-040440													
2013													
15-24	42,459	7,949	12,758	13,851	14,674	14,833	13,804	14,560	17,405	18,815	19,172	18,753	18,278
25-34	43,083	7,205	11,939	13,704	14,926	16,086	16,531	18,280	19,894	20,261	20,703	20,533	20,407
35-44	24,808	4,101	6,888	7,955	8,684	9,237	9,515	10,559	11,605	11,883	12,220	12,079	12,126
45-54	15,675	2,433	4,239	4,962	5,457	5,893	6,038	6,706	7,346	7,489	7,725	7,640	7,643
55-64	7,235	1,095	1,927	2,279	2,505	2,679	2,777	3,098	3,447	3,481	3,630	3,597	3,679
2014													
15-24	45,710	16,793	16,700	17,190	17,541	17,017	15,745	15,955	17,108	17,999	18,637	18,496	18,428
25-34	52,237	18,741	18,878	20,062	20,479	20,857	21,023	21,991	22,283	22,530	23,232	22,878	23,403
35-44	30,360	11,025	11,014	11,713	11,955	12,213	12,313	13,000	13,262	13,502	13,960	13,768	14,088
45-54	18,766	6,970	6,952	7,239	7,370	7,583	7,608	7,965	8,101	8,255	8,602	8,480	8,766
55-64	8,679	3,228	3,161	3,298	3,352	3,433	3,454	3,613	3,718	3,799	3,960	3,965	4,124
2015													
15-24	45,301	17,368	17,293	17,396	17,806	17,249	16,070	16,200	18,080	19,500	20,085	19,883	19,340
25-34	57,466	21,788	22,002	22,727	23,184	23,261	23,773	25,030	25,817	26,880	27,827	27,609	27,349
35-44	34,323	13,315	13,171	13,600	14,090	14,261	14,516	15,208	15,864	16,514	17,050	16,996	17,127
45-54	20,812	8,121	7,938	8,135	8,299	8,299	8,562	9,069	9,540	9,961	10,273	10,386	10,497
55-64	9,785	3,801	3,739	3,880	4,001	4,029	4,142	4,456	4,624	4,798	5,026	5,063	5,158
2016													
15-24	44,106	17,536	17,945	18,847	18,133	15,637	14,089	13,968	16,037	17,120	16,951	17,088	16,482
25-34	62,777	24,624	25,277	27,099	26,786	24,581	24,042	24,989	26,677	27,204	27,445	27,712	27,422
35-44	39,534	15,707	15,843	17,180	17,093	15,933	15,868	16,596	17,674	18,206	18,418	18,420	18,325
45-54	23,773	9,333	9,319	10,366	10,352	9,430	9,305	9,790	10,462	10,774	10,919	10,974	10,994
55-64	11,459	4,598	4,575	4,990	5,030	4,648	4,599	4,822	5,154	5,276	5,314	5,345	5,395
2017													
15-24	49,594	14,230	14,328	15,734	16,726	18,027	17,485	17,514	21,019	23,019	24,187	24,876	23,892
25-34	73,121	23,102	23,350	26,096	27,779	30,398	31,135	32,132	35,205	37,349	39,043	39,641	39,192
35-44	49,003	15,810	15,875	17,722	18,841	20,822	21,674	22,364	24,543	26,383	27,756	28,318	28,032
45-54	30,138	9,318	9,187	10,301	11,180	12,436	12,886	13,293	14,601	15,843	16,881	17,372	17,260
55-64	14,878	4,454	4,428	5,018	5,595	6,283	6,438	6,763	7,443	8,060	8,588	8,854	8,832
2018													
15-24	50,652	20,886	20,224	19,723	19,160	19,487	18,811	19,260	21,714	22,243	22,882	23,165	22,421
25-34	76,376	33,693	32,624	32,481	32,278	33,828	34,962	37,026	38,313	37,902	39,324	39,394	38,478
35-44	53,295	24,420	23,574	23,615	23,312	24,550	25,561	27,153	28,236	28,256	29,358	29,765	29,533
45-54	32,325	15,099	14,375	14,265	14,138	14,633	15,291	16,338	16,810	16,752	17,461	17,746	17,561
55-64	16,507	7,699	7,381	7,290	7,203	7,524	7,916	8,533	8,843	8,863	9,238	9,447	9,313

Table 2c. Number of Overall Mixed Amphetamine Salt (MAS) Users Over Time of Episode Span by Month-Year and Age Group in the Sentinel Distributed Database (SDD) from January 1, 2013 to December 31, 2019¹

Product Group	Total Overall Users	January	February	March	April	May	June	July	August	September	October	November	December
2019													
15-24	45,639	20,091	19,403	19,007	18,879	18,478	16,593	16,375	18,027	18,605	18,626	17,824	16,974
25-34	73,955	34,105	33,663	34,184	34,400	34,735	33,559	34,315	34,852	34,114	34,763	33,707	32,599
35-44	55,472	26,227	25,594	26,010	26,474	26,904	26,322	26,801	27,419	27,194	28,003	27,201	26,508
45-54	32,511	15,509	15,026	15,298	15,475	15,628	15,225	15,553	15,870	15,635	16,074	15,731	15,270
55-64	17,218	8,298	7,951	8,022	8,106	8,241	8,094	8,196	8,423	8,379	8,765	8,640	8,520
Non-040422													
2013													
15-24	7,154	940	1,529	1,579	1,536	1,553	1,996	2,133	2,236	2,478	2,220	1,982	1,908
25-34	8,537	970	1,640	1,788	1,749	1,883	2,860	3,028	2,761	2,951	2,593	2,303	2,228
35-44	4,930	538	923	1,038	1,040	1,115	1,612	1,781	1,695	1,792	1,605	1,383	1,394
45-54	3,277	337	586	644	696	769	1,062	1,168	1,148	1,193	1,108	967	960
55-64	1,592	164	274	335	358	381	557	602	585	613	571	508	533
2014													
15-24	14,700	2,001	2,215	2,233	2,273	2,416	2,334	3,145	4,830	5,673	6,166	6,512	6,114
25-34	17,888	2,603	2,930	2,816	2,826	3,048	3,116	4,692	6,482	7,140	7,388	7,519	7,232
35-44	10,810	1,613	1,836	1,823	1,788	1,953	2,089	2,915	4,090	4,505	4,649	4,746	4,619
45-54	6,842	1,093	1,233	1,188	1,204	1,334	1,346	1,872	2,440	2,719	2,962	3,077	3,031
55-64	3,402	552	595	604	588	610	678	960	1,301	1,428	1,558	1,630	1,622
2015													
15-24	13,928	4,829	4,372	4,160	4,172	4,077	3,922	3,997	4,243	4,683	4,863	4,727	4,383
25-34	17,661	5,875	5,457	5,281	5,258	5,297	5,478	5,938	6,008	6,259	6,592	6,360	6,046
35-44	11,184	3,800	3,504	3,412	3,431	3,418	3,631	3,884	3,931	4,173	4,361	4,239	4,087
45-54	6,970	2,455	2,241	2,151	2,184	2,188	2,276	2,460	2,495	2,655	2,752	2,713	2,590
55-64	3,573	1,299	1,200	1,147	1,135	1,142	1,223	1,327	1,329	1,398	1,477	1,458	1,451
2016													
15-24	14,973	3,946	4,156	5,021	5,201	4,803	4,485	4,472	5,160	5,500	5,434	5,559	5,380
25-34	21,097	5,398	5,804	7,240	7,643	7,118	7,034	7,496	7,891	7,819	7,959	8,129	7,957
35-44	14,265	3,734	3,973	5,153	5,470	5,054	5,063	5,332	5,554	5,615	5,791	5,889	5,796
45-54	8,639	2,278	2,467	3,156	3,363	3,112	3,094	3,304	3,398	3,344	3,475	3,590	3,613
55-64	4,454	1,299	1,362	1,647	1,737	1,609	1,639	1,764	1,804	1,794	1,841	1,879	1,877
2017													
15-24	29,444	4,802	5,182	6,460	7,660	9,217	9,352	9,545	12,062	13,498	13,626	13,678	13,354
25-34	41,772	7,064	7,608	9,649	11,573	14,222	15,220	16,012	18,341	19,986	20,262	20,089	20,544
35-44	28,629	5,150	5,491	6,965	8,333	10,288	11,062	11,557	13,200	14,369	14,586	14,522	14,907
45-54	18,016	3,177	3,356	4,317	5,236	6,534	6,982	7,291	8,215	9,043	9,312	9,314	9,512
55-64	9,333	1,660	1,707	2,227	2,831	3,517	3,701	3,927	4,404	4,887	5,008	5,039	5,122

Table 2c. Number of Overall Mixed Amphetamine Salt (MAS) Users Over Time of Episode Span by Month-Year and Age Group in the Sentinel Distributed Database (SDD) from January 1, 2013 to December 31, 2019¹

Product Group	Total Overall Users	January	February	March	April	May	June	July	August	September	October	November	December
2018													
15-24	30,094	11,037	9,714	9,189	8,443	8,668	8,288	8,902	10,614	10,931	11,555	12,086	11,555
25-34	45,013	16,527	14,329	13,926	13,215	14,129	14,560	16,505	17,988	17,636	18,982	19,813	19,038
35-44	31,935	12,262	10,588	10,390	9,753	10,399	10,731	12,345	13,455	13,272	14,196	14,920	14,718
45-54	19,726	7,853	6,668	6,563	6,214	6,450	6,689	7,571	8,182	8,044	8,627	9,010	8,870
55-64	10,408	4,218	3,616	3,560	3,362	3,513	3,695	4,190	4,526	4,447	4,672	4,942	4,915
2019													
15-24	27,200	10,508	10,612	10,637	10,161	9,545	8,140	7,570	8,593	9,112	8,675	7,969	7,571
25-34	43,806	17,064	17,760	18,057	17,356	16,724	14,988	14,730	15,851	16,184	15,136	13,782	13,143
35-44	33,268	13,418	13,897	13,995	13,373	13,026	11,894	11,597	12,617	13,116	12,241	11,120	10,650
45-54	19,879	8,097	8,287	8,429	8,054	7,728	7,103	7,001	7,595	7,936	7,473	6,826	6,534
55-64	10,992	4,568	4,658	4,703	4,389	4,226	3,912	3,914	4,266	4,448	4,273	3,871	3,771
Non-040439													
2013													
15-24	40,414	7,381	11,939	12,991	13,818	14,013	12,829	13,616	16,254	17,439	17,888	17,555	17,075
25-34	42,473	6,931	11,539	13,233	14,466	15,630	15,722	17,830	19,404	19,619	20,110	19,927	19,775
35-44	24,245	3,875	6,547	7,592	8,302	8,872	8,967	10,156	11,203	11,379	11,765	11,634	11,603
45-54	15,098	2,309	4,023	4,726	5,166	5,570	5,618	6,307	6,969	7,091	7,314	7,249	7,228
55-64	6,862	1,023	1,809	2,116	2,330	2,489	2,514	2,865	3,205	3,210	3,357	3,339	3,390
2014													
15-24	43,867	15,693	15,691	16,394	16,836	16,351	15,158	15,427	16,680	17,522	17,903	17,603	17,499
25-34	50,891	17,999	18,110	19,508	20,024	20,374	20,557	21,551	21,913	22,082	22,561	22,106	22,597
35-44	29,507	10,482	10,514	11,360	11,680	11,921	12,002	12,683	13,025	13,203	13,581	13,327	13,593
45-54	18,112	6,557	6,564	6,998	7,169	7,346	7,385	7,712	7,901	8,073	8,349	8,187	8,434
55-64	8,224	2,944	2,901	3,112	3,215	3,296	3,318	3,462	3,582	3,639	3,786	3,785	3,892
2015													
15-24	43,660	16,400	16,362	16,668	17,151	16,641	15,463	15,573	17,398	18,792	19,343	19,158	18,698
25-34	55,914	20,889	21,166	22,064	22,562	22,651	23,098	24,365	25,105	26,104	27,025	26,817	26,629
35-44	33,123	12,730	12,609	13,082	13,575	13,765	13,945	14,641	15,285	15,924	16,383	16,352	16,529
45-54	19,986	7,754	7,568	7,817	7,992	8,010	8,206	8,675	9,146	9,561	9,879	9,974	10,108
55-64	9,309	3,553	3,501	3,689	3,774	3,816	3,931	4,220	4,396	4,559	4,746	4,774	4,856
2016													
15-24	42,921	16,932	17,331	18,075	17,346	14,946	13,421	13,293	15,462	16,676	16,499	16,575	15,990
25-34	61,818	24,013	24,574	26,124	25,882	23,729	23,169	24,154	26,165	26,896	27,058	27,190	26,887
35-44	38,880	15,172	15,276	16,362	16,347	15,260	15,136	15,906	17,268	17,970	18,121	18,030	17,919
45-54	23,225	9,000	8,967	9,823	9,859	8,960	8,793	9,298	10,220	10,604	10,667	10,668	10,652
55-64	11,139	4,337	4,323	4,660	4,721	4,363	4,258	4,524	4,994	5,188	5,199	5,203	5,247

Table 2c. Number of Overall Mixed Amphetamine Salt (MAS) Users Over Time of Episode Span by Month-Year and Age Group in the Sentinel Distributed Database (SDD) from January 1, 2013 to December 31, 2019¹

Product Group	Total Overall Users	January	February	March	April	May	June	July	August	September	October	November	December
2017													
15-24	48,091	13,802	13,867	15,282	16,299	17,634	17,179	17,232	20,628	22,420	23,094	23,507	22,261
25-34	71,875	22,579	22,825	25,590	27,291	29,933	30,766	31,761	34,779	36,811	37,854	38,262	37,377
35-44	48,070	15,425	15,451	17,268	18,384	20,341	21,258	21,996	24,172	25,947	26,933	27,329	26,855
45-54	29,416	9,026	8,855	10,003	10,892	12,135	12,634	13,035	14,319	15,560	16,337	16,685	16,427
55-64	14,505	4,338	4,301	4,872	5,420	6,104	6,325	6,672	7,328	7,963	8,367	8,562	8,430
2018													
15-24	48,887	19,223	18,838	18,663	18,601	19,617	19,038	18,778	20,766	21,221	21,443	21,373	20,469
25-34	75,165	31,802	31,206	31,385	31,675	34,296	35,606	36,417	37,159	36,784	37,588	37,065	35,945
35-44	52,743	23,299	22,861	22,974	22,888	24,888	26,104	26,959	27,712	27,738	28,268	28,148	27,769
45-54	31,855	14,225	13,851	13,805	13,813	14,805	15,676	16,205	16,494	16,434	16,856	16,744	16,412
55-64	16,318	7,308	7,100	7,057	7,074	7,661	8,150	8,472	8,673	8,715	8,963	8,961	8,791
2019													
15-24	43,405	18,543	18,182	17,884	17,897	17,527	15,903	15,647	16,842	17,405	17,320	16,401	15,341
25-34	72,050	32,629	32,576	32,767	33,423	33,816	32,930	33,537	33,721	32,962	33,206	31,760	30,241
35-44	54,205	25,401	25,034	25,256	25,901	26,420	25,964	26,424	26,706	26,370	26,833	25,876	24,894
45-54	31,700	14,955	14,697	14,814	15,058	15,257	14,977	15,262	15,364	15,073	15,361	14,867	14,214
55-64	16,698	7,971	7,729	7,767	7,922	8,056	7,930	8,022	8,149	8,090	8,306	8,099	7,934
Non-040480													
2013													
15-24	42,459	7,949	12,758	13,851	14,674	14,833	13,804	14,560	17,405	18,815	19,172	18,753	18,278
25-34	43,083	7,205	11,939	13,704	14,926	16,086	16,531	18,280	19,894	20,261	20,703	20,533	20,407
35-44	24,809	4,101	6,888	7,955	8,684	9,237	9,515	10,559	11,605	11,883	12,220	12,079	12,127
45-54	15,675	2,433	4,239	4,962	5,457	5,893	6,038	6,706	7,346	7,489	7,725	7,640	7,643
55-64	7,235	1,095	1,927	2,279	2,505	2,679	2,777	3,098	3,447	3,481	3,630	3,597	3,679
2014													
15-24	46,251	16,881	16,912	17,510	17,903	17,424	16,133	16,360	17,667	18,583	19,161	18,973	18,801
25-34	52,582	18,820	19,101	20,365	20,864	21,222	21,357	22,368	22,716	22,940	23,592	23,178	23,621
35-44	30,635	11,076	11,168	11,928	12,202	12,488	12,570	13,284	13,604	13,827	14,281	14,093	14,321
45-54	18,964	7,000	7,056	7,414	7,584	7,806	7,827	8,196	8,347	8,506	8,831	8,713	8,970
55-64	8,765	3,238	3,198	3,378	3,448	3,523	3,547	3,734	3,860	3,930	4,096	4,100	4,234
2015													
15-24	45,649	17,590	17,453	17,586	18,022	17,462	16,193	16,297	18,225	19,674	20,282	20,077	19,524
25-34	57,720	21,883	22,075	22,804	23,307	23,399	23,837	25,097	25,946	27,025	28,019	27,812	27,540
35-44	34,515	13,410	13,254	13,689	14,200	14,373	14,559	15,268	15,970	16,653	17,208	17,146	17,270
45-54	20,999	8,215	8,009	8,223	8,396	8,403	8,618	9,127	9,626	10,085	10,423	10,537	10,633
55-64	9,879	3,858	3,767	3,925	4,025	4,066	4,175	4,489	4,664	4,853	5,094	5,126	5,205

Table 2c. Number of Overall Mixed Amphetamine Salt (MAS) Users Over Time of Episode Span by Month-Year and Age Group in the Sentinel Distributed Database (SDD) from January 1, 2013 to December 31, 2019¹

Product Group	Total Overall Users	January	February	March	April	May	June	July	August	September	October	November	December
2016													
15-24	44,144	17,712	18,111	19,004	18,263	15,734	14,153	14,013	16,062	17,096	16,905	17,059	16,481
25-34	62,843	24,803	25,473	27,290	26,937	24,700	24,091	25,059	26,740	27,198	27,464	27,696	27,417
35-44	39,660	15,859	15,998	17,330	17,234	16,051	15,948	16,669	17,737	18,251	18,469	18,523	18,413
45-54	23,834	9,462	9,467	10,498	10,477	9,528	9,368	9,830	10,508	10,803	10,938	11,011	11,016
55-64	11,498	4,652	4,638	5,050	5,070	4,688	4,621	4,859	5,212	5,325	5,343	5,393	5,428
2017													
15-24	49,698	14,211	14,282	15,671	16,672	17,960	17,517	17,660	21,218	23,405	24,456	25,042	23,947
25-34	73,282	23,074	23,331	26,062	27,731	30,316	31,231	32,384	35,542	38,016	39,530	39,968	39,335
35-44	49,149	15,877	15,936	17,758	18,867	20,853	21,772	22,600	24,833	26,862	28,116	28,512	28,124
45-54	30,236	9,312	9,194	10,322	11,179	12,408	12,943	13,436	14,786	16,157	17,101	17,488	17,277
55-64	14,991	4,500	4,471	5,046	5,612	6,287	6,486	6,881	7,571	8,278	8,757	8,972	8,870
2018													
15-24	50,829	20,863	20,182	19,799	19,456	19,947	19,246	19,712	22,314	22,827	23,284	23,214	22,253
25-34	76,210	33,692	32,685	32,702	32,764	34,538	35,636	37,593	38,961	38,403	39,627	39,260	38,073
35-44	53,238	24,481	23,658	23,836	23,707	25,121	26,114	27,687	28,849	28,790	29,618	29,661	29,154
45-54	32,301	15,079	14,431	14,438	14,435	15,035	15,719	16,696	17,264	17,145	17,722	17,729	17,361
55-64	16,507	7,708	7,371	7,391	7,406	7,794	8,191	8,772	9,102	9,089	9,377	9,417	9,165
2019													
15-24	45,827	20,005	19,320	18,849	18,968	18,820	17,295	17,101	18,676	19,303	19,136	18,128	17,101
25-34	73,775	33,996	33,537	33,778	34,479	35,218	34,556	35,329	35,683	34,980	35,332	33,960	32,544
35-44	55,163	26,088	25,480	25,794	26,580	27,334	27,096	27,637	28,131	27,871	28,333	27,348	26,402
45-54	32,442	15,486	15,031	15,236	15,584	15,939	15,801	16,169	16,357	16,132	16,403	15,885	15,217
55-64	17,111	8,166	7,893	7,917	8,149	8,403	8,369	8,527	8,718	8,651	8,910	8,686	8,460

¹Counts of prevalent users are estimated based on the entire treatment episode so the users would be counted in each year and month of the treatment episode duration.

Table 3a. Number of Mixed Amphetamine Salt (MAS) Dispensings Over Time, by Month-Year in the Sentinel Distributed Database (SDD) from January 1, 2013 to December 31, 2019

Product Group	Total	January	February	March	April	May	June	July	August	September	October	November	December
ANDA 202424	1,128,181												
2013	0	0	0	0	0	0	0	0	0	0	0	0	0
2014	59,373	0	0	0	147	1,211	1,879	9,624	11,990	9,614	9,079	8,607	7,222
2015	98,354	7,750	7,515	7,503	7,241	6,829	8,522	9,309	9,044	9,710	9,216	7,761	7,954
2016	142,203	9,081	9,272	14,581	12,350	11,204	12,077	12,215	13,870	12,790	12,214	12,146	10,403
2017	329,493	12,927	14,310	27,878	34,276	42,445	30,048	29,642	33,034	27,890	27,566	26,833	22,644
2018	279,679	16,671	18,374	27,586	25,659	26,487	23,052	22,439	28,216	25,895	27,768	21,528	16,004
2019	219,079	22,652	28,353	24,394	24,453	17,648	11,595	19,592	19,941	16,348	15,245	11,724	7,134
ANDA 040440	151,437												
2013	1	0	0	0	0	0	0	0	0	0	0	0	1
2014	19,604	959	1,686	1,828	1,648	1,604	1,411	1,949	2,303	1,734	1,797	1,399	1,286
2015	9,425	1,036	730	913	840	744	672	756	722	873	786	656	697
2016	10,131	798	866	873	743	526	549	745	1,052	1,112	848	905	1,114
2017	21,439	1,056	864	982	952	1,135	1,592	1,644	2,110	3,693	2,755	2,764	1,892
2018	43,211	2,660	3,291	3,620	3,324	3,920	3,428	4,117	5,216	3,315	3,920	3,043	3,357
2019	47,626	6,594	3,592	3,506	3,877	4,276	6,036	4,588	5,406	4,450	2,510	1,630	1,161
ANDA 040422	3,666,201												
2013	507,974	49,495	39,666	37,189	39,785	36,211	34,574	53,089	50,678	46,194	46,740	37,237	37,116
2014	510,208	46,294	48,724	46,622	40,134	37,941	37,673	40,168	41,118	43,844	42,770	37,410	47,510
2015	529,494	49,582	44,089	44,561	42,477	38,220	40,385	46,858	47,956	48,766	45,561	40,549	40,490
2016	527,406	44,346	42,904	47,570	45,624	40,400	39,335	44,413	52,767	47,226	42,504	41,744	38,573
2017	514,265	40,393	40,128	41,178	36,454	37,767	37,334	40,663	47,240	52,094	53,622	46,227	41,165
2018	597,241	58,943	53,744	53,039	48,270	50,713	48,483	51,284	56,644	50,434	46,220	41,185	38,282
2019	479,613	48,468	40,552	45,719	45,722	45,559	41,370	44,191	38,719	40,498	41,458	26,066	21,291
ANDA 040439	427,110												
2013	58,244	5,376	4,227	3,945	3,817	3,833	6,415	5,349	6,558	5,560	4,721	4,176	4,267
2014	52,821	5,588	4,488	4,062	4,145	4,160	3,965	3,831	4,045	5,285	4,970	4,248	4,034
2015	39,710	4,514	3,256	3,134	3,385	2,776	3,215	3,247	3,400	3,581	3,487	2,808	2,907
2016	39,786	2,898	3,295	4,818	3,177	2,867	2,846	2,643	2,874	4,108	4,287	3,265	2,708
2017	51,353	3,459	2,625	2,491	2,429	2,265	2,619	2,894	3,636	8,073	6,399	6,519	7,944
2018	90,059	6,703	5,171	6,297	2,784	1,184	3,611	12,485	9,345	9,914	12,581	10,748	9,236
2019	95,137	8,557	7,781	7,671	6,452	8,092	8,336	9,394	9,829	8,656	8,165	6,392	5,812
ANDA 040480	55,764												
2013	0	0	0	0	0	0	0	0	0	0	0	0	0
2014	699	0	0	16	20	32	28	35	57	81	73	176	181
2015	691	136	57	57	38	102	221	38	20	8	5	1	8
2016	5,301	19	93	250	203	129	201	227	736	765	834	965	879

Table 3a. Number of Mixed Amphetamine Salt (MAS) Dispensings Over Time, by Month-Year in the Sentinel Distributed Database (SDD) from January 1, 2013 to December 31, 2019

Product Group	Total	January	February	March	April	May	June	July	August	September	October	November	December
2017	12,564	950	805	886	968	885	502	559	1,354	1,380	1,459	1,485	1,331
2018	19,978	1,753	2,534	1,219	656	446	471	341	275	197	3,817	4,700	3,569
2019	16,531	3,986	3,499	2,498	860	511	416	513	398	359	336	722	2,433
Non-202424	4,198,916												
2013	545,065	54,191	43,193	41,157	43,919	40,291	38,826	50,076	55,221	48,088	48,228	40,381	41,494
2014	561,912	52,856	52,065	50,029	44,612	41,705	41,054	44,977	46,535	48,686	47,985	41,489	49,919
2015	571,616	53,611	46,067	48,284	45,914	41,318	43,939	50,187	51,792	52,833	49,789	43,807	44,075
2016	576,646	48,504	48,103	55,093	47,233	42,793	42,854	47,613	55,535	51,705	47,362	46,493	43,358
2017	611,061	45,899	43,126	45,690	40,987	42,604	42,038	46,779	58,291	72,425	64,579	57,178	51,465
2018	739,662	71,455	66,047	60,682	53,626	55,575	59,366	68,182	69,548	61,982	63,847	56,963	52,389
2019	592,954	64,777	50,698	56,197	53,336	59,222	53,598	53,973	48,689	47,364	46,198	31,184	27,718
Non-040440	5,080,823												
2013	548,158	54,240	43,293	41,293	44,164	40,526	39,013	50,406	55,659	48,431	48,802	40,651	41,680
2014	605,984	53,359	53,131	51,627	46,347	45,264	45,179	51,312	53,407	54,423	53,302	46,004	52,629
2015	653,376	59,630	51,896	53,123	52,001	47,613	51,911	57,698	59,246	61,441	57,395	50,015	51,407
2016	709,489	57,643	57,975	70,509	57,778	52,850	54,199	58,296	68,161	63,604	58,227	57,838	52,409
2017	949,242	59,993	59,410	80,158	83,695	93,715	73,293	79,790	95,816	96,350	87,065	75,328	64,629
2018	916,044	76,847	67,375	74,015	72,338	79,976	80,258	88,358	86,253	80,662	81,324	69,510	59,128
2019	698,530	79,253	75,263	69,057	64,607	58,240	51,190	63,679	59,172	56,218	55,114	37,420	29,317
Non-040422	1,738,402												
2013	58,528	5,378	4,232	3,950	3,855	3,840	6,415	5,367	6,577	5,617	4,741	4,211	4,345
2014	133,732	6,763	6,421	6,100	6,082	7,049	7,643	15,597	18,796	16,916	15,776	14,125	12,464
2015	147,583	13,276	11,207	11,640	11,490	10,466	12,459	13,037	13,449	14,106	13,557	11,213	11,683
2016	200,136	13,002	13,989	21,163	16,392	14,617	15,605	15,764	19,026	19,466	18,401	17,474	15,237
2017	428,992	18,536	19,037	33,787	41,480	50,721	36,197	37,256	43,969	41,137	37,020	36,878	32,974
2018	428,620	27,015	27,756	36,535	31,232	33,439	32,531	42,145	42,045	39,726	48,839	37,208	30,149
2019	340,811	42,209	39,222	32,608	30,741	27,012	23,540	30,376	32,608	26,625	23,581	18,629	13,660
Non-040439	4,875,796												
2013	520,636	50,012	40,218	37,936	40,429	36,636	35,010	54,345	51,941	47,664	48,672	38,879	38,894
2014	582,721	50,622	52,807	50,748	44,296	43,680	44,117	49,785	51,744	51,018	50,021	43,715	50,168
2015	625,323	55,672	50,717	51,203	49,818	45,510	49,306	55,759	56,656	58,977	54,784	47,815	49,106
2016	687,169	54,938	54,781	64,597	57,644	51,319	52,353	57,398	68,222	62,901	56,271	55,708	51,037
2017	918,198	57,499	59,063	77,591	83,144	93,849	72,242	76,944	91,402	94,217	81,032	70,741	60,474
2018	870,095	75,332	67,291	71,282	73,100	80,025	72,631	75,101	84,520	72,390	74,258	66,609	57,556
2019	671,654	82,049	68,665	66,070	65,514	57,503	51,584	59,184	56,249	52,893	50,674	34,693	26,576

Table 3a. Number of Mixed Amphetamine Salt (MAS) Dispensings Over Time, by Month-Year in the Sentinel Distributed Database (SDD) from January 1, 2013 to December 31, 2019

Product Group	Total	January	February	March	April	May	June	July	August	September	October	November	December
Non-040480	5,145,952												
2013	553,940	54,519	43,599	41,668	44,474	40,672	39,121	50,877	56,238	49,153	49,555	41,512	42,552
2014	617,367	55,588	54,663	52,798	47,457	46,113	46,288	52,698	55,226	54,712	53,860	46,127	51,837
2015	658,443	59,241	51,915	53,965	52,445	47,910	51,967	58,356	59,962	62,015	58,114	50,442	52,111
2016	713,748	58,357	58,859	70,837	57,994	52,731	54,464	58,447	68,330	64,251	58,823	57,902	52,753
2017	968,607	60,134	60,212	80,538	85,092	95,768	75,770	83,021	99,540	103,765	86,196	74,745	63,826
2018	926,848	77,996	70,572	80,432	75,882	83,390	80,945	89,610	85,754	76,498	78,897	68,037	58,835
2019	706,999	82,044	72,289	71,167	71,622	61,945	54,031	61,932	59,204	54,737	52,547	36,704	28,777

Table 3b. Number of Mixed Amphetamine Salt (MAS) Dispensings Over Time, by Month-Year and Sex in the Sentinel Distributed Database (SDD) from January 1, 2013 to December 31, 2019

Product Group	Total Dispensings	January	February	March	April	May	June	July	August	September	October	November	December
ANDA 202424													
2013													
Female	0	0	0	0	0	0	0	0	0	0	0	0	0
Male	0	0	0	0	0	0	0	0	0	0	0	0	0
2014													
Female	32,625	0	0	0	71	726	1,037	5,331	6,613	5,214	4,799	4,841	3,993
Male	26,748	0	0	0	76	485	842	4,293	5,377	4,400	4,280	3,766	3,229
2015													
Female	52,914	4,079	4,070	4,087	3,785	3,856	4,572	4,768	4,934	5,320	4,958	4,043	4,442
Male	45,440	3,671	3,445	3,416	3,456	2,973	3,950	4,541	4,110	4,390	4,258	3,718	3,512
2016													
Female	77,599	4,886	5,202	7,748	6,805	6,135	6,691	6,633	7,494	6,957	6,526	6,799	5,723
Male	64,604	4,195	4,070	6,833	5,545	5,069	5,386	5,582	6,376	5,833	5,688	5,347	4,680
2017													
Female	178,438	6,946	7,509	15,143	18,708	22,844	16,001	16,337	17,926	15,163	14,971	14,580	12,310
Male	151,055	5,981	6,801	12,735	15,568	19,601	14,047	13,305	15,108	12,727	12,595	12,253	10,334
2018													
Female	150,667	8,929	9,706	14,699	13,587	14,330	12,699	12,211	15,211	14,078	14,973	11,574	8,670
Male	129,012	7,742	8,668	12,887	12,072	12,157	10,353	10,228	13,005	11,817	12,795	9,954	7,334
2019													
Female	117,307	12,129	15,155	13,006	12,955	9,578	6,182	10,574	10,776	8,699	8,084	6,315	3,854
Male	101,772	10,523	13,198	11,388	11,498	8,070	5,413	9,018	9,165	7,649	7,161	5,409	3,280
ANDA 040440													
2013													
Female	1	0	0	0	0	0	0	0	0	0	0	0	1
Male	0	0	0	0	0	0	0	0	0	0	0	0	0
2014													
Female	10,507	502	952	943	873	867	747	1,068	1,209	921	996	789	640
Male	9,097	457	734	885	775	737	664	881	1,094	813	801	610	646
2015													
Female	5,039	622	359	428	471	370	347	426	355	500	422	368	371
Male	4,386	414	371	485	369	374	325	330	367	373	364	288	326
2016													
Female	5,239	414	474	447	420	286	298	399	533	523	444	474	527
Male	4,892	384	392	426	323	240	251	346	519	589	404	431	587

Table 3b. Number of Mixed Amphetamine Salt (MAS) Dispensings Over Time, by Month-Year and Sex in the Sentinel Distributed Database (SDD) from January 1, 2013 to December 31, 2019

Product Group	Total Dispensings	January	February	March	April	May	June	July	August	September	October	November	December
2017													
Female	10,928	567	462	426	447	543	871	830	1,089	1,873	1,410	1,458	952
Male	10,511	489	402	556	505	592	721	814	1,021	1,820	1,345	1,306	940
2018													
Female	22,050	1,359	1,644	1,917	1,741	1,999	1,722	2,053	2,698	1,667	1,987	1,529	1,734
Male	21,161	1,301	1,647	1,703	1,583	1,921	1,706	2,064	2,518	1,648	1,933	1,514	1,623
2019													
Female	25,154	3,465	1,878	1,891	2,063	2,237	3,244	2,460	2,785	2,346	1,306	865	614
Male	22,472	3,129	1,714	1,615	1,814	2,039	2,792	2,128	2,621	2,104	1,204	765	547
ANDA 040422													
2013													
Female	275,889	26,241	21,456	19,943	21,915	19,613	18,777	28,383	28,143	24,913	25,566	20,556	20,383
Male	232,085	23,254	18,210	17,246	17,870	16,598	15,797	24,706	22,535	21,281	21,174	16,681	16,733
2014													
Female	275,962	24,016	25,271	25,488	21,594	20,563	20,908	21,782	22,210	24,313	22,501	20,880	26,436
Male	234,246	22,278	23,453	21,134	18,540	17,378	16,765	18,386	18,908	19,531	20,269	16,530	21,074
2015													
Female	289,504	26,581	24,248	24,414	23,370	21,126	22,206	25,589	26,371	26,706	24,662	22,229	22,002
Male	239,990	23,001	19,841	20,147	19,107	17,094	18,179	21,269	21,585	22,060	20,899	18,320	18,488
2016													
Female	287,775	24,107	23,655	25,483	24,809	22,107	21,709	24,257	28,448	26,226	23,313	22,634	21,027
Male	239,631	20,239	19,249	22,087	20,815	18,293	17,626	20,156	24,319	21,000	19,191	19,110	17,546
2017													
Female	280,741	21,601	21,904	22,805	19,801	20,164	20,594	22,365	26,002	27,902	29,743	25,239	22,621
Male	233,524	18,792	18,224	18,373	16,653	17,603	16,740	18,298	21,238	24,192	23,879	20,988	18,544
2018													
Female	325,984	31,925	29,626	28,681	26,658	27,344	26,479	28,400	30,492	27,283	25,408	22,559	21,129
Male	271,257	27,018	24,118	24,358	21,612	23,369	22,004	22,884	26,152	23,151	20,812	18,626	17,153
2019													
Female	263,297	25,982	22,120	25,082	25,061	25,421	22,959	24,526	21,447	22,158	22,437	14,445	11,659
Male	216,316	22,486	18,432	20,637	20,661	20,138	18,411	19,665	17,272	18,340	19,021	11,621	9,632
ANDA 040439													
2013													
Female	31,153	2,834	2,252	2,149	2,067	1,998	3,367	2,889	3,398	3,135	2,593	2,279	2,192
Male	27,091	2,542	1,975	1,796	1,750	1,835	3,048	2,460	3,160	2,425	2,128	1,897	2,075

Table 3b. Number of Mixed Amphetamine Salt (MAS) Dispensings Over Time, by Month-Year and Sex in the Sentinel Distributed Database (SDD) from January 1, 2013 to December 31, 2019

Product Group	Total Dispensings	January	February	March	April	May	June	July	August	September	October	November	December
2014													
Female	28,214	2,934	2,357	2,058	2,281	2,112	2,143	2,116	2,210	2,798	2,705	2,216	2,284
Male	24,607	2,654	2,131	2,004	1,864	2,048	1,822	1,715	1,835	2,487	2,265	2,032	1,750
2015													
Female	21,606	2,269	1,807	1,694	1,813	1,590	1,796	1,790	1,817	2,001	1,912	1,466	1,651
Male	18,104	2,245	1,449	1,440	1,572	1,186	1,419	1,457	1,583	1,580	1,575	1,342	1,256
2016													
Female	21,719	1,526	1,659	2,621	1,776	1,583	1,558	1,402	1,638	2,291	2,325	1,852	1,488
Male	18,067	1,372	1,636	2,197	1,401	1,284	1,288	1,241	1,236	1,817	1,962	1,413	1,220
2017													
Female	27,645	1,705	1,394	1,352	1,255	1,204	1,368	1,629	1,977	4,439	3,499	3,523	4,300
Male	23,708	1,754	1,231	1,139	1,174	1,061	1,251	1,265	1,659	3,634	2,900	2,996	3,644
2018													
Female	48,597	3,603	2,733	3,376	1,467	641	2,012	6,790	5,026	5,208	6,837	5,962	4,942
Male	41,462	3,100	2,438	2,921	1,317	543	1,599	5,695	4,319	4,706	5,744	4,786	4,294
2019													
Female	51,068	4,486	4,093	4,086	3,553	4,481	4,446	5,153	5,320	4,619	4,293	3,415	3,123
Male	44,069	4,071	3,688	3,585	2,899	3,611	3,890	4,241	4,509	4,037	3,872	2,977	2,689
ANDA 040480													
2013													
Female	0	0	0	0	0	0	0	0	0	0	0	0	0
Male	0	0	0	0	0	0	0	0	0	0	0	0	0
2014													
Female	376	0	0	3	16	24	14	20	41	28	41	92	97
Male	323	0	0	13	4	8	14	15	16	53	32	84	84
2015													
Female	364	74	31	27	22	61	105	22	10	6	2	1	3
Male	327	62	26	30	16	41	116	16	10	2	3	0	5
2016													
Female	2,758	7	61	117	103	68	107	117	393	387	428	462	508
Male	2,543	12	32	133	100	61	94	110	343	378	406	503	371
2017													
Female	6,672	461	428	509	465	483	286	270	774	744	744	762	746
Male	5,892	489	377	377	503	402	216	289	580	636	715	723	585

Table 3b. Number of Mixed Amphetamine Salt (MAS) Dispensings Over Time, by Month-Year and Sex in the Sentinel Distributed Database (SDD) from January 1, 2013 to December 31, 2019

Product Group	Total Dispensings	January	February	March	April	May	June	July	August	September	October	November	December
2018													
Female	10,519	949	1,328	656	346	240	246	201	133	109	2,090	2,327	1,894
Male	9,459	804	1,206	563	310	206	225	140	142	88	1,727	2,373	1,675
2019													
Female	8,801	2,048	1,817	1,365	488	274	231	283	220	184	184	398	1,309
Male	7,730	1,938	1,682	1,133	372	237	185	230	178	175	152	324	1,124
Non-202424													
2013													
Female	295,326	28,547	23,207	21,937	24,317	21,308	21,069	27,077	30,228	26,189	26,582	22,185	22,680
Male	249,739	25,644	19,986	19,220	19,602	18,983	17,757	22,999	24,993	21,899	21,646	18,196	18,814
2014													
Female	303,658	27,437	27,154	27,224	24,158	22,420	22,656	24,313	25,210	26,615	25,661	23,062	27,748
Male	258,254	25,419	24,911	22,805	20,454	19,285	18,398	20,664	21,325	22,071	22,324	18,427	22,171
2015													
Female	312,392	28,782	25,486	26,377	25,092	22,950	24,234	27,184	28,372	29,031	26,900	23,997	23,987
Male	259,224	24,829	20,581	21,907	20,822	18,368	19,705	23,003	23,420	23,802	22,889	19,810	20,088
2016													
Female	314,440	26,301	26,171	29,521	25,862	23,586	23,686	25,946	30,102	28,326	25,989	25,284	23,666
Male	262,206	22,203	21,932	25,572	21,371	19,207	19,168	21,667	25,433	23,379	21,373	21,209	19,692
2017													
Female	332,075	24,228	23,536	25,242	21,972	22,596	23,173	25,818	32,050	38,648	35,382	31,166	28,264
Male	278,986	21,671	19,590	20,448	19,015	20,008	18,865	20,961	26,241	33,777	29,197	26,012	23,201
2018													
Female	401,252	38,543	35,960	32,653	29,300	29,878	32,498	37,468	37,362	33,307	34,660	30,971	28,652
Male	338,410	32,912	30,087	28,029	24,326	25,697	26,868	30,714	32,186	28,675	29,187	25,992	23,737
2019													
Female	323,905	34,129	27,696	30,950	29,185	32,648	29,549	29,901	26,677	25,770	25,063	17,175	15,162
Male	269,049	30,648	23,002	25,247	24,151	26,574	24,049	24,072	22,012	21,594	21,135	14,009	12,556
Non-040440													
2013													
Female	296,724	28,557	23,184	22,020	24,305	21,443	21,157	27,142	30,474	26,388	26,973	22,302	22,779
Male	251,434	25,683	20,109	19,273	19,859	19,083	17,856	23,264	25,185	22,043	21,829	18,349	18,901
2014													
Female	328,054	27,601	27,671	28,133	25,264	24,432	24,897	27,914	28,811	29,954	28,155	25,526	29,696
Male	277,930	25,758	25,460	23,494	21,083	20,832	20,282	23,398	24,596	24,469	25,147	20,478	22,933

Table 3b. Number of Mixed Amphetamine Salt (MAS) Dispensings Over Time, by Month-Year and Sex in the Sentinel Distributed Database (SDD) from January 1, 2013 to December 31, 2019

Product Group	Total Dispensings	January	February	March	April	May	June	July	August	September	October	November	December
2015													
Female	356,020	31,579	28,672	28,769	28,333	26,504	28,197	31,381	32,437	33,675	30,919	27,316	28,238
Male	297,356	28,051	23,224	24,354	23,668	21,109	23,714	26,317	26,809	27,766	26,476	22,699	23,169
2016													
Female	386,703	30,996	31,816	37,647	31,471	29,275	29,865	31,661	36,749	34,949	31,654	31,885	28,735
Male	322,786	26,647	26,159	32,862	26,307	23,575	24,334	26,635	31,412	28,655	26,573	25,953	23,674
2017													
Female	515,223	31,854	32,215	43,439	45,687	50,178	39,502	44,008	52,196	51,927	47,979	40,943	35,295
Male	434,019	28,139	27,195	36,719	38,008	43,537	33,791	35,782	43,620	44,423	39,086	34,385	29,334
2018													
Female	498,587	41,178	37,005	39,901	39,591	43,428	43,645	48,647	46,376	43,944	44,701	37,683	32,488
Male	417,457	35,669	30,370	34,114	32,747	36,548	36,613	39,711	39,877	36,718	36,623	31,827	26,640
2019													
Female	380,965	41,922	40,532	37,789	35,510	32,510	28,223	35,358	32,344	30,517	29,597	20,608	16,055
Male	317,565	37,331	34,731	31,268	29,097	25,730	22,967	28,321	26,828	25,701	25,517	16,812	13,262
Non-040422													
2013													
Female	31,320	2,836	2,257	2,149	2,105	2,005	3,367	2,907	3,408	3,173	2,609	2,287	2,217
Male	27,208	2,542	1,975	1,801	1,750	1,835	3,048	2,460	3,169	2,444	2,132	1,924	2,128
2014													
Female	72,387	3,561	3,465	3,096	3,354	3,711	4,211	8,600	10,213	9,136	8,524	7,710	6,806
Male	61,345	3,202	2,956	3,004	2,728	3,338	3,432	6,997	8,583	7,780	7,252	6,415	5,658
2015													
Female	79,714	6,962	6,069	6,185	6,091	5,893	6,652	6,927	7,315	7,795	7,351	5,890	6,584
Male	67,869	6,314	5,138	5,455	5,399	4,573	5,807	6,110	6,134	6,311	6,206	5,323	5,099
2016													
Female	108,495	6,889	7,576	11,268	9,011	8,044	8,515	8,455	10,374	10,442	9,819	9,732	8,370
Male	91,641	6,113	6,413	9,895	7,381	6,573	7,090	7,309	8,652	9,024	8,582	7,742	6,867
2017													
Female	231,232	9,758	9,976	18,156	22,338	27,185	19,235	20,589	23,699	22,322	20,155	19,826	17,993
Male	197,760	8,778	9,061	15,631	19,142	23,536	16,962	16,667	20,270	18,815	16,865	17,052	14,981
2018													
Female	229,467	14,567	14,588	19,345	16,439	17,787	17,729	22,604	22,546	21,659	26,275	19,694	16,234
Male	199,153	12,448	13,168	17,190	14,793	15,652	14,802	19,541	19,499	18,067	22,564	17,514	13,915

Table 3b. Number of Mixed Amphetamine Salt (MAS) Dispensings Over Time, by Month-Year and Sex in the Sentinel Distributed Database (SDD) from January 1, 2013 to December 31, 2019

Product Group	Total Dispensings	January	February	March	April	May	June	July	August	September	October	November	December
2019													
Female	182,912	22,208	20,919	17,715	16,503	14,778	12,486	16,699	17,552	14,166	12,425	10,060	7,401
Male	157,899	20,001	18,303	14,893	14,238	12,234	11,054	13,677	15,056	12,459	11,156	8,569	6,259
Non-040439													
2013													
Female	282,282	26,515	21,849	20,336	22,196	19,811	18,981	28,981	28,786	25,673	26,548	21,247	21,359
Male	238,354	23,497	18,369	17,600	18,233	16,825	16,029	25,364	23,155	21,991	22,124	17,632	17,535
2014													
Female	315,063	26,174	27,635	27,557	23,875	23,710	24,235	26,959	27,915	28,365	26,146	24,399	28,093
Male	267,658	24,448	25,172	23,191	20,421	19,970	19,882	22,826	23,829	22,653	23,875	19,316	22,075
2015													
Female	341,165	29,651	28,111	27,743	27,300	25,252	26,807	30,297	31,026	32,232	29,603	26,183	26,960
Male	284,158	26,021	22,606	23,460	22,518	20,258	22,499	25,462	25,630	26,745	25,181	21,632	22,146
2016													
Female	373,554	29,543	30,375	34,510	31,099	27,988	28,702	31,121	36,630	34,629	30,540	30,626	27,791
Male	313,615	25,395	24,406	30,087	26,545	23,331	23,651	26,277	31,592	28,272	25,731	25,082	23,246
2017													
Female	497,990	30,785	31,841	42,059	45,481	50,171	38,960	42,270	49,504	50,263	44,803	38,767	33,086
Male	420,208	26,714	27,222	35,532	37,663	43,678	33,282	34,674	41,898	43,954	36,229	31,974	27,388
2018													
Female	472,045	40,317	36,876	38,608	39,928	43,033	39,564	41,233	45,493	38,986	40,489	35,860	31,658
Male	398,050	35,015	30,415	32,674	33,172	36,992	33,067	33,868	39,027	33,404	33,769	30,749	25,898
2019													
Female	366,521	43,630	37,070	36,319	35,665	31,911	28,500	32,922	30,658	28,811	27,354	19,152	14,529
Male	305,133	38,419	31,595	29,751	29,849	25,592	23,084	26,262	25,591	24,082	23,320	15,541	12,047
Non-040480													
2013													
Female	299,720	28,708	23,447	22,210	24,466	21,480	21,200	27,446	30,743	26,741	27,356	22,650	23,273
Male	254,220	25,811	20,152	19,458	20,008	19,192	17,921	23,431	25,495	22,412	22,199	18,862	19,279
2014													
Female	334,132	28,734	28,633	28,750	25,833	24,855	25,505	28,579	29,784	30,119	28,497	25,659	29,184
Male	283,235	26,854	26,030	24,048	21,624	21,258	20,783	24,119	25,442	24,593	25,363	20,468	22,653
2015													
Female	358,951	31,475	28,768	29,182	28,542	26,683	28,250	31,649	32,792	34,024	31,338	27,595	28,653
Male	299,492	27,766	23,147	24,783	23,903	21,227	23,717	26,707	27,170	27,991	26,776	22,847	23,458

Table 3b. Number of Mixed Amphetamine Salt (MAS) Dispensings Over Time, by Month-Year and Sex in the Sentinel Distributed Database (SDD) from January 1, 2013 to December 31, 2019

Product Group	Total Dispensings	January	February	March	April	May	June	July	August	September	October	November	December
2016													
Female	388,716	31,287	32,261	37,869	31,597	29,154	29,922	31,789	36,867	35,152	32,019	31,982	28,817
Male	325,032	27,070	26,598	32,968	26,397	23,577	24,542	26,658	31,463	29,099	26,804	25,920	23,936
2017													
Female	524,950	31,898	32,537	43,579	46,303	51,306	40,812	45,899	54,300	55,598	47,426	40,599	34,693
Male	443,657	28,236	27,675	36,959	38,789	44,462	34,958	37,122	45,240	48,167	38,770	34,146	29,133
2018													
Female	503,251	41,802	38,316	43,561	41,220	44,777	44,357	49,173	46,104	41,630	43,108	36,875	32,328
Male	423,597	36,194	32,256	36,871	34,662	38,613	36,588	40,437	39,650	34,868	35,789	31,162	26,507
2019													
Female	385,823	43,533	39,171	38,771	38,954	34,560	29,781	34,615	32,322	29,791	28,354	20,219	15,752
Male	321,176	38,511	33,118	32,396	32,668	27,385	24,250	27,317	26,882	24,946	24,193	16,485	13,025

Table 3c. Number of Mixed Amphetamine Salt (MAS) Dispensings Over Time, by Month-Year and Age Group in the Sentinel Distributed Database (SDD) from January 1, 2013 to December 31, 2019

Product Group	Total												
	Dispensings	January	February	March	April	May	June	July	August	September	October	November	December
ANDA 202424													
2013													
15-24	0	0	0	0	0	0	0	0	0	0	0	0	0
25-34	0	0	0	0	0	0	0	0	0	0	0	0	0
35-44	0	0	0	0	0	0	0	0	0	0	0	0	0
45-54	0	0	0	0	0	0	0	0	0	0	0	0	0
55-64	0	0	0	0	0	0	0	0	0	0	0	0	0
2014													
15-24	14,562	0	0	0	25	225	329	2,087	2,901	2,388	2,546	2,263	1,798
25-34	20,297	0	0	0	51	397	615	3,476	3,993	3,412	2,803	3,042	2,508
35-44	12,772	0	0	0	33	271	447	1,976	2,855	2,010	1,917	1,738	1,525
45-54	7,548	0	0	0	24	151	240	1,362	1,400	1,197	1,184	1,072	918
55-64	4,194	0	0	0	14	167	248	723	841	607	629	492	473
2015													
15-24	23,003	1,948	1,726	1,813	1,759	1,434	1,921	1,994	2,094	2,491	2,152	1,870	1,801
25-34	34,217	2,594	2,644	2,636	2,449	2,390	2,980	3,365	3,231	3,201	3,301	2,675	2,751
35-44	21,650	1,729	1,652	1,602	1,636	1,626	1,834	2,017	1,924	2,183	2,054	1,638	1,755
45-54	12,994	994	944	950	1,000	899	1,179	1,333	1,200	1,267	1,091	1,082	1,055
55-64	6,490	485	549	502	397	480	608	600	595	568	618	496	592
2016													
15-24	30,233	2,257	1,986	2,902	2,529	2,190	2,227	2,357	3,372	2,990	2,710	2,601	2,112
25-34	49,190	3,147	3,217	5,067	4,092	3,923	4,329	4,273	4,763	4,211	4,308	4,087	3,773
35-44	33,855	2,019	2,202	3,664	3,023	2,607	2,910	3,181	3,202	2,939	2,833	2,878	2,397
45-54	19,282	1,092	1,202	2,015	1,762	1,759	1,766	1,598	1,679	1,650	1,668	1,725	1,366
55-64	9,643	566	665	933	944	725	845	806	854	1,000	695	855	755
2017													
15-24	65,875	2,902	3,023	5,029	5,744	7,724	5,690	5,733	7,836	6,192	6,020	5,554	4,428
25-34	111,006	4,662	5,146	9,233	12,004	13,995	10,277	10,263	10,767	9,068	9,089	9,048	7,454
35-44	78,382	3,016	3,130	6,912	8,266	10,463	7,337	7,015	7,265	6,651	6,395	6,326	5,606
45-54	48,553	1,537	2,101	4,428	5,367	6,620	4,466	4,179	4,682	4,012	4,012	3,821	3,328
55-64	25,677	810	910	2,276	2,895	3,643	2,278	2,452	2,484	1,967	2,050	2,084	1,828
2018													
15-24	52,190	3,914	3,520	4,781	4,531	4,653	3,858	3,901	5,635	4,973	5,175	4,200	3,049
25-34	94,157	5,421	6,250	9,251	8,785	9,071	7,868	7,598	9,377	8,694	9,512	7,274	5,056
35-44	69,881	3,806	4,387	7,109	6,561	6,549	5,786	5,795	6,894	6,392	7,053	5,382	4,167
45-54	41,190	2,322	2,852	3,978	3,769	3,942	3,510	3,434	4,225	3,770	3,993	3,041	2,354
55-64	22,261	1,208	1,365	2,467	2,013	2,272	2,030	1,711	2,085	2,066	2,035	1,631	1,378

Table 3c. Number of Mixed Amphetamine Salt (MAS) Dispensings Over Time, by Month-Year and Age Group in the Sentinel Distributed Database (SDD) from January 1, 2013 to December 31, 2019

Product Group	Total												
	Dispensings	January	February	March	April	May	June	July	August	September	October	November	December
2019													
15-24	37,425	4,247	4,762	4,120	3,981	2,959	1,939	2,898	3,402	2,941	2,680	2,118	1,378
25-34	72,240	7,702	9,671	8,000	8,194	5,793	3,721	6,735	6,430	5,196	4,859	3,736	2,203
35-44	57,437	5,837	7,404	6,400	6,500	4,609	3,193	5,087	5,161	4,337	4,088	3,039	1,782
45-54	33,409	3,175	4,191	3,685	3,782	2,762	1,783	3,097	3,247	2,457	2,316	1,809	1,105
55-64	18,568	1,691	2,325	2,189	1,996	1,525	959	1,775	1,701	1,417	1,302	1,022	666
ANDA 040440													
2013													
15-24	0	0	0	0	0	0	0	0	0	0	0	0	0
25-34	0	0	0	0	0	0	0	0	0	0	0	0	0
35-44	1	0	0	0	0	0	0	0	0	0	0	0	1
45-54	0	0	0	0	0	0	0	0	0	0	0	0	0
55-64	0	0	0	0	0	0	0	0	0	0	0	0	0
2014													
15-24	4,755	224	363	413	416	392	330	430	622	470	440	370	285
25-34	5,861	330	492	593	529	477	434	613	697	478	459	376	383
35-44	4,381	216	375	428	350	375	312	465	476	388	440	293	263
45-54	3,013	125	344	269	242	234	191	301	329	263	262	242	211
55-64	1,594	64	112	125	111	126	144	140	179	135	196	118	144
2015													
15-24	2,198	284	166	267	212	156	127	150	195	155	159	162	165
25-34	2,809	315	188	273	238	208	257	259	202	245	237	202	185
35-44	2,099	215	182	171	153	198	159	156	173	217	172	140	163
45-54	1,506	154	136	131	171	111	97	121	92	135	150	107	101
55-64	813	68	58	71	66	71	32	70	60	121	68	45	83
2016													
15-24	1,656	133	134	208	138	98	75	67	166	172	118	172	175
25-34	2,822	236	252	239	192	144	138	260	278	266	238	207	372
35-44	2,658	215	189	221	175	101	157	187	305	311	282	201	314
45-54	1,927	144	189	155	168	137	113	146	151	242	135	202	145
55-64	1,068	70	102	50	70	46	66	85	152	121	75	123	108
2017													
15-24	3,610	184	121	171	167	203	267	251	388	686	472	427	273
25-34	6,733	264	277	284	299	305	468	430	697	1,144	997	1,029	539
35-44	5,355	206	242	251	232	277	435	541	468	892	621	676	514
45-54	3,577	262	120	199	173	232	252	239	357	582	385	402	374
55-64	2,164	140	104	77	81	118	170	183	200	389	280	230	192

Table 3c. Number of Mixed Amphetamine Salt (MAS) Dispensings Over Time, by Month-Year and Age Group in the Sentinel Distributed Database (SDD) from January 1, 2013 to December 31, 2019

Product Group	Total												
	Dispensings	January	February	March	April	May	June	July	August	September	October	November	December
2018													
15-24	7,033	440	507	611	659	666	491	661	857	550	648	477	466
25-34	13,128	826	1,060	1,096	992	1,205	1,102	1,255	1,528	1,021	1,177	866	1,000
35-44	11,107	669	835	979	779	948	844	1,096	1,378	875	989	796	919
45-54	7,506	457	585	600	536	674	643	691	932	522	690	600	576
55-64	4,437	268	304	334	358	427	348	414	521	347	416	304	396
2019													
15-24	7,126	996	493	540	519	612	937	650	823	673	425	245	213
25-34	14,843	2,087	1,071	1,023	1,200	1,378	1,923	1,468	1,704	1,364	788	484	353
35-44	12,899	1,809	931	945	1,072	1,166	1,628	1,258	1,518	1,178	652	455	287
45-54	8,057	1,117	660	650	655	726	1,002	772	814	769	424	276	192
55-64	4,701	585	437	348	431	394	546	440	547	466	221	170	116
ANDA 040422													
2013													
15-24	141,315	15,489	11,517	10,592	10,623	9,135	8,594	13,192	15,557	13,531	12,832	10,346	9,907
25-34	176,780	17,236	13,340	12,854	13,709	13,135	12,133	19,482	16,881	15,671	16,323	12,886	13,130
35-44	100,945	9,327	7,628	7,343	8,218	7,450	7,354	10,927	9,365	8,917	9,455	7,407	7,554
45-54	60,785	5,199	4,849	4,539	4,876	4,396	4,444	6,632	6,044	5,430	5,601	4,420	4,355
55-64	28,149	2,244	2,332	1,861	2,359	2,095	2,049	2,856	2,831	2,645	2,529	2,178	2,170
2014													
15-24	127,626	13,354	12,276	11,928	10,458	8,769	8,814	9,544	10,834	10,964	10,869	8,745	11,071
25-34	182,040	16,475	17,564	15,900	13,665	13,865	13,484	14,518	14,541	15,962	15,086	13,776	17,204
35-44	107,810	8,823	9,687	10,339	8,711	8,111	8,011	8,822	8,551	9,287	9,177	8,057	10,234
45-54	64,279	5,168	6,546	5,603	5,193	5,022	5,064	5,096	5,093	5,255	5,285	4,750	6,204
55-64	28,453	2,474	2,651	2,852	2,107	2,174	2,300	2,188	2,099	2,376	2,353	2,082	2,797
2015													
15-24	121,915	13,136	10,676	10,407	9,611	8,218	8,259	9,849	11,831	11,540	10,739	8,925	8,724
25-34	190,873	16,936	15,864	16,044	15,293	13,786	15,256	17,896	16,931	17,645	16,374	14,674	14,174
35-44	116,788	10,398	9,498	10,067	9,935	8,599	9,157	10,031	10,113	10,419	9,985	8,925	9,661
45-54	67,652	6,394	5,619	5,408	5,081	5,015	5,166	6,179	5,944	6,105	5,665	5,573	5,503
55-64	32,266	2,718	2,432	2,635	2,557	2,602	2,547	2,903	3,137	3,057	2,798	2,452	2,428
2016													
15-24	102,882	10,940	9,574	9,859	8,136	6,995	6,943	7,503	10,733	9,272	8,326	7,733	6,868
25-34	193,000	16,253	15,345	16,743	16,427	15,318	14,632	16,532	19,254	16,794	15,635	15,627	14,440
35-44	126,810	9,520	9,673	11,309	11,214	10,113	9,932	10,899	12,500	11,650	10,239	10,024	9,737
45-54	70,253	4,911	5,426	6,478	6,522	5,205	5,165	6,682	7,038	6,591	5,514	5,676	5,045
55-64	34,461	2,722	2,886	3,181	3,325	2,769	2,663	2,797	3,242	2,919	2,790	2,684	2,483

Table 3c. Number of Mixed Amphetamine Salt (MAS) Dispensings Over Time, by Month-Year and Age Group in the Sentinel Distributed Database (SDD) from January 1, 2013 to December 31, 2019

Product Group	Total												
	Dispensings	January	February	March	April	May	June	July	August	September	October	November	December
2017													
15-24	90,276	8,242	7,179	7,342	6,561	6,351	5,978	6,338	8,711	9,139	9,696	8,071	6,668
25-34	187,022	15,102	15,286	15,260	13,586	13,901	14,072	14,751	16,867	17,880	19,134	16,544	14,639
35-44	131,442	9,506	9,767	10,375	9,108	9,852	9,886	10,858	12,098	13,893	13,226	12,032	10,841
45-54	71,328	5,245	5,198	5,547	4,948	5,200	5,060	5,606	6,497	7,601	7,720	6,570	6,136
55-64	34,197	2,298	2,698	2,654	2,251	2,463	2,338	3,110	3,067	3,581	3,846	3,010	2,881
2018													
15-24	100,033	10,628	8,760	8,891	7,781	7,964	7,430	8,501	10,396	8,487	7,757	7,026	6,412
25-34	208,029	20,472	18,635	18,115	17,588	18,160	17,090	18,247	19,251	17,204	15,706	14,034	13,527
35-44	155,563	14,828	14,396	14,100	11,875	13,473	12,847	13,078	14,702	13,572	12,153	10,751	9,788
45-54	87,960	8,605	7,762	7,826	7,180	7,212	7,364	7,801	8,076	7,398	6,798	6,181	5,757
55-64	45,656	4,410	4,191	4,107	3,846	3,904	3,752	3,657	4,219	3,773	3,806	3,193	2,798
2019													
15-24	75,682	8,337	6,412	6,681	6,674	6,473	5,974	6,837	7,011	6,793	6,486	4,417	3,587
25-34	164,272	17,176	14,075	15,532	15,626	15,996	14,691	15,308	13,104	13,435	13,832	8,482	7,015
35-44	130,153	12,697	10,865	12,853	12,778	12,576	11,278	12,074	10,087	11,026	11,286	6,877	5,756
45-54	71,679	6,811	6,219	6,831	6,897	6,843	6,269	6,668	5,646	5,974	6,386	3,994	3,141
55-64	37,827	3,447	2,981	3,822	3,747	3,671	3,158	3,304	2,871	3,270	3,468	2,296	1,792
ANDA 040439													
2013													
15-24	15,186	1,465	1,127	1,103	955	947	1,470	1,338	1,774	1,608	1,240	1,103	1,056
25-34	19,319	1,798	1,455	1,309	1,147	1,275	2,308	1,798	2,168	1,800	1,577	1,319	1,365
35-44	11,769	1,079	869	808	774	768	1,260	1,109	1,358	1,133	956	813	842
45-54	7,862	712	518	446	557	578	840	736	869	644	656	626	680
55-64	4,108	322	258	279	384	265	537	368	389	375	292	315	324
2014													
15-24	12,994	1,361	1,061	1,106	1,021	985	907	808	1,095	1,326	1,149	1,212	963
25-34	17,210	1,911	1,551	1,277	1,510	1,380	1,312	1,247	1,234	1,688	1,605	1,318	1,177
35-44	11,125	1,167	1,027	829	741	880	850	898	902	1,020	1,054	837	920
45-54	7,419	788	558	570	563	553	625	578	501	803	743	551	586
55-64	4,073	361	291	280	310	362	271	300	313	448	419	330	388
2015													
15-24	8,437	1,155	717	617	679	584	631	649	708	768	708	665	556
25-34	12,178	1,405	994	959	1,048	771	967	992	977	1,245	1,142	756	922
35-44	9,414	1,061	778	689	854	631	807	762	905	811	805	636	675
45-54	6,129	628	542	536	444	486	480	527	552	464	530	437	503
55-64	3,552	265	225	333	360	304	330	317	258	293	302	314	251

Table 3c. Number of Mixed Amphetamine Salt (MAS) Dispensings Over Time, by Month-Year and Age Group in the Sentinel Distributed Database (SDD) from January 1, 2013 to December 31, 2019

Product Group	Total												
	Dispensings	January	February	March	April	May	June	July	August	September	October	November	December
2016													
15-24	7,421	603	737	942	584	554	533	468	710	651	620	505	514
25-34	11,755	917	1,075	1,419	862	898	799	793	715	1,249	1,276	974	778
35-44	10,132	667	736	1,211	877	685	776	750	635	1,096	1,179	835	685
45-54	6,686	432	512	864	476	440	416	420	455	748	769	649	505
55-64	3,792	279	235	382	378	290	322	212	359	364	443	302	226
2017													
15-24	10,620	716	404	476	510	418	414	450	896	1,805	1,400	1,582	1,549
25-34	16,285	1,046	792	673	659	643	806	898	1,121	2,818	2,081	2,066	2,682
35-44	12,470	839	832	657	653	701	702	723	804	1,719	1,468	1,412	1,960
45-54	7,708	509	397	390	321	342	498	520	534	1,132	959	957	1,149
55-64	4,270	349	200	295	286	161	199	303	281	599	491	502	604
2018													
15-24	17,363	1,522	1,128	1,232	523	262	676	2,064	1,868	1,883	2,354	2,128	1,723
25-34	30,427	2,319	1,693	1,987	850	311	1,299	4,626	2,944	3,380	4,178	3,611	3,229
35-44	21,834	1,433	1,220	1,527	681	285	849	2,971	2,343	2,433	3,149	2,661	2,282
45-54	13,333	981	721	1,022	485	204	517	1,815	1,370	1,388	1,947	1,544	1,339
55-64	7,102	448	409	529	245	122	270	1,009	820	830	953	804	663
2019													
15-24	17,991	1,881	1,464	1,490	1,251	1,420	1,362	1,630	1,952	1,623	1,534	1,217	1,167
25-34	31,830	2,840	2,567	2,528	2,161	2,771	2,904	3,159	3,186	2,852	2,667	2,217	1,978
35-44	23,518	2,004	1,888	1,903	1,594	2,074	2,126	2,447	2,453	2,184	1,983	1,471	1,391
45-54	14,012	1,163	1,198	1,135	942	1,171	1,255	1,374	1,472	1,282	1,243	961	816
55-64	7,786	669	664	615	504	656	689	784	766	715	738	526	460
ANDA 040480													
2013													
15-24	0	0	0	0	0	0	0	0	0	0	0	0	0
25-34	0	0	0	0	0	0	0	0	0	0	0	0	0
35-44	0	0	0	0	0	0	0	0	0	0	0	0	0
45-54	0	0	0	0	0	0	0	0	0	0	0	0	0
55-64	0	0	0	0	0	0	0	0	0	0	0	0	0
2014													
15-24	176	0	0	10	6	4	1	2	15	22	22	53	41
25-34	234	0	0	3	9	17	14	14	14	33	20	49	61
35-44	111	0	0	3	2	4	4	13	9	3	7	26	40
45-54	128	0	0	0	1	7	8	3	18	20	18	23	30
55-64	50	0	0	0	2	0	1	3	1	3	6	25	9

Table 3c. Number of Mixed Amphetamine Salt (MAS) Dispensings Over Time, by Month-Year and Age Group in the Sentinel Distributed Database (SDD) from January 1, 2013 to December 31, 2019

Product Group	Total												
	Dispensings	January	February	March	April	May	June	July	August	September	October	November	December
2015													
15-24	167	42	19	14	7	24	43	8	8	2	0	0	0
25-34	214	37	17	18	10	35	84	8	1	1	2	0	1
35-44	148	21	11	9	14	19	52	11	2	3	2	0	4
45-54	110	17	6	10	5	20	32	7	8	2	1	1	1
55-64	52	19	4	6	2	4	10	4	1	0	0	0	2
2016													
15-24	1,150	1	29	69	36	35	40	55	160	170	198	183	174
25-34	1,506	7	18	46	73	37	57	72	230	217	226	289	234
35-44	1,216	7	32	58	42	24	51	44	188	190	189	191	200
45-54	982	3	9	58	39	17	32	46	119	120	137	215	187
55-64	447	1	5	19	13	16	21	10	39	68	84	87	84
2017													
15-24	2,650	228	197	188	220	213	98	119	291	260	273	297	266
25-34	3,643	299	262	272	267	217	148	142	333	441	410	463	389
35-44	3,027	210	185	230	206	212	114	143	348	336	386	332	325
45-54	2,086	144	109	120	174	165	95	108	249	217	230	248	227
55-64	1,158	69	52	76	101	78	47	47	133	126	160	145	124
2018													
15-24	3,769	355	540	318	159	111	92	91	85	49	560	773	636
25-34	5,804	497	779	338	187	116	113	82	62	52	1,177	1,367	1,034
35-44	4,968	431	607	287	153	91	108	72	49	43	961	1,243	923
45-54	3,320	300	387	170	106	74	86	73	44	35	751	746	548
55-64	2,117	170	221	106	51	54	72	23	35	18	368	571	428
2019													
15-24	3,267	710	624	522	201	111	82	123	136	114	124	144	376
25-34	4,830	1,190	1,096	739	236	147	135	178	102	66	94	195	652
35-44	4,171	1,029	890	622	187	136	108	109	73	86	61	190	680
45-54	2,645	670	522	397	153	76	65	58	50	56	39	121	438
55-64	1,618	387	367	218	83	41	26	45	37	37	18	72	287
Non-202424													
2013													
15-24	153,940	17,086	12,491	11,662	11,736	10,130	9,769	13,472	17,207	14,338	13,675	11,404	10,970
25-34	186,336	18,578	14,572	14,093	14,675	14,293	13,503	17,750	18,306	16,013	16,570	13,663	14,320
35-44	107,669	10,245	8,544	7,982	9,060	8,255	8,035	9,850	10,144	9,375	9,519	7,919	8,741
45-54	66,064	5,786	5,082	5,176	5,672	5,188	4,966	6,301	6,450	5,607	5,861	5,004	4,971
55-64	31,056	2,496	2,504	2,244	2,776	2,425	2,553	2,703	3,114	2,755	2,603	2,391	2,492

Table 3c. Number of Mixed Amphetamine Salt (MAS) Dispensings Over Time, by Month-Year and Age Group in the Sentinel Distributed Database (SDD) from January 1, 2013 to December 31, 2019

Product Group	Total												
	Dispensings	January	February	March	April	May	June	July	August	September	October	November	December
2014													
15-24	142,698	15,244	13,498	13,057	11,461	9,775	9,762	10,904	12,509	12,434	12,229	10,127	11,698
25-34	196,541	18,436	18,404	16,853	15,222	14,923	14,569	15,806	15,862	17,402	16,550	14,690	17,824
35-44	118,337	10,217	10,411	10,816	9,460	9,010	8,709	9,838	9,662	10,162	10,347	8,938	10,767
45-54	71,558	6,018	6,863	6,085	5,990	5,543	5,410	5,904	5,831	5,986	6,071	5,293	6,564
55-64	32,778	2,941	2,889	3,218	2,479	2,454	2,604	2,525	2,671	2,702	2,788	2,441	3,066
2015													
15-24	131,581	14,450	11,156	11,275	10,325	8,742	9,152	10,550	12,777	12,410	11,608	9,720	9,416
25-34	203,191	18,248	16,365	17,010	16,351	14,758	16,304	18,860	17,944	18,915	17,712	15,564	15,160
35-44	126,353	11,112	10,047	10,912	10,698	9,328	9,982	10,845	11,069	11,342	10,943	9,441	10,634
45-54	74,295	6,896	5,871	5,983	5,682	5,501	5,662	6,765	6,606	6,775	6,288	6,118	6,148
55-64	36,196	2,905	2,628	3,104	2,858	2,989	2,839	3,167	3,396	3,391	3,238	2,964	2,717
2016													
15-24	112,980	11,765	10,701	11,107	8,575	7,567	7,659	8,148	11,721	10,161	9,228	8,558	7,790
25-34	207,162	17,515	16,745	18,969	16,680	15,984	15,505	17,724	20,091	18,220	16,966	16,993	15,770
35-44	138,935	10,473	10,898	13,343	11,474	10,799	10,906	11,663	12,829	12,749	11,534	11,244	11,023
45-54	78,683	5,602	6,370	8,016	6,828	5,499	5,741	7,105	7,272	7,387	6,424	6,586	5,853
55-64	38,886	3,149	3,389	3,658	3,676	2,944	3,043	2,973	3,622	3,188	3,210	3,112	2,922
2017													
15-24	108,934	9,367	7,830	8,227	7,542	7,194	6,667	7,514	10,829	12,899	11,713	10,472	8,680
25-34	216,825	16,648	15,842	16,458	14,929	15,432	15,468	16,519	20,552	24,933	22,465	19,956	17,623
35-44	155,820	10,971	10,633	11,625	10,138	11,080	11,133	12,542	14,836	18,740	15,937	14,663	13,522
45-54	86,501	6,108	5,755	6,236	5,666	5,997	5,983	6,577	8,083	10,564	9,527	8,174	7,831
55-64	42,981	2,805	3,066	3,144	2,712	2,901	2,787	3,627	3,991	5,289	4,937	3,913	3,809
2018													
15-24	128,097	13,272	11,147	10,668	8,987	8,997	9,160	11,420	13,052	11,016	11,169	10,141	9,068
25-34	253,634	24,483	22,289	20,316	18,739	19,806	20,995	23,972	23,267	21,092	21,399	19,236	18,040
35-44	189,626	17,657	17,641	15,673	13,314	14,185	15,596	17,401	17,713	16,269	16,395	14,522	13,260
45-54	110,318	10,614	9,746	9,165	8,151	8,071	9,077	10,312	10,108	8,971	9,540	8,522	8,041
55-64	57,987	5,429	5,224	4,860	4,435	4,516	4,538	5,077	5,408	4,634	5,344	4,542	3,980
2019													
15-24	99,814	11,830	8,537	8,837	8,392	8,785	8,143	8,946	9,440	8,546	7,859	5,577	4,922
25-34	200,162	22,350	17,130	18,852	18,083	20,742	18,640	18,471	15,999	15,512	15,387	10,053	8,943
35-44	156,916	16,661	13,219	15,325	14,487	15,961	14,558	14,396	12,373	12,465	12,126	8,051	7,294
45-54	88,744	9,204	7,834	8,573	7,935	9,038	8,054	8,042	7,130	7,003	6,988	4,777	4,166
55-64	47,318	4,732	3,978	4,610	4,439	4,696	4,203	4,118	3,747	3,838	3,838	2,726	2,393

Table 3c. Number of Mixed Amphetamine Salt (MAS) Dispensings Over Time, by Month-Year and Age Group in the Sentinel Distributed Database (SDD) from January 1, 2013 to December 31, 2019

Product Group	Total												
	Dispensings	January	February	March	April	May	June	July	August	September	October	November	December
Non-040440													
2013													
15-24	154,666	17,148	12,493	11,806	11,783	10,157	9,787	13,568	17,301	14,411	13,760	11,450	11,002
25-34	187,479	18,615	14,564	14,256	14,855	14,343	13,625	17,825	18,389	16,142	16,735	13,687	14,443
35-44	108,202	10,179	8,578	7,885	9,090	8,305	8,068	9,928	10,298	9,520	9,693	7,921	8,737
45-54	66,430	5,799	5,126	5,139	5,628	5,258	4,990	6,379	6,484	5,520	5,968	5,105	5,034
55-64	31,381	2,499	2,532	2,207	2,808	2,463	2,543	2,706	3,187	2,838	2,646	2,488	2,464
2014													
15-24	154,091	15,072	13,629	13,213	11,860	10,445	10,681	12,136	14,501	14,280	14,203	11,680	12,391
25-34	212,357	18,837	19,077	17,766	15,768	16,230	16,038	18,327	18,410	19,374	18,002	16,003	18,525
35-44	127,794	10,341	10,614	11,198	9,843	9,939	9,722	11,398	10,974	11,048	11,342	9,903	11,472
45-54	76,656	6,079	6,863	6,150	6,157	5,912	5,961	6,639	6,686	6,645	6,752	5,706	7,106
55-64	35,086	3,030	2,948	3,300	2,719	2,738	2,777	2,812	2,836	3,076	3,003	2,712	3,135
2015													
15-24	151,472	16,030	12,606	12,467	11,862	10,008	10,986	12,213	14,774	14,710	13,459	11,317	11,040
25-34	231,059	19,878	18,457	18,893	18,458	16,739	19,064	21,768	20,532	21,722	20,246	17,801	17,501
35-44	144,587	12,660	11,192	11,750	12,095	11,082	11,673	12,287	12,686	13,357	12,671	10,745	12,389
45-54	85,194	7,801	6,672	6,516	6,377	6,333	6,845	7,821	7,503	7,867	7,246	6,992	7,221
55-64	41,064	3,261	2,969	3,497	3,209	3,451	3,343	3,609	3,751	3,785	3,773	3,160	3,256
2016													
15-24	142,394	14,026	12,727	13,970	10,720	9,667	9,949	10,511	15,154	13,230	11,788	11,058	9,594
25-34	252,854	20,898	20,218	24,226	20,151	19,416	19,711	21,272	24,165	22,078	20,693	21,041	18,985
35-44	170,315	12,427	13,300	17,258	13,883	13,179	13,424	14,522	15,905	15,494	14,050	13,829	13,044
45-54	96,605	6,725	7,665	10,369	8,376	7,017	7,419	8,441	8,624	8,761	7,954	8,111	7,143
55-64	47,321	3,567	4,065	4,686	4,648	3,571	3,696	3,550	4,313	4,041	3,742	3,799	3,643
2017													
15-24	177,052	12,558	11,286	14,086	14,195	15,970	12,729	13,978	19,921	18,385	17,175	14,678	12,091
25-34	330,584	22,338	21,488	27,893	30,053	32,157	26,090	28,341	32,767	32,313	29,554	25,863	21,727
35-44	235,138	13,948	14,575	20,774	20,433	23,891	18,939	19,769	22,976	24,292	20,924	18,374	16,243
45-54	136,788	7,650	8,077	11,539	12,391	14,409	10,389	11,401	13,277	14,610	12,735	10,774	9,536
55-64	69,680	3,499	3,984	5,866	6,623	7,288	5,146	6,301	6,875	6,750	6,677	5,639	5,032
2018													
15-24	168,374	16,351	13,112	13,355	12,466	13,189	12,735	15,055	17,714	14,982	15,320	13,355	10,740
25-34	311,131	25,967	23,040	24,685	25,702	28,457	27,577	30,394	28,471	26,860	27,319	22,755	19,904
35-44	231,575	18,337	16,661	19,470	17,760	20,638	21,275	22,706	21,375	20,625	20,602	17,269	14,857
45-54	134,494	10,915	9,564	10,569	10,965	11,253	12,128	13,403	12,301	12,021	11,868	10,575	8,932
55-64	70,470	5,277	4,998	5,936	5,445	6,439	6,543	6,800	6,392	6,174	6,215	5,556	4,695

Table 3c. Number of Mixed Amphetamine Salt (MAS) Dispensings Over Time, by Month-Year and Age Group in the Sentinel Distributed Database (SDD) from January 1, 2013 to December 31, 2019

Product Group	Total												
	Dispensings	January	February	March	April	May	June	July	August	September	October	November	December
2019													
15-24	123,697	15,373	13,005	11,652	10,741	9,390	8,405	10,885	11,628	10,464	9,704	6,959	5,491
25-34	232,554	27,333	25,278	22,913	21,569	19,845	17,463	21,764	19,051	18,023	18,011	11,966	9,338
35-44	181,697	19,929	19,701	18,323	17,373	15,089	13,554	16,529	15,079	14,680	14,402	9,461	7,577
45-54	104,653	10,978	11,493	10,206	9,756	9,057	7,761	9,525	8,826	8,419	8,424	5,810	4,398
55-64	55,929	5,640	5,786	5,963	5,168	4,859	4,007	4,976	4,588	4,632	4,573	3,224	2,513
Non-040422													
2013													
15-24	15,276	1,465	1,127	1,103	956	947	1,470	1,353	1,781	1,656	1,240	1,105	1,073
25-34	19,398	1,800	1,455	1,314	1,147	1,275	2,308	1,801	2,170	1,809	1,588	1,333	1,398
35-44	11,823	1,079	869	808	795	768	1,260	1,109	1,359	1,133	963	816	864
45-54	7,891	712	523	446	557	578	840	736	878	644	658	633	686
55-64	4,140	322	258	279	400	272	537	368	389	375	292	324	324
2014													
15-24	32,782	1,631	1,477	1,530	1,470	1,600	1,704	3,377	4,729	4,316	4,140	3,789	3,019
25-34	43,999	2,331	2,090	1,902	2,117	2,326	2,477	5,443	6,133	5,600	4,845	4,671	4,064
35-44	28,620	1,401	1,486	1,321	1,151	1,550	1,717	3,327	4,277	3,498	3,385	2,830	2,677
45-54	18,346	922	935	907	848	999	1,097	2,267	2,262	2,339	2,172	1,886	1,712
55-64	9,985	478	433	440	496	574	648	1,183	1,395	1,163	1,234	949	992
2015													
15-24	33,767	3,418	2,585	2,777	2,631	2,155	2,630	2,819	3,071	3,426	3,006	2,683	2,566
25-34	48,970	4,255	3,753	3,806	3,742	3,409	4,240	4,454	4,521	4,613	4,703	3,635	3,839
35-44	33,355	3,063	2,532	2,497	2,695	2,516	2,818	2,861	3,025	3,245	3,062	2,374	2,667
45-54	20,702	1,727	1,613	1,654	1,605	1,510	1,804	1,924	1,894	1,866	1,794	1,647	1,664
55-64	10,789	813	724	906	817	876	967	979	938	956	992	874	947
2016													
15-24	40,726	3,035	3,019	4,177	3,201	2,838	2,824	2,943	4,513	4,019	3,681	3,496	2,980
25-34	65,963	4,339	4,689	6,989	5,192	4,872	5,347	5,397	6,117	6,217	6,083	5,635	5,086
35-44	48,813	2,994	3,269	5,317	4,167	3,459	3,893	4,173	4,501	4,638	4,584	4,105	3,713
45-54	29,447	1,717	1,959	3,215	2,429	2,370	2,312	2,156	2,500	2,908	2,733	2,884	2,264
55-64	15,187	917	1,053	1,465	1,403	1,078	1,229	1,095	1,395	1,684	1,320	1,354	1,194
2017													
15-24	85,300	4,145	3,810	6,028	6,968	9,131	6,764	7,033	10,326	9,012	7,917	7,688	6,478
25-34	142,674	6,275	6,720	10,901	14,179	16,310	12,242	12,811	14,390	13,241	12,150	12,519	10,936
35-44	102,280	4,241	4,401	8,545	10,071	12,607	9,053	8,877	9,651	9,697	8,593	8,555	7,989
45-54	64,198	2,487	2,780	5,398	6,639	8,148	5,381	5,397	6,266	6,108	5,419	5,269	4,906
55-64	34,540	1,388	1,326	2,915	3,623	4,525	2,757	3,138	3,336	3,079	2,941	2,847	2,665

Table 3c. Number of Mixed Amphetamine Salt (MAS) Dispensings Over Time, by Month-Year and Age Group in the Sentinel Distributed Database (SDD) from January 1, 2013 to December 31, 2019

Product Group	Total												
	Dispensings	January	February	March	April	May	June	July	August	September	October	November	December
2018													
15-24	80,352	6,319	5,601	6,435	5,703	5,793	5,470	7,119	8,570	7,658	8,930	7,176	5,578
25-34	141,695	8,609	9,140	11,922	10,348	11,508	11,020	14,517	13,478	13,227	16,194	12,128	9,604
35-44	106,941	6,259	6,618	9,421	7,913	8,121	7,995	10,868	10,421	9,826	12,529	9,364	7,606
45-54	63,938	3,834	4,205	5,525	4,728	4,907	5,171	6,305	6,238	5,716	7,421	5,390	4,498
55-64	35,694	1,994	2,192	3,232	2,540	3,110	2,875	3,336	3,338	3,299	3,765	3,150	2,863
2019													
15-24	61,977	8,156	6,908	6,273	5,386	4,657	3,981	4,900	6,026	4,954	4,514	3,504	2,718
25-34	110,946	13,528	13,080	10,467	10,207	8,990	7,720	10,178	10,481	8,406	7,517	6,061	4,311
35-44	87,063	10,689	10,061	8,213	7,955	6,960	6,187	7,889	8,294	6,869	5,978	4,596	3,372
45-54	52,166	6,377	5,961	4,867	4,731	4,098	3,710	4,704	5,114	4,105	3,563	2,877	2,059
55-64	28,659	3,459	3,212	2,788	2,462	2,307	1,942	2,705	2,693	2,291	2,009	1,591	1,200
Non-040439													
2013													
15-24	143,692	15,579	11,679	10,733	10,674	9,228	8,666	13,572	15,792	13,762	13,135	10,662	10,210
25-34	181,064	17,443	13,457	13,098	14,084	13,288	12,340	19,833	17,249	16,166	16,917	13,444	13,745
35-44	103,779	9,489	7,834	7,494	8,316	7,532	7,436	11,108	9,644	9,242	9,954	7,758	7,972
45-54	62,919	5,253	4,888	4,697	4,920	4,481	4,496	6,870	6,348	5,720	5,956	4,682	4,608
55-64	29,182	2,248	2,360	1,914	2,435	2,107	2,072	2,962	2,908	2,774	2,710	2,333	2,359
2014													
15-24	147,186	14,360	13,111	12,902	11,226	9,805	10,289	11,879	14,118	13,523	13,152	10,871	11,950
25-34	204,973	17,990	19,195	17,384	15,033	15,984	15,711	18,133	17,611	18,032	16,835	15,138	17,927
35-44	123,839	9,847	10,497	11,258	9,672	9,521	9,826	10,756	10,688	10,509	10,992	9,514	10,759
45-54	73,604	5,596	7,143	6,062	5,887	5,804	5,634	6,400	6,505	6,121	6,279	5,455	6,718
55-64	33,119	2,829	2,861	3,142	2,478	2,566	2,657	2,617	2,822	2,833	2,763	2,737	2,814
2015													
15-24	145,477	14,832	12,295	12,294	11,503	9,674	10,397	11,754	14,177	14,151	12,907	10,827	10,666
25-34	223,019	18,836	18,237	18,429	17,720	16,155	18,207	21,323	19,798	20,748	19,447	17,228	16,891
35-44	137,587	11,591	10,911	11,231	11,474	10,497	10,996	11,934	12,015	12,894	11,984	10,337	11,723
45-54	80,602	7,283	6,344	6,052	6,159	5,954	6,510	7,409	7,045	7,500	6,920	6,649	6,777
55-64	38,638	3,130	2,930	3,197	2,962	3,230	3,196	3,339	3,621	3,684	3,526	2,774	3,049
2016													
15-24	136,976	13,470	11,999	13,170	10,318	9,251	9,486	10,123	14,635	12,938	11,460	10,828	9,298
25-34	246,294	19,944	19,315	22,556	20,502	19,022	19,146	20,927	24,163	21,864	20,110	20,136	18,609
35-44	165,107	11,939	12,500	15,686	14,074	12,659	13,070	14,172	16,226	15,250	13,538	13,201	12,792
45-54	93,185	6,253	7,151	8,946	8,487	6,777	7,148	8,561	8,869	8,681	7,548	7,907	6,857
55-64	45,607	3,332	3,816	4,239	4,263	3,610	3,503	3,615	4,329	4,168	3,615	3,636	3,481

Table 3c. Number of Mixed Amphetamine Salt (MAS) Dispensings Over Time, by Month-Year and Age Group in the Sentinel Distributed Database (SDD) from January 1, 2013 to December 31, 2019

Product Group	Total												
	Dispensings	January	February	March	April	May	June	July	August	September	October	November	December
2017													
15-24	169,737	12,065	10,987	13,678	14,077	15,865	12,684	13,610	18,606	17,619	16,002	13,605	10,939
25-34	319,567	21,456	22,049	27,059	29,661	31,978	25,746	26,982	30,949	31,589	27,245	24,426	20,427
35-44	228,966	13,221	14,379	20,109	20,161	24,010	18,536	19,615	22,382	24,181	19,792	17,192	15,388
45-54	132,403	7,458	7,676	11,187	12,687	14,437	10,126	10,618	12,926	14,070	11,837	10,266	9,115
55-64	67,525	3,299	3,972	5,558	6,558	7,559	5,150	6,119	6,539	6,758	6,156	5,252	4,605
2018													
15-24	157,646	15,308	12,476	12,939	12,557	13,166	11,667	12,880	16,844	13,708	13,771	12,185	10,145
25-34	295,022	25,214	23,104	23,780	26,067	28,069	24,589	25,856	27,943	23,917	24,918	22,303	19,262
35-44	220,874	18,589	16,713	18,497	17,881	20,466	19,200	19,241	21,204	18,461	18,893	16,853	14,876
45-54	128,969	10,829	9,866	10,307	10,959	11,790	11,261	11,500	12,147	10,762	10,888	10,054	8,606
55-64	67,584	5,392	5,132	5,759	5,636	6,534	5,914	5,624	6,382	5,542	5,788	5,214	4,667
2019													
15-24	115,428	14,738	11,811	10,970	10,430	9,031	8,305	9,703	10,784	9,754	8,786	6,295	4,821
25-34	224,957	28,537	23,326	22,011	22,168	19,559	17,639	20,255	18,272	16,948	16,671	11,065	8,506
35-44	176,559	21,040	17,808	17,675	17,744	15,148	13,788	15,583	14,576	13,951	13,367	8,960	6,919
45-54	100,974	11,739	10,419	9,852	9,830	8,877	7,872	9,045	8,314	7,908	7,747	5,345	4,026
55-64	53,736	5,995	5,301	5,562	5,342	4,888	3,980	4,598	4,303	4,332	4,103	3,028	2,304
Non-040480													
2013													
15-24	155,679	17,194	12,593	11,835	11,830	10,169	9,816	13,693	17,417	14,491	13,886	11,610	11,145
25-34	189,420	18,702	14,635	14,309	14,918	14,407	13,676	17,966	18,638	16,412	17,000	14,037	14,720
35-44	109,589	10,300	8,696	8,037	9,159	8,336	8,103	9,993	10,353	9,667	9,843	8,102	9,000
45-54	67,533	5,825	5,141	5,237	5,702	5,293	5,005	6,485	6,624	5,707	6,116	5,251	5,147
55-64	31,719	2,498	2,534	2,250	2,865	2,467	2,521	2,740	3,206	2,876	2,710	2,512	2,540
2014													
15-24	157,991	15,719	14,025	13,663	12,046	10,592	11,028	12,688	15,208	14,552	14,310	11,780	12,380
25-34	214,653	19,439	19,576	17,987	16,153	16,583	16,360	18,776	18,583	19,200	18,013	15,812	18,171
35-44	130,405	10,844	10,949	11,393	10,131	10,217	10,054	11,498	11,352	11,130	11,612	9,999	11,226
45-54	78,406	6,336	7,100	6,325	6,359	6,048	5,971	6,900	6,967	6,749	6,850	5,790	7,011
55-64	35,912	3,250	3,013	3,430	2,768	2,673	2,875	2,836	3,116	3,081	3,075	2,746	3,049
2015													
15-24	152,937	16,057	12,623	12,830	12,011	10,003	11,033	12,354	14,963	14,836	13,570	11,433	11,224
25-34	232,612	19,891	18,469	19,112	18,542	16,884	19,020	21,998	20,776	21,800	20,497	17,877	17,746
35-44	145,409	12,301	11,237	11,881	12,174	11,198	11,683	12,491	12,823	13,511	12,776	10,792	12,542
45-54	85,856	7,774	6,581	6,549	6,496	6,327	6,842	7,911	7,600	7,978	7,391	7,099	7,308
55-64	41,629	3,218	3,005	3,593	3,222	3,498	3,389	3,602	3,800	3,890	3,880	3,241	3,291

Table 3c. Number of Mixed Amphetamine Salt (MAS) Dispensings Over Time, by Month-Year and Age Group in the Sentinel Distributed Database (SDD) from January 1, 2013 to December 31, 2019

Product Group	Total												
	Dispensings	January	February	March	April	May	June	July	August	September	October	November	December
2016													
15-24	142,629	14,091	12,893	14,015	10,705	9,635	9,955	10,540	15,123	13,197	11,827	10,977	9,671
25-34	254,043	21,063	20,442	24,372	20,252	19,364	19,783	21,263	24,233	22,323	21,010	20,881	19,057
35-44	171,592	12,720	13,401	17,328	13,960	13,111	13,570	14,549	15,884	15,621	14,081	14,095	13,272
45-54	97,529	6,840	7,907	10,463	8,437	7,039	7,409	8,444	8,665	8,996	8,085	8,099	7,145
55-64	47,955	3,643	4,216	4,659	4,640	3,582	3,747	3,651	4,425	4,114	3,820	3,850	3,608
2017													
15-24	179,682	12,492	11,271	14,163	14,365	16,223	13,122	14,600	20,382	19,532	17,060	14,525	11,947
25-34	337,021	22,266	21,947	27,800	30,478	32,777	26,896	29,255	34,192	34,959	29,083	25,930	21,438
35-44	241,009	14,074	14,797	21,012	20,791	24,696	19,504	20,920	23,887	26,323	20,759	18,066	16,180
45-54	139,575	7,760	8,125	11,637	12,686	14,705	10,823	11,612	13,874	15,538	12,733	10,695	9,387
55-64	71,320	3,542	4,072	5,926	6,772	7,367	5,425	6,634	7,205	7,413	6,561	5,529	4,874
2018													
15-24	171,159	16,472	13,418	14,366	12,907	13,778	13,001	15,326	17,963	14,974	15,210	13,077	10,667
25-34	313,750	25,940	24,069	26,387	26,672	29,842	27,569	30,880	28,054	25,539	26,617	22,402	19,779
35-44	233,769	18,654	17,596	20,836	18,817	21,306	21,335	23,238	21,142	19,271	19,780	16,978	14,816
45-54	136,779	11,410	10,229	11,978	11,551	11,739	12,408	13,436	12,226	11,250	11,298	10,290	8,964
55-64	71,391	5,520	5,260	6,865	5,935	6,725	6,632	6,730	6,369	5,464	5,992	5,290	4,609
2019													
15-24	125,906	15,779	12,395	11,976	11,710	9,931	9,066	10,756	11,916	10,526	9,537	6,886	5,428
25-34	235,180	28,232	24,347	23,413	23,982	21,100	18,409	21,014	18,995	17,502	17,234	11,754	9,198
35-44	183,202	20,677	18,752	19,038	19,113	16,062	14,157	16,003	15,032	14,117	13,577	9,268	7,406
45-54	106,103	11,582	11,074	10,724	10,767	9,646	8,163	9,301	8,783	8,173	7,934	5,646	4,310
55-64	56,608	5,774	5,721	6,016	6,050	5,206	4,236	4,858	4,478	4,419	4,265	3,150	2,435

Table 4. Descriptive Statistics of Days Supplied per Mixed Amphetamine Salt (MAS) Dispensing in the Sentinel Distributed Database (SDD) from January 1, 2013 to December 31, 2019¹

Product Group	Dispensings (n)	Mean	Standard											
			Deviation	Min	1%	5%	10%	25%	50%	75%	90%	95%	99%	Max
ANDA 202424	1,128,181	30.54	9.80	1	6	23	30	30	30	30	30	30	90	360
ANDA 040440	151,437	30.19	8.81	1	6	23	30	30	30	30	30	30	90	180
ANDA 040422	3,666,201	29.90	7.79	1	6	22	30	30	30	30	30	30	60	365
ANDA 040439	427,110	29.91	8.56	1	5	20	30	30	30	30	30	30	90	301
ANDA 040480	55,764	29.25	8.29	1	4	15	28	30	30	30	30	30	60	140
Non-202424	4,198,916	29.90	7.91	1	6	21	30	30	30	30	30	30	60	365
Non-040440	5,080,823	30.02	8.30	1	6	22	30	30	30	30	30	30	90	365
Non-040422	1,738,402	30.32	9.40	1	6	21	30	30	30	30	30	30	90	360
Non-040439	4,875,796	30.04	8.29	1	6	22	30	30	30	30	30	30	90	365
Non-040480	5,145,952	30.04	8.31	1	6	22	30	30	30	30	30	30	90	365

¹Due to the occurrence of same-day dispensings of different ANDAs, totals may sum to greater than 100%.

Table 5. Descriptive Statistics of Cumulative Exposure Duration¹, in Days in the Sentinel Distributed Database (SDD) from January 1, 2013 to December 31, 2019

Product Group	Patients (n)	Mean	Standard											
			Deviation	Min	1%	5%	10%	25%	50%	75%	90%	95%	99%	Max
ANDA 202424	261,589	134.02	163.10	1	7	28	30	30	70	163	317	456	812	1988
ANDA 040440	69,115	66.91	85.23	1	7	27	30	30	30	63	130	210	438	1719
ANDA 040422	577,302	193.85	250.24	1	7	28	30	30	95	241	480	691	1,243	2543
ANDA 040439	145,294	89.16	120.99	1	6	23	30	30	52	92	192	300	608	2293
ANDA 040480	25,513	64.71	64.72	1	3	15	28	30	30	90	142	182	330	845
Non-202424	631,544	201.74	255.88	1	7	28	30	40	105	251	498	713	1,266	2543
Non-040440	690,088	223.47	274.36	1	7	29	30	57	120	284	557	787	1,333	2545
Non-040422	360,939	147.22	180.84	1	7	28	30	30	89	182	360	508	888	2293
Non-040439	675,388	219.57	271.05	1	7	30	30	55	120	278	547	778	1,316	2545
Non-040480	690,954	225.94	277.22	1	7	29	30	58	120	288	564	797	1,344	2545

¹Cumulative exposure is calculated across all episodes per distinct patient

Table 6. Descriptive Statistics of Treatment Exposure Duration, in Days, by Censoring Reason in the Sentinel Distributed Database (SDD) from January 1, 2013 to December 31, 2019

Product Group	Episodes (n)	Mean	Standard Deviation	Min	1%	5%	10%	25%	50%	75%	90%	95%	99%	Max
ANDA 202424														
Censoring reason 1: product discontinuation	606,753	55.51	65.92	1	7	25	30	30	30	60	100	160	331	1,938
Censoring reason 2: end of available data	218	82.55	133.67	1	2	8	12	19	35.5	104	208	289	512	1,499
Censoring reason 3: end of enrollment	40,498	69.19	108.56	1	1	3	6	15	29	78	170	263	541	1,938
Censoring reason 4: end of query period	16,148	100.02	158.69	1	1	5	9	21	48	116	250	349	868	1,988
Censoring reason 5: death	39	102.46	160.68	1	1	2	5	10	45	114	349	586	717	717
ANDA 040440														
Censoring reason 1: product discontinuation	103,178	43.47	43.27	1	7	26	30	30	30	30	67	97	221	1,445
Censoring reason 2: end of available data	28	36.82	32.22	4	4	5	5	12	29	56	80	98	142	142
Censoring reason 3: end of enrollment	5,103	44.66	72.52	1	1	2	4	12	23	47	102	162	358	1,171
Censoring reason 4: end of query period	2,060	77.71	119.47	1	1	4	8	18	29	85	206	305	596	1,437
Censoring reason 5: death	8	35.63	24.59	8	8	8	8	14	32.5	60	66	66	66	66
ANDA 040422														
Censoring reason 1: product discontinuation	1,668,600	63.08	91.44	1	7	24	30	30	30	62	123	195	464	2,543
Censoring reason 2: end of available data	1,559	157.55	257.18	1	1	5	12	23	69	170	387	667	1,437	2,456
Censoring reason 3: end of enrollment	130,354	100.99	165.85	1	1	3	6	17	40	112	264	406	837	2,543
Censoring reason 4: end of query period	51,534	150.17	255.84	1	1	5	10	21	55	153	393	672	1,294	2,543
Censoring reason 5: death	193	158.93	238.25	1	1	5	10	22	73	189	439	631	1,366	1,695
ANDA 040439														
Censoring reason 1: product discontinuation	261,275	48.06	56.52	1	7	24	30	30	30	49	90	123	277	2,293
Censoring reason 2: end of available data	60	135.92	466.39	1	1	2	5	13	20.5	38	111	1,073	2,293	2,293
Censoring reason 3: end of enrollment	15,246	53.73	95.32	1	1	2	5	12	25	56	123	196	455	2,293
Censoring reason 4: end of query period	9,118	51.66	99.12	1	1	2	6	15	26	56	107	169	462	2,293
Censoring reason 5: death	33	67.73	102.52	2	2	4	6	13	23	73	187	403	410	410
ANDA 040480														
Censoring reason 1: product discontinuation	35,262	45.42	37.89	1	6	20	30	30	30	60	90	120	199	810
Censoring reason 2: end of available data	83	23.93	31.50	1	1	1	2	9	19	28	40	42	257	257
Censoring reason 3: end of enrollment	2,440	34.34	42.67	1	1	2	5	12	22	43	76	98	219	673
Censoring reason 4: end of query period	2,665	23.15	41.14	1	1	2	5	11	19	26	32	40	184	678
Censoring reason 5: death	1	26.00		26	26	26	26	26	26	26	26	26	26	26
Non-202424														
Censoring reason 1: product discontinuation	1,876,614	63.62	92.02	1	7	24	30	30	30	62	125	199	467	2,543
Censoring reason 2: end of available data	1,690	158.66	261.00	1	1	5	10	22	63	174	412	680	1,444	2,326
Censoring reason 3: end of enrollment	148,278	101.03	165.18	1	1	3	6	17	41	112	264	406	833	2,543
Censoring reason 4: end of query period	63,506	146.41	250.64	1	1	5	9	20	50	153	391	659	1,265	2,543
Censoring reason 5: death	225	168.60	245.31	1	2	6	10	25	74	214	465	699	1,186	1,695

Table 6. Descriptive Statistics of Treatment Exposure Duration, in Days, by Censoring Reason in the Sentinel Distributed Database (SDD) from January 1, 2013 to December 31, 2019

Product Group	Episodes (n)	Mean	Standard Deviation	Min	1%	5%	10%	25%	50%	75%	90%	95%	99%	Max
Non-040440														
Censoring reason 1: product discontinuation	2,166,552	66.35	96.81	1	7	24	30	30	30	64	130	215	498	2,543
Censoring reason 2: end of available data	1,840	170.78	272.34	1	1	5	12	23	71.5	184	451	728	1,451	2,326
Censoring reason 3: end of enrollment	177,914	107.69	170.88	1	1	3	7	18	45	122	283	431	854	2,543
Censoring reason 4: end of query period	74,914	161.78	263.90	1	1	5	11	22	60	169	448	708	1,300	2,543
Censoring reason 5: death	251	172.89	244.49	1	1	5	9	22	78	223	465	631	1,186	1,695
Non-040422														
Censoring reason 1: product discontinuation	887,560	57.05	70.25	1	7	25	30	30	30	60	109	174	360	2,293
Censoring reason 2: end of available data	367	96.84	223.35	1	1	5	9	16	40	96	212	313	1,499	2,293
Censoring reason 3: end of enrollment	61,487	72.93	114.39	1	1	3	6	15	30	83	180	279	565	2,293
Censoring reason 4: end of query period	28,810	100.97	166.36	1	1	4	9	19	41	110	262	421	876	2,293
Censoring reason 5: death	78	96.67	142.99	1	1	5	8	14	47	96	308	403	727	727
Non-040439														
Censoring reason 1: product discontinuation	2,103,515	65.76	95.72	1	7	25	30	30	30	63	128	211	494	2,543
Censoring reason 2: end of available data	1,814	174.95	278.77	1	1	6	12	25	73	187	461	793	1,444	2,456
Censoring reason 3: end of enrollment	170,729	107.32	171.54	1	1	3	7	18	44	120	282	433	858	2,543
Censoring reason 4: end of query period	68,519	168.47	272.54	1	1	5	11	22	61	179	466	758	1,323	2,543
Censoring reason 5: death	230	165.81	236.42	1	1	5	9	24	78	214	457	631	1,039	1,695
Non-040480														
Censoring reason 1: product discontinuation	2,176,338	66.67	97.70	1	7	24	30	30	30	64	130	216	506	2,543
Censoring reason 2: end of available data	1,788	179.64	283.09	1	1	6	12	25	75	202	490	807	1,470	2,326
Censoring reason 3: end of enrollment	179,189	109.69	173.42	1	1	3	7	18	45	125	289	442	862	2,543
Censoring reason 4: end of query period	73,481	173.09	276.54	1	1	5	11	22	61	194	491	777	1,335	2,543
Censoring reason 5: death	254	175.60	245.95	1	1	5	9	24	78.5	231	465	707	1,186	1,695

Table 7. Descriptive Statistics of Time to First Switch or Censoring, by Switch Pattern, in Days: Episode Level in the Sentinel Distributed Database (SDD) from January 1, 2013 to December 31, 2019

Switch Pattern	Episodes (n)	Mean	Standard Deviation	Min	1%	5%	10%	25%	50%	75%	90%	95%	99%	Max
ANDA 202424 to Non-202424 to ANDA 202424														
First Switch	36,696	75.47	105.60	0	0	1	2	7	36	98	203	261	513	1,599
Censoring reason 1: product discontinuation	113,043	45.75	78.89	0	0	0	0	2	30	60	123	188	377	1,740
Censoring reason 2: end of available data	42	103.81	107.16	1	1	2	10	30	80.5	148	232	285	484	484
Censoring reason 3: end of enrollment	9,523	96.34	120.69	0	0	2	7	22	55	125	230	323	597	1,560
Censoring reason 4: end of query period	4,239	105.04	135.57	0	1	3	6	23	60	124	257	358	625	1,559
Censoring reason 5: death	11	135.55	193.98	2	2	2	5	9	69	182	289	657	657	657
ANDA 040440 to Non-040440 to ANDA 040440														
First Switch	5,765	44.18	77.08	0	0	0	1	4	24	50	113	183	375	1,316
Censoring reason 1: product discontinuation	11,028	35.30	63.96	0	0	0	0	1	7	36	94	149	306	972
Censoring reason 2: end of available data	5	23.60	33.43	0	0	0	0	7	9	20	82	82	82	82
Censoring reason 3: end of enrollment	731	77.78	102.17	0	0	1	5	18	42	95	203	278	507	890
Censoring reason 4: end of query period	444	111.55	135.76	0	1	3	8	24	71	143	270	372	761	858
Censoring reason 5: death	2	3.50	3.54	1	1	1	1	1	3.5	6	6	6	6	6
ANDA 040422 to Non-040422 to ANDA 040422														
First Switch	45,190	104.98	168.02	0	0	1	2	8	40	124	278	417	855	2,154
Censoring reason 1: product discontinuation	424,750	69.22	126.07	0	0	0	0	3	30	75	186	293	622	2,483
Censoring reason 2: end of available data	637	193.47	275.90	0	1	5	12	32	88	232	507	798	1,391	2,005
Censoring reason 3: end of enrollment	43,095	151.14	199.67	0	0	4	11	29	80	195	379	548	970	2,483
Censoring reason 4: end of query period	18,327	210.15	295.83	0	1	4	12	31	93	257	584	844	1,382	2,483
Censoring reason 5: death	86	206.85	256.27	2	2	6	13	45	103.5	242	571	749	1,306	1,306
ANDA 040439 to Non-040439 to ANDA 040439														
First Switch	14,083	57.80	101.95	0	0	1	1	4	28	65	144	226	509	1,335
Censoring reason 1: product discontinuation	35,998	42.28	78.20	0	0	0	0	1	13	40	120	180	380	1,396
Censoring reason 2: end of available data	5	56.00	68.31	2	2	2	2	5	12	123	138	138	138	138
Censoring reason 3: end of enrollment	2,673	90.17	122.62	0	0	2	5	18	47	112	229	329	611	1,396
Censoring reason 4: end of query period	1,313	68.84	98.48	0	0	2	4	13	36	81	162	291	455	1,093
Censoring reason 5: death	8	113.25	146.72	2	2	2	2	21	35.5	221	350	350	350	350
ANDA 040480 to Non-040480 to ANDA 040480														
First Switch	3,062	42.47	51.70	0	0	1	2	5	30	62	102	136	240	723
Censoring reason 1: product discontinuation	4,178	25.15	41.31	0	0	0	0	0	6	32	66	97	191	613
Censoring reason 2: end of available data	2	44.00	21.21	29	29	29	29	29	44	59	59	59	59	59
Censoring reason 3: end of enrollment	313	41.59	64.03	0	0	1	3	10	22	51	91	171	321	613
Censoring reason 4: end of query period	57	117.11	136.53	1	1	4	5	26	67	124	298	364	613	613
Censoring reason 5: death	0													

Table 7. Descriptive Statistics of Time to First Switch or Censoring, by Switch Pattern, in Days: Episode Level in the Sentinel Distributed Database (SDD) from January 1, 2013 to December 31, 2019

Switch Pattern	Episodes (n)	Mean	Standard Deviation	Min	1%	5%	10%	25%	50%	75%	90%	95%	99%	Max
Non-202424 to ANDA 202424 to Non-202424														
First Switch	31,976	115.18	179.94	0	0	1	3	10	49	140	304	449	904	2,286
Censoring reason 1: product discontinuation	474,269	72.27	131.27	0	0	0	0	3	30	84	193	303	648	2,483
Censoring reason 2: end of available data	673	221.86	318.31	0	1	7	14	36	95	256	610	862	1,465	2,266
Censoring reason 3: end of enrollment	47,806	156.36	206.82	0	0	4	11	30	82	201	393	567	995	2,483
Censoring reason 4: end of query period	20,904	225.88	310.96	0	1	5	12	32	102	278	624	892	1,454	2,483
Censoring reason 5: death	98	202.85	248.93	1	1	4	13	35	103.5	242	571	749	1,306	1,306
Non-040440 to ANDA 040440 to Non-040440														
First Switch	14,382	166.35	219.71	0	0	2	5	31	90	217	424	604	1,063	2,140
Censoring reason 1: product discontinuation	587,904	77.08	137.69	0	0	0	0	3	31	91	210	323	681	2,483
Censoring reason 2: end of available data	758	226.55	318.01	0	1	5	15	37	99.5	264	610	883	1,520	2,266
Censoring reason 3: end of enrollment	60,165	163.58	212.56	0	0	5	12	31	87	211	414	588	1,018	2,483
Censoring reason 4: end of query period	26,965	238.22	323.10	0	1	5	13	35	106	292	663	929	1,506	2,483
Censoring reason 5: death	111	218.75	267.53	2	2	4	12	35	113	304	571	883	1,126	1,306
Non-040422 to ANDA 040422 to Non-040422														
First Switch	37,240	87.45	123.12	0	0	1	2	8	39	117	228	308	593	1,731
Censoring reason 1: product discontinuation	164,549	52.27	89.85	0	0	0	0	2	30	62	138	215	443	1,740
Censoring reason 2: end of available data	73	102.52	106.00	1	1	2	4	26	80	144	218	364	484	484
Censoring reason 3: end of enrollment	14,265	106.97	134.09	0	0	3	8	23	60	140	257	369	662	1,560
Censoring reason 4: end of query period	6,818	135.00	183.98	0	1	3	8	25	69	169	347	499	913	1,937
Censoring reason 5: death	25	148.08	192.01	1	1	2	2	13	57	248	350	657	667	667
Non-040439 to ANDA 040439 to Non-040439														
First Switch	24,556	117.15	176.58	0	0	1	3	15	58	139	303	459	872	2,154
Censoring reason 1: product discontinuation	561,328	75.73	136.27	0	0	0	0	3	30	90	208	317	677	2,483
Censoring reason 2: end of available data	769	228.37	312.98	0	1	6	15	38	98	268	653	892	1,465	2,005
Censoring reason 3: end of enrollment	57,553	163.11	211.79	0	0	5	12	31	86	211	415	590	1,010	2,483
Censoring reason 4: end of query period	25,620	246.03	327.42	0	1	5	14	37	110	304	707	935	1,493	2,483
Censoring reason 5: death	99	216.55	262.11	1	1	4	9	37	113	304	639	883	1,306	1,306
Non-040480 to ANDA 040480 to Non-040480														
First Switch	5,337	166.77	206.09	0	0	2	5	32	99	217	446	554	977	2,394
Censoring reason 1: product discontinuation	597,978	79.39	141.62	0	0	0	0	3	31	92	214	333	702	2,483
Censoring reason 2: end of available data	770	249.60	341.03	0	1	7	16	40	109	295	697	924	1,594	2,266
Censoring reason 3: end of enrollment	61,391	168.26	217.55	0	0	5	12	32	89	218	425	606	1,033	2,483
Censoring reason 4: end of query period	27,902	263.08	339.76	0	1	5	15	39	123	346	754	973	1,552	2,483
Censoring reason 5: death	112	226.87	272.62	1	2	4	12	36	117	331	647	883	1,126	1,306

Table 7. Descriptive Statistics of Time to First Switch or Censoring, by Switch Pattern, in Days: Episode Level in the Sentinel Distributed Database (SDD) from January 1, 2013 to December 31, 2019

Switch Pattern	Episodes (n)	Mean	Standard Deviation	Min	1%	5%	10%	25%	50%	75%	90%	95%	99%	Max
Non-202424 to ANDA 202424 to Same Non-202424														
First Switch	34,469	111.68	175.66	0	0	1	2	10	46	135	293	434	887	2,286
Censoring reason 1: product discontinuation	477,807	72.34	131.15	0	0	0	0	3	30	85	193	303	646	2,483
Censoring reason 2: end of available data	681	221.24	316.62	0	1	7	15	36	95	256	607	862	1,465	2,266
Censoring reason 3: end of enrollment	48,296	155.99	206.30	0	0	4	11	30	82	201	392	566	994	2,483
Censoring reason 4: end of query period	21,527	224.68	307.73	0	1	5	12	33	103	278	618	880	1,433	2,483
Censoring reason 5: death	99	203.01	247.66	1	1	4	13	35	108	242	571	749	1,306	1,306
Non-040440 to ANDA 040440 to Same Non-040440														
First Switch	15,204	162.44	216.10	0	0	2	5	31	88	212	411	588	1,044	2,140
Censoring reason 1: product discontinuation	590,381	77.19	137.68	0	0	0	0	3	31	91	210	324	681	2,483
Censoring reason 2: end of available data	772	226.55	316.14	0	1	5	15	38	101	264	607	864	1,520	2,266
Censoring reason 3: end of enrollment	60,593	163.41	212.23	0	0	5	12	31	86	211	413	586	1,018	2,483
Censoring reason 4: end of query period	27,718	236.30	320.10	0	1	5	13	36	106	291	655	925	1,492	2,483
Censoring reason 5: death	112	217.67	266.57	2	2	4	12	36	110.5	299	571	883	1,126	1,306
Non-040422 to ANDA 040422 to Same Non-040422														
First Switch	40,583	86.02	121.49	0	0	1	2	8	38	114	223	305	587	1,731
Censoring reason 1: product discontinuation	167,914	52.71	90.47	0	0	0	0	2	30	63	140	217	448	1,822
Censoring reason 2: end of available data	80	104.73	104.54	1	1	2	5	28	81.5	147	226	325	484	484
Censoring reason 3: end of enrollment	14,663	106.67	133.43	0	0	3	8	23	60	139	257	367	657	1,560
Censoring reason 4: end of query period	7,316	135.77	181.76	0	1	3	9	25	71	171	352	499	908	1,937
Censoring reason 5: death	25	148.08	192.01	1	1	2	2	13	57	248	350	657	667	667
Non-040439 to ANDA 040439 to Same Non-040439														
First Switch	26,277	113.79	172.68	0	0	1	3	14	56	134	291	447	859	2,154
Censoring reason 1: product discontinuation	564,498	75.89	136.38	0	0	0	0	3	30	90	208	318	677	2,483
Censoring reason 2: end of available data	787	226.21	310.56	0	1	6	15	37	96	267	638	887	1,465	2,005
Censoring reason 3: end of enrollment	57,975	162.98	211.61	0	0	5	12	31	86	210	415	589	1,009	2,483
Censoring reason 4: end of query period	26,259	244.69	324.87	0	1	5	14	37	112	302	696	932	1,487	2,483
Censoring reason 5: death	99	216.55	262.11	1	1	4	9	37	113	304	639	883	1,306	1,306
Non-040480 to ANDA 040480 to Same Non-040480														
First Switch	5,600	165.30	202.60	0	0	2	5	33	100	216	435	546	965	2,394
Censoring reason 1: product discontinuation	598,949	79.46	141.62	0	0	0	0	3	31	93	215	334	701	2,483
Censoring reason 2: end of available data	772	249.48	340.60	0	1	7	16	40	110	295	696	924	1,594	2,266
Censoring reason 3: end of enrollment	61,560	168.22	217.37	0	0	5	12	32	89	218	425	606	1,031	2,483
Censoring reason 4: end of query period	28,143	263.07	338.73	0	1	5	15	39	124	343	752	970	1,551	2,483
Censoring reason 5: death	112	226.87	272.62	1	2	4	12	36	117	331	647	883	1,126	1,306

Table 8. Descriptive Statistics of Time to Second Switch or Censoring, by Switch Pattern, in Days: Episode Level in the Sentinel Distributed Database (SDD) from January 1, 2013 to December 31, 2019

Switch Pattern	Episodes (n)	Mean	Standard Deviation	Min	1%	5%	10%	25%	50%	75%	90%	95%	99%	Max
ANDA 202424 to Non-202424 to ANDA 202424														
Second Switch	15,769	60.69	71.31	1	22	27	28	29	33	62	116	181	397	1,701
Censoring reason 1: product discontinuation	16,489	267.30	298.31	0	3	15	29	36	159	390	661	801	1,454	1,924
Censoring reason 2: end of available data	128	486.84	434.18	0	0	4	11	89	428	721	993	1,550	1,874	1,904
Censoring reason 3: end of enrollment	5,413	236.68	289.30	0	1	5	11	29	125	341	626	791	1,410	1,915
Censoring reason 4: end of query period	5,196	396.15	375.20	0	1	10	15	64	313	670	811	1,019	1,800	1,934
Censoring reason 5: death	8	454.00	417.71	38	38	38	38	108	389	690	1,221	1,221	1,221	1,221
ANDA 040440 to Non-040440 to ANDA 040440														
Second Switch	1,547	78.53	88.01	7	21	27	28	30	37	91	168	247	427	1,252
Censoring reason 1: product discontinuation	2,845	308.09	352.23	0	4	23	29	66	183	430	728	1,066	1,698	2,069
Censoring reason 2: end of available data	29	441.28	439.88	0	0	8	29	155	392	503	876	1,509	1,938	1,938
Censoring reason 3: end of enrollment	1,190	290.69	356.55	0	2	11	20	57	154	395	749	1,090	1,651	2,069
Censoring reason 4: end of query period	1,595	343.30	392.13	0	7	25	46	88	210	474	749	1,156	1,938	2,086
Censoring reason 5: death	1	157.00		157	157	157	157	157	157	157	157	157	157	157
ANDA 040422 to Non-040422 to ANDA 040422														
Second Switch	21,964	57.67	70.46	1	21	26	27	29	32	61	112	169	357	1,357
Censoring reason 1: product discontinuation	20,506	274.11	380.68	0	3	17	29	29	109	358	735	1,135	1,803	2,385
Censoring reason 2: end of available data	63	448.48	577.46	1	1	17	21	50	244	616	1,295	1,881	2,241	2,241
Censoring reason 3: end of enrollment	5,395	243.53	345.39	0	0	4	10	24	100	325	656	1,004	1,631	2,318
Censoring reason 4: end of query period	3,184	404.70	467.99	0	1	11	20	64	276	547	956	1,497	2,035	2,462
Censoring reason 5: death	14	346.57	419.91	5	5	5	10	15	264.5	427	746	1,520	1,520	1,520
ANDA 040439 to Non-040439 to ANDA 040439														
Second Switch	5,367	67.24	74.85	3	22	27	28	30	35	83	130	183	367	1,146
Censoring reason 1: product discontinuation	6,909	339.75	421.25	0	4	20	29	60	190	427	883	1,281	2,006	2,444
Censoring reason 2: end of available data	67	1,002.27	769.57	1	1	70	80	245	1015	1,786	2,069	2,218	2,402	2,402
Censoring reason 3: end of enrollment	2,425	346.94	436.54	0	1	7	14	50	186	440	960	1,336	2,008	2,402
Censoring reason 4: end of query period	2,108	500.56	546.44	0	3	15	27	105	342.5	662	1,283	1,903	2,283	2,479
Censoring reason 5: death	10	689.00	728.61	96	96	96	101	192	341.5	1,363	1,873	2,093	2,093	2,093
ANDA 040480 to Non-040480 to ANDA 040480														
Second Switch	738	104.82	104.40	8	23	27	28	30	56	177	267	300	422	624
Censoring reason 1: product discontinuation	1,648	258.61	223.67	0	5	29	29	98	215.5	310	586	728	994	1,784
Censoring reason 2: end of available data	26	335.04	382.92	10	10	11	29	141	237.5	309	615	1,198	1,784	1,784
Censoring reason 3: end of enrollment	656	236.15	219.03	0	2	12	24	74	197	299	537	673	994	1,784
Censoring reason 4: end of query period	797	408.82	288.35	0	11	68	190	247	288	604	773	971	1,198	2,001
Censoring reason 5: death	3	226.67	276.62	6	6	6	6	6	137	537	537	537	537	537

Table 8. Descriptive Statistics of Time to Second Switch or Censoring, by Switch Pattern, in Days: Episode Level in the Sentinel Distributed Database (SDD) from January 1, 2013 to December 31, 2019

Switch Pattern	Episodes (n)	Mean	Standard Deviation	Min	1%	5%	10%	25%	50%	75%	90%	95%	99%	Max
Non-202424 to ANDA 202424 to Non-202424														
Second Switch	16,720	56.89	66.13	1	21	26	27	29	32	61	101	160	331	1,658
Censoring reason 1: product discontinuation	13,652	245.14	339.03	0	4	17	29	29	94.5	313	666	1,000	1,625	2,018
Censoring reason 2: end of available data	40	212.35	304.18	5	5	9	11	26	104	265	605	786	1,582	1,582
Censoring reason 3: end of enrollment	3,320	208.23	306.52	0	0	4	9	23	81	260	585	888	1,539	1,933
Censoring reason 4: end of query period	1,866	353.67	429.51	0	2	11	20	58	210.5	486	923	1,323	1,967	2,041
Censoring reason 5: death	8	323.00	235.92	6	6	6	6	139	310.5	482	716	716	716	716
Non-040440 to ANDA 040440 to Non-040440														
Second Switch	8,382	44.00	42.56	2	20	26	27	29	31	36	71	95	231	1,090
Censoring reason 1: product discontinuation	5,727	121.87	212.99	0	3	16	29	29	29	114	332	499	1,158	2,099
Censoring reason 2: end of available data	7	117.00	134.40	3	3	3	3	5	59	196	365	365	365	365
Censoring reason 3: end of enrollment	783	93.97	171.72	0	0	2	4	13	26	88	273	456	893	1,629
Censoring reason 4: end of query period	326	200.40	247.24	0	1	5	12	21	84	321	624	760	922	1,022
Censoring reason 5: death	1	8.00		8	8	8	8	8	8	8	8	8	8	8
Non-040422 to ANDA 040422 to Non-040422														
Second Switch	17,288	61.53	80.24	2	21	27	28	29	32	61	117	188	428	1,701
Censoring reason 1: product discontinuation	16,489	286.46	356.26	0	3	16	29	29	149	393	705	1,023	1,744	2,444
Censoring reason 2: end of available data	110	694.75	602.28	0	0	14	71	229	556	963	1,737	1,938	2,258	2,402
Censoring reason 3: end of enrollment	5,171	261.98	343.71	0	0	5	11	31	132	349	683	968	1,671	2,402
Censoring reason 4: end of query period	4,039	438.53	461.60	0	1	11	20	74	298	680	942	1,477	2,091	2,455
Censoring reason 5: death	13	590.54	518.57	35	35	35	105	182	436	758	1,333	1,652	1,652	1,652
Non-040439 to ANDA 040439 to Non-040439														
Second Switch	13,117	47.78	53.97	1	20	26	27	29	31	51	87	119	250	1,332
Censoring reason 1: product discontinuation	10,359	170.93	280.14	0	3	15	29	29	54	197	460	696	1,518	2,318
Censoring reason 2: end of available data	7	195.71	252.83	22	22	22	22	25	29	400	671	671	671	671
Censoring reason 3: end of enrollment	1,888	143.58	237.49	0	0	3	6	16	41	171	423	619	1,189	2,318
Censoring reason 4: end of query period	1,235	267.02	335.73	0	1	6	13	28	113	438	726	820	1,574	2,412
Censoring reason 5: death	10	203.10	472.57	5	5	5	8	13	24	57	923	1,520	1,520	1,520
Non-040480 to ANDA 040480 to Non-040480														
Second Switch	2,817	51.29	41.42	1	21	26	27	29	32	60	97	137	199	573
Censoring reason 1: product discontinuation	1,964	99.49	139.15	0	1	10	20	29	29	102	285	411	639	1,280
Censoring reason 2: end of available data	24	89.25	159.00	0	0	0	1	6	26	38	432	435	486	486
Censoring reason 3: end of enrollment	438	63.07	109.42	0	0	2	3	12	26	60	149	337	558	838
Censoring reason 4: end of query period	669	94.07	195.11	0	0	1	4	11	19	28	406	533	879	1,285
Censoring reason 5: death	0													

Table 8. Descriptive Statistics of Time to Second Switch or Censoring, by Switch Pattern, in Days: Episode Level in the Sentinel Distributed Database (SDD) from January 1, 2013 to December 31, 2019

Switch Pattern	Episodes (n)	Mean	Standard Deviation	Min	1%	5%	10%	25%	50%	75%	90%	95%	99%	Max
Non-202424 to ANDA 202424 to Same Non-202424														
Second Switch	12,732	53.52	59.09	1	21	26	27	29	31	59	94	149	308	1,152
Censoring reason 1: product discontinuation	19,337	254.45	337.57	0	4	22	29	29	119	330	664	992	1,629	2,018
Censoring reason 2: end of available data	60	278.35	349.65	5	5	11	17	48	198	346	637	786	1,984	1,984
Censoring reason 3: end of enrollment	3,914	234.63	325.93	0	1	5	10	25	104	300	637	940	1,582	1,984
Censoring reason 4: end of query period	2,799	400.66	424.82	0	4	14	26	94	273	570	943	1,341	1,967	2,041
Censoring reason 5: death	8	323.00	235.92	6	6	6	6	139	310.5	482	716	716	716	716
Non-040440 to ANDA 040440 to Same Non-040440														
Second Switch	5,187	42.64	38.64	2	20	26	27	29	31	36	67	93	209	873
Censoring reason 1: product discontinuation	9,643	134.31	221.58	0	4	24	29	29	29	142	368	538	1,174	2,099
Censoring reason 2: end of available data	8	112.88	124.97	3	3	3	3	14	71.5	183	365	365	365	365
Censoring reason 3: end of enrollment	912	112.87	191.33	0	0	2	4	14	29	128	333	476	920	1,698
Censoring reason 4: end of query period	442	247.55	281.17	0	1	8	14	26	139	373	666	818	1,110	1,797
Censoring reason 5: death	1	8.00		8	8	8	8	8	8	8	8	8	8	8
Non-040422 to ANDA 040422 to Same Non-040422														
Second Switch	12,483	55.80	68.60	2	20	26	27	29	32	59	95	155	369	1,701
Censoring reason 1: product discontinuation	22,904	309.73	375.54	0	4	22	29	36	173	428	750	1,097	1,811	2,476
Censoring reason 2: end of available data	181	751.01	623.91	0	0	38	80	257	603	1,072	1,904	2,010	2,258	2,402
Censoring reason 3: end of enrollment	6,172	297.77	373.04	0	1	6	12	42	164	397	750	1,073	1,811	2,402
Censoring reason 4: end of query period	6,065	481.08	467.92	0	3	14	26	109	362	693	1,015	1,526	2,105	2,472
Censoring reason 5: death	19	613.05	583.78	35	35	35	67	158	387	1,221	1,652	1,756	1,756	1,756
Non-040439 to ANDA 040439 to Same Non-040439														
Second Switch	8,942	46.04	50.91	1	19	26	27	29	31	37	82	109	240	1,332
Censoring reason 1: product discontinuation	15,681	186.93	294.63	0	4	21	29	29	60	228	483	727	1,584	2,400
Censoring reason 2: end of available data	8	265.63	306.42	22	22	22	22	26	113	536	755	755	755	755
Censoring reason 3: end of enrollment	2,313	184.38	283.51	0	0	3	8	18	59	252	486	733	1,438	2,400
Censoring reason 4: end of query period	1,913	302.99	346.52	0	1	9	15	43	186	477	732	823	1,849	2,412
Censoring reason 5: death	11	227.45	455.54	5	5	5	10	13	26	325	471	1,520	1,520	1,520
Non-040480 to ANDA 040480 to Same Non-040480														
Second Switch	1,516	49.20	41.23	1	17	26	27	29	31	57	94	133	213	409
Censoring reason 1: product discontinuation	3,339	112.00	149.67	0	3	15	29	29	52	121	336	443	677	1,292
Censoring reason 2: end of available data	32	119.66	172.06	0	0	0	1	9	31	190	432	445	486	486
Censoring reason 3: end of enrollment	518	93.18	150.00	0	0	2	4	13	33.5	80	328	409	672	1,292
Censoring reason 4: end of query period	886	141.53	224.41	0	0	1	4	12	21.5	301	433	672	903	1,292
Censoring reason 5: death	0													

Table 9. Descriptive Statistics of Switch Pattern Episode Duration¹, by Switch Pattern in Days in the Sentinel Distributed Database (SDD) from January 1, 2013 to December 31, 2019

Switch	Switch Pattern	Switch Pattern Episodes (n)	Mean	Standard Deviation	Min	1%	5%	10%	25%	50%	75%	90%	95%	99%	Max
ANDA 202424 to Non-202424	ANDA 202424 to Non-202424 to ANDA 202424	153,338	141.67	127.08	60	60	60	60	64	93	163	278	373	678	2009
ANDA 040440 to Non-040440	ANDA 040440 to Non-040440 to ANDA 040440	17,185	143.31	131.93	60	60	60	60	64	94	164	277	384	677	2153
ANDA 040422 to Non-040422	ANDA 040422 to Non-040422 to ANDA 040422	485,437	148.28	155.80	60	60	60	60	64	93	160	300	427	836	2543
ANDA 040439 to Non-040439	ANDA 040439 to Non-040439 to ANDA 040439	51,214	140.03	133.13	60	60	60	60	64	93	158	272	373	687	2515
ANDA 040480 to Non-040480	ANDA 040480 to Non-040480 to ANDA 040480	7,287	155.74	132.52	60	60	60	60	64	96	189	341	415	681	1269
Non-202424_non to ANDA 202424	Non-202424_non to ANDA 202424 to Non-202424	524,014	147.57	156.75	60	60	60	60	64	93	159	297	426	842	2543
Non-040440_non to ANDA 040440	Non-040440_non to ANDA 040440 to Non-040440	625,227	148.17	159.49	60	60	60	60	64	92	158	300	434	866	2543
Non-040422_non to ANDA 040422	Non-040422_non to ANDA 040422 to Non-040422	207,640	142.73	134.35	60	60	60	60	64	93	160	282	392	720	2515
Non-040439_non to ANDA 040439	Non-040439_non to ANDA 040439 to Non-040439	607,676	148.41	159.17	60	60	60	60	64	93	159	300	433	865	2543
Non-040480_non to ANDA 040480	Non-040480_non to ANDA 040480 to Non-040480	627,156	148.50	161.10	60	60	60	60	64	92	158	300	438	875	2543
Non-202424_same to ANDA 202424	Non-202424_same to ANDA 202424 to Same Non-202424	530,593	147.18	155.44	60	60	60	60	64	93	159	295	423	838	2543
Non-040440_same to ANDA 040440	Non-040440_same to ANDA 040440 to Same Non-040440	629,184	147.68	158.06	60	60	60	60	64	92	158	297	430	857	2543
Non-040422_same to ANDA 040422	Non-040422_same to ANDA 040422 to Same Non-040422	214,774	141.76	131.29	60	60	60	60	64	93	160	278	385	701	2515
Non-040439_same to ANDA 040439	Non-040439_same to ANDA 040439 to Same Non-040439	613,116	147.89	157.81	60	60	60	60	64	93	158	296	428	857	2543
Non-040480_same to ANDA 040480	Non-040480_same to ANDA 040480 to Same Non-040480	628,595	148.31	160.39	60	60	60	60	64	92	158	300	435	870	2543

¹Switch Pattern Duration is calculated from the index dispensing date to episode end date of last switch product in a switch pattern. If no switch is observed, switch pattern duration is calculated from index dispensing until earliest censoring date due to product discontinuation, end of data/query, disenrollment or death

Table 10a. Frequency Distribution of Time to First Switch¹, by Switch Pattern, in Days in the Sentinel Distributed Database (SDD) from January 1, 2013 to December 31, 2019

Switch	ANDA 202424 to Non-202424		ANDA 040440 to Non-040440		ANDA 040422 to Non-040422		ANDA 040439 to Non-040439		ANDA 040480 to Non-040480		Non-202424 to ANDA 202424		Non-040440 to ANDA 040440	
Switch Pattern	ANDA 202424 to Non-202424 to ANDA 202424		ANDA 040440 to Non-040440 to ANDA 040440		ANDA 040422 to Non-040422 to ANDA 040422		ANDA 040439 to Non-040439 to ANDA 040439		ANDA 040480 to Non-040480 to ANDA 040480		Non-202424 to ANDA 202424 to Non-202424		Non-040440 to ANDA 040440 to Non-040440	
Number of Patients	33,954		5,584		41,893		13,369		2,988		30,113		13,929	
Days from Index	Episodes (N)	Episodes (%)	Episodes (N)	Episodes (%)	Episodes (N)	Episodes (%)	Episodes (N)	Episodes (%)	Episodes (N)	Episodes (%)	Episodes (N)	Episodes (%)	Episodes (N)	Episodes (%)
Overall	36,696	100.0%	5,765	100.0%	45,190	100.0%	14,083	100.0%	3,062	100.0%	31,976	100.0%	14,382	100.0%
0-30	15,423	42.0%	3,452	59.9%	17,716	39.2%	7,483	53.1%	1,579	51.6%	11,800	36.9%	3,497	24.3%
0-60	22,557	61.5%	4,531	78.6%	25,904	57.3%	10,241	72.7%	2,260	73.8%	17,356	54.3%	5,719	39.8%
0-90	26,503	72.2%	4,990	86.6%	30,361	67.2%	11,470	81.4%	2,627	85.8%	20,584	64.4%	7,209	50.1%
0-120	29,073	79.2%	5,228	90.7%	33,493	74.1%	12,217	86.7%	2,852	93.1%	22,804	71.3%	8,396	58.4%
0-150	30,904	84.2%	5,365	93.1%	35,645	78.9%	12,753	90.6%	2,942	96.1%	24,444	76.4%	9,330	64.9%
0-180	32,154	87.6%	5,469	94.9%	37,229	82.4%	13,064	92.8%	2,994	97.8%	25,674	80.3%	10,058	69.9%
0-210	33,305	90.8%	5,552	96.3%	38,549	85.3%	13,290	94.4%	3,012	98.4%	26,711	83.5%	10,640	74.0%
0-240	34,305	93.5%	5,613	97.4%	39,628	87.7%	13,443	95.5%	3,033	99.1%	27,555	86.2%	11,186	77.8%
0-270	35,022	95.4%	5,640	97.8%	40,471	89.6%	13,544	96.2%	3,043	99.4%	28,182	88.1%	11,640	80.9%
0-300	35,404	96.5%	5,670	98.4%	41,205	91.2%	13,631	96.8%	3,048	99.5%	28,727	89.8%	12,022	83.6%
0-330	35,651	97.2%	5,682	98.6%	41,828	92.6%	13,697	97.3%	3,054	99.7%	29,213	91.4%	12,315	85.6%
0-365	35,832	97.6%	5,700	98.9%	42,329	93.7%	13,769	97.8%	3,058	99.9%	29,638	92.7%	12,588	87.5%
366+	864	2.4%	65	1.1%	2,861	6.3%	314	2.2%	4	0.1%	2,338	7.3%	1,794	12.5%

¹Time to first switch after use of the same ANDA product for 60 days

Table 10a. Frequency Distribution of Time to First Switch, by Switch Pattern, in Days in the Sentinel Distributed Database (SDD) from January 1, 2013 to December 31, 2019

Non-040422 to ANDA 040422		Non-040439 to ANDA 040439		Non-040480 to ANDA 040480		Non-202424 to ANDA 202424		Non-040440 to ANDA 040440		Non-040422 to ANDA 040422		Non-040439 to ANDA 040439		Non-040480 to ANDA 040480	
Non-040422 to ANDA 040422 to Non-040422		Non-040439 to ANDA 040439 to Non-040439		Non-040480 to ANDA 040480 to Non-040480		Non-202424 to ANDA 202424 to Same Non- 202424		Non-040440 to ANDA 040440 to Same Non- 040440		Non-040422 to ANDA 040422 to Same Non- 040422		Non-040439 to ANDA 040439 to Same Non-040439		Non-040480 to ANDA 040480 to Same Non- 040480	
34,813		23,354		5,181		31,546		14,333		36,573		24,244		5,306	
Episodes (N)	Episodes (%)	Episodes (N)	Episodes (%)	Episodes (N)	Episodes (%)	Episodes (N)	Episodes (%)	Episodes (N)	Episodes (%)	Episodes (N)	Episodes (%)	Episodes (N)	Episodes (%)	Episodes (N)	Episodes (%)
37,240	100.0%	24,556	100.0%	5,337	100.0%	34,469	100.0%	15,204	100.0%	40,583	100.0%	26,277	100.0%	5,600	100.0%
14,716	39.5%	8,104	33.0%	1,208	22.6%	12,908	37.4%	3,767	24.8%	16,163	39.8%	8,805	33.5%	1,271	22.7%
21,618	58.1%	12,741	51.9%	1,952	36.6%	18,966	55.0%	6,139	40.4%	23,743	58.5%	13,837	52.7%	2,040	36.4%
25,570	68.7%	15,558	63.4%	2,502	46.9%	22,474	65.2%	7,737	50.9%	28,091	69.2%	16,874	64.2%	2,604	46.5%
28,225	75.8%	17,487	71.2%	2,957	55.4%	24,873	72.2%	8,990	59.1%	30,971	76.3%	18,935	72.1%	3,075	54.9%
30,214	81.1%	18,797	76.5%	3,329	62.4%	26,619	77.2%	9,968	65.6%	33,120	81.6%	20,325	77.3%	3,460	61.8%
31,624	84.9%	19,788	80.6%	3,608	67.6%	27,947	81.1%	10,743	70.7%	34,640	85.4%	21,370	81.3%	3,773	67.4%
32,850	88.2%	20,593	83.9%	3,925	73.5%	29,042	84.3%	11,366	74.8%	35,939	88.6%	22,214	84.5%	4,126	73.7%
33,903	91.0%	21,216	86.4%	4,187	78.5%	29,917	86.8%	11,935	78.5%	37,061	91.3%	22,863	87.0%	4,418	78.9%
34,739	93.3%	21,713	88.4%	4,376	82.0%	30,572	88.7%	12,411	81.6%	37,934	93.5%	23,377	89.0%	4,620	82.5%
35,269	94.7%	22,073	89.9%	4,483	84.0%	31,141	90.3%	12,807	84.2%	38,490	94.8%	23,752	90.4%	4,732	84.5%
35,622	95.7%	22,385	91.2%	4,582	85.9%	31,645	91.8%	13,108	86.2%	38,867	95.8%	24,077	91.6%	4,836	86.4%
35,929	96.5%	22,683	92.4%	4,661	87.3%	32,090	93.1%	13,388	88.1%	39,199	96.6%	24,377	92.8%	4,918	87.8%
1,311	3.5%	1,873	7.6%	676	12.7%	2,379	6.9%	1,816	11.9%	1,384	3.4%	1,900	7.2%	682	12.2%

Table 10b. Frequency Distribution of Time to First Switch, by Switch Pattern and Year, in Days, in the Sentinel Distributed Database (SDD) from January 1, 2013 to December 31, 2019¹

Switch	ANDA 202424 to Non-202424		ANDA 040440 to Non-040440		ANDA 040422 to Non-040422		ANDA 040439 to Non-040439		ANDA 040480 to Non-040480		Non-202424 to ANDA 202424		Non-040440 to ANDA 040440	
Switch Pattern	ANDA 202424 to Non-202424 to ANDA 202424		ANDA 040440 to Non-040440 to ANDA 040440		ANDA 040422 to Non-040422 to ANDA 040422		ANDA 040439 to Non-040439 to ANDA 040439		ANDA 040480 to Non-040480 to ANDA 040480		Non-202424 to ANDA 202424 to Non-202424		Non-040440 to ANDA 040440 to Non-040440	
Number of Patients	33,954		5,584		41,893		13,369		2,988		30,113		13,929	
Days from Index	Episodes (N)	Episodes (%)	Episodes (N)	Episodes (%)	Episodes (N)	Episodes (%)	Episodes (N)	Episodes (%)	Episodes (N)	Episodes (%)	Episodes (N)	Episodes (%)	Episodes (N)	Episodes (%)
Overall	36,696	100.0%	5,765	100.0%	45,190	100.0%	14,083	100.0%	3,062	100.0%	31,976	100.0%	14,382	100.0%
2013	0	0.0%	0	0.0%	4,847	10.7%	1,760	12.5%	0	0.0%	998	3.1%	740	5.1%
2014	2,135	5.8%	786	13.6%	6,136	13.6%	1,225	8.7%	26	0.8%	3,956	12.4%	1,035	7.2%
2015	1,758	4.8%	284	4.9%	3,573	7.9%	856	6.1%	6	0.2%	2,576	8.1%	585	4.1%
2016	2,700	7.4%	269	4.7%	4,335	9.6%	1,215	8.6%	268	8.8%	3,324	10.4%	961	6.7%
2017	13,250	36.1%	844	14.6%	8,223	18.2%	2,068	14.7%	731	23.9%	7,241	22.6%	4,231	29.4%
2018	10,019	27.3%	1,934	33.5%	12,259	27.1%	4,247	30.2%	1,322	43.2%	9,865	30.9%	4,514	31.4%
2019	6,834	18.6%	1,648	28.6%	5,817	12.9%	2,712	19.3%	709	23.2%	4,016	12.6%	2,316	16.1%
0-30	15,423	0.0%	3,452	0.0%	17,716	0.0%	7,483	0.0%	1,579	0.0%	11,800	0.0%	3,497	0.0%
2013	0	0.0%	0	0.0%	1,204	6.8%	937	12.5%	0	0.0%	0	0.0%	90	2.6%
2014	1,008	6.5%	414	12.0%	2,131	12.0%	597	8.0%	12	0.8%	1,239	10.5%	385	11.0%
2015	758	4.9%	145	4.2%	1,182	6.7%	293	3.9%	3	0.2%	858	7.3%	153	4.4%
2016	941	6.1%	135	3.9%	1,467	8.3%	449	6.0%	123	7.8%	984	8.3%	156	4.5%
2017	4,264	27.6%	474	13.7%	3,409	19.2%	779	10.4%	361	22.9%	2,738	23.2%	648	18.5%
2018	4,853	31.5%	1,195	34.6%	5,101	28.8%	2,569	34.3%	590	37.4%	3,817	32.3%	1,140	32.6%
2019	3,599	23.3%	1,089	31.5%	3,222	18.2%	1,859	24.8%	490	31.0%	2,164	18.3%	925	26.5%
0-60	22,557	0.0%	4,531	0.0%	25,904	0.0%	10,241	0.0%	2,260	0.0%	17,356	0.0%	5,719	0.0%
2013	0	0.0%	0	0.0%	1,937	7.5%	1,274	12.4%	0	0.0%	0	0.0%	163	2.9%
2014	1,464	6.5%	572	12.6%	3,276	12.6%	848	8.3%	19	0.8%	1,933	11.1%	562	9.8%
2015	1,047	4.6%	194	4.3%	1,781	6.9%	403	3.9%	5	0.2%	1,275	7.3%	230	4.0%
2016	1,369	6.1%	180	4.0%	2,124	8.2%	678	6.6%	164	7.3%	1,426	8.2%	234	4.1%
2017	6,491	28.8%	614	13.6%	4,877	18.8%	1,136	11.1%	538	23.8%	4,002	23.1%	1,129	19.7%
2018	6,956	30.8%	1,561	34.5%	7,407	28.6%	3,490	34.1%	909	40.2%	5,698	32.8%	1,927	33.7%
2019	5,230	23.2%	1,410	31.1%	4,502	17.4%	2,412	23.6%	625	27.7%	3,022	17.4%	1,474	25.8%
0-90	26,503	0.0%	4,990	0.0%	30,361	0.0%	11,470	0.0%	2,627	0.0%	20,584	0.0%	7,209	0.0%
2013	0	0.0%	0	0.0%	2,453	8.1%	1,439	12.5%	0	0.0%	4	0.0%	252	3.5%
2014	1,694	6.4%	654	13.1%	4,056	13.4%	942	8.2%	19	0.7%	2,449	11.9%	680	9.4%
2015	1,230	4.6%	214	4.3%	2,152	7.1%	478	4.2%	5	0.2%	1,525	7.4%	291	4.0%

Table 10b. Frequency Distribution of Time to First Switch, by Switch Pattern and Year, in Days, in the Sentinel Distributed Database (SDD) from January 1, 2013 to December 31, 2019¹

Switch	ANDA 202424 to Non-202424		ANDA 040440 to Non-040440		ANDA 040422 to Non-040422		ANDA 040439 to Non-040439		ANDA 040480 to Non-040480		Non-202424 to ANDA 202424		Non-040440 to ANDA 040440	
Switch Pattern	ANDA 202424 to Non-202424 to ANDA 202424		ANDA 040440 to Non-040440 to ANDA 040440		ANDA 040422 to Non-040422 to ANDA 040422		ANDA 040439 to Non-040439 to ANDA 040439		ANDA 040480 to Non-040480 to ANDA 040480		Non-202424 to ANDA 202424 to Non-202424		Non-040440 to ANDA 040440 to Non-040440	
Number of Patients	33,954		5,584		41,893		13,369		2,988		30,113		13,929	
Days from Index	Episodes (N)	Episodes (%)	Episodes (N)	Episodes (%)	Episodes (N)	Episodes (%)	Episodes (N)	Episodes (%)	Episodes (N)	Episodes (%)	Episodes (N)	Episodes (%)	Episodes (N)	Episodes (%)
2016	1,621	6.1%	209	4.2%	2,467	8.1%	799	7.0%	189	7.2%	1,701	8.3%	281	3.9%
2017	7,910	29.8%	690	13.8%	5,555	18.3%	1,433	12.5%	634	24.1%	4,676	22.7%	1,537	21.3%
2018	8,026	30.3%	1,708	34.2%	8,602	28.3%	3,819	33.3%	1,110	42.3%	6,785	33.0%	2,342	32.5%
2019	6,022	22.7%	1,515	30.4%	5,076	16.7%	2,560	22.3%	670	25.5%	3,444	16.7%	1,826	25.3%
0-120	29,073	0.0%	5,228	0.0%	33,493	0.0%	12,217	0.0%	2,852	0.0%	22,804	0.0%	8,396	0.0%
2013	0	0.0%	0	0.0%	2,856	8.5%	1,526	12.5%	0	0.0%	11	0.0%	321	3.8%
2014	1,834	6.3%	690	13.2%	4,632	13.8%	1,002	8.2%	23	0.8%	2,857	12.5%	770	9.2%
2015	1,351	4.6%	236	4.5%	2,414	7.2%	534	4.4%	5	0.2%	1,697	7.4%	328	3.9%
2016	1,775	6.1%	223	4.3%	2,768	8.3%	900	7.4%	203	7.1%	1,943	8.5%	319	3.8%
2017	9,053	31.1%	731	14.0%	6,001	17.9%	1,650	13.5%	678	23.8%	5,137	22.5%	1,862	22.2%
2018	8,635	29.7%	1,775	34.0%	9,406	28.1%	3,976	32.5%	1,255	44.0%	7,468	32.7%	2,734	32.6%
2019	6,425	22.1%	1,573	30.1%	5,416	16.2%	2,629	21.5%	688	24.1%	3,691	16.2%	2,062	24.6%
0-150	30,904	0.0%	5,365	0.0%	35,645	0.0%	12,753	0.0%	2,942	0.0%	24,444	0.0%	9,330	0.0%
2013	0	0.0%	0	0.0%	3,128	8.8%	1,593	12.5%	0	0.0%	39	0.2%	384	4.1%
2014	1,907	6.2%	719	13.4%	5,042	14.1%	1,036	8.1%	23	0.8%	3,166	13.0%	831	8.9%
2015	1,438	4.7%	250	4.7%	2,603	7.3%	575	4.5%	5	0.2%	1,836	7.5%	355	3.8%
2016	1,898	6.1%	230	4.3%	2,964	8.3%	966	7.6%	217	7.4%	2,095	8.6%	367	3.9%
2017	10,023	32.4%	750	14.0%	6,277	17.6%	1,815	14.2%	701	23.8%	5,460	22.3%	2,120	22.7%
2018	9,039	29.2%	1,812	33.8%	10,007	28.1%	4,098	32.1%	1,298	44.1%	7,998	32.7%	3,089	33.1%
2019	6,599	21.4%	1,604	29.9%	5,624	15.8%	2,670	20.9%	698	23.7%	3,850	15.8%	2,184	23.4%
0-180	32,154	0.0%	5,469	0.0%	37,229	0.0%	13,064	0.0%	2,994	0.0%	25,674	0.0%	10,058	0.0%
2013	0	0.0%	0	0.0%	3,374	9.1%	1,636	12.5%	0	0.0%	95	0.4%	442	4.4%
2014	1,949	6.1%	735	13.4%	5,301	14.2%	1,069	8.2%	25	0.8%	3,347	13.0%	867	8.6%
2015	1,488	4.6%	255	4.7%	2,739	7.4%	612	4.7%	5	0.2%	1,935	7.5%	377	3.7%
2016	1,979	6.2%	232	4.2%	3,104	8.3%	1,020	7.8%	243	8.1%	2,218	8.6%	420	4.2%
2017	10,738	33.4%	775	14.2%	6,513	17.5%	1,891	14.5%	711	23.7%	5,733	22.3%	2,343	23.3%
2018	9,303	28.9%	1,846	33.8%	10,469	28.1%	4,144	31.7%	1,308	43.7%	8,414	32.8%	3,348	33.3%
2019	6,697	20.8%	1,626	29.7%	5,729	15.4%	2,692	20.6%	702	23.4%	3,932	15.3%	2,261	22.5%

Table 10b. Frequency Distribution of Time to First Switch, by Switch Pattern and Year, in Days, in the Sentinel Distributed Database (SDD) from January 1, 2013 to December 31, 2019¹

Switch	ANDA 202424 to Non-202424		ANDA 040440 to Non-040440		ANDA 040422 to Non-040422		ANDA 040439 to Non-040439		ANDA 040480 to Non-040480		Non-202424 to ANDA 202424		Non-040440 to ANDA 040440	
Switch Pattern	ANDA 202424 to Non-202424 to ANDA 202424		ANDA 040440 to Non-040440 to ANDA 040440		ANDA 040422 to Non-040422 to ANDA 040422		ANDA 040439 to Non-040439 to ANDA 040439		ANDA 040480 to Non-040480 to ANDA 040480		Non-202424 to ANDA 202424 to Non-202424		Non-040440 to ANDA 040440 to Non-040440	
Number of Patients	33,954		5,584		41,893		13,369		2,988		30,113		13,929	
Days from Index	Episodes (N)	Episodes (%)	Episodes (N)	Episodes (%)	Episodes (N)	Episodes (%)	Episodes (N)	Episodes (%)	Episodes (N)	Episodes (%)	Episodes (N)	Episodes (%)	Episodes (N)	Episodes (%)
0-210	33,305	0.0%	5,552	0.0%	38,549	0.0%	13,290	0.0%	3,012	0.0%	26,711	0.0%	10,640	0.0%
2013	0	0.0%	0	0.0%	3,614	9.4%	1,672	12.6%	0	0.0%	198	0.7%	488	4.6%
2014	1,987	6.0%	748	13.5%	5,466	14.2%	1,094	8.2%	25	0.8%	3,470	13.0%	884	8.3%
2015	1,524	4.6%	265	4.8%	2,865	7.4%	650	4.9%	6	0.2%	2,023	7.6%	391	3.7%
2016	2,046	6.1%	236	4.3%	3,249	8.4%	1,042	7.8%	252	8.4%	2,345	8.8%	448	4.2%
2017	11,478	34.5%	799	14.4%	6,740	17.5%	1,938	14.6%	714	23.7%	5,976	22.4%	2,563	24.1%
2018	9,504	28.5%	1,866	33.6%	10,835	28.1%	4,188	31.5%	1,311	43.5%	8,719	32.6%	3,573	33.6%
2019	6,766	20.3%	1,638	29.5%	5,780	15.0%	2,706	20.4%	704	23.4%	3,980	14.9%	2,293	21.6%
0-240	34,305	0.0%	5,613	0.0%	39,628	0.0%	13,443	0.0%	3,033	0.0%	27,555	0.0%	11,186	0.0%
2013	0	0.0%	0	0.0%	3,813	9.6%	1,696	12.6%	0	0.0%	300	1.1%	533	4.8%
2014	2,014	5.9%	762	13.6%	5,603	14.1%	1,116	8.3%	25	0.8%	3,570	13.0%	909	8.1%
2015	1,559	4.5%	274	4.9%	2,958	7.5%	683	5.1%	6	0.2%	2,090	7.6%	401	3.6%
2016	2,130	6.2%	239	4.3%	3,385	8.5%	1,057	7.9%	259	8.5%	2,474	9.0%	475	4.2%
2017	12,117	35.3%	809	14.4%	6,919	17.5%	1,969	14.6%	721	23.8%	6,161	22.4%	2,771	24.8%
2018	9,676	28.2%	1,884	33.6%	11,146	28.1%	4,212	31.3%	1,314	43.3%	8,958	32.5%	3,791	33.9%
2019	6,809	19.8%	1,645	29.3%	5,804	14.6%	2,710	20.2%	708	23.3%	4,002	14.5%	2,306	20.6%
0-270	35,022	0.0%	5,640	0.0%	40,471	0.0%	13,544	0.0%	3,043	0.0%	28,182	0.0%	11,640	0.0%
2013	0	0.0%	0	0.0%	3,984	9.8%	1,712	12.6%	0	0.0%	387	1.4%	576	4.9%
2014	2,029	5.8%	767	13.6%	5,682	14.0%	1,127	8.3%	25	0.8%	3,627	12.9%	916	7.9%
2015	1,588	4.5%	277	4.9%	3,041	7.5%	701	5.2%	6	0.2%	2,134	7.6%	412	3.5%
2016	2,185	6.2%	242	4.3%	3,484	8.6%	1,067	7.9%	261	8.6%	2,564	9.1%	490	4.2%
2017	12,572	35.9%	815	14.5%	7,065	17.5%	2,001	14.8%	725	23.8%	6,298	22.3%	2,991	25.7%
2018	9,824	28.1%	1,892	33.5%	11,402	28.2%	4,224	31.2%	1,318	43.3%	9,160	32.5%	3,941	33.9%
2019	6,824	19.5%	1,647	29.2%	5,813	14.4%	2,712	20.0%	708	23.3%	4,012	14.2%	2,314	19.9%
0-300	35,404	0.0%	5,670	0.0%	41,205	0.0%	13,631	0.0%	3,048	0.0%	28,727	0.0%	12,022	0.0%
2013	0	0.0%	0	0.0%	4,138	10.0%	1,718	12.6%	0	0.0%	490	1.7%	602	5.0%
2014	2,041	5.8%	772	13.6%	5,732	13.9%	1,137	8.3%	25	0.8%	3,666	12.8%	927	7.7%
2015	1,607	4.5%	280	4.9%	3,111	7.6%	727	5.3%	6	0.2%	2,179	7.6%	421	3.5%

Table 10b. Frequency Distribution of Time to First Switch, by Switch Pattern and Year, in Days, in the Sentinel Distributed Database (SDD) from January 1, 2013 to December 31, 2019¹

Switch	ANDA 202424 to Non-202424		ANDA 040440 to Non-040440		ANDA 040422 to Non-040422		ANDA 040439 to Non-040439		ANDA 040480 to Non-040480		Non-202424 to ANDA 202424		Non-040440 to ANDA 040440	
Switch Pattern	ANDA 202424 to Non-202424 to ANDA 202424		ANDA 040440 to Non-040440 to ANDA 040440		ANDA 040422 to Non-040422 to ANDA 040422		ANDA 040439 to Non-040439 to ANDA 040439		ANDA 040480 to Non-040480 to ANDA 040480		Non-202424 to ANDA 202424 to Non-202424		Non-040440 to ANDA 040440 to Non-040440	
Number of Patients	33,954		5,584		41,893		13,369		2,988		30,113		13,929	
Days from Index	Episodes (N)	Episodes (%)	Episodes (N)	Episodes (%)	Episodes (N)	Episodes (%)	Episodes (N)	Episodes (%)	Episodes (N)	Episodes (%)	Episodes (N)	Episodes (%)	Episodes (N)	Episodes (%)
2016	2,236	6.3%	244	4.3%	3,578	8.7%	1,081	7.9%	264	8.7%	2,657	9.2%	510	4.2%
2017	12,817	36.2%	823	14.5%	7,185	17.4%	2,022	14.8%	725	23.8%	6,395	22.3%	3,139	26.1%
2018	9,869	27.9%	1,903	33.6%	11,644	28.3%	4,234	31.1%	1,319	43.3%	9,324	32.5%	4,107	34.2%
2019	6,834	19.3%	1,648	29.1%	5,817	14.1%	2,712	19.9%	709	23.3%	4,016	14.0%	2,316	19.3%
0-330	35,651	0.0%	5,682	0.0%	41,828	0.0%	13,697	0.0%	3,054	0.0%	29,213	0.0%	12,315	0.0%
2013	0	0.0%	0	0.0%	4,275	10.2%	1,724	12.6%	0	0.0%	568	1.9%	635	5.2%
2014	2,052	5.8%	775	13.6%	5,785	13.8%	1,140	8.3%	25	0.8%	3,706	12.7%	932	7.6%
2015	1,623	4.6%	280	4.9%	3,163	7.6%	750	5.5%	6	0.2%	2,217	7.6%	426	3.5%
2016	2,283	6.4%	245	4.3%	3,673	8.8%	1,090	8.0%	266	8.7%	2,736	9.4%	528	4.3%
2017	12,941	36.3%	823	14.5%	7,280	17.4%	2,040	14.9%	728	23.8%	6,486	22.2%	3,264	26.5%
2018	9,918	27.8%	1,911	33.6%	11,835	28.3%	4,241	31.0%	1,320	43.2%	9,484	32.5%	4,214	34.2%
2019	6,834	19.2%	1,648	29.0%	5,817	13.9%	2,712	19.8%	709	23.2%	4,016	13.7%	2,316	18.8%
0-365	35,832	0.0%	5,700	0.0%	42,329	0.0%	13,769	0.0%	3,058	0.0%	29,638	0.0%	12,588	0.0%
2013	0	0.0%	0	0.0%	4,385	10.4%	1,734	12.6%	0	0.0%	639	2.2%	659	5.2%
2014	2,061	5.8%	778	13.6%	5,816	13.7%	1,147	8.3%	25	0.8%	3,728	12.6%	942	7.5%
2015	1,637	4.6%	282	4.9%	3,215	7.6%	776	5.6%	6	0.2%	2,263	7.6%	433	3.4%
2016	2,343	6.5%	247	4.3%	3,735	8.8%	1,105	8.0%	268	8.8%	2,797	9.4%	548	4.4%
2017	13,007	36.3%	823	14.4%	7,398	17.5%	2,051	14.9%	729	23.8%	6,579	22.2%	3,385	26.9%
2018	9,950	27.8%	1,922	33.7%	11,963	28.3%	4,244	30.8%	1,321	43.2%	9,616	32.4%	4,305	34.2%
2019	6,834	19.1%	1,648	28.9%	5,817	13.7%	2,712	19.7%	709	23.2%	4,016	13.6%	2,316	18.4%
366+	864	100.0%	65	100.0%	2,861	0.0%	314	100.0%	4	100.0%	2,338	0.0%	1,794	0.0%
2013	0	0.0%	0	0.0%	462	16.1%	26	8.3%	0	0.0%	359	15.4%	81	4.5%
2014	74	8.6%	8	12.3%	320	11.2%	78	24.8%	1	25.0%	228	9.8%	93	5.2%
2015	121	14.0%	2	3.1%	358	12.5%	80	25.5%	0	0.0%	313	13.4%	152	8.5%
2016	357	41.3%	22	33.8%	600	21.0%	110	35.0%	0	0.0%	527	22.5%	413	23.0%
2017	243	28.1%	21	32.3%	825	28.8%	17	5.4%	2	50.0%	662	28.3%	846	47.2%
2018	69	8.0%	12	18.5%	296	10.3%	3	1.0%	1	25.0%	249	10.7%	209	11.6%
2019	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%

Table 10b. Frequency Distribution of Time to First Switch, by Switch Pattern and Year, in Days, in the Sentinel Distributed Database (SDD) from January 1, 2013 to December 31, 2019¹

Switch	ANDA 202424 to Non-202424	ANDA 040440 to Non-040440	ANDA 040422 to Non-040422	ANDA 040439 to Non-040439	ANDA 040480 to Non-040480	Non-202424 to ANDA 202424	Non-040440 to ANDA 040440
Switch Pattern	ANDA 202424 to Non-202424 to ANDA 202424	ANDA 040440 to Non-040440 to ANDA 040440	ANDA 040422 to Non-040422 to ANDA 040422	ANDA 040439 to Non-040439 to ANDA 040439	ANDA 040480 to Non-040480 to ANDA 040480	Non-202424 to ANDA 202424 to Non-202424	Non-040440 to ANDA 040440 to Non-040440
Number of Patients	33,954	5,584	41,893	13,369	2,988	30,113	13,929
Days from Index	Episodes (N) Episodes (%)	Episodes (N) Episodes (%)	Episodes (N) Episodes (%)	Episodes (N) Episodes (%)	Episodes (N) Episodes (%)	Episodes (N) Episodes (%)	Episodes (N) Episodes (%)

¹Time to first switch after use of the same ANDA product for 60 days

Table 10b. Frequency Distribution of Time to First Switch, by Switch Pattern and Year, in Days, in the Sentinel Distributed Database (SDD) from January 1, 2013 to December 31, 2019

Non-040422 to ANDA 040422		Non-040439 to ANDA 040439		Non-040480 to ANDA 040480		Non-202424 to ANDA 202424		Non-040440 to ANDA 040440		Non-040422 to ANDA 040422		Non-040439 to ANDA 040439		Non-040480 to ANDA 040480	
Non-040422 to ANDA 040422 to Non-040422		Non-040439 to ANDA 040439 to Non-040439		Non-040480 to ANDA 040480 to Non- 040480		Non-202424 to ANDA 202424 to Same Non- 202424		Non-040440 to ANDA 040440 to Same Non- 040440		Non-040422 to ANDA 040422 to Same Non- 040422		Non-040439 to ANDA 040439 to Same Non-040439		Non-040480 to ANDA 040480 to Same Non- 040480	
34,813		23,354		5,181		31,546		14,333		36,573		24,244		5,306	
Episodes (N)	Episodes (%)	Episodes (N)	Episodes (%)	Episodes (N)	Episodes (%)	Episodes (N)	Episodes (%)	Episodes (N)	Episodes (%)	Episodes (N)	Episodes (%)	Episodes (N)	Episodes (%)	Episodes (N)	Episodes (%)
37,240	100.0%	24,556	100.0%	5,337	100.0%	34,469	100.0%	15,204	100.0%	40,583	100.0%	26,277	100.0%	5,600	100.0%
1,753	4.7%	3,541	14.4%	18	0.3%	998	2.9%	740	4.9%	1,824	4.5%	3,605	13.7%	18	0.3%
3,408	9.2%	1,970	8.0%	94	1.8%	4,007	11.6%	1,064	7.0%	3,673	9.1%	2,034	7.7%	95	1.7%
2,399	6.4%	1,195	4.9%	169	3.2%	2,657	7.7%	603	4.0%	2,552	6.3%	1,243	4.7%	170	3.0%
3,388	9.1%	1,626	6.6%	495	9.3%	3,417	9.9%	977	6.4%	3,540	8.7%	1,684	6.4%	500	8.9%
11,713	31.5%	5,455	22.2%	2,215	41.5%	7,542	21.9%	4,359	28.7%	12,206	30.1%	5,570	21.2%	2,262	40.4%
8,599	23.1%	7,305	29.7%	1,697	31.8%	11,190	32.5%	4,937	32.5%	9,846	24.3%	7,951	30.3%	1,803	32.2%
5,980	16.1%	3,464	14.1%	649	12.2%	4,658	13.5%	2,524	16.6%	6,942	17.1%	4,190	15.9%	752	13.4%
14,716	0.0%	8,104	0.0%	1,208	0.0%	12,908	0.0%	3,767	0.0%	16,163	0.0%	8,805	0.0%	1,271	0.0%
947	6.4%	1,141	14.1%	0	0.0%	0	0.0%	90	2.4%	987	6.1%	1,168	13.3%	0	0.0%
1,630	11.1%	642	7.9%	14	1.2%	1,265	9.8%	402	10.7%	1,742	10.8%	670	7.6%	14	1.1%
972	6.6%	328	4.0%	32	2.6%	892	6.9%	160	4.2%	1,035	6.4%	346	3.9%	33	2.6%
1,172	8.0%	548	6.8%	99	8.2%	1,029	8.0%	163	4.3%	1,239	7.7%	580	6.6%	101	7.9%
3,401	23.1%	1,320	16.3%	411	34.0%	2,848	22.1%	688	18.3%	3,603	22.3%	1,364	15.5%	431	33.9%
3,498	23.8%	2,499	30.8%	446	36.9%	4,352	33.7%	1,247	33.1%	3,963	24.5%	2,732	31.0%	469	36.9%
3,096	21.0%	1,626	20.1%	206	17.1%	2,522	19.5%	1,017	27.0%	3,594	22.2%	1,945	22.1%	223	17.5%
21,618	0.0%	12,741	0.0%	1,952	0.0%	18,966	0.0%	6,139	0.0%	23,743	0.0%	13,837	0.0%	2,040	0.0%
1,277	5.9%	1,830	14.4%	0	0.0%	0	0.0%	163	2.7%	1,327	5.6%	1,871	13.5%	0	0.0%
2,338	10.8%	1,019	8.0%	23	1.2%	1,969	10.4%	583	9.5%	2,497	10.5%	1,057	7.6%	23	1.1%
1,334	6.2%	508	4.0%	46	2.4%	1,320	7.0%	243	4.0%	1,417	6.0%	535	3.9%	47	2.3%
1,724	8.0%	787	6.2%	163	8.4%	1,485	7.8%	241	3.9%	1,810	7.6%	826	6.0%	165	8.1%
5,241	24.2%	2,164	17.0%	668	34.2%	4,161	21.9%	1,186	19.3%	5,533	23.3%	2,228	16.1%	701	34.4%
5,162	23.9%	3,983	31.3%	728	37.3%	6,496	34.3%	2,120	34.5%	5,868	24.7%	4,356	31.5%	757	37.1%
4,542	21.0%	2,450	19.2%	324	16.6%	3,535	18.6%	1,603	26.1%	5,291	22.3%	2,964	21.4%	347	17.0%
25,570	0.0%	15,558	0.0%	2,502	0.0%	22,474	0.0%	7,737	0.0%	28,091	0.0%	16,874	0.0%	2,604	0.0%
1,443	5.6%	2,272	14.6%	1	0.0%	4	0.0%	252	3.3%	1,501	5.3%	2,318	13.7%	1	0.0%
2,686	10.5%	1,248	8.0%	39	1.6%	2,490	11.1%	704	9.1%	2,866	10.2%	1,292	7.7%	39	1.5%
1,575	6.2%	623	4.0%	53	2.1%	1,577	7.0%	305	3.9%	1,681	6.0%	657	3.9%	54	2.1%

Table 10b. Frequency Distribution of Time to First Switch, by Switch Pattern and Year, in Days, in the Sentinel Distributed Database (SDD) from January 1, 2013 to December 31, 2019

Non-040422 to ANDA 040422		Non-040439 to ANDA 040439		Non-040480 to ANDA 040480		Non-202424 to ANDA 202424		Non-040440 to ANDA 040440		Non-040422 to ANDA 040422		Non-040439 to ANDA 040439		Non-040480 to ANDA 040480	
Non-040422 to ANDA 040422 to Non-040422		Non-040439 to ANDA 040439 to Non-040439		Non-040480 to ANDA 040480 to Non- 040480		Non-202424 to ANDA 202424 to Same Non- 202424		Non-040440 to ANDA 040440 to Same Non- 040440		Non-040422 to ANDA 040422 to Same Non- 040422		Non-040439 to ANDA 040439 to Same Non-040439		Non-040480 to ANDA 040480 to Same Non- 040480	
34,813		23,354		5,181		31,546		14,333		36,573		24,244		5,306	
Episodes (N)	Episodes (%)	Episodes (N)	Episodes (%)	Episodes (N)	Episodes (%)	Episodes (N)	Episodes (%)	Episodes (N)	Episodes (%)	Episodes (N)	Episodes (%)	Episodes (N)	Episodes (%)	Episodes (N)	Episodes (%)
2,040	8.0%	903	5.8%	197	7.9%	1,766	7.9%	288	3.7%	2,139	7.6%	949	5.6%	200	7.7%
6,494	25.4%	2,720	17.5%	869	34.7%	4,875	21.7%	1,609	20.8%	6,840	24.3%	2,796	16.6%	907	34.8%
6,128	24.0%	4,925	31.7%	933	37.3%	7,740	34.4%	2,585	33.4%	6,998	24.9%	5,395	32.0%	968	37.2%
5,204	20.4%	2,867	18.4%	410	16.4%	4,022	17.9%	1,994	25.8%	6,066	21.6%	3,467	20.5%	435	16.7%
28,225	0.0%	17,487	0.0%	2,957	0.0%	24,873	0.0%	8,990	0.0%	30,971	0.0%	18,935	0.0%	3,075	0.0%
1,530	5.4%	2,611	14.9%	1	0.0%	11	0.0%	321	3.6%	1,593	5.1%	2,665	14.1%	1	0.0%
2,885	10.2%	1,415	8.1%	47	1.6%	2,901	11.7%	794	8.8%	3,087	10.0%	1,468	7.8%	47	1.5%
1,737	6.2%	725	4.1%	58	2.0%	1,754	7.1%	343	3.8%	1,853	6.0%	761	4.0%	59	1.9%
2,264	8.0%	976	5.6%	228	7.7%	2,016	8.1%	329	3.7%	2,372	7.7%	1,025	5.4%	232	7.5%
7,510	26.6%	3,078	17.6%	1,059	35.8%	5,364	21.6%	1,944	21.6%	7,894	25.5%	3,160	16.7%	1,098	35.7%
6,752	23.9%	5,551	31.7%	1,093	37.0%	8,520	34.3%	3,014	33.5%	7,712	24.9%	6,063	32.0%	1,137	37.0%
5,547	19.7%	3,131	17.9%	471	15.9%	4,307	17.3%	2,245	25.0%	6,460	20.9%	3,793	20.0%	501	16.3%
30,214	0.0%	18,797	0.0%	3,329	0.0%	26,619	0.0%	9,968	0.0%	33,120	0.0%	20,325	0.0%	3,460	0.0%
1,595	5.3%	2,814	15.0%	2	0.1%	39	0.1%	384	3.9%	1,660	5.0%	2,872	14.1%	2	0.1%
3,004	9.9%	1,527	8.1%	51	1.5%	3,211	12.1%	856	8.6%	3,218	9.7%	1,583	7.8%	51	1.5%
1,859	6.2%	795	4.2%	59	1.8%	1,896	7.1%	371	3.7%	1,980	6.0%	834	4.1%	60	1.7%
2,416	8.0%	1,027	5.5%	255	7.7%	2,170	8.2%	378	3.8%	2,530	7.6%	1,077	5.3%	259	7.5%
8,363	27.7%	3,371	17.9%	1,207	36.3%	5,699	21.4%	2,213	22.2%	8,782	26.5%	3,457	17.0%	1,246	36.0%
7,246	24.0%	5,978	31.8%	1,239	37.2%	9,122	34.3%	3,392	34.0%	8,287	25.0%	6,529	32.1%	1,291	37.3%
5,731	19.0%	3,285	17.5%	516	15.5%	4,482	16.8%	2,374	23.8%	6,663	20.1%	3,973	19.5%	551	15.9%
31,624	0.0%	19,788	0.0%	3,608	0.0%	27,947	0.0%	10,743	0.0%	34,640	0.0%	21,370	0.0%	3,773	0.0%
1,638	5.2%	2,967	15.0%	2	0.1%	95	0.3%	442	4.1%	1,704	4.9%	3,025	14.2%	2	0.1%
3,085	9.8%	1,621	8.2%	57	1.6%	3,392	12.1%	892	8.3%	3,307	9.5%	1,679	7.9%	57	1.5%
1,927	6.1%	838	4.2%	60	1.7%	2,000	7.2%	393	3.7%	2,054	5.9%	880	4.1%	61	1.6%
2,528	8.0%	1,059	5.4%	275	7.6%	2,298	8.2%	432	4.0%	2,646	7.6%	1,111	5.2%	279	7.4%
9,012	28.5%	3,650	18.4%	1,303	36.1%	5,988	21.4%	2,443	22.7%	9,452	27.3%	3,743	17.5%	1,343	35.6%
7,597	24.0%	6,277	31.7%	1,352	37.5%	9,603	34.4%	3,678	34.2%	8,696	25.1%	6,847	32.0%	1,417	37.6%
5,837	18.5%	3,376	17.1%	559	15.5%	4,571	16.4%	2,463	22.9%	6,781	19.6%	4,085	19.1%	614	16.3%

Table 10b. Frequency Distribution of Time to First Switch, by Switch Pattern and Year, in Days, in the Sentinel Distributed Database (SDD) from January 1, 2013 to December 31, 2019

Non-040422 to ANDA 040422		Non-040439 to ANDA 040439		Non-040480 to ANDA 040480		Non-202424 to ANDA 202424		Non-040440 to ANDA 040440		Non-040422 to ANDA 040422		Non-040439 to ANDA 040439		Non-040480 to ANDA 040480	
Non-040422 to ANDA 040422 to Non-040422		Non-040439 to ANDA 040439 to Non-040439		Non-040480 to ANDA 040480 to Non- 040480		Non-202424 to ANDA 202424 to Same Non- 202424		Non-040440 to ANDA 040440 to Same Non- 040440		Non-040422 to ANDA 040422 to Same Non- 040422		Non-040439 to ANDA 040439 to Same Non-040439		Non-040480 to ANDA 040480 to Same Non- 040480	
34,813		23,354		5,181		31,546		14,333		36,573		24,244		5,306	
Episodes (N)	Episodes (%)	Episodes (N)	Episodes (%)	Episodes (N)	Episodes (%)	Episodes (N)	Episodes (%)	Episodes (N)	Episodes (%)	Episodes (N)	Episodes (%)	Episodes (N)	Episodes (%)	Episodes (N)	Episodes (%)
32,850	0.0%	20,593	0.0%	3,925	0.0%	29,042	0.0%	11,366	0.0%	35,939	0.0%	22,214	0.0%	4,126	0.0%
1,669	5.1%	3,080	15.0%	2	0.1%	198	0.7%	488	4.3%	1,735	4.8%	3,140	14.1%	2	0.0%
3,151	9.6%	1,681	8.2%	61	1.6%	3,515	12.1%	911	8.0%	3,376	9.4%	1,741	7.8%	61	1.5%
1,995	6.1%	890	4.3%	68	1.7%	2,093	7.2%	407	3.6%	2,128	5.9%	935	4.2%	69	1.7%
2,598	7.9%	1,094	5.3%	289	7.4%	2,428	8.4%	460	4.0%	2,720	7.6%	1,146	5.2%	293	7.1%
9,684	29.5%	3,910	19.0%	1,429	36.4%	6,242	21.5%	2,668	23.5%	10,143	28.2%	4,009	18.0%	1,470	35.6%
7,847	23.9%	6,514	31.6%	1,461	37.2%	9,946	34.2%	3,933	34.6%	8,977	25.0%	7,100	32.0%	1,541	37.3%
5,906	18.0%	3,424	16.6%	615	15.7%	4,620	15.9%	2,499	22.0%	6,860	19.1%	4,143	18.7%	690	16.7%
33,903	0.0%	21,216	0.0%	4,187	0.0%	29,917	0.0%	11,935	0.0%	37,061	0.0%	22,863	0.0%	4,418	0.0%
1,688	5.0%	3,160	14.9%	3	0.1%	300	1.0%	533	4.5%	1,755	4.7%	3,223	14.1%	3	0.1%
3,190	9.4%	1,738	8.2%	63	1.5%	3,615	12.1%	936	7.8%	3,423	9.2%	1,800	7.9%	63	1.4%
2,056	6.1%	931	4.4%	79	1.9%	2,161	7.2%	417	3.5%	2,192	5.9%	976	4.3%	80	1.8%
2,677	7.9%	1,123	5.3%	306	7.3%	2,560	8.6%	488	4.1%	2,800	7.6%	1,176	5.1%	310	7.0%
10,273	30.3%	4,131	19.5%	1,575	37.6%	6,432	21.5%	2,884	24.2%	10,743	29.0%	4,234	18.5%	1,616	36.6%
8,075	23.8%	6,685	31.5%	1,525	36.4%	10,207	34.1%	4,163	34.9%	9,245	24.9%	7,283	31.9%	1,614	36.5%
5,944	17.5%	3,448	16.3%	636	15.2%	4,642	15.5%	2,514	21.1%	6,903	18.6%	4,171	18.2%	732	16.6%
34,739	0.0%	21,713	0.0%	4,376	0.0%	30,572	0.0%	12,411	0.0%	37,934	0.0%	23,377	0.0%	4,620	0.0%
1,705	4.9%	3,216	14.8%	3	0.1%	387	1.3%	576	4.6%	1,772	4.7%	3,279	14.0%	3	0.1%
3,214	9.3%	1,771	8.2%	65	1.5%	3,673	12.0%	944	7.6%	3,450	9.1%	1,833	7.8%	65	1.4%
2,099	6.0%	963	4.4%	93	2.1%	2,208	7.2%	428	3.4%	2,238	5.9%	1,008	4.3%	94	2.0%
2,729	7.9%	1,150	5.3%	316	7.2%	2,651	8.7%	503	4.1%	2,853	7.5%	1,203	5.1%	320	6.9%
10,771	31.0%	4,324	19.9%	1,663	38.0%	6,574	21.5%	3,109	25.1%	11,246	29.6%	4,430	19.0%	1,705	36.9%
8,252	23.8%	6,829	31.5%	1,591	36.4%	10,425	34.1%	4,329	34.9%	9,446	24.9%	7,438	31.8%	1,685	36.5%
5,969	17.2%	3,460	15.9%	645	14.7%	4,654	15.2%	2,522	20.3%	6,929	18.3%	4,186	17.9%	748	16.2%
35,269	0.0%	22,073	0.0%	4,483	0.0%	31,141	0.0%	12,807	0.0%	38,490	0.0%	23,752	0.0%	4,732	0.0%
1,711	4.9%	3,263	14.8%	7	0.2%	490	1.6%	602	4.7%	1,779	4.6%	3,326	14.0%	7	0.1%
3,238	9.2%	1,793	8.1%	66	1.5%	3,712	11.9%	955	7.5%	3,478	9.0%	1,855	7.8%	66	1.4%
2,137	6.1%	995	4.5%	104	2.3%	2,253	7.2%	438	3.4%	2,277	5.9%	1,041	4.4%	105	2.2%

Table 10b. Frequency Distribution of Time to First Switch, by Switch Pattern and Year, in Days, in the Sentinel Distributed Database (SDD) from January 1, 2013 to December 31, 2019

Non-040422 to ANDA 040422		Non-040439 to ANDA 040439		Non-040480 to ANDA 040480		Non-202424 to ANDA 202424		Non-040440 to ANDA 040440		Non-040422 to ANDA 040422		Non-040439 to ANDA 040439		Non-040480 to ANDA 040480	
Non-040422 to ANDA 040422 to Non-040422		Non-040439 to ANDA 040439 to Non-040439		Non-040480 to ANDA 040480 to Non- 040480		Non-202424 to ANDA 202424 to Same Non- 202424		Non-040440 to ANDA 040440 to Same Non- 040440		Non-040422 to ANDA 040422 to Same Non- 040422		Non-040439 to ANDA 040439 to Same Non-040439		Non-040480 to ANDA 040480 to Same Non- 040480	
34,813		23,354		5,181		31,546		14,333		36,573		24,244		5,306	
Episodes (N)	Episodes (%)	Episodes (N)	Episodes (%)	Episodes (N)	Episodes (%)	Episodes (N)	Episodes (%)	Episodes (N)	Episodes (%)	Episodes (N)	Episodes (%)	Episodes (N)	Episodes (%)	Episodes (N)	Episodes (%)
2,780	7.9%	1,179	5.3%	323	7.2%	2,746	8.8%	523	4.1%	2,905	7.5%	1,233	5.2%	327	6.9%
11,076	31.4%	4,442	20.1%	1,721	38.4%	6,674	21.4%	3,259	25.4%	11,554	30.0%	4,550	19.2%	1,763	37.3%
8,347	23.7%	6,937	31.4%	1,613	36.0%	10,608	34.1%	4,506	35.2%	9,555	24.8%	7,557	31.8%	1,712	36.2%
5,980	17.0%	3,464	15.7%	649	14.5%	4,658	15.0%	2,524	19.7%	6,942	18.0%	4,190	17.6%	752	15.9%
35,622	0.0%	22,385	0.0%	4,582	0.0%	31,645	0.0%	13,108	0.0%	38,867	0.0%	24,077	0.0%	4,836	0.0%
1,717	4.8%	3,317	14.8%	7	0.2%	568	1.8%	635	4.8%	1,785	4.6%	3,381	14.0%	7	0.1%
3,251	9.1%	1,812	8.1%	67	1.5%	3,752	11.9%	960	7.3%	3,497	9.0%	1,875	7.8%	67	1.4%
2,172	6.1%	1,022	4.6%	105	2.3%	2,292	7.2%	443	3.4%	2,313	6.0%	1,068	4.4%	106	2.2%
2,824	7.9%	1,202	5.4%	345	7.5%	2,825	8.9%	541	4.1%	2,949	7.6%	1,256	5.2%	349	7.2%
11,256	31.6%	4,526	20.2%	1,768	38.6%	6,768	21.4%	3,386	25.8%	11,739	30.2%	4,634	19.2%	1,812	37.5%
8,422	23.6%	7,042	31.5%	1,641	35.8%	10,782	34.1%	4,619	35.2%	9,642	24.8%	7,673	31.9%	1,743	36.0%
5,980	16.8%	3,464	15.5%	649	14.2%	4,658	14.7%	2,524	19.3%	6,942	17.9%	4,190	17.4%	752	15.6%
35,929	0.0%	22,683	0.0%	4,661	0.0%	32,090	0.0%	13,388	0.0%	39,199	0.0%	24,377	0.0%	4,918	0.0%
1,728	4.8%	3,359	14.8%	7	0.2%	639	2.0%	659	4.9%	1,796	4.6%	3,423	14.0%	7	0.1%
3,271	9.1%	1,822	8.0%	67	1.4%	3,776	11.8%	970	7.2%	3,518	9.0%	1,885	7.7%	67	1.4%
2,208	6.1%	1,044	4.6%	110	2.4%	2,340	7.3%	450	3.4%	2,352	6.0%	1,090	4.5%	111	2.3%
2,892	8.0%	1,232	5.4%	356	7.6%	2,886	9.0%	561	4.2%	3,020	7.7%	1,286	5.3%	360	7.3%
11,359	31.6%	4,627	20.4%	1,810	38.8%	6,866	21.4%	3,508	26.2%	11,843	30.2%	4,735	19.4%	1,854	37.7%
8,491	23.6%	7,135	31.5%	1,662	35.7%	10,925	34.0%	4,716	35.2%	9,728	24.8%	7,768	31.9%	1,767	35.9%
5,980	16.6%	3,464	15.3%	649	13.9%	4,658	14.5%	2,524	18.9%	6,942	17.7%	4,190	17.2%	752	15.3%
1,311	0.0%	1,873	0.0%	676	100.0%	2,379	0.0%	1,816	0.0%	1,384	0.0%	1,900	0.0%	682	100.0%
25	1.9%	182	9.7%	11	1.6%	359	15.1%	81	4.5%	28	2.0%	182	9.6%	11	1.6%
137	10.5%	148	7.9%	27	4.0%	231	9.7%	94	5.2%	155	11.2%	149	7.8%	28	4.1%
191	14.6%	151	8.1%	59	8.7%	317	13.3%	153	8.4%	200	14.5%	153	8.1%	59	8.7%
496	37.8%	394	21.0%	139	20.6%	531	22.3%	416	22.9%	520	37.6%	398	20.9%	140	20.5%
354	27.0%	828	44.2%	405	59.9%	676	28.4%	851	46.9%	363	26.2%	835	43.9%	408	59.8%
108	8.2%	170	9.1%	35	5.2%	265	11.1%	221	12.2%	118	8.5%	183	9.6%	36	5.3%
0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%

Table 10b. Frequency Distribution of Time to First Switch, by Switch Pattern and Year, in Days, in the Sentinel Distributed Database (SDD) from January 1, 2013 to December 31, 2019

Non-040422 to ANDA 040422	Non-040439 to ANDA 040439	Non-040480 to ANDA 040480	Non-202424 to ANDA 202424	Non-040440 to ANDA 040440	Non-040422 to ANDA 040422	Non-040439 to ANDA 040439	Non-040480 to ANDA 040480
Non-040422 to ANDA 040422 to Non-040422	Non-040439 to ANDA 040439 to Non-040439	Non-040480 to ANDA 040480 to Non- 040480	Non-202424 to ANDA 202424 to Same Non- 202424	Non-040440 to ANDA 040440 to Same Non- 040440	Non-040422 to ANDA 040422 to Same Non- 040422	Non-040439 to ANDA 040439 to Same Non-040439	Non-040480 to ANDA 040480 to Same Non- 040480
34,813	23,354	5,181	31,546	14,333	36,573	24,244	5,306
Episodes Episodes (N) (%)	Episodes Episodes (N) (%)	Episodes Episodes (N) (%)	Episodes Episodes (N) (%)	Episodes Episodes (N) (%)	Episodes Episodes (N) (%)	Episodes Episodes (N) (%)	Episodes Episodes (N) (%)

Table 11a. Frequency Distribution of Time to Second Switch, by Switch Pattern, in Days in the Sentinel Distributed Database (SDD) from January 1, 2013 to December 31, 2019

Switch	Non-202424 to ANDA 202424		Non-040440 to ANDA 040440		Non-040422 to ANDA 040422		Non-040439 to ANDA 040439		Non-040480 to ANDA 040480		ANDA 202424 to Non-202424		ANDA 040440 to Non-040440	
Switch Pattern	ANDA 202424 to Non-202424 to ANDA 202424		ANDA 040440 to Non-040440 to ANDA 040440		ANDA 040422 to Non-040422 to ANDA 040422		ANDA 040439 to Non-040439 to ANDA 040439		ANDA 040480 to Non-040480 to ANDA 040480		Non-202424 to ANDA 202424 to Non-202424		Non-040440 to ANDA 040440 to Non-040440	
Number of Patients	15,058		1,528		20,989		5,203		736		16,083		8,231	
Days from Index	Episodes (N)	Episodes (%)	Episodes (N)	Episodes (%)	Episodes (N)	Episodes (%)	Episodes (N)	Episodes (%)	Episodes (N)	Episodes (%)	Episodes (N)	Episodes (%)	Episodes (N)	Episodes (%)
Overall	15,769	100.0%	1,547	100.0%	21,964	100.0%	5,367	100.0%	738	100.0%	16,720	100.0%	8,382	100.0%
0-30	5,629	35.7%	500	32.3%	8,855	40.3%	1,704	31.7%	222	30.1%	6,687	40.0%	3,939	47.0%
0-60	11,416	72.4%	931	60.2%	16,447	74.9%	3,492	65.1%	407	55.1%	12,430	74.3%	7,084	84.5%
0-90	13,432	85.2%	1,147	74.1%	18,961	86.3%	4,241	79.0%	476	64.5%	14,391	86.1%	7,837	93.5%
0-120	14,311	90.8%	1,279	82.7%	20,065	91.4%	4,700	87.6%	513	69.5%	15,361	91.9%	8,125	96.9%
0-150	14,729	93.4%	1,344	86.9%	20,631	93.9%	4,942	92.1%	539	73.0%	15,765	94.3%	8,226	98.1%
0-180	14,975	95.0%	1,404	90.8%	20,994	95.6%	5,082	94.7%	556	75.3%	16,040	95.9%	8,260	98.5%
0-210	15,152	96.1%	1,437	92.9%	21,246	96.7%	5,159	96.1%	583	79.0%	16,217	97.0%	8,290	98.9%
0-240	15,275	96.9%	1,460	94.4%	21,406	97.5%	5,217	97.2%	619	83.9%	16,340	97.7%	8,307	99.1%
0-270	15,382	97.5%	1,484	95.9%	21,530	98.0%	5,248	97.8%	668	90.5%	16,429	98.3%	8,327	99.3%
0-300	15,455	98.0%	1,496	96.7%	21,622	98.4%	5,274	98.3%	702	95.1%	16,494	98.6%	8,336	99.5%
0-330	15,510	98.4%	1,516	98.0%	21,706	98.8%	5,298	98.7%	723	98.0%	16,550	99.0%	8,344	99.5%
0-365	15,565	98.7%	1,528	98.8%	21,759	99.1%	5,312	99.0%	727	98.5%	16,589	99.2%	8,358	99.7%
366+	204	1.3%	19	1.2%	205	0.9%	55	1.0%	11	1.5%	131	0.8%	24	0.3%

Table 11a. Frequency Distribution of Time to Second Switch, by Switch Pattern, in Days in the Sentinel Distributed Database (SDD) from January 1, 2013 to December 31, 2019

ANDA 040422 to Non-040422		ANDA 040439 to Non-040439		ANDA 040480 to Non-040480		ANDA 202424 to Same Non-202424		ANDA 040440 to Same Non-040440		ANDA 040422 to Same Non-040422		ANDA 040439 to Same Non-040439		ANDA 040480 to Same Non-040480	
Non-040422 to ANDA 040422 to Non-040422		Non-040439 to ANDA 040439 to Non-040439		Non-040480 to ANDA 040480 to Non-040480		Non-202424 to ANDA 202424 to Same Non-202424		Non-040440 to ANDA 040440 to Same Non-040440		Non-040422 to ANDA 040422 to Same Non-040422		Non-040439 to ANDA 040439 to Same Non-040439		Non-040480 to ANDA 040480 to Same Non-040480	
16,577		12,731		2,780		12,275		5,123		11,988		8,720		1,501	
Episodes (N)	Episodes (%)	Episodes (N)	Episodes (%)	Episodes (N)	Episodes (%)	Episodes (N)	Episodes (%)	Episodes (N)	Episodes (%)	Episodes (N)	Episodes (%)	Episodes (N)	Episodes (%)	Episodes (N)	Episodes (%)
17,288	100.0%	13,117	100.0%	2,817	100.0%	12,732	100.0%	5,187	100.0%	12,483	100.0%	8,942	100.0%	1,516	100.0%
6,589	38.1%	5,614	42.8%	1,168	41.5%	5,403	42.4%	2,484	47.9%	4,966	39.8%	3,968	44.4%	690	45.5%
12,855	74.4%	10,703	81.6%	2,121	75.3%	9,771	76.7%	4,432	85.4%	9,612	77.0%	7,465	83.5%	1,191	78.6%
14,822	85.7%	11,995	91.4%	2,452	87.0%	11,185	87.8%	4,886	94.2%	10,986	88.0%	8,276	92.6%	1,346	88.8%
15,668	90.6%	12,493	95.2%	2,617	92.9%	11,836	93.0%	5,044	97.2%	11,541	92.5%	8,565	95.8%	1,412	93.1%
16,063	92.9%	12,707	96.9%	2,709	96.2%	12,109	95.1%	5,104	98.4%	11,800	94.5%	8,693	97.2%	1,461	96.4%
16,347	94.6%	12,839	97.9%	2,774	98.5%	12,286	96.5%	5,121	98.7%	11,982	96.0%	8,764	98.0%	1,487	98.1%
16,512	95.5%	12,924	98.5%	2,793	99.1%	12,406	97.4%	5,136	99.0%	12,080	96.8%	8,814	98.6%	1,500	98.9%
16,649	96.3%	12,972	98.9%	2,802	99.5%	12,482	98.0%	5,144	99.2%	12,162	97.4%	8,854	99.0%	1,505	99.3%
16,756	96.9%	13,006	99.2%	2,805	99.6%	12,542	98.5%	5,157	99.4%	12,217	97.9%	8,871	99.2%	1,508	99.5%
16,844	97.4%	13,027	99.3%	2,809	99.7%	12,591	98.9%	5,162	99.5%	12,267	98.3%	8,886	99.4%	1,511	99.7%
16,926	97.9%	13,036	99.4%	2,812	99.8%	12,629	99.2%	5,167	99.6%	12,318	98.7%	8,892	99.4%	1,513	99.8%
17,017	98.4%	13,052	99.5%	2,812	99.8%	12,656	99.4%	5,178	99.8%	12,356	99.0%	8,902	99.6%	1,513	99.8%
271	1.6%	65	0.5%	5	0.2%	76	0.6%	9	0.2%	127	1.0%	40	0.4%	3	0.2%

Table 11b. Frequency Distribution of Time to Second Switch, by Switch Pattern and Year, in Days, in the Sentinel Distributed Database (SDD) from January 1, 2013 to December 31, 2019

Switch	Non-202424 to ANDA 202424	Non-040440 to ANDA 040440	Non-040422 to ANDA 040422	Non-040439 to ANDA 040439	Non-040480 to ANDA 040480	ANDA 202424 to Non-202424	ANDA 040440 to Non-040440
Switch Pattern	ANDA 202424 to Non-202424	ANDA 040440 to Non-040440	ANDA 040422 to Non-040422	ANDA 040439 to Non-040439	ANDA 040480 to Non-040480	Non-202424 to ANDA 202424	Non-040440 to ANDA 040440
Number of Patients	15,058	1,528	20,989	5,203	736	16,083	8,231
Days from Index	Episodes (N) Episodes (%)	Episodes (N) Episodes (%)	Episodes (N) Episodes (%)	Episodes (N) Episodes (%)	Episodes (N) Episodes (%)	Episodes (N) Episodes (%)	Episodes (N) Episodes (%)
Overall	15,769 100.0%	1,547 100.0%	21,964 100.0%	5,367 100.0%	738 100.0%	16,720 100.0%	8,382 100.0%
2013	0 0.0%	0 0.0%	2,611 11.9%	605 11.3%	0 0.0%	464 2.8%	394 4.7%
2014	888 5.6%	248 16.0%	2,891 13.2%	409 7.6%	6 0.8%	1,824 10.9%	560 6.7%
2015	851 5.4%	61 3.9%	1,767 8.0%	348 6.5%	1 0.1%	1,271 7.6%	288 3.4%
2016	1,303 8.3%	78 5.0%	2,107 9.6%	506 9.4%	87 11.8%	1,689 10.1%	528 6.3%
2017	5,925 37.6%	288 18.6%	4,216 19.2%	890 16.6%	218 29.5%	4,122 24.7%	2,667 31.8%
2018	4,692 29.8%	603 39.0%	6,069 27.6%	1,802 33.6%	342 46.3%	5,618 33.6%	2,754 32.9%
2019	2,110 13.4%	269 17.4%	2,303 10.5%	807 15.0%	84 11.4%	1,732 10.4%	1,191 14.2%
0-30	5,629 0.0%	500 100.0%	8,855 0.0%	1,704 0.0%	222 100.0%	6,687 0.0%	3,939 0.0%
2013	0 0.0%	0 0.0%	1,121 12.7%	212 12.4%	0 0.0%	156 2.3%	158 4.0%
2014	309 5.5%	101 20.2%	1,189 13.4%	166 9.7%	3 1.4%	724 10.8%	245 6.2%
2015	371 6.6%	27 5.4%	792 8.9%	130 7.6%	0 0.0%	565 8.4%	137 3.5%
2016	503 8.9%	24 4.8%	908 10.3%	170 10.0%	23 10.4%	704 10.5%	232 5.9%
2017	2,114 37.6%	81 16.2%	1,746 19.7%	269 15.8%	69 31.1%	1,707 25.5%	1,308 33.2%
2018	1,561 27.7%	169 33.8%	2,086 23.6%	449 26.3%	112 50.5%	2,096 31.3%	1,263 32.1%
2019	771 13.7%	98 19.6%	1,013 11.4%	308 18.1%	15 6.8%	735 11.0%	596 15.1%
0-60	11,416 0.0%	931 100.0%	16,447 0.0%	3,492 0.0%	407 100.0%	12,430 0.0%	7,084 0.0%
2013	0 0.0%	0 0.0%	2,096 12.7%	419 12.0%	0 0.0%	304 2.4%	295 4.2%
2014	642 5.6%	176 18.9%	2,233 13.6%	299 8.6%	6 1.5%	1,357 10.9%	474 6.7%
2015	663 5.8%	51 5.5%	1,400 8.5%	249 7.1%	0 0.0%	996 8.0%	232 3.3%
2016	977 8.6%	50 5.4%	1,601 9.7%	353 10.1%	53 13.0%	1,232 9.9%	416 5.9%
2017	4,219 37.0%	152 16.3%	3,202 19.5%	521 14.9%	130 31.9%	3,113 25.0%	2,256 31.8%
2018	3,298 28.9%	311 33.4%	4,042 24.6%	1,031 29.5%	186 45.7%	4,043 32.5%	2,360 33.3%
2019	1,617 14.2%	191 20.5%	1,873 11.4%	620 17.8%	32 7.9%	1,385 11.1%	1,051 14.8%
0-90	13,432 0.0%	1,147 0.0%	18,961 0.0%	4,241 0.0%	476 100.0%	14,391 0.0%	7,837 0.0%
2013	0 0.0%	0 0.0%	2,348 12.4%	487 11.5%	0 0.0%	366 2.5%	339 4.3%
2014	755 5.6%	210 18.3%	2,554 13.5%	342 8.1%	6 1.3%	1,558 10.8%	524 6.7%
2015	742 5.5%	53 4.6%	1,571 8.3%	297 7.0%	1 0.2%	1,118 7.8%	259 3.3%
2016	1,105 8.2%	59 5.1%	1,786 9.4%	427 10.1%	64 13.4%	1,398 9.7%	469 6.0%
2017	4,986 37.1%	187 16.3%	3,666 19.3%	652 15.4%	167 35.1%	3,578 24.9%	2,493 31.8%

Table 11b. Frequency Distribution of Time to Second Switch, by Switch Pattern and Year, in Days, in the Sentinel Distributed Database (SDD) from January 1, 2013 to December 31, 2019

Switch	Non-202424 to ANDA 202424		Non-040440 to ANDA 040440		Non-040422 to ANDA 040422		Non-040439 to ANDA 040439		Non-040480 to ANDA 040480		ANDA 202424 to Non-202424		ANDA 040440 to Non-040440	
Switch Pattern	ANDA 202424 to Non-202424		ANDA 040440 to Non-040440		ANDA 040422 to Non-040422		ANDA 040439 to Non-040439		ANDA 040480 to Non-040480		Non-202424 to ANDA 202424		Non-040440 to ANDA 040440	
Number of Patients	15,058		1,528		20,989		5,203		736		16,083		8,231	
Days from Index	Episodes (N)	Episodes (%)	Episodes (N)	Episodes (%)	Episodes (N)	Episodes (%)	Episodes (N)	Episodes (%)	Episodes (N)	Episodes (%)	Episodes (N)	Episodes (%)	Episodes (N)	Episodes (%)
2018	3,930	29.3%	406	35.4%	4,902	25.9%	1,322	31.2%	200	42.0%	4,796	33.3%	2,602	33.2%
2019	1,914	14.2%	232	20.2%	2,134	11.3%	714	16.8%	38	8.0%	1,577	11.0%	1,151	14.7%
0-120	14,311	0.0%	1,279	0.0%	20,065	0.0%	4,700	0.0%	513	100.0%	15,361	0.0%	8,125	0.0%
2013	0	0.0%	0	0.0%	2,434	12.1%	523	11.1%	0	0.0%	401	2.6%	359	4.4%
2014	799	5.6%	230	18.0%	2,682	13.4%	363	7.7%	6	1.2%	1,662	10.8%	538	6.6%
2015	778	5.4%	57	4.5%	1,628	8.1%	321	6.8%	1	0.2%	1,168	7.6%	271	3.3%
2016	1,169	8.2%	65	5.1%	1,879	9.4%	455	9.7%	73	14.2%	1,481	9.6%	495	6.1%
2017	5,292	37.0%	214	16.7%	3,866	19.3%	760	16.2%	188	36.6%	3,806	24.8%	2,589	31.9%
2018	4,241	29.6%	466	36.4%	5,331	26.6%	1,510	32.1%	206	40.2%	5,187	33.8%	2,691	33.1%
2019	2,032	14.2%	247	19.3%	2,245	11.2%	768	16.3%	39	7.6%	1,656	10.8%	1,182	14.5%
0-150	14,729	0.0%	1,344	0.0%	20,631	0.0%	4,942	0.0%	539	100.0%	15,765	0.0%	8,226	0.0%
2013	0	0.0%	0	0.0%	2,492	12.1%	539	10.9%	0	0.0%	418	2.7%	371	4.5%
2014	819	5.6%	236	17.6%	2,741	13.3%	377	7.6%	6	1.1%	1,710	10.8%	547	6.6%
2015	804	5.5%	58	4.3%	1,663	8.1%	329	6.7%	1	0.2%	1,190	7.5%	278	3.4%
2016	1,199	8.1%	68	5.1%	1,923	9.3%	472	9.6%	77	14.3%	1,519	9.6%	507	6.2%
2017	5,447	37.0%	227	16.9%	3,983	19.3%	809	16.4%	197	36.5%	3,900	24.7%	2,619	31.8%
2018	4,384	29.8%	496	36.9%	5,552	26.9%	1,628	32.9%	215	39.9%	5,333	33.8%	2,719	33.1%
2019	2,076	14.1%	259	19.3%	2,277	11.0%	788	15.9%	43	8.0%	1,695	10.8%	1,185	14.4%
0-180	14,975	0.0%	1,404	0.0%	20,994	0.0%	5,082	0.0%	556	100.0%	16,040	0.0%	8,260	0.0%
2013	0	0.0%	0	0.0%	2,523	12.0%	564	11.1%	0	0.0%	435	2.7%	373	4.5%
2014	832	5.6%	242	17.2%	2,777	13.2%	382	7.5%	6	1.1%	1,744	10.9%	548	6.6%
2015	817	5.5%	58	4.1%	1,687	8.0%	331	6.5%	1	0.2%	1,206	7.5%	281	3.4%
2016	1,220	8.1%	72	5.1%	1,946	9.3%	484	9.5%	78	14.0%	1,548	9.7%	510	6.2%
2017	5,554	37.1%	236	16.8%	4,061	19.3%	835	16.4%	201	36.2%	3,958	24.7%	2,631	31.9%
2018	4,458	29.8%	534	38.0%	5,705	27.2%	1,689	33.2%	222	39.9%	5,438	33.9%	2,730	33.1%
2019	2,094	14.0%	262	18.7%	2,295	10.9%	797	15.7%	48	8.6%	1,711	10.7%	1,187	14.4%
0-210	15,152	0.0%	1,437	0.0%	21,246	0.0%	5,159	0.0%	583	100.0%	16,217	0.0%	8,290	0.0%
2013	0	0.0%	0	0.0%	2,544	12.0%	576	11.2%	0	0.0%	439	2.7%	379	4.6%
2014	839	5.5%	244	17.0%	2,800	13.2%	388	7.5%	6	1.0%	1,760	10.9%	549	6.6%
2015	819	5.4%	59	4.1%	1,700	8.0%	334	6.5%	1	0.2%	1,216	7.5%	283	3.4%

Table 11b. Frequency Distribution of Time to Second Switch, by Switch Pattern and Year, in Days, in the Sentinel Distributed Database (SDD) from January 1, 2013 to December 31, 2019

Switch	Non-202424 to ANDA 202424		Non-040440 to ANDA 040440		Non-040422 to ANDA 040422		Non-040439 to ANDA 040439		Non-040480 to ANDA 040480		ANDA 202424 to Non-202424		ANDA 040440 to Non-040440	
Switch Pattern	ANDA 202424 to Non-202424		ANDA 040440 to Non-040440		ANDA 040422 to Non-040422		ANDA 040439 to Non-040439		ANDA 040480 to Non-040480		Non-202424 to ANDA 202424		Non-040440 to ANDA 040440	
Number of Patients	15,058		1,528		20,989		5,203		736		16,083		8,231	
Days from Index	Episodes (N)	Episodes (%)	Episodes (N)	Episodes (%)	Episodes (N)	Episodes (%)	Episodes (N)	Episodes (%)	Episodes (N)	Episodes (%)	Episodes (N)	Episodes (%)	Episodes (N)	Episodes (%)
2016	1,231	8.1%	73	5.1%	1,974	9.3%	486	9.4%	82	14.1%	1,567	9.7%	512	6.2%
2017	5,629	37.2%	247	17.2%	4,104	19.3%	848	16.4%	202	34.6%	4,009	24.7%	2,639	31.8%
2018	4,528	29.9%	547	38.1%	5,824	27.4%	1,727	33.5%	235	40.3%	5,502	33.9%	2,738	33.0%
2019	2,106	13.9%	267	18.6%	2,300	10.8%	800	15.5%	57	9.8%	1,724	10.6%	1,190	14.4%
0-240	15,275	0.0%	1,460	0.0%	21,406	0.0%	5,217	0.0%	619	100.0%	16,340	0.0%	8,307	0.0%
2013	0	0.0%	0	0.0%	2,556	11.9%	586	11.2%	0	0.0%	443	2.7%	379	4.6%
2014	846	5.5%	247	16.9%	2,819	13.2%	392	7.5%	6	1.0%	1,770	10.8%	550	6.6%
2015	825	5.4%	60	4.1%	1,712	8.0%	334	6.4%	1	0.2%	1,225	7.5%	283	3.4%
2016	1,245	8.2%	74	5.1%	1,995	9.3%	488	9.4%	83	13.4%	1,596	9.8%	516	6.2%
2017	5,676	37.2%	254	17.4%	4,135	19.3%	855	16.4%	206	33.3%	4,041	24.7%	2,647	31.9%
2018	4,574	29.9%	558	38.2%	5,886	27.5%	1,757	33.7%	256	41.4%	5,536	33.9%	2,741	33.0%
2019	2,109	13.8%	267	18.3%	2,303	10.8%	805	15.4%	67	10.8%	1,729	10.6%	1,191	14.3%
0-270	15,382	0.0%	1,484	0.0%	21,530	0.0%	5,248	0.0%	668	100.0%	16,429	0.0%	8,327	0.0%
2013	0	0.0%	0	0.0%	2,567	11.9%	588	11.2%	0	0.0%	447	2.7%	382	4.6%
2014	850	5.5%	247	16.6%	2,830	13.1%	396	7.5%	6	0.9%	1,778	10.8%	551	6.6%
2015	830	5.4%	60	4.0%	1,722	8.0%	335	6.4%	1	0.1%	1,229	7.5%	285	3.4%
2016	1,257	8.2%	74	5.0%	2,006	9.3%	491	9.4%	83	12.4%	1,614	9.8%	517	6.2%
2017	5,713	37.1%	262	17.7%	4,155	19.3%	859	16.4%	208	31.1%	4,063	24.7%	2,652	31.8%
2018	4,622	30.0%	573	38.6%	5,947	27.6%	1,774	33.8%	290	43.4%	5,568	33.9%	2,749	33.0%
2019	2,110	13.7%	268	18.1%	2,303	10.7%	805	15.3%	80	12.0%	1,730	10.5%	1,191	14.3%
0-300	15,455	0.0%	1,496	0.0%	21,622	0.0%	5,274	0.0%	702	100.0%	16,494	0.0%	8,336	0.0%
2013	0	0.0%	0	0.0%	2,576	11.9%	592	11.2%	0	0.0%	447	2.7%	384	4.6%
2014	855	5.5%	247	16.5%	2,836	13.1%	398	7.5%	6	0.9%	1,785	10.8%	551	6.6%
2015	832	5.4%	60	4.0%	1,726	8.0%	337	6.4%	1	0.1%	1,236	7.5%	286	3.4%
2016	1,268	8.2%	74	4.9%	2,021	9.3%	492	9.3%	83	11.8%	1,627	9.9%	519	6.2%
2017	5,748	37.2%	267	17.8%	4,169	19.3%	868	16.5%	208	29.6%	4,077	24.7%	2,655	31.8%
2018	4,642	30.0%	579	38.7%	5,991	27.7%	1,780	33.8%	320	45.6%	5,590	33.9%	2,750	33.0%
2019	2,110	13.7%	269	18.0%	2,303	10.7%	807	15.3%	84	12.0%	1,732	10.5%	1,191	14.3%
0-330	15,510	0.0%	1,516	0.0%	21,706	0.0%	5,298	0.0%	723	100.0%	16,550	0.0%	8,344	0.0%
2013	0	0.0%	0	0.0%	2,580	11.9%	594	11.2%	0	0.0%	448	2.7%	387	4.6%

Table 11b. Frequency Distribution of Time to Second Switch, by Switch Pattern and Year, in Days, in the Sentinel Distributed Database (SDD) from January 1, 2013 to December 31, 2019

Switch	Non-202424 to ANDA 202424		Non-040440 to ANDA 040440		Non-040422 to ANDA 040422		Non-040439 to ANDA 040439		Non-040480 to ANDA 040480		ANDA 202424 to Non-202424		ANDA 040440 to Non-040440	
Switch Pattern	ANDA 202424 to Non-202424		ANDA 040440 to Non-040440		ANDA 040422 to Non-040422		ANDA 040439 to Non-040439		ANDA 040480 to Non-040480		Non-202424 to ANDA 202424		Non-040440 to ANDA 040440	
Number of Patients	15,058		1,528		20,989		5,203		736		16,083		8,231	
Days from Index	Episodes (N)	Episodes (%)	Episodes (N)	Episodes (%)	Episodes (N)	Episodes (%)	Episodes (N)	Episodes (%)	Episodes (N)	Episodes (%)	Episodes (N)	Episodes (%)	Episodes (N)	Episodes (%)
2014	864	5.6%	247	16.3%	2,846	13.1%	399	7.5%	6	0.8%	1,793	10.8%	552	6.6%
2015	833	5.4%	60	4.0%	1,732	8.0%	339	6.4%	1	0.1%	1,239	7.5%	286	3.4%
2016	1,274	8.2%	74	4.9%	2,039	9.4%	496	9.4%	83	11.5%	1,644	9.9%	520	6.2%
2017	5,768	37.2%	277	18.3%	4,183	19.3%	871	16.4%	209	28.9%	4,089	24.7%	2,657	31.8%
2018	4,661	30.1%	589	38.9%	6,023	27.7%	1,792	33.8%	340	47.0%	5,605	33.9%	2,751	33.0%
2019	2,110	13.6%	269	17.7%	2,303	10.6%	807	15.2%	84	11.6%	1,732	10.5%	1,191	14.3%
0-365	15,565	0.0%	1,528	0.0%	21,759	0.0%	5,312	0.0%	727	100.0%	16,589	0.0%	8,358	0.0%
2013	0	0.0%	0	0.0%	2,586	11.9%	595	11.2%	0	0.0%	451	2.7%	390	4.7%
2014	868	5.6%	247	16.2%	2,853	13.1%	400	7.5%	6	0.8%	1,800	10.9%	553	6.6%
2015	837	5.4%	60	3.9%	1,736	8.0%	341	6.4%	1	0.1%	1,244	7.5%	287	3.4%
2016	1,285	8.3%	76	5.0%	2,049	9.4%	497	9.4%	84	11.6%	1,654	10.0%	523	6.3%
2017	5,789	37.2%	280	18.3%	4,191	19.3%	876	16.5%	210	28.9%	4,097	24.7%	2,660	31.8%
2018	4,676	30.0%	596	39.0%	6,041	27.8%	1,796	33.8%	342	47.0%	5,611	33.8%	2,754	33.0%
2019	2,110	13.6%	269	17.6%	2,303	10.6%	807	15.2%	84	11.6%	1,732	10.4%	1,191	14.2%
366+	204	100.0%	19	100.0%	205	100.0%	55	100.0%	11	100.0%	131	100.0%	24	100.0%
2013	0	0.0%	0	0.0%	25	12.2%	10	18.2%	0	0.0%	13	9.9%	4	16.7%
2014	20	9.8%	1	5.3%	38	18.5%	9	16.4%	0	0.0%	24	18.3%	7	29.2%
2015	14	6.9%	1	5.3%	31	15.1%	7	12.7%	0	0.0%	27	20.6%	1	4.2%
2016	18	8.8%	2	10.5%	58	28.3%	9	16.4%	3	27.3%	35	26.7%	5	20.8%
2017	136	66.7%	8	42.1%	25	12.2%	14	25.5%	8	72.7%	25	19.1%	7	29.2%
2018	16	7.8%	7	36.8%	28	13.7%	6	10.9%	0	0.0%	7	5.3%	0	0.0%
2019	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%

Table 11b. Frequency Distribution of Time to Second Switch, by Switch Pattern and Year, in Days, in the Sentinel Distributed Database (SDD) from January 1, 2013 to December 31, 2019

Switch	ANDA 040422 to Non-040422		ANDA 040439 to Non-040439		ANDA 040480 to Non-040480		ANDA 202424 to Same Non-202424		ANDA 040440 to Same Non-040440		ANDA 040422 to Same Non-040422		ANDA 040439 to Same Non-040439		ANDA 040480 to Same Non-040480	
Switch Pattern	Non-040422 to ANDA 040422 to Non-040422		Non-040439 to ANDA 040439 to Non-040439		Non-040480 to ANDA 040480 to Non-040480		Non-202424 to ANDA 202424 to Same Non-202424		Non-040440 to ANDA 040440 to Same Non-040440		Non-040422 to ANDA 040422 to Same Non-040422		Non-040439 to ANDA 040439 to Same Non-040439		Non-040480 to ANDA 040480 to Same Non-040480	
Number of Patients	16,577		12,731		2,780		12,275		5,123		11,988		8,720		1,501	
Days from Index	Episodes (N)	Episodes (%)	Episodes (N)	Episodes (%)	Episodes (N)	Episodes (%)	Episodes (N)	Episodes (%)	Episodes (N)	Episodes (%)	Episodes (N)	Episodes (%)	Episodes (N)	Episodes (%)	Episodes (N)	Episodes (%)
Overall	17,288	100.0%	13,117	100.0%	2,817	100.0%	12,732	100.0%	5,187	100.0%	12,483	100.0%	8,942	100.0%	1,516	100.0%
2013	666	3.9%	1,942	14.8%	11	0.4%	397	3.1%	313	6.0%	428	3.4%	1,637	18.3%	5	0.3%
2014	1,410	8.2%	996	7.6%	37	1.3%	1,564	12.3%	421	8.1%	1,119	9.0%	764	8.5%	18	1.2%
2015	1,115	6.4%	642	4.9%	80	2.8%	1,114	8.7%	205	4.0%	945	7.6%	496	5.5%	36	2.4%
2016	1,654	9.6%	821	6.3%	283	10.0%	1,385	10.9%	306	5.9%	1,267	10.1%	598	6.7%	153	10.1%
2017	5,789	33.5%	2,911	22.2%	1,385	49.2%	2,975	23.4%	1,440	27.8%	3,959	31.7%	1,671	18.7%	694	45.8%
2018	4,398	25.4%	4,245	32.4%	946	33.6%	3,937	30.9%	1,702	32.8%	3,095	24.8%	2,711	30.3%	552	36.4%
2019	2,256	13.0%	1,560	11.9%	75	2.7%	1,360	10.7%	800	15.4%	1,670	13.4%	1,065	11.9%	58	3.8%
0-30	6,589	0.0%	5,614	0.0%	1,168	0.0%	5,403	0.0%	2,484	0.0%	4,966	0.0%	3,968	0.0%	690	100.0%
2013	215	3.3%	885	15.8%	3	0.3%	142	2.6%	121	4.9%	155	3.1%	767	19.3%	2	0.3%
2014	517	7.8%	458	8.2%	14	1.2%	638	11.8%	184	7.4%	425	8.6%	345	8.7%	7	1.0%
2015	469	7.1%	290	5.2%	18	1.5%	505	9.3%	102	4.1%	414	8.3%	227	5.7%	12	1.7%
2016	628	9.5%	368	6.6%	122	10.4%	617	11.4%	152	6.1%	491	9.9%	278	7.0%	78	11.3%
2017	2,163	32.8%	1,278	22.8%	620	53.1%	1,311	24.3%	731	29.4%	1,569	31.6%	735	18.5%	323	46.8%
2018	1,724	26.2%	1,689	30.1%	354	30.3%	1,565	29.0%	790	31.8%	1,228	24.7%	1,139	28.7%	240	34.8%
2019	873	13.2%	646	11.5%	37	3.2%	625	11.6%	404	16.3%	684	13.8%	477	12.0%	28	4.1%
0-60	12,855	0.0%	10,703	0.0%	2,121	0.0%	9,771	0.0%	4,432	0.0%	9,612	0.0%	7,465	0.0%	1,191	0.0%
2013	427	3.3%	1,651	15.4%	10	0.5%	267	2.7%	230	5.2%	301	3.1%	1,410	18.9%	4	0.3%
2014	1,001	7.8%	840	7.8%	29	1.4%	1,190	12.2%	360	8.1%	836	8.7%	644	8.6%	15	1.3%
2015	863	6.7%	526	4.9%	58	2.7%	884	9.0%	166	3.7%	748	7.8%	414	5.5%	27	2.3%
2016	1,227	9.5%	622	5.8%	210	9.9%	1,059	10.8%	259	5.8%	957	10.0%	472	6.3%	121	10.2%
2017	4,133	32.2%	2,393	22.4%	1,094	51.6%	2,334	23.9%	1,243	28.0%	2,980	31.0%	1,393	18.7%	566	47.5%
2018	3,402	26.5%	3,359	31.4%	655	30.9%	2,912	29.8%	1,461	33.0%	2,416	25.1%	2,205	29.5%	406	34.1%
2019	1,802	14.0%	1,312	12.3%	65	3.1%	1,125	11.5%	713	16.1%	1,374	14.3%	927	12.4%	52	4.4%
0-90	14,822	0.0%	11,995	0.0%	2,452	0.0%	11,185	0.0%	4,886	0.0%	10,986	0.0%	8,276	0.0%	1,346	0.0%
2013	502	3.4%	1,822	15.2%	10	0.4%	319	2.9%	264	5.4%	340	3.1%	1,547	18.7%	4	0.3%
2014	1,176	7.9%	914	7.6%	34	1.4%	1,364	12.2%	401	8.2%	964	8.8%	697	8.4%	18	1.3%
2015	972	6.6%	579	4.8%	63	2.6%	992	8.9%	188	3.8%	834	7.6%	451	5.4%	30	2.2%
2016	1,408	9.5%	697	5.8%	249	10.2%	1,184	10.6%	282	5.8%	1,092	9.9%	522	6.3%	139	10.3%
2017	4,795	32.4%	2,648	22.1%	1,243	50.7%	2,658	23.8%	1,353	27.7%	3,428	31.2%	1,547	18.7%	631	46.9%

Table 11b. Frequency Distribution of Time to Second Switch, by Switch Pattern and Year, in Days, in the Sentinel Distributed Database (SDD) from January 1, 2013 to December 31, 2019

Switch	ANDA 040422 to Non-040422		ANDA 040439 to Non-040439		ANDA 040480 to Non-040480		ANDA 202424 to Same Non-202424		ANDA 040440 to Same Non-040440		ANDA 040422 to Same Non-040422		ANDA 040439 to Same Non-040439		ANDA 040480 to Same Non-040480	
Switch Pattern	Non-040422 to ANDA 040422 to Non-040422		Non-040439 to ANDA 040439 to Non-040439		Non-040480 to ANDA 040480 to Non-040480		Non-202424 to ANDA 202424 to Same Non-202424		Non-040440 to ANDA 040440 to Same Non-040440		Non-040422 to ANDA 040422 to Same Non-040422		Non-040439 to ANDA 040439 to Same Non-040439		Non-040480 to ANDA 040480 to Same Non-040480	
Number of Patients	16,577		12,731		2,780		12,275		5,123		11,988		8,720		1,501	
Days from Index	Episodes (N)	Episodes (%)	Episodes (N)	Episodes (%)	Episodes (N)	Episodes (%)	Episodes (N)	Episodes (%)	Episodes (N)	Episodes (%)	Episodes (N)	Episodes (%)	Episodes (N)	Episodes (%)	Episodes (N)	Episodes (%)
2018	3,888	26.2%	3,863	32.2%	783	31.9%	3,407	30.5%	1,619	33.1%	2,762	25.1%	2,488	30.1%	468	34.8%
2019	2,081	14.0%	1,472	12.3%	70	2.9%	1,261	11.3%	779	15.9%	1,566	14.3%	1,024	12.4%	56	4.2%
0-120	15,668	0.0%	12,493	0.0%	2,617	0.0%	11,836	0.0%	5,044	0.0%	11,541	0.0%	8,565	0.0%	1,412	0.0%
2013	543	3.5%	1,868	15.0%	10	0.4%	343	2.9%	281	5.6%	368	3.2%	1,584	18.5%	4	0.3%
2014	1,252	8.0%	934	7.5%	37	1.4%	1,442	12.2%	410	8.1%	1,018	8.8%	712	8.3%	18	1.3%
2015	1,030	6.6%	594	4.8%	70	2.7%	1,040	8.8%	195	3.9%	879	7.6%	459	5.4%	31	2.2%
2016	1,491	9.5%	732	5.9%	266	10.2%	1,250	10.6%	293	5.8%	1,156	10.0%	545	6.4%	147	10.4%
2017	5,066	32.3%	2,761	22.1%	1,312	50.1%	2,796	23.6%	1,400	27.8%	3,590	31.1%	1,601	18.7%	652	46.2%
2018	4,102	26.2%	4,069	32.6%	849	32.4%	3,652	30.9%	1,670	33.1%	2,907	25.2%	2,606	30.4%	503	35.6%
2019	2,184	13.9%	1,535	12.3%	73	2.8%	1,313	11.1%	795	15.8%	1,623	14.1%	1,058	12.4%	57	4.0%
0-150	16,063	0.0%	12,707	0.0%	2,709	0.0%	12,109	0.0%	5,104	0.0%	11,800	0.0%	8,693	0.0%	1,461	0.0%
2013	563	3.5%	1,896	14.9%	10	0.4%	357	2.9%	293	5.7%	374	3.2%	1,606	18.5%	4	0.3%
2014	1,291	8.0%	944	7.4%	37	1.4%	1,480	12.2%	414	8.1%	1,046	8.9%	721	8.3%	18	1.2%
2015	1,055	6.6%	610	4.8%	72	2.7%	1,057	8.7%	200	3.9%	901	7.6%	472	5.4%	31	2.1%
2016	1,526	9.5%	751	5.9%	275	10.2%	1,276	10.5%	300	5.9%	1,178	10.0%	556	6.4%	151	10.3%
2017	5,203	32.4%	2,818	22.2%	1,343	49.6%	2,853	23.6%	1,414	27.7%	3,675	31.1%	1,628	18.7%	669	45.8%
2018	4,200	26.1%	4,140	32.6%	898	33.1%	3,749	31.0%	1,684	33.0%	2,974	25.2%	2,647	30.4%	530	36.3%
2019	2,225	13.9%	1,548	12.2%	74	2.7%	1,337	11.0%	799	15.7%	1,652	14.0%	1,063	12.2%	58	4.0%
0-180	16,347	0.0%	12,839	0.0%	2,774	0.0%	12,286	0.0%	5,121	0.0%	11,982	0.0%	8,764	0.0%	1,487	0.0%
2013	592	3.6%	1,907	14.9%	10	0.4%	372	3.0%	295	5.8%	395	3.3%	1,614	18.4%	4	0.3%
2014	1,312	8.0%	953	7.4%	37	1.3%	1,507	12.3%	415	8.1%	1,062	8.9%	727	8.3%	18	1.2%
2015	1,068	6.5%	618	4.8%	75	2.7%	1,072	8.7%	201	3.9%	911	7.6%	478	5.5%	33	2.2%
2016	1,562	9.6%	763	5.9%	277	10.0%	1,290	10.5%	300	5.9%	1,204	10.0%	562	6.4%	152	10.2%
2017	5,305	32.5%	2,867	22.3%	1,367	49.3%	2,887	23.5%	1,421	27.7%	3,736	31.2%	1,653	18.9%	678	45.6%
2018	4,265	26.1%	4,179	32.5%	934	33.7%	3,810	31.0%	1,689	33.0%	3,012	25.1%	2,667	30.4%	544	36.6%
2019	2,243	13.7%	1,552	12.1%	74	2.7%	1,348	11.0%	800	15.6%	1,662	13.9%	1,063	12.1%	58	3.9%
0-210	16,512	0.0%	12,924	0.0%	2,793	0.0%	12,406	0.0%	5,136	0.0%	12,080	0.0%	8,814	0.0%	1,500	0.0%
2013	609	3.7%	1,915	14.8%	10	0.4%	376	3.0%	300	5.8%	406	3.4%	1,621	18.4%	4	0.3%
2014	1,328	8.0%	957	7.4%	37	1.3%	1,518	12.2%	416	8.1%	1,073	8.9%	730	8.3%	18	1.2%
2015	1,077	6.5%	623	4.8%	75	2.7%	1,079	8.7%	202	3.9%	916	7.6%	480	5.4%	33	2.2%

Table 11b. Frequency Distribution of Time to Second Switch, by Switch Pattern and Year, in Days, in the Sentinel Distributed Database (SDD) from January 1, 2013 to December 31, 2019

Switch	ANDA 040422 to Non-040422		ANDA 040439 to Non-040439		ANDA 040480 to Non-040480		ANDA 202424 to Same Non-202424		ANDA 040440 to Same Non-040440		ANDA 040422 to Same Non-040422		ANDA 040439 to Same Non-040439		ANDA 040480 to Same Non-040480	
Switch Pattern	Non-040422 to ANDA 040422 to Non-040422		Non-040439 to ANDA 040439 to Non-040439		Non-040480 to ANDA 040480 to Non-040480		Non-202424 to ANDA 202424 to Same Non-202424		Non-040440 to ANDA 040440 to Same Non-040440		Non-040422 to ANDA 040422 to Same Non-040422		Non-040439 to ANDA 040439 to Same Non-040439		Non-040480 to ANDA 040480 to Same Non-040480	
Number of Patients	16,577		12,731		2,780		12,275		5,123		11,988		8,720		1,501	
Days from Index	Episodes (N)	Episodes (%)	Episodes (N)	Episodes (%)	Episodes (N)	Episodes (%)	Episodes (N)	Episodes (%)	Episodes (N)	Episodes (%)	Episodes (N)	Episodes (%)	Episodes (N)	Episodes (%)	Episodes (N)	Episodes (%)
2016	1,577	9.6%	773	6.0%	280	10.0%	1,304	10.5%	300	5.8%	1,216	10.1%	568	6.4%	152	10.1%
2017	5,365	32.5%	2,895	22.4%	1,376	49.3%	2,919	23.5%	1,424	27.7%	3,762	31.1%	1,665	18.9%	687	45.8%
2018	4,302	26.1%	4,203	32.5%	940	33.7%	3,854	31.1%	1,694	33.0%	3,039	25.2%	2,685	30.5%	548	36.5%
2019	2,254	13.7%	1,558	12.1%	75	2.7%	1,356	10.9%	800	15.6%	1,668	13.8%	1,065	12.1%	58	3.9%
0-240	16,649	0.0%	12,972	0.0%	2,802	0.0%	12,482	0.0%	5,144	0.0%	12,162	0.0%	8,854	0.0%	1,505	0.0%
2013	622	3.7%	1,921	14.8%	11	0.4%	378	3.0%	300	5.8%	415	3.4%	1,626	18.4%	5	0.3%
2014	1,341	8.1%	964	7.4%	37	1.3%	1,526	12.2%	416	8.1%	1,082	8.9%	737	8.3%	18	1.2%
2015	1,084	6.5%	628	4.8%	76	2.7%	1,085	8.7%	202	3.9%	921	7.6%	485	5.5%	34	2.3%
2016	1,592	9.6%	783	6.0%	282	10.1%	1,322	10.6%	302	5.9%	1,224	10.1%	576	6.5%	153	10.2%
2017	5,431	32.6%	2,898	22.3%	1,379	49.2%	2,936	23.5%	1,429	27.8%	3,796	31.2%	1,667	18.8%	689	45.8%
2018	4,323	26.0%	4,219	32.5%	942	33.6%	3,878	31.1%	1,695	33.0%	3,054	25.1%	2,698	30.5%	548	36.4%
2019	2,256	13.6%	1,559	12.0%	75	2.7%	1,357	10.9%	800	15.6%	1,670	13.7%	1,065	12.0%	58	3.9%
0-270	16,756	0.0%	13,006	0.0%	2,805	0.0%	12,542	0.0%	5,157	0.0%	12,217	0.0%	8,871	0.0%	1,508	0.0%
2013	627	3.7%	1,925	14.8%	11	0.4%	382	3.0%	303	5.9%	416	3.4%	1,628	18.4%	5	0.3%
2014	1,352	8.1%	967	7.4%	37	1.3%	1,533	12.2%	417	8.1%	1,087	8.9%	739	8.3%	18	1.2%
2015	1,089	6.5%	631	4.9%	77	2.7%	1,087	8.7%	203	3.9%	924	7.6%	488	5.5%	34	2.3%
2016	1,604	9.6%	788	6.1%	282	10.1%	1,336	10.7%	302	5.9%	1,233	10.1%	579	6.5%	153	10.1%
2017	5,482	32.7%	2,904	22.3%	1,381	49.2%	2,946	23.5%	1,431	27.7%	3,821	31.3%	1,669	18.8%	691	45.8%
2018	4,346	25.9%	4,231	32.5%	942	33.6%	3,900	31.1%	1,701	33.0%	3,066	25.1%	2,703	30.5%	549	36.4%
2019	2,256	13.5%	1,560	12.0%	75	2.7%	1,358	10.8%	800	15.5%	1,670	13.7%	1,065	12.0%	58	3.8%
0-300	16,844	0.0%	13,027	0.0%	2,809	0.0%	12,591	0.0%	5,162	0.0%	12,267	0.0%	8,886	0.0%	1,511	0.0%
2013	634	3.8%	1,929	14.8%	11	0.4%	382	3.0%	304	5.9%	418	3.4%	1,631	18.4%	5	0.3%
2014	1,361	8.1%	971	7.5%	37	1.3%	1,538	12.2%	417	8.1%	1,092	8.9%	743	8.4%	18	1.2%
2015	1,091	6.5%	631	4.8%	77	2.7%	1,091	8.7%	204	4.0%	926	7.5%	488	5.5%	34	2.3%
2016	1,610	9.6%	792	6.1%	283	10.1%	1,348	10.7%	303	5.9%	1,237	10.1%	582	6.5%	153	10.1%
2017	5,528	32.8%	2,907	22.3%	1,382	49.2%	2,954	23.5%	1,433	27.8%	3,846	31.4%	1,670	18.8%	692	45.8%
2018	4,364	25.9%	4,237	32.5%	944	33.6%	3,918	31.1%	1,701	33.0%	3,078	25.1%	2,707	30.5%	551	36.5%
2019	2,256	13.4%	1,560	12.0%	75	2.7%	1,360	10.8%	800	15.5%	1,670	13.6%	1,065	12.0%	58	3.8%
0-330	16,926	0.0%	13,036	0.0%	2,812	0.0%	12,629	0.0%	5,167	0.0%	12,318	0.0%	8,892	0.0%	1,513	0.0%
2013	638	3.8%	1,929	14.8%	11	0.4%	383	3.0%	307	5.9%	419	3.4%	1,631	18.3%	5	0.3%

Table 11b. Frequency Distribution of Time to Second Switch, by Switch Pattern and Year, in Days, in the Sentinel Distributed Database (SDD) from January 1, 2013 to December 31, 2019

Switch	ANDA 040422 to Non-040422		ANDA 040439 to Non-040439		ANDA 040480 to Non-040480		ANDA 202424 to Same Non-202424		ANDA 040440 to Same Non-040440		ANDA 040422 to Same Non-040422		ANDA 040439 to Same Non-040439		ANDA 040480 to Same Non-040480	
Switch Pattern	Non-040422 to ANDA 040422 to Non-040422		Non-040439 to ANDA 040439 to Non-040439		Non-040480 to ANDA 040480 to Non-040480		Non-202424 to ANDA 202424 to Same Non-202424		Non-040440 to ANDA 040440 to Same Non-040440		Non-040422 to ANDA 040422 to Same Non-040422		Non-040439 to ANDA 040439 to Same Non-040439		Non-040480 to ANDA 040480 to Same Non-040480	
Number of Patients	16,577		12,731		2,780		12,275		5,123		11,988		8,720		1,501	
Days from Index	Episodes (N)	Episodes (%)	Episodes (N)	Episodes (%)	Episodes (N)	Episodes (%)	Episodes (N)	Episodes (%)	Episodes (N)	Episodes (%)	Episodes (N)	Episodes (%)	Episodes (N)	Episodes (%)	Episodes (N)	Episodes (%)
2014	1,371	8.1%	973	7.5%	37	1.3%	1,545	12.2%	418	8.1%	1,102	8.9%	745	8.4%	18	1.2%
2015	1,094	6.5%	631	4.8%	78	2.8%	1,093	8.7%	204	3.9%	929	7.5%	488	5.5%	35	2.3%
2016	1,617	9.6%	796	6.1%	283	10.1%	1,361	10.8%	303	5.9%	1,243	10.1%	585	6.6%	153	10.1%
2017	5,571	32.9%	2,909	22.3%	1,383	49.2%	2,959	23.4%	1,434	27.8%	3,868	31.4%	1,670	18.8%	693	45.8%
2018	4,379	25.9%	4,238	32.5%	945	33.6%	3,928	31.1%	1,701	32.9%	3,087	25.1%	2,708	30.5%	551	36.4%
2019	2,256	13.3%	1,560	12.0%	75	2.7%	1,360	10.8%	800	15.5%	1,670	13.6%	1,065	12.0%	58	3.8%
0-365	17,017	0.0%	13,052	0.0%	2,812	0.0%	12,656	0.0%	5,178	0.0%	12,356	0.0%	8,902	0.0%	1,513	0.0%
2013	642	3.8%	1,930	14.8%	11	0.4%	386	3.0%	310	6.0%	420	3.4%	1,631	18.3%	5	0.3%
2014	1,376	8.1%	976	7.5%	37	1.3%	1,550	12.2%	419	8.1%	1,106	9.0%	748	8.4%	18	1.2%
2015	1,098	6.5%	634	4.9%	78	2.8%	1,098	8.7%	205	4.0%	932	7.5%	491	5.5%	35	2.3%
2016	1,623	9.5%	801	6.1%	283	10.1%	1,366	10.8%	306	5.9%	1,248	10.1%	588	6.6%	153	10.1%
2017	5,635	33.1%	2,910	22.3%	1,383	49.2%	2,963	23.4%	1,436	27.7%	3,891	31.5%	1,670	18.8%	693	45.8%
2018	4,387	25.8%	4,241	32.5%	945	33.6%	3,933	31.1%	1,702	32.9%	3,089	25.0%	2,709	30.4%	551	36.4%
2019	2,256	13.3%	1,560	12.0%	75	2.7%	1,360	10.7%	800	15.4%	1,670	13.5%	1,065	12.0%	58	3.8%
366+	271	100.0%	65	100.0%	5	100.0%	76	100.0%	9	100.0%	127	100.0%	40	100.0%	3	100.0%
2013	24	8.9%	12	18.5%	0	0.0%	11	14.5%	3	33.3%	8	6.3%	6	15.0%	0	0.0%
2014	34	12.5%	20	30.8%	0	0.0%	14	18.4%	2	22.2%	13	10.2%	16	40.0%	0	0.0%
2015	17	6.3%	8	12.3%	2	40.0%	16	21.1%	0	0.0%	13	10.2%	5	12.5%	1	33.3%
2016	31	11.4%	20	30.8%	0	0.0%	19	25.0%	0	0.0%	19	15.0%	10	25.0%	0	0.0%
2017	154	56.8%	1	1.5%	2	40.0%	12	15.8%	4	44.4%	68	53.5%	1	2.5%	1	33.3%
2018	11	4.1%	4	6.2%	1	20.0%	4	5.3%	0	0.0%	6	4.7%	2	5.0%	1	33.3%
2019	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%

Table 12a. Descriptive Statistics of Time to First Switch¹, by Switch Pattern, in Days in the Sentinel Distributed Database (SDD) from January 1, 2013 to December 31, 2019

Switch	Switch Pattern	Switch Pattern		Standard												
		Episodes (n)	Mean	Deviation	Min	1%	5%	10%	25%	50%	75%	90%	95%	99%	Max	
ANDA 202424 to Non-202424	ANDA 202424 to Non-202424 to ANDA 202424	36,696	75.47	105.60	0	0	1	2	7	36	98	203	261	513	1599	
ANDA 040440 to Non-040440	ANDA 040440 to Non-040440 to ANDA 040440	5,765	44.18	77.08	0	0	0	1	4	24	50	113	183	375	1316	
ANDA 040422 to Non-040422	ANDA 040422 to Non-040422 to ANDA 040422	45,190	104.98	168.02	0	0	1	2	8	40	124	278	417	855	2154	
ANDA 040439 to Non-040439	ANDA 040439 to Non-040439 to ANDA 040439	14,083	57.80	101.95	0	0	1	1	4	28	65	144	226	509	1335	
ANDA 040480 to Non-040480	ANDA 040480 to Non-040480 to ANDA 040480	3,062	42.47	51.70	0	0	1	2	5	30	62	102	136	240	723	
Non-202424 to ANDA 202424	Non-202424 to ANDA 202424 to Non-202424	31,976	115.18	179.94	0	0	1	3	10	49	140	304	449	904	2286	
Non-040440 to ANDA 040440	Non-040440 to ANDA 040440 to Non-040440	14,382	166.35	219.71	0	0	2	5	31	90	217	424	604	1,063	2140	
Non-040422 to ANDA 040422	Non-040422 to ANDA 040422 to Non-040422	37,240	87.45	123.12	0	0	1	2	8	39	117	228	308	593	1731	
Non-040439 to ANDA 040439	Non-040439 to ANDA 040439 to Non-040439	24,556	117.15	176.58	0	0	1	3	15	58	139	303	459	872	2154	
Non-040480 to ANDA 040480	Non-040480 to ANDA 040480 to Non-040480	5,337	166.77	206.09	0	0	2	5	32	99	217	446	554	977	2394	
Non-202424 to ANDA 202424	Non-202424 to ANDA 202424 to Same Non-202424	34,469	111.68	175.66	0	0	1	2	10	46	135	293	434	887	2286	
Non-040440 to ANDA 040440	Non-040440 to ANDA 040440 to Same Non-040440	15,204	162.44	216.10	0	0	2	5	31	88	212	411	588	1,044	2140	
Non-040422 to ANDA 040422	Non-040422 to ANDA 040422 to Same Non-040422	40,583	86.02	121.49	0	0	1	2	8	38	114	223	305	587	1731	
Non-040439 to ANDA 040439	Non-040439 to ANDA 040439 to Same Non-040439	26,277	113.79	172.68	0	0	1	3	14	56	134	291	447	859	2154	
Non-040480 to ANDA 040480	Non-040480 to ANDA 040480 to Same Non-040480	5,600	165.30	202.60	0	0	2	5	33	100	216	435	546	965	2394	

¹Time to first switch after use of the same ANDA product for 60 days

Table 12b. Descriptive Statistics of Time to First Switch¹, by Switch Pattern and Year, in Days, in the Sentinel Distributed Database (SDD) from January 1, 2013 to December 31, 2019

Switch Pattern	Switch Pattern Episodes (n)	Standard Mean	Standard Deviation	Min	1%	5%	10%	25%	50%	75%	90%	95%	99%	Max
ANDA 202424 to Non-202424 to ANDA 202424														
2013	0													
2014	2,135	72.07	143.93	0	0	1	2	6	32	73	159	270	786	1599
2015	1,758	103.52	176.79	0	0	1	2	7	36	113	259	485	920	1175
2016	2,700	137.21	177.36	0	0	1	3	12	59	196	411	522	713	1194
2017	13,250	94.33	98.81	0	0	1	3	20	62	148	229	272	448	877
2018	10,019	54.59	72.30	0	0	1	2	5	31	69	148	213	332	648
2019	6,834	38.98	44.61	0	0	1	2	5	29	58	96	127	210	291
ANDA 040440 to Non-040440 to ANDA 040440														
2013	0													
2014	786	51.72	77.80	0	0	1	2	5	29	64	133	210	369	689
2015	284	61.55	94.28	0	0	1	1	5	30	86	186	216	365	883
2016	269	89.17	167.51	0	0	1	1	4	30	78	283	460	782	1316
2017	844	56.60	96.76	0	0	0	1	4	27	63	158	221	516	933
2018	1,934	39.61	63.41	0	0	0	1	4	22	41	97	170	336	445
2019	1,648	29.26	39.58	0	0	0	1	3	13	35	79	116	186	293
ANDA 040422 to Non-040422 to ANDA 040422														
2013	4,847	148.43	187.20	0	0	2	4	31	89	214	356	456	852	2154
2014	6,136	103.73	180.46	0	0	2	3	12	53	118	221	374	963	2038
2015	3,573	149.61	244.63	0	0	2	3	17	61	165	366	683	1,306	1598
2016	4,335	167.86	245.82	0	0	1	3	13	62	211	492	794	1,077	1298
2017	8,223	113.07	166.64	0	0	1	2	7	37	134	366	511	714	959
2018	12,259	79.50	100.05	0	0	1	2	7	36	111	228	301	437	643
2019	5,817	38.09	44.48	0	0	1	2	5	27	56	101	132	195	285
ANDA 040439 to Non-040439 to ANDA 040439														
2013	1,760	57.03	102.37	0	0	0	1	5	28	65	143	211	449	1170
2014	1,225	86.27	162.39	0	0	1	2	6	31	81	224	454	783	1335
2015	856	137.38	176.18	0	0	1	2	15	65	205	359	476	906	1223
2016	1,215	105.77	151.97	0	0	1	2	10	41	123	339	464	646	1151
2017	2,068	71.75	80.41	0	0	1	2	9	49	103	165	237	361	942
2018	4,247	34.23	47.79	0	0	0	1	4	18	40	91	129	222	469
2019	2,712	25.11	34.12	0	0	0	1	3	10	33	64	95	172	250
ANDA 040480 to Non-040480 to ANDA 040480														
2013	0													
2014	26	63.81	121.87	0	0	0	1	6	31	93	152	154	617	617
2015	6	50.50	67.93	2	2	2	2	8	27.5	54	184	184	184	184
2016	268	66.72	76.70	0	0	0	1	4	33	114	179	214	305	364
2017	731	44.82	57.03	0	0	1	2	7	31	62	103	139	247	723
2018	1,322	45.17	44.00	0	0	1	2	7	33	67	101	121	185	372
2019	709	25.01	35.39	0	0	0	1	3	9	33	64	92	173	276
Non-202424 to ANDA 202424 to Non-202424														
2013	998	375.49	276.07	76	105	156	183	224	304	424	568	868	1,807	2286
2014	3,956	116.36	201.30	0	0	2	4	22	63	129	236	428	1,169	2013
2015	2,576	163.19	261.84	0	0	1	3	17	61.5	180	448	767	1,301	1715
2016	3,324	187.01	250.98	0	0	1	3	25	84	244	528	797	1,091	1350
2017	7,241	114.01	158.66	0	0	1	2	9	45	147	338	475	708	959
2018	9,865	82.76	100.00	0	0	1	3	9	40	118	228	309	433	644
2019	4,016	40.81	47.14	0	0	1	2	5	28	60	107	141	206	285

Table 12b. Descriptive Statistics of Time to First Switch¹, by Switch Pattern and Year, in Days, in the Sentinel Distributed Database (SDD) from January 1, 2013 to December 31, 2019

Switch Pattern	Switch Pattern Episodes (n)	Standard Mean	Standard Deviation	Min	1%	5%	10%	25%	50%	75%	90%	95%	99%	Max
Non-040440 to ANDA 040440 to Non-040440														
2013	740	206.92	270.35	0	3	6	26	67	142.5	253	377	529	1,718	2140
2014	1,035	144.70	298.20	0	0	1	3	10	48	123	328	646	1,628	2013
2015	585	303.24	417.25	0	0	2	5	29	91	390	1,044	1,215	1,498	1596
2016	961	368.52	339.72	0	0	4	10	61	246	632	887	1,009	1,143	1309
2017	4,231	212.17	199.97	0	1	4	12	57	150	307	527	634	811	980
2018	4,514	119.01	115.44	0	0	2	4	30	83	185	291	357	458	604
2019	2,316	53.14	50.15	0	0	1	3	9	37	81	124	154	208	279
Non-040422 to ANDA 040422 to Non-040422														
2013	1,753	56.35	106.21	0	0	0	1	5	28	64	137	208	449	1681
2014	3,408	73.99	142.20	0	0	1	2	6	31	75	174	299	712	1731
2015	2,399	118.36	192.18	0	0	1	2	8	40	132	320	507	938	1560
2016	3,388	141.86	190.36	0	0	1	3	12	59	183	446	557	755	1316
2017	11,713	108.70	113.79	0	0	2	4	26	69	168	253	306	533	942
2018	8,599	72.44	86.84	0	0	1	2	7	37	102	195	251	392	648
2019	5,980	40.97	47.14	0	0	1	2	5	30	60	103	140	219	285
Non-040439 to ANDA 040439 to Non-040439														
2013	3,541	104.60	166.74	0	0	2	3	19	58	124	253	368	662	2154
2014	1,970	122.34	216.09	0	0	1	3	20	58	131	272	465	1,278	2038
2015	1,195	189.28	286.14	0	0	2	4	27	82	213	529	976	1,310	1582
2016	1,626	223.32	301.45	0	0	1	3	12	64	343	716	909	1,152	1373
2017	5,455	164.91	186.15	0	0	2	5	31	91	236	452	583	771	984
2018	7,305	84.32	97.51	0	0	1	3	12	53	116	221	302	439	644
2019	3,464	46.32	49.84	0	0	1	2	6	32	66	119	151	216	291
Non-040480 to ANDA 040480 to Non-040480														
2013	18	787.67	710.69	61	61	61	125	284	478.5	1,209	2,082	2,394	2,394	2394
2014	94	373.76	497.90	0	0	5	12	62	122.5	570	1,246	1,487	1,928	1928
2015	169	369.73	382.43	0	0	3	7	41	252	541	1,029	1,119	1,448	1516
2016	495	261.06	285.85	0	0	3	6	35	136	407	718	884	1,063	1282
2017	2,215	189.23	183.25	0	0	3	7	39	125	270	488	544	732	993
2018	1,697	104.91	101.86	0	0	2	5	29	74	157	242	297	487	648
2019	649	79.83	71.11	0	0	1	3	22	61	127	191	213	252	287
Non-202424 to ANDA 202424 to Same Non-202424														
2013	998	375.49	276.07	76	105	156	183	224	304	424	568	868	1,807	2286
2014	4,007	115.96	200.97	0	0	2	4	21	62	128	236	428	1,159	2013
2015	2,657	161.53	259.75	0	0	1	3	15	61	179	440	766	1,294	1715
2016	3,417	184.45	249.64	0	0	1	3	24	81	241	526	792	1,091	1350
2017	7,542	113.20	157.45	0	0	1	2	9	46	146	333	470	705	970
2018	11,190	81.39	98.42	0	0	1	2	8	39	116	222	304	430	644
2019	4,658	39.98	46.14	0	0	1	1	5	28	59	103	137	201	285
Non-040440 to ANDA 040440 to Same Non-040440														
2013	740	206.92	270.35	0	3	6	26	67	142.5	253	377	529	1,718	2140
2014	1,064	142.68	295.22	0	0	1	3	10	46	122	302	641	1,628	2013
2015	603	297.98	415.72	0	0	2	5	28	87	378	1,042	1,215	1,487	1596
2016	977	365.93	339.99	0	0	3	9	61	241	630	889	1,009	1,143	1309
2017	4,359	209.26	198.93	0	0	4	11	55	147	302	522	633	809	980
2018	4,937	117.79	114.39	0	0	2	4	30	81	183	289	356	458	604
2019	2,524	53.08	50.36	0	0	1	3	9	36.5	81	124	154	208	279

Table 12b. Descriptive Statistics of Time to First Switch¹, by Switch Pattern and Year, in Days, in the Sentinel Distributed Database (SDD) from January 1, 2013 to December 31, 2019

Switch Pattern	Switch Pattern Episodes (n)	Standard		Min	1%	5%	10%	25%	50%	75%	90%	95%	99%	Max
		Mean	Deviation											
Non-040422 to ANDA 040422 to Same Non-040422														
2013	1,824	56.58	106.66	0	0	0	1	5	28	64	136	210	485	1681
2014	3,673	76.25	145.28	0	0	1	2	6	32	78	180	313	733	1731
2015	2,552	117.10	189.17	0	0	1	2	8	40	132	318	494	936	1560
2016	3,540	141.22	190.09	0	0	1	3	11	58	183	446	557	748	1316
2017	12,206	107.22	113.04	0	0	2	3	25	68	165	251	305	528	942
2018	9,846	72.93	86.64	0	0	1	2	8	38	102	196	252	386	648
2019	6,942	40.67	46.64	0	0	1	2	5	30	59	101	136	215	287
Non-040439 to ANDA 040439 to Same Non-040439														
2013	3,605	103.83	165.61	0	0	2	3	19	58	124	250	367	658	2154
2014	2,034	120.62	213.43	0	0	1	3	18	57	130	265	465	1,271	2038
2015	1,243	185.54	282.57	0	0	2	4	27	80	209	500	935	1,305	1582
2016	1,684	219.02	299.62	0	0	1	2	11	62	336	712	903	1,152	1373
2017	5,570	163.54	185.33	0	0	2	5	31	90	232	450	581	767	984
2018	7,951	83.73	96.97	0	0	1	3	12	53	115	219	299	439	644
2019	4,190	46.41	49.59	0	0	1	2	6	32	66	118	152	216	291
Non-040480 to ANDA 040480 to Same Non-040480														
2013	18	787.67	710.69	61	61	61	125	284	478.5	1,209	2,082	2,394	2,394	2394
2014	95	375.16	495.44	0	0	5	12	62	126	570	1,246	1,487	1,928	1928
2015	170	367.58	382.32	0	0	3	7	37	251.5	541	1,010	1,119	1,448	1516
2016	500	259.59	285.18	0	1	3	6	35	135	404	716	881	1,060	1282
2017	2,262	186.99	182.76	0	0	3	7	38	124	267	487	542	732	993
2018	1,803	107.31	102.65	0	0	2	5	29	79	161	243	302	482	648
2019	752	89.29	76.04	0	0	1	3	25	66.5	156	203	222	254	287

¹Time to first switch after use of the same ANDA product for 60 days

Table 13a. Descriptive Statistics of Time to Second Switch, by Switch Pattern, in Days in the Sentinel Distributed Database (SDD) from January 1, 2013 to December 31, 2019

Switch	Switch Pattern	Switch Pattern Episodes (n)	Standard												
			Mean	Deviatio	Min	1%	5%	10%	25%	50%	75%	90%	95%	99%	Max
Non-202424 to ANDA 202424	ANDA 202424 to Non-202424 to ANDA 202424	15,769	60.69	71.31	1	22	27	28	29	33	62	116	181	397	1701
Non-040440 to ANDA 040440	ANDA 040440 to Non-040440 to ANDA 040440	1,547	78.53	88.01	7	21	27	28	30	37	91	168	247	427	1252
Non-040422 to ANDA 040422	ANDA 040422 to Non-040422 to ANDA 040422	21,964	57.67	70.46	1	21	26	27	29	32	61	112	169	357	1357
Non-040439 to ANDA 040439	ANDA 040439 to Non-040439 to ANDA 040439	5,367	67.24	74.85	3	22	27	28	30	35	83	130	183	367	1146
Non-040480 to ANDA 040480	ANDA 040480 to Non-040480 to ANDA 040480	738	104.82	104.40	8	23	27	28	30	56	177	267	300	422	624
ANDA 202424 to Non-202424	Non-202424_non to ANDA 202424 to Non-202424	16,720	56.89	66.13	1	21	26	27	29	32	61	101	160	331	1658
ANDA 040440 to Non-040440	Non-040440_non to ANDA 040440 to Non-040440	8,382	44.00	42.56	2	20	26	27	29	31	36	71	95	231	1090
ANDA 040422 to Non-040422	Non-040422_non to ANDA 040422 to Non-040422	17,288	61.53	80.24	2	21	27	28	29	32	61	117	188	428	1701
ANDA 040439 to Non-040439	Non-040439_non to ANDA 040439 to Non-040439	13,117	47.78	53.97	1	20	26	27	29	31	51	87	119	250	1332
ANDA 040480 to Non-040480	Non-040480_non to ANDA 040480 to Non-040480	2,817	51.29	41.42	1	21	26	27	29	32	60	97	137	199	573
ANDA 202424 to Same Non-202424	Non-202424_same to ANDA 202424 to Same Non-202424	12,732	53.52	59.09	1	21	26	27	29	31	59	94	149	308	1152
ANDA 040440 to Same Non-040440	Non-040440_same to ANDA 040440 to Same Non-040440	5,187	42.64	38.64	2	20	26	27	29	31	36	67	93	209	873
ANDA 040422 to Same Non-040422	Non-040422_same to ANDA 040422 to Same Non-040422	12,483	55.80	68.60	2	20	26	27	29	32	59	95	155	369	1701
ANDA 040439 to Same Non-040439	Non-040439_same to ANDA 040439 to Same Non-040439	8,942	46.04	50.91	1	19	26	27	29	31	37	82	109	240	1332
ANDA 040480 to Same Non-040480	Non-040480_same to ANDA 040480 to Same Non-040480	1,516	49.20	41.23	1	17	26	27	29	31	57	94	133	213	409

Table 13b. Descriptive Statistics of Time to Second Switch, by Switch Pattern and Year, in Days, in the Sentinel Distributed Database (SDD) from January 1, 2013 to December 31, 2019

Switch Pattern	Switch Pattern Episodes (n)	Mean	Std	Min	1%	5%	10%	25%	50%	75%	90%	95%	99%	Max
ANDA 202424 to Non-202424 to ANDA 202424														
2013	0													
2014	888	66.23	99.12	11	18	25	27	29	33	63	121	225	489	1701
2015	851	58.15	82.40	9	15	25	27	29	31	58	112	156	476	799
2016	1,303	63.63	85.18	8	22	26	27	29	32	61	122	221	429	1093
2017	5,925	65.73	81.13	7	23	27	28	29	33	63	124	210	453	908
2018	4,692	59.19	56.10	1	23	27	28	30	33	63	119	180	305	586
2019	2,110	46.73	29.80	4	21	27	28	29	32	59	89	103	165	245
ANDA 040440 to Non-040440 to ANDA 040440														
2013	0													
2014	248	55.67	58.65	8	17	25	27	29	32	64	112	146	233	720
2015	61	56.85	97.81	23	23	27	27	29	31	37	94	129	750	750
2016	78	87.79	152.70	24	24	25	27	29	37	90	162	331	1,252	1252
2017	288	102.61	112.24	16	25	27	28	30	59	122	246	318	519	833
2018	603	88.12	82.82	7	24	27	28	30	60	117	190	268	382	533
2019	269	54.58	41.85	7	14	26	27	29	33	62	117	133	210	274
ANDA 040422 to Non-040422 to ANDA 040422														
2013	2,611	52.44	69.21	4	19	25	27	29	31	55	91	145	359	1152
2014	2,891	57.70	89.51	9	22	26	27	29	32	59	94	153	477	1357
2015	1,767	58.51	93.76	11	22	25	27	29	31	57	94	173	572	1346
2016	2,107	66.24	93.60	6	20	25	27	29	31	59	127	249	511	832
2017	4,216	55.09	57.83	6	22	26	27	29	32	60	103	155	309	881
2018	6,069	64.12	61.11	1	20	27	28	29	34	70	133	188	313	519
2019	2,303	42.82	26.66	3	15	26	27	29	31	55	81	95	152	221
ANDA 040439 to Non-040439 to ANDA 040439														
2013	605	67.10	80.74	15	23	25	27	30	33	64	154	198	432	928
2014	409	67.58	108.26	11	21	24	26	28	32	61	132	211	549	1072
2015	348	65.87	109.81	11	17	25	27	29	32	63	100	164	496	1146
2016	506	66.69	90.42	3	22	26	27	29	34	64	121	157	455	964
2017	890	74.88	76.76	12	23	27	28	30	55	92	148	208	475	559
2018	1,802	72.27	59.84	3	25	27	28	31	57	92	149	195	305	486
2019	807	48.42	34.53	9	22	27	28	30	32	59	93	120	192	272
ANDA 040480 to Non-040480 to ANDA 040480														
2013	0													
2014	6	34.17	10.34	27	27	27	27	30	30.5	32	55	55	55	55
2015	1	63.00		63	63	63	63	63	63	63	63	63	63	63
2016	87	81.26	92.41	24	24	27	28	30	58	92	182	217	547	547
2017	218	79.62	98.64	8	20	26	28	30	52.5	90	149	267	560	624
2018	342	120.49	108.87	12	24	27	28	29	44.5	241	285	304	329	358
2019	84	136.33	95.66	17	17	28	29	31	139.5	235	258	266	290	290
Non-202424 to ANDA 202424 to Non-202424														
2013	464	76.30	111.52	12	23	27	28	30	34	81	150	218	646	1152
2014	1,824	60.80	90.10	9	23	26	27	29	32	61	111	171	476	1658
2015	1,271	59.94	88.61	11	20	25	26	29	31	57	96	182	572	845
2016	1,689	68.21	90.93	3	21	25	27	29	32	62	152	252	503	1118
2017	4,122	54.92	57.08	6	23	26	27	29	32	60	98	156	311	734
2018	5,618	54.95	47.51	1	21	27	28	29	32	62	100	151	261	560
2019	1,732	45.25	32.43	2	14	26	27	29	31	56	88	111	183	287

Table 13b. Descriptive Statistics of Time to Second Switch, by Switch Pattern and Year, in Days, in the Sentinel Distributed Database (SDD) from January 1, 2013 to December 31, 2019

Switch Pattern	Switch Pattern Episodes (n)	Mean	Std	Min	1%	5%	10%	25%	50%	75%	90%	95%	99%	Max
Non-040440 to ANDA 040440 to Non-040440														
2013	394	59.72	77.21	12	23	25	27	29	32	61	118	183	393	873
2014	560	48.03	70.52	9	21	25	27	29	31	36	76	102	395	1090
2015	288	49.65	49.90	12	16	25	27	28	31	57	91	127	286	512
2016	528	53.88	62.89	12	22	26	27	29	31	57	95	134	344	547
2017	2,667	43.74	39.72	2	20	26	27	28	31	37	79	95	225	653
2018	2,754	41.44	29.10	3	20	27	28	29	31	36	65	91	155	352
2019	1,191	37.69	20.26	2	14	26	27	29	30	35	62	83	102	216
Non-040422 to ANDA 040422 to Non-040422														
2013	666	85.46	124.19	15	23	25	27	30	34	90	183	294	600	1518
2014	1,410	70.31	114.11	7	19	25	27	29	33	63	127	235	518	1701
2015	1,115	58.48	87.67	9	16	25	27	29	31	59	98	158	554	1113
2016	1,654	64.31	90.33	8	22	26	27	29	32	61	120	196	464	1093
2017	5,789	70.58	89.60	4	23	27	28	29	33	63	152	280	467	833
2018	4,398	51.54	48.49	2	21	27	28	29	32	59	92	143	277	533
2019	2,256	44.66	28.08	4	17	27	28	29	32	57	84	102	156	224
Non-040439 to ANDA 040439 to Non-040439														
2013	1,942	44.84	52.44	4	19	25	27	29	31	36	67	95	247	891
2014	996	55.88	101.74	10	20	25	27	29	31	36	82	161	611	1332
2015	642	55.40	93.74	13	22	26	27	29	31	43	89	150	548	1047
2016	821	64.18	86.36	11	22	26	27	29	31	60	128	224	471	842
2017	2,911	45.67	35.97	4	20	26	27	29	31	53	88	122	186	421
2018	4,245	46.85	36.68	1	21	27	28	29	32	58	89	112	210	469
2019	1,560	40.96	24.31	3	14	27	28	29	31	37	67	92	133	248
Non-040480 to ANDA 040480 to Non-040480														
2013	11	53.27	54.25	26	26	26	27	29	36	59	60	213	213	213
2014	37	45.92	24.59	23	23	27	28	30	31	58	90	96	116	116
2015	80	72.35	86.01	25	25	28	29	31	34	69	151	232	573	573
2016	283	50.43	38.53	10	14	26	27	29	31	61	93	123	215	273
2017	1,385	47.73	37.07	13	23	27	28	29	31	58	91	122	185	398
2018	946	56.10	42.87	1	15	27	27	29	33	64	121	151	189	369
2019	75	39.37	26.71	21	21	24	26	28	31	35	66	94	182	182
Non-202424 to ANDA 202424 to Same Non-202424														
2013	397	74.57	108.13	17	23	27	28	29	33	67	152	229	646	1152
2014	1,564	56.13	70.34	9	22	26	27	29	32	60	97	153	356	855
2015	1,114	54.53	72.78	11	21	24	26	29	31	56	92	153	423	822
2016	1,385	60.72	76.92	3	21	25	27	29	31	59	118	236	431	643
2017	2,975	50.65	50.86	7	22	26	27	29	31	58	92	128	270	734
2018	3,937	53.43	46.85	1	20	27	28	29	32	61	97	148	265	464
2019	1,360	42.74	30.05	3	14	26	27	29	31	37	71	97	179	287
Non-040440 to ANDA 040440 to Same Non-040440														
2013	313	62.11	81.20	12	23	25	27	29	32	61	122	184	350	873
2014	421	42.78	40.38	9	20	25	27	29	31	35	70	90	255	422
2015	205	46.43	41.65	12	16	25	27	28	31	56	89	120	254	356
2016	306	45.29	42.62	12	22	26	27	28	31	36	70	118	285	344
2017	1,440	43.04	41.09	2	18	26	27	28	30	35	68	95	225	653
2018	1,702	40.48	27.16	3	20	27	28	29	31	36	64	90	153	342
2019	800	36.80	17.60	3	21	26	27	28	30	35	61	73	101	159

Table 13b. Descriptive Statistics of Time to Second Switch, by Switch Pattern and Year, in Days, in the Sentinel Distributed Database (SDD) from January 1, 2013 to December 31, 2019

Switch Pattern	Switch Pattern Episodes (n)	Mean	Std	Min	1%	5%	10%	25%	50%	75%	90%	95%	99%	Max
Non040422 to ANDA 040422 to Same Non-040422														
2013	428	67.94	79.94	15	21	25	27	29	32	64	163	217	462	614
2014	1,119	60.35	88.52	7	18	25	27	29	32	61	110	181	399	1701
2015	945	55.87	85.58	9	15	25	27	29	31	56	94	148	469	1113
2016	1,267	61.32	84.72	8	22	26	27	29	32	60	111	179	449	1093
2017	3,959	61.29	76.46	4	23	27	28	29	32	60	117	208	425	833
2018	3,095	50.10	45.17	2	21	27	28	29	32	58	91	128	269	533
2019	1,670	43.00	26.51	4	17	27	28	29	31	55	71	94	151	224
Non-040439 to ANDA 040439 to Same Non-040439														
2013	1,637	42.46	41.32	4	19	25	27	29	31	36	65	93	201	785
2014	764	56.78	101.29	10	18	25	27	29	31	35	88	178	553	1332
2015	496	52.45	80.69	13	21	25	27	29	31	37	83	150	366	997
2016	598	58.05	74.99	11	22	26	27	29	31	56	114	213	453	528
2017	1,671	44.11	32.86	7	21	26	27	29	31	37	84	114	181	421
2018	2,711	45.43	35.80	1	20	27	28	29	31	56	85	101	208	520
2019	1,065	38.72	19.71	7	14	26	27	29	31	36	63	85	116	184
Non-040480 to ANDA 040480 to Same Non-040480														
2013	5	67.80	81.32	26	26	26	26	27	36	37	213	213	213	213
2014	18	44.17	21.78	27	27	27	28	30	31.5	57	90	90	90	90
2015	36	70.75	84.08	28	28	28	28	30	33	62	179	306	409	409
2016	153	44.58	31.14	14	14	26	27	28	30	54	89	105	157	215
2017	694	47.31	39.73	13	21	27	28	29	31	56	90	128	214	398
2018	552	52.64	42.38	1	13	25	27	29	32	62	119	146	188	369
2019	58	37.84	20.55	21	21	23	26	28	31	35	61	90	133	133

Figure 1a. Number of Overall Mixed Amphetamine Salt (MAS) Users Over Time




Figure 1b. Number of Overall Mixed Amphetamine Salt (MAS) Users Over Time, by Sex: (ANDA 202424)




Figure 1b. Number of Overall Mixed Amphetamine Salt (MAS) Users Over Time, by Sex: (ANDA 040440)




Figure 1b. Number of Overall Mixed Amphetamine Salt (MAS) Users Over Time, by Sex: (ANDA 040422)




Figure 1b. Number of Overall Mixed Amphetamine Salt (MAS) Users Over Time, by Sex: (ANDA 040439)




Figure 1b. Number of Overall Mixed Amphetamine Salt (MAS) Users Over Time, by Sex: (ANDA 040480)




Figure 1b. Number of Overall Mixed Amphetamine Salt (MAS) Users Over Time, by Sex: (Non-202424)




Figure 1b. Number of Overall Mixed Amphetamine Salt (MAS) Users Over Time, by Sex: (Non-040440)




Figure 1b. Number of Overall Mixed Amphetamine Salt (MAS) Users Over Time, by Sex: (Non-040422)




Figure 1b. Number of Overall Mixed Amphetamine Salt (MAS) Users Over Time, by Sex: (Non-040439)




Figure 1b. Number of Overall Mixed Amphetamine Salt (MAS) Users Over Time, by Sex: (Non-040480)




Figure 1c. Number of Overall Users Over Time, by Age Group: (ANDA 202424)




Figure 1c. Number of Overall Users Over Time, by Age Group: (ANDA 040440)




Figure 1c. Number of Overall Users Over Time, by Age Group: (ANDA 040422)




Figure 1c. Number of Overall Users Over Time, by Age Group: (ANDA 040439)




Figure 1c. Number of Overall Users Over Time, by Age Group: (ANDA 040480)




Figure 1c. Number of Overall Users Over Time, by Age Group: (Non-202424)




Figure 1c. Number of Overall Users Over Time, by Age Group: (Non-040440)




Figure 1c. Number of Overall Users Over Time, by Age Group: (Non-040422)




Figure 1c. Number of Overall Users Over Time, by Age Group: (Non-040439)




Figure 1c. Number of Overall Users Over Time, by Age Group: (Non-040480)




Figure 2a. Number of Mixed Amphetamine Salts (MAS) Dispensings Over Time, by Month-Year




Figure 2b. Number of Mixed Amphetamine Salts (MAS) Dispensings Over Time, by Month-Year, by Sex: (ANDA 202424)




Figure 2b. Number of Mixed Amphetamine Salts (MAS) Dispensings Over Time, by Month-Year, by Sex: (ANDA 040440)




Figure 2b. Number of Mixed Amphetamine Salts (MAS) Dispensings Over Time, by Month-Year, by Sex: (ANDA 040422)




Figure 2b. Number of Mixed Amphetamine Salts (MAS) Dispensings Over Time, by Month-Year, by Sex: (ANDA 040439)




Figure 2b. Number of Mixed Amphetamine Salts (MAS) Dispensings Over Time, by Month-Year, by Sex: (ANDA 040480)




Figure 2b. Number of Mixed Amphetamine Salts (MAS) Dispensings Over Time, by Month-Year, by Sex: (Non-202424)




Figure 2b. Number of Mixed Amphetamine Salts (MAS) Dispensings Over Time, by Month-Year, by Sex: (Non-040440)




Figure 2b. Number of Mixed Amphetamine Salts (MAS) Dispensings Over Time, by Month-Year, by Sex: (Non-040422)




Figure 2b. Number of Mixed Amphetamine Salts (MAS) Dispensings Over Time, by Month-Year, by Sex: (Non-040439)




Figure 2b. Number of Mixed Amphetamine Salts (MAS) Dispensings Over Time, by Month-Year, by Sex: (Non-040480)




Figure 2c. Number of Mixed Amphetamine Salts (MAS) Dispensings Over Time, by Month-Year, by Age Group: (ANDA 202424)




Figure 2c. Number of Mixed Amphetamine Salts (MAS) Dispensings Over Time, by Month-Year, by Age Group: (ANDA 040440)




Figure 2c. Number of Mixed Amphetamine Salts (MAS) Dispensings Over Time, by Month-Year, by Age Group: (ANDA 040422)




Figure 2c. Number of Mixed Amphetamine Salts (MAS) Dispensings Over Time, by Month-Year, by Age Group: (ANDA 040439)




Figure 2c. Number of Mixed Amphetamine Salts (MAS) Dispensings Over Time, by Month-Year, by Age Group: (ANDA 040480)




Figure 2c. Number of Mixed Amphetamine Salts (MAS) Dispensings Over Time, by Month-Year, by Age Group: (Non-202424)




Figure 2c. Number of Mixed Amphetamine Salts (MAS) Dispensings Over Time, by Month-Year, by Age Group: (Non-040440)




Figure 2c. Number of Mixed Amphetamine Salts (MAS) Dispensings Over Time, by Month-Year, by Age Group: (Non-040422)




Figure 2c. Number of Mixed Amphetamine Salts (MAS) Dispensings Over Time, by Month-Year, by Age Group: (Non-040439)




Figure 2c. Number of Mixed Amphetamine Salts (MAS) Dispensings Over Time, by Month-Year, by Age Group: (Non-040480)




Figure 3.1. Survival Curve for Time to First Switch, in Days




Figure 3.2. Survival Curve for Time to First Switch, in Days




Figure 3.3. Survival Curve for Time to First Switch, in Days




Figure 4.1. Survival Curve for Time to Second Switch, in Days




Figure 4.2. Survival Curve for Time to Second Switch, in Days




Figure 4.3. Survival Curve for Time to Second Switch, in Days




Figure 5.1. Survival Curve for Time to Censoring at First Switch Evaluation, in Days, by Censoring Reason (Non-202424)




Figure 5.2. Survival Curve for Time to Censoring at First Switch Evaluation, in Days, by Censoring Reason (Non-040440)




Figure 5.3. Survival Curve for Time to Censoring at First Switch Evaluation, in Days, by Censoring Reason (Non-040422)




Figure 5.4. Survival Curve for Time to Censoring at First Switch Evaluation, in Days, by Censoring Reason (Non-040439)




Figure 5.5. Survival Curve for Time to Censoring at First Switch Evaluation, in Days, by Censoring Reason (Non-040480)




Figure 5.6. Survival Curve for Time to Censoring at First Switch Evaluation, in Days, by Censoring Reason (ANDA 202424)




Figure 5.7. Survival Curve for Time to Censoring at First Switch Evaluation, in Days, by Censoring Reason (ANDA 040440)




Figure 5.8. Survival Curve for Time to Censoring at First Switch Evaluation, in Days, by Censoring Reason (ANDA 040422)




Figure 5.9. Survival Curve for Time to Censoring at First Switch Evaluation, in Days, by Censoring Reason (ANDA 040439)




Figure 5.10. Survival Curve for Time to Censoring at First Switch Evaluation, in Days, by Censoring Reason (ANDA 040480)




Figure 5.11. Survival Curve for Time to Censoring at First Switch Evaluation, in Days, by Censoring Reason (ANDA 202424)




Figure 5.12. Survival Curve for Time to Censoring at First Switch Evaluation, in Days, by Censoring Reason (ANDA 040440)




Figure 5.13. Survival Curve for Time to Censoring at First Switch Evaluation, in Days, by Censoring Reason (ANDA 040422)




Figure 5.14. Survival Curve for Time to Censoring at First Switch Evaluation, in Days, by Censoring Reason (ANDA 040439)




Figure 5.15. Survival Curve for Time to Censoring at First Switch Evaluation, in Days, by Censoring Reason (ANDA 040480)




Figure 6.1. Survival Curve for Time to Censoring at Second Switch Evaluation, in Days, by Censoring Reason (ANDA 202424)




Figure 6.2. Survival Curve for Time to Censoring at Second Switch Evaluation, in Days, by Censoring Reason (ANDA 040440)




Figure 6.3. Survival Curve for Time to Censoring at Second Switch Evaluation, in Days, by Censoring Reason (ANDA 040422)




Figure 6.4. Survival Curve for Time to Censoring at Second Switch Evaluation, in Days, by Censoring Reason (ANDA 040439)




Figure 6.5. Survival Curve for Time to Censoring at Second Switch Evaluation, in Days, by Censoring Reason (ANDA 040480)




Figure 6.6. Survival Curve for Time to Censoring at Second Switch Evaluation, in Days, by Censoring Reason (Non-202424)




Figure 6.7. Survival Curve for Time to Censoring at Second Switch Evaluation, in Days, by Censoring Reason (Non-040440)




Figure 6.8. Survival Curve for Time to Censoring at Second Switch Evaluation, in Days, by Censoring Reason (Non-040422)




Figure 6.9. Survival Curve for Time to Censoring at Second Switch Evaluation, in Days, by Censoring Reason (Non-040439)




Figure 6.10. Survival Curve for Time to Censoring at Second Switch Evaluation, in Days, by Censoring Reason (Non-040480)




Figure 6.11. Survival Curve for Time to Censoring at Second Switch Evaluation, in Days, by Censoring Reason (Same Non-202424)




Figure 6.12. Survival Curve for Time to Censoring at Second Switch Evaluation, in Days, by Censoring Reason (Same Non-040440)




Figure 6.13. Survival Curve for Time to Censoring at Second Switch Evaluation, in Days, by Censoring Reason (Same Non-040422)




Figure 6.14. Survival Curve for Time to Censoring at Second Switch Evaluation, in Days, by Censoring Reason (Same Non-040439)





Figure 6.15. Survival Curve for Time to Censoring at Second Switch Evaluation, in Days, by Censoring Reason (Same Non-040480)



Appendix A. Start and End Dates for Each Data Partner (DP) as of Request Distribution Date (November 9, 2021)

DP ID	Start Date¹	End Date¹
DP01	01/01/2008	12/31/2019
DP02	01/01/2008	12/31/2019
DP03	01/01/2007	12/31/2019
DP04	01/01/2000	12/31/2019
DP05	01/01/2006	12/31/2019

¹The start and end dates are based on the minimum and maximum dates within each DP. The month with the maximum date must have at least 80% of the number of records in the previous month

Appendix B. Computed Start Marketing Dates for Each Cohort at Each Data Partner (DP)

Cohort	DP ID	Computed Start Date
ANDA 202424	DP01	04/11/2014
ANDA 202424	DP02	04/11/2014
ANDA 202424	DP03	04/14/2014
ANDA 202424	DP04	04/19/2014
ANDA 202424	DP05	04/16/2014
ANDA 040440	DP01	01/02/2014
ANDA 040440	DP02	12/30/2013
ANDA 040440	DP03	12/30/2013
ANDA 040440	DP04	01/08/2014
ANDA 040440	DP05	01/02/2014
ANDA 040422	DP01	01/01/2013
ANDA 040422	DP02	01/01/2013
ANDA 040422	DP03	01/01/2013
ANDA 040422	DP04	01/01/2013
ANDA 040422	DP05	01/01/2013
ANDA 040439	DP01	01/01/2013
ANDA 040439	DP02	01/01/2013
ANDA 040439	DP03	01/02/2013
ANDA 040439	DP04	01/02/2013
ANDA 040439	DP05	01/01/2013
ANDA 040480	DP01	03/24/2014
ANDA 040480	DP02	03/17/2014
ANDA 040480	DP03	03/20/2014
ANDA 040480	DP04	04/15/2014
ANDA 040480	DP05	03/20/2014
Non-202424	DP01	01/01/2013
Non-202424	DP02	01/01/2013
Non-202424	DP03	01/01/2013
Non-202424	DP04	01/01/2013
Non-202424	DP05	01/01/2013
Non-040440	DP01	01/01/2013
Non-040440	DP02	01/01/2013
Non-040440	DP03	01/01/2013
Non-040440	DP04	01/01/2013
Non-040440	DP05	01/01/2013
Non-040422	DP01	01/01/2013
Non-040422	DP02	01/01/2013
Non-040422	DP03	01/02/2013
Non-040422	DP04	01/02/2013
Non-040422	DP05	01/01/2013
Non-040439	DP01	01/01/2013
Non-040439	DP02	01/01/2013
Non-040439	DP03	01/01/2013
Non-040439	DP04	01/01/2013
Non-040439	DP05	01/01/2013
Non-040480	DP01	01/01/2013
Non-040480	DP02	01/01/2013
Non-040480	DP03	01/01/2013
Non-040480	DP04	01/01/2013
Non-040480	DP05	01/01/2013

* Computed Start Marketing Date represents the first observed dispensing date among all valid users within each cohort within each Data Partner site.

Appendix C. List of Generic and Brand Names for Medical Products Used to Define Exposures in this Request

Generic Name	Brand Name
ANDA 202424	
dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	dextroamphetamine-amphetamine
ANDA 040440	
dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	dextroamphetamine-amphetamine
ANDA 040422	
dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Adderall
dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	dextroamphetamine-amphetamine
ANDA 040439	
dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	dextroamphetamine-amphetamine
ANDA 040480	
dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	dextroamphetamine-amphetamine
ANDA 040444	
dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	dextroamphetamine-amphetamine
ANDA 040456	
dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	dextroamphetamine-amphetamine
ANDA 206340	
dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	dextroamphetamine-amphetamine
ANDA 206721	
dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	dextroamphetamine-amphetamine
ANDA 207340	
dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	dextroamphetamine-amphetamine
ANDA 207388	
dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	dextroamphetamine-amphetamine
ANDA 209799	
dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	dextroamphetamine-amphetamine
ANDA 211352	
dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	dextroamphetamine-amphetamine

Appendix D. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes Used to Define Inclusions in this Request

Code	Description	Code Category	Code Type
ADHD			
314.00	Attention deficit disorder of childhood without mention of hyperactivity	Diagnosis	ICD-09-CM
314.01	Attention deficit disorder of childhood with hyperactivity	Diagnosis	ICD-09-CM
314.1	Hyperkinesis of childhood with developmental delay	Diagnosis	ICD-09-CM
314.2	Hyperkinetic conduct disorder of childhood	Diagnosis	ICD-09-CM
314.8	Other specified manifestations of hyperkinetic syndrome of childhood	Diagnosis	ICD-09-CM
314.9	Unspecified hyperkinetic syndrome of childhood	Diagnosis	ICD-09-CM
F90.0	Attention-deficit hyperactivity disorder, predominantly inattentive type	Diagnosis	ICD-10-CM
F90.1	Attention-deficit hyperactivity disorder, predominantly hyperactive type	Diagnosis	ICD-10-CM
F90.2	Attention-deficit hyperactivity disorder, combined type	Diagnosis	ICD-10-CM
F90.8	Attention-deficit hyperactivity disorder, other type	Diagnosis	ICD-10-CM
F90.9	Attention-deficit hyperactivity disorder, unspecified type	Diagnosis	ICD-10-CM
Narcolepsy			
347	Cataplexy and narcolepsy	Diagnosis	ICD-09-CM
347.0	Narcolepsy	Diagnosis	ICD-09-CM
347.00	Narcolepsy, without cataplexy	Diagnosis	ICD-09-CM
347.01	Narcolepsy, with cataplexy	Diagnosis	ICD-09-CM
347.1	Narcolepsy in conditions classified elsewhere	Diagnosis	ICD-09-CM
347.10	Narcolepsy in conditions classified elsewhere, without cataplexy	Diagnosis	ICD-09-CM
347.11	Narcolepsy in conditions classified elsewhere, with cataplexy	Diagnosis	ICD-09-CM
G47.4	Narcolepsy and cataplexy	Diagnosis	ICD-10-CM
G47.41	Narcolepsy	Diagnosis	ICD-10-CM
G47.411	Narcolepsy with cataplexy	Diagnosis	ICD-10-CM
G47.419	Narcolepsy without cataplexy	Diagnosis	ICD-10-CM
G47.42	Narcolepsy in conditions classified elsewhere	Diagnosis	ICD-10-CM
G47.421	Narcolepsy in conditions classified elsewhere with cataplexy	Diagnosis	ICD-10-CM
G47.429	Narcolepsy in conditions classified elsewhere without cataplexy	Diagnosis	ICD-10-CM

Appendix E. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
Anxiety Disorders			
293.84	Anxiety disorder in conditions classified elsewhere	Diagnosis	ICD-09-CM
300	Anxiety, dissociative and somatoform disorders	Diagnosis	ICD-09-CM
300.0	Anxiety states	Diagnosis	ICD-09-CM
300.00	Anxiety state, unspecified	Diagnosis	ICD-09-CM
300.01	Panic disorder without agoraphobia	Diagnosis	ICD-09-CM
300.02	Generalized anxiety disorder	Diagnosis	ICD-09-CM
300.09	Other anxiety states	Diagnosis	ICD-09-CM
300.10	Hysteria, unspecified	Diagnosis	ICD-09-CM
300.11	Conversion disorder	Diagnosis	ICD-09-CM
300.12	Dissociative amnesia	Diagnosis	ICD-09-CM
300.13	Dissociative fugue	Diagnosis	ICD-09-CM
300.14	Dissociative identity disorder	Diagnosis	ICD-09-CM
300.15	Dissociative disorder or reaction, unspecified	Diagnosis	ICD-09-CM
300.2	Phobic disorders	Diagnosis	ICD-09-CM
300.20	Phobia, unspecified	Diagnosis	ICD-09-CM
300.21	Agoraphobia with panic disorder	Diagnosis	ICD-09-CM
300.22	Agoraphobia without mention of panic attacks	Diagnosis	ICD-09-CM
300.23	Social phobia	Diagnosis	ICD-09-CM
300.29	Other isolated or specific phobias	Diagnosis	ICD-09-CM
300.3	Obsessive-compulsive disorders	Diagnosis	ICD-09-CM
300.6	Depersonalization disorder	Diagnosis	ICD-09-CM
300.7	Hypochondriasis	Diagnosis	ICD-09-CM
300.81	Somatization disorder	Diagnosis	ICD-09-CM
300.82	Undifferentiated somatoform disorder	Diagnosis	ICD-09-CM
300.89	Other somatoform disorders	Diagnosis	ICD-09-CM
309.24	Adjustment disorder with anxiety	Diagnosis	ICD-09-CM
309.81	Posttraumatic stress disorder	Diagnosis	ICD-09-CM
313.0	Overanxious disorder specific to childhood and adolescence	Diagnosis	ICD-09-CM
F06.4	Anxiety disorder due to known physiological condition	Diagnosis	ICD-10-CM
F40	Phobic anxiety disorders	Diagnosis	ICD-10-CM
F40.0	Agoraphobia	Diagnosis	ICD-10-CM
F40.00	Agoraphobia, unspecified	Diagnosis	ICD-10-CM
F40.01	Agoraphobia with panic disorder	Diagnosis	ICD-10-CM
F40.02	Agoraphobia without panic disorder	Diagnosis	ICD-10-CM
F40.1	Social phobias	Diagnosis	ICD-10-CM
F40.10	Social phobia, unspecified	Diagnosis	ICD-10-CM
F40.11	Social phobia, generalized	Diagnosis	ICD-10-CM
F40.2	Specific (isolated) phobias	Diagnosis	ICD-10-CM
F40.21	Animal type phobia	Diagnosis	ICD-10-CM
F40.210	Arachnophobia	Diagnosis	ICD-10-CM
F40.218	Other animal type phobia	Diagnosis	ICD-10-CM
F40.22	Natural environment type phobia	Diagnosis	ICD-10-CM
F40.220	Fear of thunderstorms	Diagnosis	ICD-10-CM
F40.228	Other natural environment type phobia	Diagnosis	ICD-10-CM
F40.23	Blood, injection, injury type phobia	Diagnosis	ICD-10-CM
F40.230	Fear of blood	Diagnosis	ICD-10-CM
F40.231	Fear of injections and transfusions	Diagnosis	ICD-10-CM
F40.232	Fear of other medical care	Diagnosis	ICD-10-CM
F40.233	Fear of injury	Diagnosis	ICD-10-CM

Appendix E. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
F40.24	Situational type phobia	Diagnosis	ICD-10-CM
F40.240	Claustrophobia	Diagnosis	ICD-10-CM
F40.241	Acrophobia	Diagnosis	ICD-10-CM
F40.242	Fear of bridges	Diagnosis	ICD-10-CM
F40.243	Fear of flying	Diagnosis	ICD-10-CM
F40.248	Other situational type phobia	Diagnosis	ICD-10-CM
F40.29	Other specified phobia	Diagnosis	ICD-10-CM
F40.290	Androphobia	Diagnosis	ICD-10-CM
F40.291	Gynephobia	Diagnosis	ICD-10-CM
F40.298	Other specified phobia	Diagnosis	ICD-10-CM
F40.8	Other phobic anxiety disorders	Diagnosis	ICD-10-CM
F40.9	Phobic anxiety disorder, unspecified	Diagnosis	ICD-10-CM
F41	Other anxiety disorders	Diagnosis	ICD-10-CM
F41.0	Panic disorder [episodic paroxysmal anxiety]	Diagnosis	ICD-10-CM
F41.1	Generalized anxiety disorder	Diagnosis	ICD-10-CM
F41.3	Other mixed anxiety disorders	Diagnosis	ICD-10-CM
F41.8	Other specified anxiety disorders	Diagnosis	ICD-10-CM
F41.9	Anxiety disorder, unspecified	Diagnosis	ICD-10-CM
F42	Obsessive-compulsive disorder	Diagnosis	ICD-10-CM
F42.4	Excoriation (skin-picking) disorder	Diagnosis	ICD-10-CM
F42.8	Other obsessive-compulsive disorder	Diagnosis	ICD-10-CM
F42.9	Obsessive-compulsive disorder, unspecified	Diagnosis	ICD-10-CM
F43.0	Acute stress reaction	Diagnosis	ICD-10-CM
F43.1	Post-traumatic stress disorder (PTSD)	Diagnosis	ICD-10-CM
F43.10	Post-traumatic stress disorder, unspecified	Diagnosis	ICD-10-CM
F43.11	Post-traumatic stress disorder, acute	Diagnosis	ICD-10-CM
F43.12	Post-traumatic stress disorder, chronic	Diagnosis	ICD-10-CM
F44.9	Dissociative and conversion disorder, unspecified	Diagnosis	ICD-10-CM
F45.8	Other somatoform disorders	Diagnosis	ICD-10-CM
F48.8	Other specified nonpsychotic mental disorders	Diagnosis	ICD-10-CM
F93.0	Separation anxiety disorder of childhood	Diagnosis	ICD-10-CM
Mood Disorders			
293.83	Mood disorder in conditions classified elsewhere	Diagnosis	ICD-09-CM
296.0	Bipolar I disorder, single manic episode	Diagnosis	ICD-09-CM
296.00	Bipolar I disorder, single manic episode, unspecified	Diagnosis	ICD-09-CM
296.01	Bipolar I disorder, single manic episode, mild	Diagnosis	ICD-09-CM
296.02	Bipolar I disorder, single manic episode, moderate	Diagnosis	ICD-09-CM
296.03	Bipolar I disorder, single manic episode, severe, without mention of psychotic behavior	Diagnosis	ICD-09-CM
296.04	Bipolar I disorder, single manic episode, severe, specified as with psychotic behavior	Diagnosis	ICD-09-CM
296.05	Bipolar I disorder, single manic episode, in partial or unspecified remission	Diagnosis	ICD-09-CM
296.06	Bipolar I disorder, single manic episode, in full remission	Diagnosis	ICD-09-CM
296.1	Manic disorder, recurrent episode	Diagnosis	ICD-09-CM
296.10	Manic disorder, recurrent episode, unspecified	Diagnosis	ICD-09-CM
296.11	Manic disorder, recurrent episode, mild	Diagnosis	ICD-09-CM
296.12	Manic disorder, recurrent episode, moderate	Diagnosis	ICD-09-CM
296.13	Manic disorder, recurrent episode, severe, without mention of psychotic behavior	Diagnosis	ICD-09-CM
296.14	Manic disorder, recurrent episode, severe, specified as with psychotic behavior	Diagnosis	ICD-09-CM
296.15	Manic disorder, recurrent episode, in partial or unspecified remission	Diagnosis	ICD-09-CM
296.16	Manic disorder, recurrent episode, in full remission	Diagnosis	ICD-09-CM
296.2	Major depressive disorder, single episode	Diagnosis	ICD-09-CM
296.20	Major depressive disorder, single episode, unspecified	Diagnosis	ICD-09-CM

Appendix E. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
296.21	Major depressive disorder, single episode, mild	Diagnosis	ICD-09-CM
296.22	Major depressive disorder, single episode, moderate	Diagnosis	ICD-09-CM
296.23	Major depressive disorder, single episode, severe, without mention of psychotic behavior	Diagnosis	ICD-09-CM
296.24	Major depressive disorder, single episode, severe, specified as with psychotic behavior	Diagnosis	ICD-09-CM
296.25	Major depressive disorder, single episode, in partial or unspecified remission	Diagnosis	ICD-09-CM
296.26	Major depressive disorder, single episode in full remission	Diagnosis	ICD-09-CM
296.30	Major depressive disorder, recurrent episode, unspecified	Diagnosis	ICD-09-CM
296.31	Major depressive disorder, recurrent episode, mild	Diagnosis	ICD-09-CM
296.32	Major depressive disorder, recurrent episode, moderate	Diagnosis	ICD-09-CM
296.33	Major depressive disorder, recurrent episode, severe, without mention of psychotic behavior	Diagnosis	ICD-09-CM
296.34	Major depressive disorder, recurrent episode, severe, specified as with psychotic behavior	Diagnosis	ICD-09-CM
296.35	Major depressive disorder, recurrent episode, in partial or unspecified remission	Diagnosis	ICD-09-CM
296.36	Major depressive disorder, recurrent episode, in full remission	Diagnosis	ICD-09-CM
296.4	Bipolar I disorder, most recent episode (or current) manic	Diagnosis	ICD-09-CM
296.40	Bipolar I disorder, most recent episode (or current) manic, unspecified	Diagnosis	ICD-09-CM
296.41	Bipolar I disorder, most recent episode (or current) manic, mild	Diagnosis	ICD-09-CM
296.42	Bipolar I disorder, most recent episode (or current) manic, moderate	Diagnosis	ICD-09-CM
296.43	Bipolar I disorder, most recent episode (or current) manic, severe, without mention of psychotic behavior	Diagnosis	ICD-09-CM
296.44	Bipolar I disorder, most recent episode (or current) manic, severe, specified as with psychotic behavior	Diagnosis	ICD-09-CM
296.45	Bipolar I disorder, most recent episode (or current) manic, in partial or unspecified remission	Diagnosis	ICD-09-CM
296.46	Bipolar I disorder, most recent episode (or current) manic, in full remission	Diagnosis	ICD-09-CM
296.5	Bipolar I disorder, most recent episode (or current), depressed	Diagnosis	ICD-09-CM
296.50	Bipolar I disorder, most recent episode (or current) depressed, unspecified	Diagnosis	ICD-09-CM
296.51	Bipolar I disorder, most recent episode (or current) depressed, mild	Diagnosis	ICD-09-CM
296.52	Bipolar I disorder, most recent episode (or current) depressed, moderate	Diagnosis	ICD-09-CM
296.53	Bipolar I disorder, most recent episode (or current) depressed, severe, without mention of psychotic behavior	Diagnosis	ICD-09-CM
296.54	Bipolar I disorder, most recent episode (or current) depressed, severe, specified as with psychotic behavior	Diagnosis	ICD-09-CM
296.55	Bipolar I disorder, most recent episode (or current) depressed, in partial or unspecified remission	Diagnosis	ICD-09-CM
296.56	Bipolar I disorder, most recent episode (or current) depressed, in full remission	Diagnosis	ICD-09-CM
296.6	Bipolar I disorder, most recent episode (or current), mixed	Diagnosis	ICD-09-CM
296.60	Bipolar I disorder, most recent episode (or current) mixed, unspecified	Diagnosis	ICD-09-CM
296.61	Bipolar I disorder, most recent episode (or current) mixed, mild	Diagnosis	ICD-09-CM
296.62	Bipolar I disorder, most recent episode (or current) mixed, moderate	Diagnosis	ICD-09-CM
296.63	Bipolar I disorder, most recent episode (or current) mixed, severe, without mention of psychotic behavior	Diagnosis	ICD-09-CM
296.64	Bipolar I disorder, most recent episode (or current) mixed, severe, specified as with psychotic behavior	Diagnosis	ICD-09-CM
296.65	Bipolar I disorder, most recent episode (or current) mixed, in partial or unspecified remission	Diagnosis	ICD-09-CM
296.66	Bipolar I disorder, most recent episode (or current) mixed, in full remission	Diagnosis	ICD-09-CM
296.7	Bipolar I disorder, most recent episode (or current) unspecified	Diagnosis	ICD-09-CM
296.8	Other and unspecified bipolar disorders	Diagnosis	ICD-09-CM
296.80	Bipolar disorder, unspecified	Diagnosis	ICD-09-CM
296.81	Atypical manic disorder	Diagnosis	ICD-09-CM
296.82	Atypical depressive disorder	Diagnosis	ICD-09-CM
296.89	Other and unspecified bipolar disorders	Diagnosis	ICD-09-CM
296.90	Unspecified episodic mood disorder	Diagnosis	ICD-09-CM
296.99	Other specified episodic mood disorder	Diagnosis	ICD-09-CM
300.4	Dysthymic disorder	Diagnosis	ICD-09-CM
309.0	Adjustment disorder with depressed mood	Diagnosis	ICD-09-CM
309.1	Prolonged depressive reaction as adjustment reaction	Diagnosis	ICD-09-CM
309.28	Adjustment disorder with mixed anxiety and depressed mood	Diagnosis	ICD-09-CM
311	Depressive disorder, not elsewhere classified	Diagnosis	ICD-09-CM
F06.3	Mood disorder due to known physiological condition	Diagnosis	ICD-10-CM

Appendix E. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
F06.30	Mood disorder due to known physiological condition, unspecified	Diagnosis	ICD-10-CM
F06.31	Mood disorder due to known physiological condition with depressive features	Diagnosis	ICD-10-CM
F06.32	Mood disorder due to known physiological condition with major depressive-like episode	Diagnosis	ICD-10-CM
F06.33	Mood disorder due to known physiological condition with manic features	Diagnosis	ICD-10-CM
F06.34	Mood disorder due to known physiological condition with mixed features	Diagnosis	ICD-10-CM
F30	Manic episode	Diagnosis	ICD-10-CM
F30.1	Manic episode without psychotic symptoms	Diagnosis	ICD-10-CM
F30.10	Manic episode without psychotic symptoms, unspecified	Diagnosis	ICD-10-CM
F30.11	Manic episode without psychotic symptoms, mild	Diagnosis	ICD-10-CM
F30.12	Manic episode without psychotic symptoms, moderate	Diagnosis	ICD-10-CM
F30.13	Manic episode, severe, without psychotic symptoms	Diagnosis	ICD-10-CM
F30.2	Manic episode, severe with psychotic symptoms	Diagnosis	ICD-10-CM
F30.3	Manic episode in partial remission	Diagnosis	ICD-10-CM
F30.4	Manic episode in full remission	Diagnosis	ICD-10-CM
F30.8	Other manic episodes	Diagnosis	ICD-10-CM
F30.9	Manic episode, unspecified	Diagnosis	ICD-10-CM
F31	Bipolar disorder	Diagnosis	ICD-10-CM
F31.0	Bipolar disorder, current episode hypomanic	Diagnosis	ICD-10-CM
F31.1	Bipolar disorder, current episode manic without psychotic features	Diagnosis	ICD-10-CM
F31.10	Bipolar disorder, current episode manic without psychotic features, unspecified	Diagnosis	ICD-10-CM
F31.11	Bipolar disorder, current episode manic without psychotic features, mild	Diagnosis	ICD-10-CM
F31.12	Bipolar disorder, current episode manic without psychotic features, moderate	Diagnosis	ICD-10-CM
F31.13	Bipolar disorder, current episode manic without psychotic features, severe	Diagnosis	ICD-10-CM
F31.2	Bipolar disorder, current episode manic severe with psychotic features	Diagnosis	ICD-10-CM
F31.3	Bipolar disorder, current episode depressed, mild or moderate severity	Diagnosis	ICD-10-CM
F31.30	Bipolar disorder, current episode depressed, mild or moderate severity, unspecified	Diagnosis	ICD-10-CM
F31.31	Bipolar disorder, current episode depressed, mild	Diagnosis	ICD-10-CM
F31.32	Bipolar disorder, current episode depressed, moderate	Diagnosis	ICD-10-CM
F31.4	Bipolar disorder, current episode depressed, severe, without psychotic features	Diagnosis	ICD-10-CM
F31.5	Bipolar disorder, current episode depressed, severe, with psychotic features	Diagnosis	ICD-10-CM
F31.6	Bipolar disorder, current episode mixed	Diagnosis	ICD-10-CM
F31.60	Bipolar disorder, current episode mixed, unspecified	Diagnosis	ICD-10-CM
F31.61	Bipolar disorder, current episode mixed, mild	Diagnosis	ICD-10-CM
F31.62	Bipolar disorder, current episode mixed, moderate	Diagnosis	ICD-10-CM
F31.63	Bipolar disorder, current episode mixed, severe, without psychotic features	Diagnosis	ICD-10-CM
F31.64	Bipolar disorder, current episode mixed, severe, with psychotic features	Diagnosis	ICD-10-CM
F31.7	Bipolar disorder, currently in remission	Diagnosis	ICD-10-CM
F31.70	Bipolar disorder, currently in remission, most recent episode unspecified	Diagnosis	ICD-10-CM
F31.71	Bipolar disorder, in partial remission, most recent episode hypomanic	Diagnosis	ICD-10-CM
F31.72	Bipolar disorder, in full remission, most recent episode hypomanic	Diagnosis	ICD-10-CM
F31.73	Bipolar disorder, in partial remission, most recent episode manic	Diagnosis	ICD-10-CM
F31.74	Bipolar disorder, in full remission, most recent episode manic	Diagnosis	ICD-10-CM
F31.75	Bipolar disorder, in partial remission, most recent episode depressed	Diagnosis	ICD-10-CM
F31.76	Bipolar disorder, in full remission, most recent episode depressed	Diagnosis	ICD-10-CM
F31.77	Bipolar disorder, in partial remission, most recent episode mixed	Diagnosis	ICD-10-CM
F31.78	Bipolar disorder, in full remission, most recent episode mixed	Diagnosis	ICD-10-CM
F31.8	Other bipolar disorders	Diagnosis	ICD-10-CM
F31.81	Bipolar II disorder	Diagnosis	ICD-10-CM
F31.89	Other bipolar disorder	Diagnosis	ICD-10-CM
F31.9	Bipolar disorder, unspecified	Diagnosis	ICD-10-CM
F32	Major depressive disorder, single episode	Diagnosis	ICD-10-CM

Appendix E. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
F32.0	Major depressive disorder, single episode, mild	Diagnosis	ICD-10-CM
F32.1	Major depressive disorder, single episode, moderate	Diagnosis	ICD-10-CM
F32.2	Major depressive disorder, single episode, severe without psychotic features	Diagnosis	ICD-10-CM
F32.3	Major depressive disorder, single episode, severe with psychotic features	Diagnosis	ICD-10-CM
F32.4	Major depressive disorder, single episode, in partial remission	Diagnosis	ICD-10-CM
F32.5	Major depressive disorder, single episode, in full remission	Diagnosis	ICD-10-CM
F32.8	Other depressive episodes	Diagnosis	ICD-10-CM
F32.81	Premenstrual dysphoric disorder	Diagnosis	ICD-10-CM
F32.89	Other specified depressive episodes	Diagnosis	ICD-10-CM
F32.9	Major depressive disorder, single episode, unspecified	Diagnosis	ICD-10-CM
F33	Major depressive disorder, recurrent	Diagnosis	ICD-10-CM
F33.0	Major depressive disorder, recurrent, mild	Diagnosis	ICD-10-CM
F33.1	Major depressive disorder, recurrent, moderate	Diagnosis	ICD-10-CM
F33.2	Major depressive disorder, recurrent severe without psychotic features	Diagnosis	ICD-10-CM
F33.3	Major depressive disorder, recurrent, severe with psychotic symptoms	Diagnosis	ICD-10-CM
F33.4	Major depressive disorder, recurrent, in remission	Diagnosis	ICD-10-CM
F33.40	Major depressive disorder, recurrent, in remission, unspecified	Diagnosis	ICD-10-CM
F33.41	Major depressive disorder, recurrent, in partial remission	Diagnosis	ICD-10-CM
F33.42	Major depressive disorder, recurrent, in full remission	Diagnosis	ICD-10-CM
F33.8	Other recurrent depressive disorders	Diagnosis	ICD-10-CM
F33.9	Major depressive disorder, recurrent, unspecified	Diagnosis	ICD-10-CM
F34	Persistent mood [affective] disorders	Diagnosis	ICD-10-CM
F34.0	Cyclothymic disorder	Diagnosis	ICD-10-CM
F34.1	Dysthymic disorder	Diagnosis	ICD-10-CM
F34.8	Other persistent mood [affective] disorders	Diagnosis	ICD-10-CM
F34.81	Disruptive mood dysregulation disorder	Diagnosis	ICD-10-CM
F34.89	Other specified persistent mood disorders	Diagnosis	ICD-10-CM
F34.9	Persistent mood [affective] disorder, unspecified	Diagnosis	ICD-10-CM
F39	Unspecified mood [affective] disorder	Diagnosis	ICD-10-CM
F43.21	Adjustment disorder with depressed mood	Diagnosis	ICD-10-CM
F43.23	Adjustment disorder with mixed anxiety and depressed mood	Diagnosis	ICD-10-CM
Nicotine Use (including tobacco)			
305.1	Nondependent tobacco use disorder	Diagnosis	ICD-09-CM
649.0	Tobacco use disorder complicating pregnancy, childbirth, or the puerperium	Diagnosis	ICD-09-CM
649.00	Tobacco use disorder complicating pregnancy, childbirth, or the puerperium, unspecified	Diagnosis	ICD-09-CM
649.01	Tobacco use disorder complicating pregnancy, childbirth, or the puerperium, delivered, ♀	Diagnosis	ICD-09-CM
649.02	Tobacco use disorder complicating pregnancy, childbirth, or the puerperium, delivered, ♂	Diagnosis	ICD-09-CM
649.03	Tobacco use disorder complicating pregnancy, childbirth, or the puerperium, antepartum	Diagnosis	ICD-09-CM
649.04	Tobacco use disorder complicating pregnancy, childbirth, or the puerperium, postpartum	Diagnosis	ICD-09-CM
989.84	Toxic effect of tobacco	Diagnosis	ICD-09-CM
99406	Smoking and tobacco use cessation counseling visit; intermediate, greater than 3 minute:	Procedure	C4
99407	Smoking and tobacco use cessation counseling visit; intensive, greater than 10 minutes	Procedure	C4
C9801	Smoking and tobacco cessation counseling visit for the asymptomatic patient; intermediate	Procedure	HC
C9802	Smoking and tobacco cessation counseling visit for the asymptomatic patient; intensive, ♀	Procedure	HC
D1320	tobacco counseling for the control and prevention of oral disease	Procedure	HC
F17	Nicotine dependence	Diagnosis	ICD-10-CM
F17.2	Nicotine dependence	Diagnosis	ICD-10-CM
F17.20	Nicotine dependence, unspecified	Diagnosis	ICD-10-CM
F17.200	Nicotine dependence, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F17.201	Nicotine dependence, unspecified, in remission	Diagnosis	ICD-10-CM
F17.203	Nicotine dependence, unspecified, with withdrawal	Diagnosis	ICD-10-CM

Appendix E. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
F17.208	Nicotine dependence, unspecified, with other nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.209	Nicotine dependence, unspecified, with unspecified nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.21	Nicotine dependence, cigarettes	Diagnosis	ICD-10-CM
F17.210	Nicotine dependence, cigarettes, uncomplicated	Diagnosis	ICD-10-CM
F17.211	Nicotine dependence, cigarettes, in remission	Diagnosis	ICD-10-CM
F17.213	Nicotine dependence, cigarettes, with withdrawal	Diagnosis	ICD-10-CM
F17.218	Nicotine dependence, cigarettes, with other nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.219	Nicotine dependence, cigarettes, with unspecified nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.22	Nicotine dependence, chewing tobacco	Diagnosis	ICD-10-CM
F17.220	Nicotine dependence, chewing tobacco, uncomplicated	Diagnosis	ICD-10-CM
F17.221	Nicotine dependence, chewing tobacco, in remission	Diagnosis	ICD-10-CM
F17.223	Nicotine dependence, chewing tobacco, with withdrawal	Diagnosis	ICD-10-CM
F17.228	Nicotine dependence, chewing tobacco, with other nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.229	Nicotine dependence, chewing tobacco, with unspecified nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.29	Nicotine dependence, other tobacco product	Diagnosis	ICD-10-CM
F17.290	Nicotine dependence, other tobacco product, uncomplicated	Diagnosis	ICD-10-CM
F17.291	Nicotine dependence, other tobacco product, in remission	Diagnosis	ICD-10-CM
F17.293	Nicotine dependence, other tobacco product, with withdrawal	Diagnosis	ICD-10-CM
F17.298	Nicotine dependence, other tobacco product, with other nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.299	Nicotine dependence, other tobacco product, with unspecified nicotine-induced disorder	Diagnosis	ICD-10-CM
G0375	Smoking and tobacco use cessation counseling visit; intermediate, greater than 3 minute	Procedure	HC
G0376	Smoking and tobacco use cessation counseling visit; intensive, greater than 10 minutes	Procedure	HC
G0436	Smoking and tobacco cessation counseling visit for the asymptomatic patient; intermediate	Procedure	HC
G0437	Smoking and tobacco cessation counseling visit for the asymptomatic patient; intensive, >	Procedure	HC
G8093	Newly diagnosed chronic obstructive pulmonary disease (COPD) patient documented to have	Procedure	HC
G8094	Newly diagnosed chronic obstructive pulmonary disease (COPD) patient not documented to have	Procedure	HC
G8402	Tobacco (smoke) use cessation intervention, counseling	Procedure	HC
G8403	Tobacco (smoke) use cessation intervention not counseled	Procedure	HC
G8453	Tobacco use cessation intervention, counseling	Procedure	HC
G8454	Tobacco use cessation intervention not counseled, reason not specified	Procedure	HC
G8455	Current tobacco smoker	Procedure	HC
G8456	Current smokeless tobacco user	Procedure	HC
G8688	Currently a smokeless tobacco user (e.g., chew, snuff) and no exposure to secondhand smoke	Procedure	HC
G8690	Current tobacco smoker or current exposure to secondhand smoke	Procedure	HC
G8692	Current smokeless tobacco user (e.g., chew, snuff) and no exposure to secondhand smoke	Procedure	HC
G9016	Smoking cessation counseling, individual, in the absence of or in addition to any other evaluation	Procedure	HC
G9276	Documentation that patient is a current tobacco user	Procedure	HC
G9458	Patient documented as tobacco user and received tobacco cessation intervention (must include	Procedure	HC
O99.330	Smoking (tobacco) complicating pregnancy, unspecified trimester	Diagnosis	ICD-10-CM
O99.331	Smoking (tobacco) complicating pregnancy, first trimester	Diagnosis	ICD-10-CM
O99.332	Smoking (tobacco) complicating pregnancy, second trimester	Diagnosis	ICD-10-CM
O99.333	Smoking (tobacco) complicating pregnancy, third trimester	Diagnosis	ICD-10-CM
O99.334	Smoking (tobacco) complicating childbirth	Diagnosis	ICD-10-CM
O99.335	Smoking (tobacco) complicating the puerperium	Diagnosis	ICD-10-CM
T65.211	Toxic effect of chewing tobacco, accidental (unintentional)	Diagnosis	ICD-10-CM
T65.211A	Toxic effect of chewing tobacco, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T65.212	Toxic effect of chewing tobacco, intentional self-harm	Diagnosis	ICD-10-CM
T65.212A	Toxic effect of chewing tobacco, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T65.213	Toxic effect of chewing tobacco, assault	Diagnosis	ICD-10-CM
T65.213A	Toxic effect of chewing tobacco, assault, initial encounter	Diagnosis	ICD-10-CM
T65.214	Toxic effect of chewing tobacco, undetermined	Diagnosis	ICD-10-CM

Appendix E. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
T65.214A	Toxic effect of chewing tobacco, undetermined, initial encounter	Diagnosis	ICD-10-CM
T65.221	Toxic effect of tobacco cigarettes, accidental (unintentional)	Diagnosis	ICD-10-CM
T65.221A	Toxic effect of tobacco cigarettes, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T65.222	Toxic effect of tobacco cigarettes, intentional self-harm	Diagnosis	ICD-10-CM
T65.222A	Toxic effect of tobacco cigarettes, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T65.223	Toxic effect of tobacco cigarettes, assault	Diagnosis	ICD-10-CM
T65.223A	Toxic effect of tobacco cigarettes, assault, initial encounter	Diagnosis	ICD-10-CM
T65.224	Toxic effect of tobacco cigarettes, undetermined	Diagnosis	ICD-10-CM
T65.224A	Toxic effect of tobacco cigarettes, undetermined, initial encounter	Diagnosis	ICD-10-CM
T65.291	Toxic effect of other tobacco and nicotine, accidental (unintentional)	Diagnosis	ICD-10-CM
T65.291A	Toxic effect of other tobacco and nicotine, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T65.292	Toxic effect of other tobacco and nicotine, intentional self-harm	Diagnosis	ICD-10-CM
T65.292A	Toxic effect of other tobacco and nicotine, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T65.293	Toxic effect of other tobacco and nicotine, assault	Diagnosis	ICD-10-CM
T65.293A	Toxic effect of other tobacco and nicotine, assault, initial encounter	Diagnosis	ICD-10-CM
T65.294	Toxic effect of other tobacco and nicotine, undetermined	Diagnosis	ICD-10-CM
T65.294A	Toxic effect of other tobacco and nicotine, undetermined, initial encounter	Diagnosis	ICD-10-CM
V15.82	Personal history of tobacco use, presenting hazards to health	Diagnosis	ICD-10-CM
Z72.0	Tobacco use	Diagnosis	ICD-10-CM
Z87.891	Personal history of nicotine dependence	Diagnosis	ICD-10-CM
Obesity			
0D1607A	Bypass Stomach to Jejunum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-CM
0D160JA	Bypass Stomach to Jejunum with Synthetic Substitute, Open Approach	Procedure	ICD-10-CM
0D160KA	Bypass Stomach to Jejunum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-CM
0D160ZA	Bypass Stomach to Jejunum, Open Approach	Procedure	ICD-10-CM
0D1687A	Bypass Stomach to Jejunum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-CM
0D168JA	Bypass Stomach to Jejunum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-CM
0D168KA	Bypass Stomach to Jejunum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-CM
0D168ZA	Bypass Stomach to Jejunum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-CM
0DQ64ZZ	Repair Stomach, Percutaneous Endoscopic Approach	Procedure	ICD-10-CM
0DV64CZ	Restriction of Stomach with Extraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-CM
278.0	Overweight and obesity	Diagnosis	ICD-09-CM
278.00	Obesity, unspecified	Diagnosis	ICD-09-CM
278.01	Morbid obesity	Diagnosis	ICD-09-CM
278.03	Obesity hypoventilation syndrome	Diagnosis	ICD-09-CM
278.1	Localized adiposity	Diagnosis	ICD-09-CM
44.31	High gastric bypass	Procedure	ICD-09-CM
44.68	Laparoscopic gastroplasty	Procedure	ICD-09-CM
44.95	Laparoscopic gastric restrictive procedure	Procedure	ICD-09-CM
E65	Localized adiposity	Diagnosis	ICD-10-CM
E66.01	Morbid (severe) obesity due to excess calories	Diagnosis	ICD-10-CM
E66.09	Other obesity due to excess calories	Diagnosis	ICD-10-CM
E66.1	Drug-induced obesity	Diagnosis	ICD-10-CM
E66.2	Morbid (severe) obesity with alveolar hypoventilation	Diagnosis	ICD-10-CM
E66.8	Other obesity	Diagnosis	ICD-10-CM
E66.9	Obesity, unspecified	Diagnosis	ICD-10-CM
V45.86	Bariatric surgery status	Diagnosis	ICD-09-CM
V85.3	Body Mass Index between 30-39, adult	Diagnosis	ICD-09-CM
V85.30	Body Mass Index 30.0-30.9, adult	Diagnosis	ICD-09-CM
V85.31	Body Mass Index 31.0-31.9, adult	Diagnosis	ICD-09-CM
V85.32	Body Mass Index 32.0-32.9, adult	Diagnosis	ICD-09-CM

Appendix E. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
V85.33	Body Mass Index 33.0-33.9, adult	Diagnosis	ICD-09-CM
V85.34	Body Mass Index 34.0-34.9, adult	Diagnosis	ICD-09-CM
V85.35	Body Mass Index 35.0-35.9, adult	Diagnosis	ICD-09-CM
V85.36	Body Mass Index 36.0-36.9, adult	Diagnosis	ICD-09-CM
V85.37	Body Mass Index 37.0-37.9, adult	Diagnosis	ICD-09-CM
V85.38	Body Mass Index 38.0-38.9, adult	Diagnosis	ICD-09-CM
V85.39	Body Mass Index 39.0-39.9, adult	Diagnosis	ICD-09-CM
V85.4	Body Mass Index 40 and over, adult	Diagnosis	ICD-09-CM
V85.41	Body Mass Index 40.0-44.9, adult	Diagnosis	ICD-09-CM
V85.42	Body Mass Index 45.0-49.9, adult	Diagnosis	ICD-09-CM
V85.43	Body Mass Index 50.0-59.9, adult	Diagnosis	ICD-09-CM
V85.44	Body Mass Index 60.0-69.9, adult	Diagnosis	ICD-09-CM
V85.45	Body Mass Index 70 and over, adult	Diagnosis	ICD-09-CM
Z68.30	Body mass index (BMI) 30.0-30.9, adult	Diagnosis	ICD-10-CM
Z68.31	Body mass index (BMI) 31.0-31.9, adult	Diagnosis	ICD-10-CM
Z68.32	Body mass index (BMI) 32.0-32.9, adult	Diagnosis	ICD-10-CM
Z68.33	Body mass index (BMI) 33.0-33.9, adult	Diagnosis	ICD-10-CM
Z68.34	Body mass index (BMI) 34.0-34.9, adult	Diagnosis	ICD-10-CM
Z68.35	Body mass index (BMI) 35.0-35.9, adult	Diagnosis	ICD-10-CM
Z68.36	Body mass index (BMI) 36.0-36.9, adult	Diagnosis	ICD-10-CM
Z68.37	Body mass index (BMI) 37.0-37.9, adult	Diagnosis	ICD-10-CM
Z68.38	Body mass index (BMI) 38.0-38.9, adult	Diagnosis	ICD-10-CM
Z68.39	Body mass index (BMI) 39.0-39.9, adult	Diagnosis	ICD-10-CM
Z68.41	Body mass index (BMI) 40.0-44.9, adult	Diagnosis	ICD-10-CM
Z68.42	Body mass index (BMI) 45.0-49.9, adult	Diagnosis	ICD-10-CM
Z68.43	Body mass index (BMI) 50-59.9, adult	Diagnosis	ICD-10-CM
Z68.44	Body mass index (BMI) 60.0-69.9, adult	Diagnosis	ICD-10-CM
Z68.45	Body mass index (BMI) 70 or greater, adult	Diagnosis	ICD-10-CM
Z98.84	Bariatric surgery status	Diagnosis	ICD-10-CM
Other Psychotic Disorders			
293.81	Psychotic disorder with delusions in conditions classified elsewhere	Diagnosis	ICD-09-CM
293.82	Psychotic disorder with hallucinations in conditions classified elsewhere	Diagnosis	ICD-09-CM
297.0	Paranoid state, simple	Diagnosis	ICD-09-CM
297.1	Delusional disorder	Diagnosis	ICD-09-CM
297.2	Paraphrenia	Diagnosis	ICD-09-CM
297.3	Shared psychotic disorder	Diagnosis	ICD-09-CM
297.8	Other specified paranoid states	Diagnosis	ICD-09-CM
297.9	Unspecified paranoid state	Diagnosis	ICD-09-CM
298.0	Depressive type psychosis	Diagnosis	ICD-09-CM
298.1	Excitative type psychosis	Diagnosis	ICD-09-CM
298.3	Acute paranoid reaction	Diagnosis	ICD-09-CM
298.4	Psychogenic paranoid psychosis	Diagnosis	ICD-09-CM
298.8	Other and unspecified reactive psychosis	Diagnosis	ICD-09-CM
298.9	Unspecified psychosis	Diagnosis	ICD-09-CM
F06.0	Psychotic disorder with hallucinations due to known physiological condition	Diagnosis	ICD-10-CM
F06.2	Psychotic disorder with delusions due to known physiological condition	Diagnosis	ICD-10-CM
F21	Schizotypal disorder	Diagnosis	ICD-10-CM
F22	Delusional disorders	Diagnosis	ICD-10-CM
F23	Brief psychotic disorder	Diagnosis	ICD-10-CM
F24	Shared psychotic disorder	Diagnosis	ICD-10-CM
F28	Other psychotic disorder not due to a substance or known physiological condition	Diagnosis	ICD-10-CM

Appendix E. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
F29	Unspecified psychosis not due to a substance or known physiological condition	Diagnosis	ICD-10-CM
Personality Disorders			
301.10	Affective personality disorder, unspecified	Diagnosis	ICD-09-CM
301.12	Chronic depressive personality disorder	Diagnosis	ICD-09-CM
301.13	Cyclothymic disorder	Diagnosis	ICD-09-CM
301	Personality disorders	Diagnosis	ICD-09-CM
301.0	Paranoid personality disorder	Diagnosis	ICD-09-CM
301.1	Affective personality disorder	Diagnosis	ICD-09-CM
301.11	Chronic hypomanic personality disorder	Diagnosis	ICD-09-CM
301.2	Schizoid personality disorder	Diagnosis	ICD-09-CM
301.20	Schizoid personality disorder, unspecified	Diagnosis	ICD-09-CM
301.21	Introverted personality	Diagnosis	ICD-09-CM
301.22	Schizotypal personality disorder	Diagnosis	ICD-09-CM
301.3	Explosive personality disorder	Diagnosis	ICD-09-CM
301.4	Obsessive-compulsive personality disorder	Diagnosis	ICD-09-CM
301.5	Histrionic personality disorder	Diagnosis	ICD-09-CM
301.50	Histrionic personality disorder, unspecified	Diagnosis	ICD-09-CM
301.59	Other histrionic personality disorder	Diagnosis	ICD-09-CM
301.6	Dependent personality disorder	Diagnosis	ICD-09-CM
301.7	Antisocial personality disorder	Diagnosis	ICD-09-CM
301.8	Other personality disorders	Diagnosis	ICD-09-CM
301.81	Narcissistic personality disorder	Diagnosis	ICD-09-CM
301.82	Avoidant personality disorder	Diagnosis	ICD-09-CM
301.83	Borderline personality disorder	Diagnosis	ICD-09-CM
301.84	Passive-aggressive personality	Diagnosis	ICD-09-CM
301.89	Other personality disorder	Diagnosis	ICD-09-CM
F60	Specific personality disorders	Diagnosis	ICD-10-CM
F60.0	Paranoid personality disorder	Diagnosis	ICD-10-CM
F60.1	Schizoid personality disorder	Diagnosis	ICD-10-CM
F60.2	Antisocial personality disorder	Diagnosis	ICD-10-CM
F60.3	Borderline personality disorder	Diagnosis	ICD-10-CM
F60.4	Histrionic personality disorder	Diagnosis	ICD-10-CM
F60.5	Obsessive-compulsive personality disorder	Diagnosis	ICD-10-CM
F60.6	Avoidant personality disorder	Diagnosis	ICD-10-CM
F60.7	Dependent personality disorder	Diagnosis	ICD-10-CM
F60.8	Other specific personality disorders	Diagnosis	ICD-10-CM
F60.81	Narcissistic personality disorder	Diagnosis	ICD-10-CM
F60.89	Other specific personality disorders	Diagnosis	ICD-10-CM
F60.9	Personality disorder, unspecified	Diagnosis	ICD-10-CM
Schizophrenia			
295	Schizophrenic disorders	Diagnosis	ICD-09-CM
295.0	Simple type schizophrenia	Diagnosis	ICD-09-CM
295.00	Simple schizophrenia, unspecified condition	Diagnosis	ICD-09-CM
295.01	Simple schizophrenia, subchronic condition	Diagnosis	ICD-09-CM
295.02	Simple schizophrenia, chronic condition	Diagnosis	ICD-09-CM
295.03	Simple schizophrenia, subchronic condition with acute exacerbation	Diagnosis	ICD-09-CM
295.04	Simple schizophrenia, chronic condition with acute exacerbation	Diagnosis	ICD-09-CM
295.05	Simple schizophrenia, in remission	Diagnosis	ICD-09-CM
295.1	Disorganized type schizophrenia	Diagnosis	ICD-09-CM
295.10	Disorganized schizophrenia, unspecified condition	Diagnosis	ICD-09-CM
295.11	Disorganized schizophrenia, subchronic condition	Diagnosis	ICD-09-CM

Appendix E. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
295.12	Disorganized schizophrenia, chronic condition	Diagnosis	ICD-09-CM
295.13	Disorganized schizophrenia, subchronic condition with acute exacerbation	Diagnosis	ICD-09-CM
295.14	Disorganized schizophrenia, chronic condition with acute exacerbation	Diagnosis	ICD-09-CM
295.15	Disorganized schizophrenia, in remission	Diagnosis	ICD-09-CM
295.2	Catatonic type schizophrenia	Diagnosis	ICD-09-CM
295.20	Catatonic schizophrenia, unspecified condition	Diagnosis	ICD-09-CM
295.21	Catatonic schizophrenia, subchronic condition	Diagnosis	ICD-09-CM
295.22	Catatonic schizophrenia, chronic condition	Diagnosis	ICD-09-CM
295.23	Catatonic schizophrenia, subchronic condition with acute exacerbation	Diagnosis	ICD-09-CM
295.24	Catatonic schizophrenia, chronic condition with acute exacerbation	Diagnosis	ICD-09-CM
295.25	Catatonic schizophrenia, in remission	Diagnosis	ICD-09-CM
295.3	Paranoid type schizophrenia	Diagnosis	ICD-09-CM
295.30	Paranoid schizophrenia, unspecified condition	Diagnosis	ICD-09-CM
295.31	Paranoid schizophrenia, subchronic condition	Diagnosis	ICD-09-CM
295.32	Paranoid schizophrenia, chronic condition	Diagnosis	ICD-09-CM
295.33	Paranoid schizophrenia, subchronic condition with acute exacerbation	Diagnosis	ICD-09-CM
295.34	Paranoid schizophrenia, chronic condition with acute exacerbation	Diagnosis	ICD-09-CM
295.35	Paranoid schizophrenia, in remission	Diagnosis	ICD-09-CM
295.4	Schizophreniform disorder	Diagnosis	ICD-09-CM
295.40	Schizophreniform disorder, unspecified	Diagnosis	ICD-09-CM
295.41	Schizophreniform disorder, subchronic	Diagnosis	ICD-09-CM
295.42	Schizophreniform disorder, chronic	Diagnosis	ICD-09-CM
295.43	Schizophreniform disorder, subchronic with acute exacerbation	Diagnosis	ICD-09-CM
295.44	Schizophreniform disorder, chronic with acute exacerbation	Diagnosis	ICD-09-CM
295.45	Schizophreniform disorder, in remission	Diagnosis	ICD-09-CM
295.5	Latent schizophrenia	Diagnosis	ICD-09-CM
295.50	Latent schizophrenia, unspecified condition	Diagnosis	ICD-09-CM
295.51	Latent schizophrenia, subchronic condition	Diagnosis	ICD-09-CM
295.52	Latent schizophrenia, chronic condition	Diagnosis	ICD-09-CM
295.53	Latent schizophrenia, subchronic condition with acute exacerbation	Diagnosis	ICD-09-CM
295.54	Latent schizophrenia, chronic condition with acute exacerbation	Diagnosis	ICD-09-CM
295.55	Latent schizophrenia, in remission	Diagnosis	ICD-09-CM
295.6	Schizophrenic disorders, residual type	Diagnosis	ICD-09-CM
295.60	Schizophrenic disorders, residual type, unspecified	Diagnosis	ICD-09-CM
295.61	Schizophrenic disorders, residual type, subchronic	Diagnosis	ICD-09-CM
295.62	Schizophrenic disorders, residual type, chronic	Diagnosis	ICD-09-CM
295.63	Schizophrenic disorders, residual type, subchronic with acute exacerbation	Diagnosis	ICD-09-CM
295.64	Schizophrenic disorders, residual type, chronic with acute exacerbation	Diagnosis	ICD-09-CM
295.65	Schizophrenic disorders, residual type, in remission	Diagnosis	ICD-09-CM
295.7	Schizoaffective disorder	Diagnosis	ICD-09-CM
295.70	Schizoaffective disorder, unspecified	Diagnosis	ICD-09-CM
295.71	Schizoaffective disorder, subchronic	Diagnosis	ICD-09-CM
295.72	Schizoaffective disorder, chronic	Diagnosis	ICD-09-CM
295.73	Schizoaffective disorder, subchronic with acute exacerbation	Diagnosis	ICD-09-CM
295.74	Schizoaffective disorder, chronic with acute exacerbation	Diagnosis	ICD-09-CM
295.75	Schizoaffective disorder, in remission	Diagnosis	ICD-09-CM
295.8	Other specified types of schizophrenia	Diagnosis	ICD-09-CM
295.80	Other specified types of schizophrenia, unspecified condition	Diagnosis	ICD-09-CM
295.81	Other specified types of schizophrenia, subchronic condition	Diagnosis	ICD-09-CM
295.82	Other specified types of schizophrenia, chronic condition	Diagnosis	ICD-09-CM
295.83	Other specified types of schizophrenia, subchronic condition with acute exacerbation	Diagnosis	ICD-09-CM

Appendix E. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
295.84	Other specified types of schizophrenia, chronic condition with acute exacerbation	Diagnosis	ICD-09-CM
295.85	Other specified types of schizophrenia, in remission	Diagnosis	ICD-09-CM
295.9	Unspecified schizophrenia	Diagnosis	ICD-09-CM
295.90	Unspecified schizophrenia, unspecified condition	Diagnosis	ICD-09-CM
295.91	Unspecified schizophrenia, subchronic condition	Diagnosis	ICD-09-CM
295.92	Unspecified schizophrenia, chronic condition	Diagnosis	ICD-09-CM
295.93	Unspecified schizophrenia, subchronic condition with acute exacerbation	Diagnosis	ICD-09-CM
295.94	Unspecified schizophrenia, chronic condition with acute exacerbation	Diagnosis	ICD-09-CM
295.95	Unspecified schizophrenia, in remission	Diagnosis	ICD-09-CM
F20	Schizophrenia	Diagnosis	ICD-10-CM
F20.0	Paranoid schizophrenia	Diagnosis	ICD-10-CM
F20.1	Disorganized schizophrenia	Diagnosis	ICD-10-CM
F20.2	Catatonic schizophrenia	Diagnosis	ICD-10-CM
F20.3	Undifferentiated schizophrenia	Diagnosis	ICD-10-CM
F20.5	Residual schizophrenia	Diagnosis	ICD-10-CM
F20.8	Other schizophrenia	Diagnosis	ICD-10-CM
F20.81	Schizophreniform disorder	Diagnosis	ICD-10-CM
F20.89	Other schizophrenia	Diagnosis	ICD-10-CM
F20.9	Schizophrenia, unspecified	Diagnosis	ICD-10-CM
F25	Schizoaffective disorders	Diagnosis	ICD-10-CM
F25.0	Schizoaffective disorder, bipolar type	Diagnosis	ICD-10-CM
F25.1	Schizoaffective disorder, depressive type	Diagnosis	ICD-10-CM
F25.8	Other schizoaffective disorders	Diagnosis	ICD-10-CM
F25.9	Schizoaffective disorder, unspecified	Diagnosis	ICD-10-CM
Sleep disorders excluding narcolepsy			
307.4	Specific disorders of sleep of nonorganic origin	Diagnosis	ICD-09-CM
307.40	Nonorganic sleep disorder, unspecified	Diagnosis	ICD-09-CM
307.41	Transient disorder of initiating or maintaining sleep	Diagnosis	ICD-09-CM
307.42	Persistent disorder of initiating or maintaining sleep	Diagnosis	ICD-09-CM
307.43	Transient disorder of initiating or maintaining wakefulness	Diagnosis	ICD-09-CM
307.44	Persistent disorder of initiating or maintaining wakefulness	Diagnosis	ICD-09-CM
307.45	Circadian rhythm sleep disorder of nonorganic origin	Diagnosis	ICD-09-CM
307.46	Sleep arousal disorder	Diagnosis	ICD-09-CM
307.47	Other dysfunctions of sleep stages or arousal from sleep	Diagnosis	ICD-09-CM
307.48	Repetitive intrusions of sleep	Diagnosis	ICD-09-CM
307.49	Other specific disorder of sleep of nonorganic origin	Diagnosis	ICD-09-CM
327	Organic sleep disorders	Diagnosis	ICD-09-CM
327.0	Organic disorders of initiating and maintaining sleep [Organic insomnia]	Diagnosis	ICD-09-CM
327.00	Organic insomnia, unspecified	Diagnosis	ICD-09-CM
327.01	Insomnia due to medical condition classified elsewhere	Diagnosis	ICD-09-CM
327.02	Insomnia due to mental disorder	Diagnosis	ICD-09-CM
327.09	Other organic insomnia	Diagnosis	ICD-09-CM
327.1	Organic disorders of excessive somnolence [Organic hypersomnia]	Diagnosis	ICD-09-CM
327.10	Organic hypersomnia, unspecified	Diagnosis	ICD-09-CM
327.11	Idiopathic hypersomnia with long sleep time	Diagnosis	ICD-09-CM
327.12	Idiopathic hypersomnia without long sleep time	Diagnosis	ICD-09-CM
327.13	Recurrent hypersomnia	Diagnosis	ICD-09-CM
327.14	Hypersomnia due to medical condition classified elsewhere	Diagnosis	ICD-09-CM
327.15	Hypersomnia due to mental disorder	Diagnosis	ICD-09-CM
327.19	Other organic hypersomnia	Diagnosis	ICD-09-CM
327.2	Organic sleep apnea	Diagnosis	ICD-09-CM

Appendix E. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
327.20	Organic sleep apnea, unspecified	Diagnosis	ICD-09-CM
327.21	Primary central sleep apnea	Diagnosis	ICD-09-CM
327.23	Obstructive sleep apnea (adult) (pediatric)	Diagnosis	ICD-09-CM
327.24	Idiopathic sleep related nonobstructive alveolar hypoventilation	Diagnosis	ICD-09-CM
327.25	Congenital central alveolar hypoventilation syndrome	Diagnosis	ICD-09-CM
327.26	Sleep related hypoventilation/hypoxemia in conditions classifiable elsewhere	Diagnosis	ICD-09-CM
327.27	Central sleep apnea in conditions classified elsewhere	Diagnosis	ICD-09-CM
327.29	Other organic sleep apnea	Diagnosis	ICD-09-CM
327.3	Circadian rhythm sleep disorder	Diagnosis	ICD-09-CM
327.30	Circadian rhythm sleep disorder, unspecified	Diagnosis	ICD-09-CM
327.31	Circadian rhythm sleep disorder, delayed sleep phase type	Diagnosis	ICD-09-CM
327.32	Circadian rhythm sleep disorder, advanced sleep phase type	Diagnosis	ICD-09-CM
327.33	Circadian rhythm sleep disorder, irregular sleep-wake type	Diagnosis	ICD-09-CM
327.34	Circadian rhythm sleep disorder, free-running type	Diagnosis	ICD-09-CM
327.35	Circadian rhythm sleep disorder, jet lag type	Diagnosis	ICD-09-CM
327.36	Circadian rhythm sleep disorder, shift work type	Diagnosis	ICD-09-CM
327.37	Circadian rhythm sleep disorder in conditions classified elsewhere	Diagnosis	ICD-09-CM
327.39	Other circadian rhythm sleep disorder	Diagnosis	ICD-09-CM
327.4	Organic parasomnia	Diagnosis	ICD-09-CM
327.40	Organic parasomnia, unspecified	Diagnosis	ICD-09-CM
327.41	Confusional arousals	Diagnosis	ICD-09-CM
327.42	REM sleep behavior disorder	Diagnosis	ICD-09-CM
327.43	Recurrent isolated sleep paralysis	Diagnosis	ICD-09-CM
327.44	Parasomnia in conditions classified elsewhere	Diagnosis	ICD-09-CM
327.49	Other organic parasomnia	Diagnosis	ICD-09-CM
327.5	Organic sleep related movement disorders	Diagnosis	ICD-09-CM
327.51	Periodic limb movement disorder	Diagnosis	ICD-09-CM
327.52	Sleep related leg cramps	Diagnosis	ICD-09-CM
327.53	Sleep related bruxism	Diagnosis	ICD-09-CM
327.59	Other organic sleep related movement disorders	Diagnosis	ICD-09-CM
327.8	Other organic sleep disorders	Diagnosis	ICD-09-CM
780.50	Unspecified sleep disturbance	Diagnosis	ICD-09-CM
780.51	Insomnia with sleep apnea, unspecified	Diagnosis	ICD-09-CM
780.52	Insomnia, unspecified	Diagnosis	ICD-09-CM
780.53	Hypersomnia with sleep apnea, unspecified	Diagnosis	ICD-09-CM
780.54	Hypersomnia, unspecified	Diagnosis	ICD-09-CM
780.55	Disruption of 24 hour sleep wake cycle, unspecified	Diagnosis	ICD-09-CM
780.56	Dysfunctions associated with sleep stages or arousal from sleep	Diagnosis	ICD-09-CM
780.57	Unspecified sleep apnea	Diagnosis	ICD-09-CM
780.58	Sleep related movement disorder, unspecified	Diagnosis	ICD-09-CM
780.59	Other sleep disturbances	Diagnosis	ICD-09-CM
F51	Sleep disorders not due to a substance or known physiological condition	Diagnosis	ICD-10-CM
F51.0	Insomnia not due to a substance or known physiological condition	Diagnosis	ICD-10-CM
F51.01	Primary insomnia	Diagnosis	ICD-10-CM
F51.02	Adjustment insomnia	Diagnosis	ICD-10-CM
F51.03	Paradoxical insomnia	Diagnosis	ICD-10-CM
F51.04	Psychophysilogic insomnia	Diagnosis	ICD-10-CM
F51.05	Insomnia due to other mental disorder	Diagnosis	ICD-10-CM
F51.09	Other insomnia not due to a substance or known physiological condition	Diagnosis	ICD-10-CM
F51.1	Hypersomnia not due to a substance or known physiological condition	Diagnosis	ICD-10-CM
F51.11	Primary hypersomnia	Diagnosis	ICD-10-CM

Appendix E. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
F51.12	Insufficient sleep syndrome	Diagnosis	ICD-10-CM
F51.13	Hypersomnia due to other mental disorder	Diagnosis	ICD-10-CM
F51.19	Other hypersomnia not due to a substance or known physiological condition	Diagnosis	ICD-10-CM
F51.3	Sleepwalking [somnambulism]	Diagnosis	ICD-10-CM
F51.4	Sleep terrors [night terrors]	Diagnosis	ICD-10-CM
F51.5	Nightmare disorder	Diagnosis	ICD-10-CM
F51.8	Other sleep disorders not due to a substance or known physiological condition	Diagnosis	ICD-10-CM
F51.9	Sleep disorder not due to a substance or known physiological condition, unspecified	Diagnosis	ICD-10-CM
G47	Sleep disorders	Diagnosis	ICD-10-CM
G47.0	Insomnia	Diagnosis	ICD-10-CM
G47.00	Insomnia, unspecified	Diagnosis	ICD-10-CM
G47.01	Insomnia due to medical condition	Diagnosis	ICD-10-CM
G47.09	Other insomnia	Diagnosis	ICD-10-CM
G47.1	Hypersomnia	Diagnosis	ICD-10-CM
G47.10	Hypersomnia, unspecified	Diagnosis	ICD-10-CM
G47.11	Idiopathic hypersomnia with long sleep time	Diagnosis	ICD-10-CM
G47.12	Idiopathic hypersomnia without long sleep time	Diagnosis	ICD-10-CM
G47.13	Recurrent hypersomnia	Diagnosis	ICD-10-CM
G47.14	Hypersomnia due to medical condition	Diagnosis	ICD-10-CM
G47.19	Other hypersomnia	Diagnosis	ICD-10-CM
G47.2	Circadian rhythm sleep disorders	Diagnosis	ICD-10-CM
G47.20	Circadian rhythm sleep disorder, unspecified type	Diagnosis	ICD-10-CM
G47.21	Circadian rhythm sleep disorder, delayed sleep phase type	Diagnosis	ICD-10-CM
G47.22	Circadian rhythm sleep disorder, advanced sleep phase type	Diagnosis	ICD-10-CM
G47.23	Circadian rhythm sleep disorder, irregular sleep wake type	Diagnosis	ICD-10-CM
G47.24	Circadian rhythm sleep disorder, free running type	Diagnosis	ICD-10-CM
G47.25	Circadian rhythm sleep disorder, jet lag type	Diagnosis	ICD-10-CM
G47.26	Circadian rhythm sleep disorder, shift work type	Diagnosis	ICD-10-CM
G47.27	Circadian rhythm sleep disorder in conditions classified elsewhere	Diagnosis	ICD-10-CM
G47.29	Other circadian rhythm sleep disorder	Diagnosis	ICD-10-CM
G47.3	Sleep apnea	Diagnosis	ICD-10-CM
G47.30	Sleep apnea, unspecified	Diagnosis	ICD-10-CM
G47.31	Primary central sleep apnea	Diagnosis	ICD-10-CM
G47.33	Obstructive sleep apnea (adult) (pediatric)	Diagnosis	ICD-10-CM
G47.34	Idiopathic sleep related nonobstructive alveolar hypoventilation	Diagnosis	ICD-10-CM
G47.35	Congenital central alveolar hypoventilation syndrome	Diagnosis	ICD-10-CM
G47.36	Sleep related hypoventilation in conditions classified elsewhere	Diagnosis	ICD-10-CM
G47.37	Central sleep apnea in conditions classified elsewhere	Diagnosis	ICD-10-CM
G47.39	Other sleep apnea	Diagnosis	ICD-10-CM
G47.5	Parasomnia	Diagnosis	ICD-10-CM
G47.50	Parasomnia, unspecified	Diagnosis	ICD-10-CM
G47.51	Confusional arousals	Diagnosis	ICD-10-CM
G47.52	REM sleep behavior disorder	Diagnosis	ICD-10-CM
G47.53	Recurrent isolated sleep paralysis	Diagnosis	ICD-10-CM
G47.54	Parasomnia in conditions classified elsewhere	Diagnosis	ICD-10-CM
G47.59	Other parasomnia	Diagnosis	ICD-10-CM
G47.6	Sleep related movement disorders	Diagnosis	ICD-10-CM
G47.61	Periodic limb movement disorder	Diagnosis	ICD-10-CM
G47.62	Sleep related leg cramps	Diagnosis	ICD-10-CM
G47.63	Sleep related bruxism	Diagnosis	ICD-10-CM
G47.69	Other sleep related movement disorders	Diagnosis	ICD-10-CM

Appendix E. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
G47.8	Other sleep disorders	Diagnosis	ICD-10-CM
G47.9	Sleep disorder, unspecified	Diagnosis	ICD-10-CM
Substance use disorders			
291.0	Alcohol withdrawal delirium	Diagnosis	ICD-09-CM
291.1	Alcohol-induced persisting amnestic disorder	Diagnosis	ICD-09-CM
291.2	Alcohol-induced persisting dementia	Diagnosis	ICD-09-CM
291.3	Alcohol-induced psychotic disorder with hallucinations	Diagnosis	ICD-09-CM
291.4	Idiosyncratic alcohol intoxication	Diagnosis	ICD-09-CM
291.5	Alcohol-induced psychotic disorder with delusions	Diagnosis	ICD-09-CM
291.8	Other specified alcohol-induced mental disorders	Diagnosis	ICD-09-CM
291.81	Alcohol withdrawal	Diagnosis	ICD-09-CM
291.82	Alcohol induced sleep disorders	Diagnosis	ICD-09-CM
291.89	Other specified alcohol-induced mental disorders	Diagnosis	ICD-09-CM
291.9	Unspecified alcohol-induced mental disorders	Diagnosis	ICD-09-CM
292.0	Drug withdrawal	Diagnosis	ICD-09-CM
292.1	Drug-induced psychotic disorder	Diagnosis	ICD-09-CM
292.11	Drug-induced psychotic disorder with delusions	Diagnosis	ICD-09-CM
292.12	Drug-induced psychotic disorder with hallucinations	Diagnosis	ICD-09-CM
292.2	Pathological drug intoxication	Diagnosis	ICD-09-CM
292.8	Other specified drug-induced mental disorders	Diagnosis	ICD-09-CM
292.81	Drug-induced delirium	Diagnosis	ICD-09-CM
292.82	Drug-induced persisting dementia	Diagnosis	ICD-09-CM
292.83	Drug-induced persisting amnestic disorder	Diagnosis	ICD-09-CM
292.84	Drug-induced mood disorder	Diagnosis	ICD-09-CM
292.85	Drug induced sleep disorders	Diagnosis	ICD-09-CM
292.89	Other specified drug-induced mental disorder	Diagnosis	ICD-09-CM
292.9	Unspecified drug-induced mental disorder	Diagnosis	ICD-09-CM
303.0	Acute alcoholic intoxication	Diagnosis	ICD-09-CM
303.00	Acute alcoholic intoxication, unspecified	Diagnosis	ICD-09-CM
303.01	Acute alcoholic intoxication, continuous	Diagnosis	ICD-09-CM
303.02	Acute alcoholic intoxication, episodic	Diagnosis	ICD-09-CM
303.03	Acute alcoholic intoxication, in remission	Diagnosis	ICD-09-CM
303.9	Other and unspecified alcohol dependence	Diagnosis	ICD-09-CM
303.90	Other and unspecified alcohol dependence, unspecified	Diagnosis	ICD-09-CM
303.91	Other and unspecified alcohol dependence, continuous	Diagnosis	ICD-09-CM
303.92	Other and unspecified alcohol dependence, episodic	Diagnosis	ICD-09-CM
303.93	Other and unspecified alcohol dependence, in remission	Diagnosis	ICD-09-CM
304.0	Opioid type dependence	Diagnosis	ICD-09-CM
304.00	Opioid type dependence, unspecified	Diagnosis	ICD-09-CM
304.01	Opioid type dependence, continuous	Diagnosis	ICD-09-CM
304.02	Opioid type dependence, episodic	Diagnosis	ICD-09-CM
304.03	Opioid type dependence, in remission	Diagnosis	ICD-09-CM
304.1	Sedative, hypnotic or anxiolytic dependence	Diagnosis	ICD-09-CM
304.10	Sedative, hypnotic or anxiolytic dependence, unspecified	Diagnosis	ICD-09-CM
304.11	Sedative, hypnotic or anxiolytic dependence, continuous	Diagnosis	ICD-09-CM
304.12	Sedative, hypnotic or anxiolytic dependence, episodic	Diagnosis	ICD-09-CM
304.13	Sedative, hypnotic or anxiolytic dependence, in remission	Diagnosis	ICD-09-CM
304.2	Cocaine dependence	Diagnosis	ICD-09-CM
304.20	Cocaine dependence, unspecified	Diagnosis	ICD-09-CM
304.21	Cocaine dependence, continuous	Diagnosis	ICD-09-CM
304.22	Cocaine dependence, episodic	Diagnosis	ICD-09-CM

Appendix E. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
304.23	Cocaine dependence, in remission	Diagnosis	ICD-09-CM
304.3	Cannabis dependence	Diagnosis	ICD-09-CM
304.30	Cannabis dependence, unspecified	Diagnosis	ICD-09-CM
304.31	Cannabis dependence, continuous	Diagnosis	ICD-09-CM
304.32	Cannabis dependence, episodic	Diagnosis	ICD-09-CM
304.33	Cannabis dependence, in remission	Diagnosis	ICD-09-CM
304.4	Amphetamine and other psychostimulant dependence	Diagnosis	ICD-09-CM
304.40	Amphetamine and other psychostimulant dependence, unspecified	Diagnosis	ICD-09-CM
304.41	Amphetamine and other psychostimulant dependence, continuous	Diagnosis	ICD-09-CM
304.42	Amphetamine and other psychostimulant dependence, episodic	Diagnosis	ICD-09-CM
304.43	Amphetamine and other psychostimulant dependence, in remission	Diagnosis	ICD-09-CM
304.5	Hallucinogen dependence	Diagnosis	ICD-09-CM
304.50	Hallucinogen dependence, unspecified	Diagnosis	ICD-09-CM
304.51	Hallucinogen dependence, continuous	Diagnosis	ICD-09-CM
304.52	Hallucinogen dependence, episodic	Diagnosis	ICD-09-CM
304.53	Hallucinogen dependence, in remission	Diagnosis	ICD-09-CM
304.6	Other specified drug dependence	Diagnosis	ICD-09-CM
304.60	Other specified drug dependence, unspecified	Diagnosis	ICD-09-CM
304.61	Other specified drug dependence, continuous	Diagnosis	ICD-09-CM
304.62	Other specified drug dependence, episodic	Diagnosis	ICD-09-CM
304.63	Other specified drug dependence, in remission	Diagnosis	ICD-09-CM
304.7	Combinations of opioid type drug with any other drug dependence	Diagnosis	ICD-09-CM
304.70	Combinations of opioid type drug with any other drug dependence, unspecified	Diagnosis	ICD-09-CM
304.71	Combinations of opioid type drug with any other drug dependence, continuous	Diagnosis	ICD-09-CM
304.72	Combinations of opioid type drug with any other drug dependence, episodic	Diagnosis	ICD-09-CM
304.73	Combinations of opioid type drug with any other drug dependence, in remission	Diagnosis	ICD-09-CM
304.8	Combinations of drug dependence excluding opioid type drug	Diagnosis	ICD-09-CM
304.80	Combinations of drug dependence excluding opioid type drug, unspecified	Diagnosis	ICD-09-CM
304.81	Combinations of drug dependence excluding opioid type drug, continuous	Diagnosis	ICD-09-CM
304.82	Combinations of drug dependence excluding opioid type drug, episodic	Diagnosis	ICD-09-CM
304.83	Combinations of drug dependence excluding opioid type drug, in remission	Diagnosis	ICD-09-CM
304.9	Unspecified drug dependence	Diagnosis	ICD-09-CM
304.90	Unspecified drug dependence, unspecified	Diagnosis	ICD-09-CM
304.91	Unspecified drug dependence, continuous	Diagnosis	ICD-09-CM
304.92	Unspecified drug dependence, episodic	Diagnosis	ICD-09-CM
304.93	Unspecified drug dependence, in remission	Diagnosis	ICD-09-CM
305.0	Nondependent alcohol abuse	Diagnosis	ICD-09-CM
305.00	Nondependent alcohol abuse, unspecified	Diagnosis	ICD-09-CM
305.01	Nondependent alcohol abuse, continuous	Diagnosis	ICD-09-CM
305.02	Nondependent alcohol abuse, episodic	Diagnosis	ICD-09-CM
305.03	Nondependent alcohol abuse, in remission	Diagnosis	ICD-09-CM
305.2	Nondependent cannabis abuse	Diagnosis	ICD-09-CM
305.20	Nondependent cannabis abuse, unspecified	Diagnosis	ICD-09-CM
305.21	Nondependent cannabis abuse, continuous	Diagnosis	ICD-09-CM
305.22	Nondependent cannabis abuse, episodic	Diagnosis	ICD-09-CM
305.23	Nondependent cannabis abuse, in remission	Diagnosis	ICD-09-CM
305.3	Nondependent hallucinogen abuse	Diagnosis	ICD-09-CM
305.30	Nondependent hallucinogen abuse, unspecified	Diagnosis	ICD-09-CM
305.31	Nondependent hallucinogen abuse, continuous	Diagnosis	ICD-09-CM
305.32	Nondependent hallucinogen abuse, episodic	Diagnosis	ICD-09-CM
305.33	Nondependent hallucinogen abuse, in remission	Diagnosis	ICD-09-CM

Appendix E. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
305.4	Nondependent sedative, hypnotic or anxiolytic abuse	Diagnosis	ICD-09-CM
305.40	Nondependent sedative, hypnotic or anxiolytic abuse, unspecified	Diagnosis	ICD-09-CM
305.41	Nondependent sedative hypnotic or anxiolytic abuse, continuous	Diagnosis	ICD-09-CM
305.42	Nondependent sedative, hypnotic or anxiolytic abuse, episodic	Diagnosis	ICD-09-CM
305.43	Nondependent sedative, hypnotic or anxiolytic abuse, in remission	Diagnosis	ICD-09-CM
305.5	Nondependent opioid abuse	Diagnosis	ICD-09-CM
305.50	Nondependent opioid abuse, unspecified	Diagnosis	ICD-09-CM
305.51	Nondependent opioid abuse, continuous	Diagnosis	ICD-09-CM
305.52	Nondependent opioid abuse, episodic	Diagnosis	ICD-09-CM
305.53	Nondependent opioid abuse, in remission	Diagnosis	ICD-09-CM
305.6	Nondependent cocaine abuse	Diagnosis	ICD-09-CM
305.60	Nondependent cocaine abuse, unspecified	Diagnosis	ICD-09-CM
305.61	Nondependent cocaine abuse, continuous	Diagnosis	ICD-09-CM
305.62	Nondependent cocaine abuse, episodic	Diagnosis	ICD-09-CM
305.63	Nondependent cocaine abuse, in remission	Diagnosis	ICD-09-CM
305.7	Nondependent amphetamine or related acting sympathomimetic abuse	Diagnosis	ICD-09-CM
305.70	Nondependent amphetamine or related acting sympathomimetic abuse, unspecified	Diagnosis	ICD-09-CM
305.71	Nondependent amphetamine or related acting sympathomimetic abuse, continuous	Diagnosis	ICD-09-CM
305.72	Nondependent amphetamine or related acting sympathomimetic abuse, episodic	Diagnosis	ICD-09-CM
305.73	Nondependent amphetamine or related acting sympathomimetic abuse, in remission	Diagnosis	ICD-09-CM
305.8	Nondependent antidepressant type abuse	Diagnosis	ICD-09-CM
305.80	Nondependent antidepressant type abuse, unspecified	Diagnosis	ICD-09-CM
305.81	Nondependent antidepressant type abuse, continuous	Diagnosis	ICD-09-CM
305.82	Nondependent antidepressant type abuse, episodic	Diagnosis	ICD-09-CM
305.83	Nondependent antidepressant type abuse, in remission	Diagnosis	ICD-09-CM
305.9	Other, mixed, or unspecified nondependent drug abuse	Diagnosis	ICD-09-CM
305.90	Other, mixed, or unspecified nondependent drug abuse, unspecified	Diagnosis	ICD-09-CM
305.91	Other, mixed, or unspecified nondependent drug abuse, continuous	Diagnosis	ICD-09-CM
305.92	Other, mixed, or unspecified nondependent drug abuse, episodic	Diagnosis	ICD-09-CM
305.93	Other, mixed, or unspecified nondependent drug abuse, in remission	Diagnosis	ICD-09-CM
357.5	Alcoholic polyneuropathy	Diagnosis	ICD-09-CM
425.5	Alcoholic cardiomyopathy	Diagnosis	ICD-09-CM
535.3	Alcoholic gastritis	Diagnosis	ICD-09-CM
535.30	Alcoholic gastritis without mention of hemorrhage	Diagnosis	ICD-09-CM
535.31	Alcoholic gastritis with hemorrhage	Diagnosis	ICD-09-CM
571.0	Alcoholic fatty liver	Diagnosis	ICD-09-CM
571.1	Acute alcoholic hepatitis	Diagnosis	ICD-09-CM
571.2	Alcoholic cirrhosis of liver	Diagnosis	ICD-09-CM
571.3	Unspecified alcoholic liver damage	Diagnosis	ICD-09-CM
648.3	Maternal drug dependence complicating pregnancy, childbirth, or the puerperium	Diagnosis	ICD-09-CM
648.30	Maternal drug dependence complicating pregnancy, childbirth, or the puerperium, unspecified	Diagnosis	ICD-09-CM
648.31	Maternal drug dependence, with delivery	Diagnosis	ICD-09-CM
648.32	Maternal drug dependence, with delivery, with current postpartum complication	Diagnosis	ICD-09-CM
648.33	Maternal drug dependence, antepartum	Diagnosis	ICD-09-CM
648.34	Maternal drug dependence complicating pregnancy, childbirth, or the puerperium, postpartum	Diagnosis	ICD-09-CM
790.3	Excessive blood level of alcohol	Diagnosis	ICD-09-CM
94.46	Alcoholism counseling	Procedure	ICD-09-CM
94.53	Referral for alcoholism rehabilitation	Procedure	ICD-09-CM
94.6	Alcohol and drug rehabilitation and detoxification	Procedure	ICD-09-CM
94.61	Alcohol rehabilitation	Procedure	ICD-09-CM
94.62	Alcohol detoxification	Procedure	ICD-09-CM

Appendix E. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
94.63	Alcohol rehabilitation and detoxification	Procedure	ICD-09-CM
94.67	Combined alcohol and drug rehabilitation	Procedure	ICD-09-CM
94.68	Combined alcohol and drug detoxification	Procedure	ICD-09-CM
94.69	Combined alcohol and drug rehabilitation and detoxification	Procedure	ICD-09-CM
E860.0	Accidental poisoning by alcoholic beverages	Diagnosis	ICD-09-CM
F10	Alcohol related disorders	Diagnosis	ICD-10-CM
F10.1	Alcohol abuse	Diagnosis	ICD-10-CM
F10.10	Alcohol abuse, uncomplicated	Diagnosis	ICD-10-CM
F10.11	Alcohol abuse, in remission	Diagnosis	ICD-10-CM
F10.12	Alcohol abuse with intoxication	Diagnosis	ICD-10-CM
F10.120	Alcohol abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F10.121	Alcohol abuse with intoxication delirium	Diagnosis	ICD-10-CM
F10.129	Alcohol abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F10.14	Alcohol abuse with alcohol-induced mood disorder	Diagnosis	ICD-10-CM
F10.15	Alcohol abuse with alcohol-induced psychotic disorder	Diagnosis	ICD-10-CM
F10.150	Alcohol abuse with alcohol-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F10.151	Alcohol abuse with alcohol-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F10.159	Alcohol abuse with alcohol-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F10.18	Alcohol abuse with other alcohol-induced disorders	Diagnosis	ICD-10-CM
F10.180	Alcohol abuse with alcohol-induced anxiety disorder	Diagnosis	ICD-10-CM
F10.181	Alcohol abuse with alcohol-induced sexual dysfunction	Diagnosis	ICD-10-CM
F10.182	Alcohol abuse with alcohol-induced sleep disorder	Diagnosis	ICD-10-CM
F10.188	Alcohol abuse with other alcohol-induced disorder	Diagnosis	ICD-10-CM
F10.19	Alcohol abuse with unspecified alcohol-induced disorder	Diagnosis	ICD-10-CM
F10.2	Alcohol dependence	Diagnosis	ICD-10-CM
F10.20	Alcohol dependence, uncomplicated	Diagnosis	ICD-10-CM
F10.21	Alcohol dependence, in remission	Diagnosis	ICD-10-CM
F10.22	Alcohol dependence with intoxication	Diagnosis	ICD-10-CM
F10.220	Alcohol dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F10.221	Alcohol dependence with intoxication delirium	Diagnosis	ICD-10-CM
F10.229	Alcohol dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F10.23	Alcohol dependence with withdrawal	Diagnosis	ICD-10-CM
F10.230	Alcohol dependence with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F10.231	Alcohol dependence with withdrawal delirium	Diagnosis	ICD-10-CM
F10.232	Alcohol dependence with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM
F10.239	Alcohol dependence with withdrawal, unspecified	Diagnosis	ICD-10-CM
F10.24	Alcohol dependence with alcohol-induced mood disorder	Diagnosis	ICD-10-CM
F10.25	Alcohol dependence with alcohol-induced psychotic disorder	Diagnosis	ICD-10-CM
F10.250	Alcohol dependence with alcohol-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F10.251	Alcohol dependence with alcohol-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F10.259	Alcohol dependence with alcohol-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F10.26	Alcohol dependence with alcohol-induced persisting amnesic disorder	Diagnosis	ICD-10-CM
F10.27	Alcohol dependence with alcohol-induced persisting dementia	Diagnosis	ICD-10-CM
F10.28	Alcohol dependence with other alcohol-induced disorders	Diagnosis	ICD-10-CM
F10.280	Alcohol dependence with alcohol-induced anxiety disorder	Diagnosis	ICD-10-CM
F10.281	Alcohol dependence with alcohol-induced sexual dysfunction	Diagnosis	ICD-10-CM
F10.282	Alcohol dependence with alcohol-induced sleep disorder	Diagnosis	ICD-10-CM
F10.288	Alcohol dependence with other alcohol-induced disorder	Diagnosis	ICD-10-CM
F10.29	Alcohol dependence with unspecified alcohol-induced disorder	Diagnosis	ICD-10-CM
F10.9	Alcohol use, unspecified	Diagnosis	ICD-10-CM
F10.92	Alcohol use, unspecified with intoxication	Diagnosis	ICD-10-CM

Appendix E. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
F10.920	Alcohol use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F10.921	Alcohol use, unspecified with intoxication delirium	Diagnosis	ICD-10-CM
F10.929	Alcohol use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F10.94	Alcohol use, unspecified with alcohol-induced mood disorder	Diagnosis	ICD-10-CM
F10.95	Alcohol use, unspecified with alcohol-induced psychotic disorder	Diagnosis	ICD-10-CM
F10.950	Alcohol use, unspecified with alcohol-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F10.951	Alcohol use, unspecified with alcohol-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F10.959	Alcohol use, unspecified with alcohol-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F10.96	Alcohol use, unspecified with alcohol-induced persisting amnesic disorder	Diagnosis	ICD-10-CM
F10.97	Alcohol use, unspecified with alcohol-induced persisting dementia	Diagnosis	ICD-10-CM
F10.98	Alcohol use, unspecified with other alcohol-induced disorders	Diagnosis	ICD-10-CM
F10.980	Alcohol use, unspecified with alcohol-induced anxiety disorder	Diagnosis	ICD-10-CM
F10.981	Alcohol use, unspecified with alcohol-induced sexual dysfunction	Diagnosis	ICD-10-CM
F10.982	Alcohol use, unspecified with alcohol-induced sleep disorder	Diagnosis	ICD-10-CM
F10.988	Alcohol use, unspecified with other alcohol-induced disorder	Diagnosis	ICD-10-CM
F10.99	Alcohol use, unspecified with unspecified alcohol-induced disorder	Diagnosis	ICD-10-CM
F11	Opioid related disorders	Diagnosis	ICD-10-CM
F11.1	Opioid abuse	Diagnosis	ICD-10-CM
F11.10	Opioid abuse, uncomplicated	Diagnosis	ICD-10-CM
F11.11	Opioid abuse, in remission	Diagnosis	ICD-10-CM
F11.12	Opioid abuse with intoxication	Diagnosis	ICD-10-CM
F11.120	Opioid abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F11.121	Opioid abuse with intoxication delirium	Diagnosis	ICD-10-CM
F11.122	Opioid abuse with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F11.129	Opioid abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F11.14	Opioid abuse with opioid-induced mood disorder	Diagnosis	ICD-10-CM
F11.15	Opioid abuse with opioid-induced psychotic disorder	Diagnosis	ICD-10-CM
F11.150	Opioid abuse with opioid-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F11.151	Opioid abuse with opioid-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F11.159	Opioid abuse with opioid-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F11.18	Opioid abuse with other opioid-induced disorder	Diagnosis	ICD-10-CM
F11.181	Opioid abuse with opioid-induced sexual dysfunction	Diagnosis	ICD-10-CM
F11.182	Opioid abuse with opioid-induced sleep disorder	Diagnosis	ICD-10-CM
F11.188	Opioid abuse with other opioid-induced disorder	Diagnosis	ICD-10-CM
F11.19	Opioid abuse with unspecified opioid-induced disorder	Diagnosis	ICD-10-CM
F11.2	Opioid dependence	Diagnosis	ICD-10-CM
F11.20	Opioid dependence, uncomplicated	Diagnosis	ICD-10-CM
F11.21	Opioid dependence, in remission	Diagnosis	ICD-10-CM
F11.22	Opioid dependence with intoxication	Diagnosis	ICD-10-CM
F11.220	Opioid dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F11.221	Opioid dependence with intoxication delirium	Diagnosis	ICD-10-CM
F11.222	Opioid dependence with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F11.229	Opioid dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F11.23	Opioid dependence with withdrawal	Diagnosis	ICD-10-CM
F11.24	Opioid dependence with opioid-induced mood disorder	Diagnosis	ICD-10-CM
F11.25	Opioid dependence with opioid-induced psychotic disorder	Diagnosis	ICD-10-CM
F11.250	Opioid dependence with opioid-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F11.251	Opioid dependence with opioid-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F11.259	Opioid dependence with opioid-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F11.28	Opioid dependence with other opioid-induced disorder	Diagnosis	ICD-10-CM
F11.281	Opioid dependence with opioid-induced sexual dysfunction	Diagnosis	ICD-10-CM

Appendix E. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
F11.282	Opioid dependence with opioid-induced sleep disorder	Diagnosis	ICD-10-CM
F11.288	Opioid dependence with other opioid-induced disorder	Diagnosis	ICD-10-CM
F11.29	Opioid dependence with unspecified opioid-induced disorder	Diagnosis	ICD-10-CM
F11.9	Opioid use, unspecified	Diagnosis	ICD-10-CM
F11.90	Opioid use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F11.92	Opioid use, unspecified with intoxication	Diagnosis	ICD-10-CM
F11.920	Opioid use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F11.921	Opioid use, unspecified with intoxication delirium	Diagnosis	ICD-10-CM
F11.922	Opioid use, unspecified with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F11.929	Opioid use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F11.93	Opioid use, unspecified with withdrawal	Diagnosis	ICD-10-CM
F11.94	Opioid use, unspecified with opioid-induced mood disorder	Diagnosis	ICD-10-CM
F11.95	Opioid use, unspecified with opioid-induced psychotic disorder	Diagnosis	ICD-10-CM
F11.950	Opioid use, unspecified with opioid-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F11.951	Opioid use, unspecified with opioid-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F11.959	Opioid use, unspecified with opioid-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F11.98	Opioid use, unspecified with other specified opioid-induced disorder	Diagnosis	ICD-10-CM
F11.981	Opioid use, unspecified with opioid-induced sexual dysfunction	Diagnosis	ICD-10-CM
F11.982	Opioid use, unspecified with opioid-induced sleep disorder	Diagnosis	ICD-10-CM
F11.988	Opioid use, unspecified with other opioid-induced disorder	Diagnosis	ICD-10-CM
F11.99	Opioid use, unspecified with unspecified opioid-induced disorder	Diagnosis	ICD-10-CM
F12	Cannabis related disorders	Diagnosis	ICD-10-CM
F12.1	Cannabis abuse	Diagnosis	ICD-10-CM
F12.10	Cannabis abuse, uncomplicated	Diagnosis	ICD-10-CM
F12.11	Cannabis abuse, in remission	Diagnosis	ICD-10-CM
F12.12	Cannabis abuse with intoxication	Diagnosis	ICD-10-CM
F12.120	Cannabis abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F12.121	Cannabis abuse with intoxication delirium	Diagnosis	ICD-10-CM
F12.122	Cannabis abuse with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F12.129	Cannabis abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F12.15	Cannabis abuse with psychotic disorder	Diagnosis	ICD-10-CM
F12.150	Cannabis abuse with psychotic disorder with delusions	Diagnosis	ICD-10-CM
F12.151	Cannabis abuse with psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F12.159	Cannabis abuse with psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F12.18	Cannabis abuse with cannabis-induced disorder	Diagnosis	ICD-10-CM
F12.180	Cannabis abuse with cannabis-induced anxiety disorder	Diagnosis	ICD-10-CM
F12.188	Cannabis abuse with other cannabis-induced disorder	Diagnosis	ICD-10-CM
F12.19	Cannabis abuse with unspecified cannabis-induced disorder	Diagnosis	ICD-10-CM
F12.2	Cannabis dependence	Diagnosis	ICD-10-CM
F12.20	Cannabis dependence, uncomplicated	Diagnosis	ICD-10-CM
F12.21	Cannabis dependence, in remission	Diagnosis	ICD-10-CM
F12.22	Cannabis dependence with intoxication	Diagnosis	ICD-10-CM
F12.220	Cannabis dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F12.221	Cannabis dependence with intoxication delirium	Diagnosis	ICD-10-CM
F12.222	Cannabis dependence with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F12.229	Cannabis dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F12.23	Cannabis dependence with withdrawal	Diagnosis	ICD-10-CM
F12.25	Cannabis dependence with psychotic disorder	Diagnosis	ICD-10-CM
F12.250	Cannabis dependence with psychotic disorder with delusions	Diagnosis	ICD-10-CM
F12.251	Cannabis dependence with psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F12.259	Cannabis dependence with psychotic disorder, unspecified	Diagnosis	ICD-10-CM

Appendix E. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
F12.28	Cannabis dependence with cannabis-induced disorder	Diagnosis	ICD-10-CM
F12.280	Cannabis dependence with cannabis-induced anxiety disorder	Diagnosis	ICD-10-CM
F12.288	Cannabis dependence with other cannabis-induced disorder	Diagnosis	ICD-10-CM
F12.29	Cannabis dependence with unspecified cannabis-induced disorder	Diagnosis	ICD-10-CM
F12.9	Cannabis use, unspecified	Diagnosis	ICD-10-CM
F12.90	Cannabis use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F12.92	Cannabis use, unspecified with intoxication	Diagnosis	ICD-10-CM
F12.920	Cannabis use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F12.921	Cannabis use, unspecified with intoxication delirium	Diagnosis	ICD-10-CM
F12.922	Cannabis use, unspecified with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F12.929	Cannabis use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F12.93	Cannabis use, unspecified with withdrawal	Diagnosis	ICD-10-CM
F12.95	Cannabis use, unspecified with psychotic disorder	Diagnosis	ICD-10-CM
F12.950	Cannabis use, unspecified with psychotic disorder with delusions	Diagnosis	ICD-10-CM
F12.951	Cannabis use, unspecified with psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F12.959	Cannabis use, unspecified with psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F12.98	Cannabis use, unspecified with other cannabis-induced disorder	Diagnosis	ICD-10-CM
F12.980	Cannabis use, unspecified with anxiety disorder	Diagnosis	ICD-10-CM
F12.988	Cannabis use, unspecified with other cannabis-induced disorder	Diagnosis	ICD-10-CM
F12.99	Cannabis use, unspecified with unspecified cannabis-induced disorder	Diagnosis	ICD-10-CM
F13	Sedative, hypnotic, or anxiolytic related disorders	Diagnosis	ICD-10-CM
F13.1	Sedative, hypnotic or anxiolytic-related abuse	Diagnosis	ICD-10-CM
F13.10	Sedative, hypnotic or anxiolytic abuse, uncomplicated	Diagnosis	ICD-10-CM
F13.11	Sedative, hypnotic or anxiolytic abuse, in remission	Diagnosis	ICD-10-CM
F13.12	Sedative, hypnotic or anxiolytic abuse with intoxication	Diagnosis	ICD-10-CM
F13.120	Sedative, hypnotic or anxiolytic abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F13.121	Sedative, hypnotic or anxiolytic abuse with intoxication delirium	Diagnosis	ICD-10-CM
F13.129	Sedative, hypnotic or anxiolytic abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F13.14	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced mood	Diagnosis	ICD-10-CM
F13.15	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced psych	Diagnosis	ICD-10-CM
F13.150	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced psych	Diagnosis	ICD-10-CM
F13.151	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced psych	Diagnosis	ICD-10-CM
F13.159	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced psych	Diagnosis	ICD-10-CM
F13.18	Sedative, hypnotic or anxiolytic abuse with other sedative, hypnotic or anxiolytic-inducec	Diagnosis	ICD-10-CM
F13.180	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced anxie	Diagnosis	ICD-10-CM
F13.181	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced sexu	Diagnosis	ICD-10-CM
F13.182	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced sleep	Diagnosis	ICD-10-CM
F13.188	Sedative, hypnotic or anxiolytic abuse with other sedative, hypnotic or anxiolytic-inducec	Diagnosis	ICD-10-CM
F13.19	Sedative, hypnotic or anxiolytic abuse with unspecified sedative, hypnotic or anxiolytic-in	Diagnosis	ICD-10-CM
F13.2	Sedative, hypnotic or anxiolytic-related dependence	Diagnosis	ICD-10-CM
F13.20	Sedative, hypnotic or anxiolytic dependence, uncomplicated	Diagnosis	ICD-10-CM
F13.21	Sedative, hypnotic or anxiolytic dependence, in remission	Diagnosis	ICD-10-CM
F13.22	Sedative, hypnotic or anxiolytic dependence with intoxication	Diagnosis	ICD-10-CM
F13.220	Sedative, hypnotic or anxiolytic dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F13.221	Sedative, hypnotic or anxiolytic dependence with intoxication delirium	Diagnosis	ICD-10-CM
F13.229	Sedative, hypnotic or anxiolytic dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F13.23	Sedative, hypnotic or anxiolytic dependence with withdrawal	Diagnosis	ICD-10-CM
F13.230	Sedative, hypnotic or anxiolytic dependence with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F13.231	Sedative, hypnotic or anxiolytic dependence with withdrawal delirium	Diagnosis	ICD-10-CM
F13.232	Sedative, hypnotic or anxiolytic dependence with withdrawal with perceptual disturbanc	Diagnosis	ICD-10-CM
F13.239	Sedative, hypnotic or anxiolytic dependence with withdrawal, unspecified	Diagnosis	ICD-10-CM

Appendix E. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
F13.24	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced	Diagnosis	ICD-10-CM
F13.25	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced	Diagnosis	ICD-10-CM
F13.250	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced	Diagnosis	ICD-10-CM
F13.251	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced	Diagnosis	ICD-10-CM
F13.259	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced	Diagnosis	ICD-10-CM
F13.26	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced	Diagnosis	ICD-10-CM
F13.27	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced	Diagnosis	ICD-10-CM
F13.28	Sedative, hypnotic or anxiolytic dependence with other sedative, hypnotic or anxiolytic-induced	Diagnosis	ICD-10-CM
F13.280	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced	Diagnosis	ICD-10-CM
F13.281	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced	Diagnosis	ICD-10-CM
F13.282	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced	Diagnosis	ICD-10-CM
F13.288	Sedative, hypnotic or anxiolytic dependence with other sedative, hypnotic or anxiolytic-induced	Diagnosis	ICD-10-CM
F13.29	Sedative, hypnotic or anxiolytic dependence with unspecified sedative, hypnotic or anxiolytic	Diagnosis	ICD-10-CM
F13.9	Sedative, hypnotic or anxiolytic-related use, unspecified	Diagnosis	ICD-10-CM
F13.90	Sedative, hypnotic, or anxiolytic use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F13.92	Sedative, hypnotic or anxiolytic use, unspecified with intoxication	Diagnosis	ICD-10-CM
F13.920	Sedative, hypnotic or anxiolytic use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F13.921	Sedative, hypnotic or anxiolytic use, unspecified with intoxication delirium	Diagnosis	ICD-10-CM
F13.929	Sedative, hypnotic or anxiolytic use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F13.93	Sedative, hypnotic or anxiolytic use, unspecified with withdrawal	Diagnosis	ICD-10-CM
F13.930	Sedative, hypnotic or anxiolytic use, unspecified with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F13.931	Sedative, hypnotic or anxiolytic use, unspecified with withdrawal delirium	Diagnosis	ICD-10-CM
F13.932	Sedative, hypnotic or anxiolytic use, unspecified with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM
F13.939	Sedative, hypnotic or anxiolytic use, unspecified with withdrawal, unspecified	Diagnosis	ICD-10-CM
F13.94	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced	Diagnosis	ICD-10-CM
F13.95	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced	Diagnosis	ICD-10-CM
F13.950	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced	Diagnosis	ICD-10-CM
F13.951	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced	Diagnosis	ICD-10-CM
F13.959	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced	Diagnosis	ICD-10-CM
F13.96	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced	Diagnosis	ICD-10-CM
F13.97	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced	Diagnosis	ICD-10-CM
F13.98	Sedative, hypnotic or anxiolytic use, unspecified with other sedative, hypnotic or anxiolytic-induced	Diagnosis	ICD-10-CM
F13.980	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced	Diagnosis	ICD-10-CM
F13.981	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced	Diagnosis	ICD-10-CM
F13.982	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced	Diagnosis	ICD-10-CM
F13.988	Sedative, hypnotic or anxiolytic use, unspecified with other sedative, hypnotic or anxiolytic-induced	Diagnosis	ICD-10-CM
F13.99	Sedative, hypnotic or anxiolytic use, unspecified with unspecified sedative, hypnotic or anxiolytic	Diagnosis	ICD-10-CM
F14	Cocaine related disorders	Diagnosis	ICD-10-CM
F14.1	Cocaine abuse	Diagnosis	ICD-10-CM
F14.10	Cocaine abuse, uncomplicated	Diagnosis	ICD-10-CM
F14.11	Cocaine abuse, in remission	Diagnosis	ICD-10-CM
F14.12	Cocaine abuse with intoxication	Diagnosis	ICD-10-CM
F14.120	Cocaine abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F14.121	Cocaine abuse with intoxication with delirium	Diagnosis	ICD-10-CM
F14.122	Cocaine abuse with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F14.129	Cocaine abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F14.14	Cocaine abuse with cocaine-induced mood disorder	Diagnosis	ICD-10-CM
F14.15	Cocaine abuse with cocaine-induced psychotic disorder	Diagnosis	ICD-10-CM
F14.150	Cocaine abuse with cocaine-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F14.151	Cocaine abuse with cocaine-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F14.159	Cocaine abuse with cocaine-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM

Appendix E. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
F14.18	Cocaine abuse with other cocaine-induced disorder	Diagnosis	ICD-10-CM
F14.180	Cocaine abuse with cocaine-induced anxiety disorder	Diagnosis	ICD-10-CM
F14.181	Cocaine abuse with cocaine-induced sexual dysfunction	Diagnosis	ICD-10-CM
F14.182	Cocaine abuse with cocaine-induced sleep disorder	Diagnosis	ICD-10-CM
F14.188	Cocaine abuse with other cocaine-induced disorder	Diagnosis	ICD-10-CM
F14.19	Cocaine abuse with unspecified cocaine-induced disorder	Diagnosis	ICD-10-CM
F14.2	Cocaine dependence	Diagnosis	ICD-10-CM
F14.20	Cocaine dependence, uncomplicated	Diagnosis	ICD-10-CM
F14.21	Cocaine dependence, in remission	Diagnosis	ICD-10-CM
F14.22	Cocaine dependence with intoxication	Diagnosis	ICD-10-CM
F14.220	Cocaine dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F14.221	Cocaine dependence with intoxication delirium	Diagnosis	ICD-10-CM
F14.222	Cocaine dependence with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F14.229	Cocaine dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F14.23	Cocaine dependence with withdrawal	Diagnosis	ICD-10-CM
F14.24	Cocaine dependence with cocaine-induced mood disorder	Diagnosis	ICD-10-CM
F14.25	Cocaine dependence with cocaine-induced psychotic disorder	Diagnosis	ICD-10-CM
F14.250	Cocaine dependence with cocaine-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F14.251	Cocaine dependence with cocaine-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F14.259	Cocaine dependence with cocaine-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F14.28	Cocaine dependence with other cocaine-induced disorder	Diagnosis	ICD-10-CM
F14.280	Cocaine dependence with cocaine-induced anxiety disorder	Diagnosis	ICD-10-CM
F14.281	Cocaine dependence with cocaine-induced sexual dysfunction	Diagnosis	ICD-10-CM
F14.282	Cocaine dependence with cocaine-induced sleep disorder	Diagnosis	ICD-10-CM
F14.288	Cocaine dependence with other cocaine-induced disorder	Diagnosis	ICD-10-CM
F14.29	Cocaine dependence with unspecified cocaine-induced disorder	Diagnosis	ICD-10-CM
F14.9	Cocaine use, unspecified	Diagnosis	ICD-10-CM
F14.90	Cocaine use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F14.92	Cocaine use, unspecified with intoxication	Diagnosis	ICD-10-CM
F14.920	Cocaine use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F14.921	Cocaine use, unspecified with intoxication delirium	Diagnosis	ICD-10-CM
F14.922	Cocaine use, unspecified with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F14.929	Cocaine use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F14.94	Cocaine use, unspecified with cocaine-induced mood disorder	Diagnosis	ICD-10-CM
F14.95	Cocaine use, unspecified with cocaine-induced psychotic disorder	Diagnosis	ICD-10-CM
F14.950	Cocaine use, unspecified with cocaine-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F14.951	Cocaine use, unspecified with cocaine-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F14.959	Cocaine use, unspecified with cocaine-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F14.98	Cocaine use, unspecified with other specified cocaine-induced disorder	Diagnosis	ICD-10-CM
F14.980	Cocaine use, unspecified with cocaine-induced anxiety disorder	Diagnosis	ICD-10-CM
F14.981	Cocaine use, unspecified with cocaine-induced sexual dysfunction	Diagnosis	ICD-10-CM
F14.982	Cocaine use, unspecified with cocaine-induced sleep disorder	Diagnosis	ICD-10-CM
F14.988	Cocaine use, unspecified with other cocaine-induced disorder	Diagnosis	ICD-10-CM
F14.99	Cocaine use, unspecified with unspecified cocaine-induced disorder	Diagnosis	ICD-10-CM
F15	Other stimulant related disorders	Diagnosis	ICD-10-CM
F15.1	Other stimulant abuse	Diagnosis	ICD-10-CM
F15.10	Other stimulant abuse, uncomplicated	Diagnosis	ICD-10-CM
F15.11	Other stimulant abuse, in remission	Diagnosis	ICD-10-CM
F15.12	Other stimulant abuse with intoxication	Diagnosis	ICD-10-CM
F15.120	Other stimulant abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F15.121	Other stimulant abuse with intoxication delirium	Diagnosis	ICD-10-CM

Appendix E. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
F15.122	Other stimulant abuse with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F15.129	Other stimulant abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F15.14	Other stimulant abuse with stimulant-induced mood disorder	Diagnosis	ICD-10-CM
F15.15	Other stimulant abuse with stimulant-induced psychotic disorder	Diagnosis	ICD-10-CM
F15.150	Other stimulant abuse with stimulant-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F15.151	Other stimulant abuse with stimulant-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F15.159	Other stimulant abuse with stimulant-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F15.18	Other stimulant abuse with other stimulant-induced disorder	Diagnosis	ICD-10-CM
F15.180	Other stimulant abuse with stimulant-induced anxiety disorder	Diagnosis	ICD-10-CM
F15.181	Other stimulant abuse with stimulant-induced sexual dysfunction	Diagnosis	ICD-10-CM
F15.182	Other stimulant abuse with stimulant-induced sleep disorder	Diagnosis	ICD-10-CM
F15.188	Other stimulant abuse with other stimulant-induced disorder	Diagnosis	ICD-10-CM
F15.19	Other stimulant abuse with unspecified stimulant-induced disorder	Diagnosis	ICD-10-CM
F15.2	Other stimulant dependence	Diagnosis	ICD-10-CM
F15.20	Other stimulant dependence, uncomplicated	Diagnosis	ICD-10-CM
F15.21	Other stimulant dependence, in remission	Diagnosis	ICD-10-CM
F15.22	Other stimulant dependence with intoxication	Diagnosis	ICD-10-CM
F15.220	Other stimulant dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F15.221	Other stimulant dependence with intoxication delirium	Diagnosis	ICD-10-CM
F15.222	Other stimulant dependence with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F15.229	Other stimulant dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F15.23	Other stimulant dependence with withdrawal	Diagnosis	ICD-10-CM
F15.24	Other stimulant dependence with stimulant-induced mood disorder	Diagnosis	ICD-10-CM
F15.25	Other stimulant dependence with stimulant-induced psychotic disorder	Diagnosis	ICD-10-CM
F15.250	Other stimulant dependence with stimulant-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F15.251	Other stimulant dependence with stimulant-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F15.259	Other stimulant dependence with stimulant-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F15.28	Other stimulant dependence with other stimulant-induced disorder	Diagnosis	ICD-10-CM
F15.280	Other stimulant dependence with stimulant-induced anxiety disorder	Diagnosis	ICD-10-CM
F15.281	Other stimulant dependence with stimulant-induced sexual dysfunction	Diagnosis	ICD-10-CM
F15.282	Other stimulant dependence with stimulant-induced sleep disorder	Diagnosis	ICD-10-CM
F15.288	Other stimulant dependence with other stimulant-induced disorder	Diagnosis	ICD-10-CM
F15.29	Other stimulant dependence with unspecified stimulant-induced disorder	Diagnosis	ICD-10-CM
F15.9	Other stimulant use, unspecified	Diagnosis	ICD-10-CM
F15.90	Other stimulant use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F15.92	Other stimulant use, unspecified with intoxication	Diagnosis	ICD-10-CM
F15.920	Other stimulant use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F15.921	Other stimulant use, unspecified with intoxication delirium	Diagnosis	ICD-10-CM
F15.922	Other stimulant use, unspecified with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F15.929	Other stimulant use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F15.93	Other stimulant use, unspecified with withdrawal	Diagnosis	ICD-10-CM
F15.94	Other stimulant use, unspecified with stimulant-induced mood disorder	Diagnosis	ICD-10-CM
F15.95	Other stimulant use, unspecified with stimulant-induced psychotic disorder	Diagnosis	ICD-10-CM
F15.950	Other stimulant use, unspecified with stimulant-induced psychotic disorder with delusion	Diagnosis	ICD-10-CM
F15.951	Other stimulant use, unspecified with stimulant-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F15.959	Other stimulant use, unspecified with stimulant-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F15.98	Other stimulant use, unspecified with other stimulant-induced disorder	Diagnosis	ICD-10-CM
F15.980	Other stimulant use, unspecified with stimulant-induced anxiety disorder	Diagnosis	ICD-10-CM
F15.981	Other stimulant use, unspecified with stimulant-induced sexual dysfunction	Diagnosis	ICD-10-CM
F15.982	Other stimulant use, unspecified with stimulant-induced sleep disorder	Diagnosis	ICD-10-CM
F15.988	Other stimulant use, unspecified with other stimulant-induced disorder	Diagnosis	ICD-10-CM

Appendix E. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
F15.99	Other stimulant use, unspecified with unspecified stimulant-induced disorder	Diagnosis	ICD-10-CM
F16	Hallucinogen related disorders	Diagnosis	ICD-10-CM
F16.1	Hallucinogen abuse	Diagnosis	ICD-10-CM
F16.10	Hallucinogen abuse, uncomplicated	Diagnosis	ICD-10-CM
F16.11	Hallucinogen abuse, in remission	Diagnosis	ICD-10-CM
F16.12	Hallucinogen abuse with intoxication	Diagnosis	ICD-10-CM
F16.120	Hallucinogen abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F16.121	Hallucinogen abuse with intoxication with delirium	Diagnosis	ICD-10-CM
F16.122	Hallucinogen abuse with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F16.129	Hallucinogen abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F16.14	Hallucinogen abuse with hallucinogen-induced mood disorder	Diagnosis	ICD-10-CM
F16.15	Hallucinogen abuse with hallucinogen-induced psychotic disorder	Diagnosis	ICD-10-CM
F16.150	Hallucinogen abuse with hallucinogen-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F16.151	Hallucinogen abuse with hallucinogen-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F16.159	Hallucinogen abuse with hallucinogen-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F16.18	Hallucinogen abuse with other hallucinogen-induced disorder	Diagnosis	ICD-10-CM
F16.180	Hallucinogen abuse with hallucinogen-induced anxiety disorder	Diagnosis	ICD-10-CM
F16.183	Hallucinogen abuse with hallucinogen persisting perception disorder (flashbacks)	Diagnosis	ICD-10-CM
F16.188	Hallucinogen abuse with other hallucinogen-induced disorder	Diagnosis	ICD-10-CM
F16.19	Hallucinogen abuse with unspecified hallucinogen-induced disorder	Diagnosis	ICD-10-CM
F16.2	Hallucinogen dependence	Diagnosis	ICD-10-CM
F16.20	Hallucinogen dependence, uncomplicated	Diagnosis	ICD-10-CM
F16.21	Hallucinogen dependence, in remission	Diagnosis	ICD-10-CM
F16.22	Hallucinogen dependence with intoxication	Diagnosis	ICD-10-CM
F16.220	Hallucinogen dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F16.221	Hallucinogen dependence with intoxication with delirium	Diagnosis	ICD-10-CM
F16.229	Hallucinogen dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F16.24	Hallucinogen dependence with hallucinogen-induced mood disorder	Diagnosis	ICD-10-CM
F16.25	Hallucinogen dependence with hallucinogen-induced psychotic disorder	Diagnosis	ICD-10-CM
F16.250	Hallucinogen dependence with hallucinogen-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F16.251	Hallucinogen dependence with hallucinogen-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F16.259	Hallucinogen dependence with hallucinogen-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F16.28	Hallucinogen dependence with other hallucinogen-induced disorder	Diagnosis	ICD-10-CM
F16.280	Hallucinogen dependence with hallucinogen-induced anxiety disorder	Diagnosis	ICD-10-CM
F16.283	Hallucinogen dependence with hallucinogen persisting perception disorder (flashbacks)	Diagnosis	ICD-10-CM
F16.288	Hallucinogen dependence with other hallucinogen-induced disorder	Diagnosis	ICD-10-CM
F16.29	Hallucinogen dependence with unspecified hallucinogen-induced disorder	Diagnosis	ICD-10-CM
F16.9	Hallucinogen use, unspecified	Diagnosis	ICD-10-CM
F16.90	Hallucinogen use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F16.92	Hallucinogen use, unspecified with intoxication	Diagnosis	ICD-10-CM
F16.920	Hallucinogen use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F16.921	Hallucinogen use, unspecified with intoxication with delirium	Diagnosis	ICD-10-CM
F16.929	Hallucinogen use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F16.94	Hallucinogen use, unspecified with hallucinogen-induced mood disorder	Diagnosis	ICD-10-CM
F16.95	Hallucinogen use, unspecified with hallucinogen-induced psychotic disorder	Diagnosis	ICD-10-CM
F16.950	Hallucinogen use, unspecified with hallucinogen-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F16.951	Hallucinogen use, unspecified with hallucinogen-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F16.959	Hallucinogen use, unspecified with hallucinogen-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F16.98	Hallucinogen use, unspecified with other specified hallucinogen-induced disorder	Diagnosis	ICD-10-CM
F16.980	Hallucinogen use, unspecified with hallucinogen-induced anxiety disorder	Diagnosis	ICD-10-CM
F16.983	Hallucinogen use, unspecified with hallucinogen persisting perception disorder (flashback)	Diagnosis	ICD-10-CM

Appendix E. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
F16.988	Hallucinogen use, unspecified with other hallucinogen-induced disorder	Diagnosis	ICD-10-CM
F16.99	Hallucinogen use, unspecified with unspecified hallucinogen-induced disorder	Diagnosis	ICD-10-CM
F18	Inhalant related disorders	Diagnosis	ICD-10-CM
F18.1	Inhalant abuse	Diagnosis	ICD-10-CM
F18.10	Inhalant abuse, uncomplicated	Diagnosis	ICD-10-CM
F18.11	Inhalant abuse, in remission	Diagnosis	ICD-10-CM
F18.12	Inhalant abuse with intoxication	Diagnosis	ICD-10-CM
F18.120	Inhalant abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F18.121	Inhalant abuse with intoxication delirium	Diagnosis	ICD-10-CM
F18.129	Inhalant abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F18.14	Inhalant abuse with inhalant-induced mood disorder	Diagnosis	ICD-10-CM
F18.15	Inhalant abuse with inhalant-induced psychotic disorder	Diagnosis	ICD-10-CM
F18.150	Inhalant abuse with inhalant-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F18.151	Inhalant abuse with inhalant-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F18.159	Inhalant abuse with inhalant-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F18.17	Inhalant abuse with inhalant-induced dementia	Diagnosis	ICD-10-CM
F18.18	Inhalant abuse with other inhalant-induced disorders	Diagnosis	ICD-10-CM
F18.180	Inhalant abuse with inhalant-induced anxiety disorder	Diagnosis	ICD-10-CM
F18.188	Inhalant abuse with other inhalant-induced disorder	Diagnosis	ICD-10-CM
F18.19	Inhalant abuse with unspecified inhalant-induced disorder	Diagnosis	ICD-10-CM
F18.2	Inhalant dependence	Diagnosis	ICD-10-CM
F18.20	Inhalant dependence, uncomplicated	Diagnosis	ICD-10-CM
F18.21	Inhalant dependence, in remission	Diagnosis	ICD-10-CM
F18.22	Inhalant dependence with intoxication	Diagnosis	ICD-10-CM
F18.220	Inhalant dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F18.221	Inhalant dependence with intoxication delirium	Diagnosis	ICD-10-CM
F18.229	Inhalant dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F18.24	Inhalant dependence with inhalant-induced mood disorder	Diagnosis	ICD-10-CM
F18.25	Inhalant dependence with inhalant-induced psychotic disorder	Diagnosis	ICD-10-CM
F18.250	Inhalant dependence with inhalant-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F18.251	Inhalant dependence with inhalant-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F18.259	Inhalant dependence with inhalant-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F18.27	Inhalant dependence with inhalant-induced dementia	Diagnosis	ICD-10-CM
F18.28	Inhalant dependence with other inhalant-induced disorders	Diagnosis	ICD-10-CM
F18.280	Inhalant dependence with inhalant-induced anxiety disorder	Diagnosis	ICD-10-CM
F18.288	Inhalant dependence with other inhalant-induced disorder	Diagnosis	ICD-10-CM
F18.29	Inhalant dependence with unspecified inhalant-induced disorder	Diagnosis	ICD-10-CM
F18.9	Inhalant use, unspecified	Diagnosis	ICD-10-CM
F18.90	Inhalant use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F18.92	Inhalant use, unspecified with intoxication	Diagnosis	ICD-10-CM
F18.920	Inhalant use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F18.921	Inhalant use, unspecified with intoxication with delirium	Diagnosis	ICD-10-CM
F18.929	Inhalant use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F18.94	Inhalant use, unspecified with inhalant-induced mood disorder	Diagnosis	ICD-10-CM
F18.95	Inhalant use, unspecified with inhalant-induced psychotic disorder	Diagnosis	ICD-10-CM
F18.950	Inhalant use, unspecified with inhalant-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F18.951	Inhalant use, unspecified with inhalant-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F18.959	Inhalant use, unspecified with inhalant-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F18.97	Inhalant use, unspecified with inhalant-induced persisting dementia	Diagnosis	ICD-10-CM
F18.98	Inhalant use, unspecified with other inhalant-induced disorders	Diagnosis	ICD-10-CM
F18.980	Inhalant use, unspecified with inhalant-induced anxiety disorder	Diagnosis	ICD-10-CM

Appendix E. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
F18.988	Inhalant use, unspecified with other inhalant-induced disorder	Diagnosis	ICD-10-CM
F18.99	Inhalant use, unspecified with unspecified inhalant-induced disorder	Diagnosis	ICD-10-CM
F19	Other psychoactive substance related disorders	Diagnosis	ICD-10-CM
F19.1	Other psychoactive substance abuse	Diagnosis	ICD-10-CM
F19.10	Other psychoactive substance abuse, uncomplicated	Diagnosis	ICD-10-CM
F19.11	Other psychoactive substance abuse, in remission	Diagnosis	ICD-10-CM
F19.12	Other psychoactive substance abuse with intoxication	Diagnosis	ICD-10-CM
F19.120	Other psychoactive substance abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F19.121	Other psychoactive substance abuse with intoxication delirium	Diagnosis	ICD-10-CM
F19.122	Other psychoactive substance abuse with intoxication with perceptual disturbances	Diagnosis	ICD-10-CM
F19.129	Other psychoactive substance abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F19.14	Other psychoactive substance abuse with psychoactive substance-induced mood disorder	Diagnosis	ICD-10-CM
F19.15	Other psychoactive substance abuse with psychoactive substance-induced psychotic disorder	Diagnosis	ICD-10-CM
F19.150	Other psychoactive substance abuse with psychoactive substance-induced psychotic disorder	Diagnosis	ICD-10-CM
F19.151	Other psychoactive substance abuse with psychoactive substance-induced psychotic disorder	Diagnosis	ICD-10-CM
F19.159	Other psychoactive substance abuse with psychoactive substance-induced psychotic disorder	Diagnosis	ICD-10-CM
F19.16	Other psychoactive substance abuse with psychoactive substance-induced persisting amnesia	Diagnosis	ICD-10-CM
F19.17	Other psychoactive substance abuse with psychoactive substance-induced persisting delirium	Diagnosis	ICD-10-CM
F19.18	Other psychoactive substance abuse with other psychoactive substance-induced disorder	Diagnosis	ICD-10-CM
F19.180	Other psychoactive substance abuse with psychoactive substance-induced anxiety disorder	Diagnosis	ICD-10-CM
F19.181	Other psychoactive substance abuse with psychoactive substance-induced sexual dysfunction	Diagnosis	ICD-10-CM
F19.182	Other psychoactive substance abuse with psychoactive substance-induced sleep disorder	Diagnosis	ICD-10-CM
F19.188	Other psychoactive substance abuse with other psychoactive substance-induced disorder	Diagnosis	ICD-10-CM
F19.19	Other psychoactive substance abuse with unspecified psychoactive substance-induced disorder	Diagnosis	ICD-10-CM
F19.2	Other psychoactive substance dependence	Diagnosis	ICD-10-CM
F19.20	Other psychoactive substance dependence, uncomplicated	Diagnosis	ICD-10-CM
F19.21	Other psychoactive substance dependence, in remission	Diagnosis	ICD-10-CM
F19.22	Other psychoactive substance dependence with intoxication	Diagnosis	ICD-10-CM
F19.220	Other psychoactive substance dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F19.221	Other psychoactive substance dependence with intoxication delirium	Diagnosis	ICD-10-CM
F19.222	Other psychoactive substance dependence with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F19.229	Other psychoactive substance dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F19.23	Other psychoactive substance dependence with withdrawal	Diagnosis	ICD-10-CM
F19.230	Other psychoactive substance dependence with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F19.231	Other psychoactive substance dependence with withdrawal delirium	Diagnosis	ICD-10-CM
F19.232	Other psychoactive substance dependence with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM
F19.239	Other psychoactive substance dependence with withdrawal, unspecified	Diagnosis	ICD-10-CM
F19.24	Other psychoactive substance dependence with psychoactive substance-induced mood disorder	Diagnosis	ICD-10-CM
F19.25	Other psychoactive substance dependence with psychoactive substance-induced psychotic disorder	Diagnosis	ICD-10-CM
F19.250	Other psychoactive substance dependence with psychoactive substance-induced psychotic disorder	Diagnosis	ICD-10-CM
F19.251	Other psychoactive substance dependence with psychoactive substance-induced psychotic disorder	Diagnosis	ICD-10-CM
F19.259	Other psychoactive substance dependence with psychoactive substance-induced psychotic disorder	Diagnosis	ICD-10-CM
F19.26	Other psychoactive substance dependence with psychoactive substance-induced persisting delirium	Diagnosis	ICD-10-CM
F19.27	Other psychoactive substance dependence with psychoactive substance-induced persisting delirium	Diagnosis	ICD-10-CM
F19.28	Other psychoactive substance dependence with other psychoactive substance-induced disorder	Diagnosis	ICD-10-CM
F19.280	Other psychoactive substance dependence with psychoactive substance-induced anxiety disorder	Diagnosis	ICD-10-CM
F19.281	Other psychoactive substance dependence with psychoactive substance-induced sexual dysfunction	Diagnosis	ICD-10-CM
F19.282	Other psychoactive substance dependence with psychoactive substance-induced sleep disorder	Diagnosis	ICD-10-CM
F19.288	Other psychoactive substance dependence with other psychoactive substance-induced disorder	Diagnosis	ICD-10-CM
F19.29	Other psychoactive substance dependence with unspecified psychoactive substance-induced disorder	Diagnosis	ICD-10-CM
F19.9	Other psychoactive substance use, unspecified	Diagnosis	ICD-10-CM

Appendix E. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
F19.90	Other psychoactive substance use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F19.92	Other psychoactive substance use, unspecified with intoxication	Diagnosis	ICD-10-CM
F19.920	Other psychoactive substance use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F19.921	Other psychoactive substance use, unspecified with intoxication with delirium	Diagnosis	ICD-10-CM
F19.922	Other psychoactive substance use, unspecified with intoxication with perceptual disturba	Diagnosis	ICD-10-CM
F19.929	Other psychoactive substance use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F19.93	Other psychoactive substance use, unspecified with withdrawal	Diagnosis	ICD-10-CM
F19.930	Other psychoactive substance use, unspecified with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F19.931	Other psychoactive substance use, unspecified with withdrawal delirium	Diagnosis	ICD-10-CM
F19.932	Other psychoactive substance use, unspecified with withdrawal with perceptual disturba	Diagnosis	ICD-10-CM
F19.939	Other psychoactive substance use, unspecified with withdrawal, unspecified	Diagnosis	ICD-10-CM
F19.94	Other psychoactive substance use, unspecified with psychoactive substance-induced mo	Diagnosis	ICD-10-CM
F19.95	Other psychoactive substance use, unspecified with psychoactive substance-induced psy	Diagnosis	ICD-10-CM
F19.950	Other psychoactive substance use, unspecified with psychoactive substance-induced psy	Diagnosis	ICD-10-CM
F19.951	Other psychoactive substance use, unspecified with psychoactive substance-induced psy	Diagnosis	ICD-10-CM
F19.959	Other psychoactive substance use, unspecified with psychoactive substance-induced psy	Diagnosis	ICD-10-CM
F19.96	Other psychoactive substance use, unspecified with psychoactive substance-induced per	Diagnosis	ICD-10-CM
F19.97	Other psychoactive substance use, unspecified with psychoactive substance-induced per	Diagnosis	ICD-10-CM
F19.98	Other psychoactive substance use, unspecified with other psychoactive substance-induce	Diagnosis	ICD-10-CM
F19.980	Other psychoactive substance use, unspecified with psychoactive substance-induced anx	Diagnosis	ICD-10-CM
F19.981	Other psychoactive substance use, unspecified with psychoactive substance-induced sex	Diagnosis	ICD-10-CM
F19.982	Other psychoactive substance use, unspecified with psychoactive substance-induced slee	Diagnosis	ICD-10-CM
F19.988	Other psychoactive substance use, unspecified with other psychoactive substance-induce	Diagnosis	ICD-10-CM
F19.99	Other psychoactive substance use, unspecified with unspecified psychoactive substance-i	Diagnosis	ICD-10-CM
F55.0	Abuse of antacids	Diagnosis	ICD-10-CM
F55.1	Abuse of herbal or folk remedies	Diagnosis	ICD-10-CM
F55.2	Abuse of laxatives	Diagnosis	ICD-10-CM
F55.3	Abuse of steroids or hormones	Diagnosis	ICD-10-CM
F55.4	Abuse of vitamins	Diagnosis	ICD-10-CM
F55.8	Abuse of other non-psychoactive substances	Diagnosis	ICD-10-CM
G62.1	Alcoholic polyneuropathy	Diagnosis	ICD-10-CM
HZ2ZZZZ	Detoxification Services for Substance Abuse Treatment	Procedure	ICD-10-CM
HZ30ZZZ	Individual Counseling for Substance Abuse Treatment, Cognitive	Procedure	ICD-10-CM
HZ31ZZZ	Individual Counseling for Substance Abuse Treatment, Behavioral	Procedure	ICD-10-CM
HZ32ZZZ	Individual Counseling for Substance Abuse Treatment, Cognitive-Behavioral	Procedure	ICD-10-CM
HZ33ZZZ	Individual Counseling for Substance Abuse Treatment, 12-Step	Procedure	ICD-10-CM
HZ34ZZZ	Individual Counseling for Substance Abuse Treatment, Interpersonal	Procedure	ICD-10-CM
HZ35ZZZ	Individual Counseling for Substance Abuse Treatment, Vocational	Procedure	ICD-10-CM
HZ36ZZZ	Individual Counseling for Substance Abuse Treatment, Psychoeducation	Procedure	ICD-10-CM
HZ37ZZZ	Individual Counseling for Substance Abuse Treatment, Motivational Enhancement	Procedure	ICD-10-CM
HZ38ZZZ	Individual Counseling for Substance Abuse Treatment, Confrontational	Procedure	ICD-10-CM
HZ39ZZZ	Individual Counseling for Substance Abuse Treatment, Continuing Care	Procedure	ICD-10-CM
HZ3BZZZ	Individual Counseling for Substance Abuse Treatment, Spiritual	Procedure	ICD-10-CM
HZ40ZZZ	Group Counseling for Substance Abuse Treatment, Cognitive	Procedure	ICD-10-CM
HZ41ZZZ	Group Counseling for Substance Abuse Treatment, Behavioral	Procedure	ICD-10-CM
HZ42ZZZ	Group Counseling for Substance Abuse Treatment, Cognitive-Behavioral	Procedure	ICD-10-CM
HZ43ZZZ	Group Counseling for Substance Abuse Treatment, 12-Step	Procedure	ICD-10-CM
HZ44ZZZ	Group Counseling for Substance Abuse Treatment, Interpersonal	Procedure	ICD-10-CM
HZ45ZZZ	Group Counseling for Substance Abuse Treatment, Vocational	Procedure	ICD-10-CM
HZ46ZZZ	Group Counseling for Substance Abuse Treatment, Psychoeducation	Procedure	ICD-10-CM
HZ47ZZZ	Group Counseling for Substance Abuse Treatment, Motivational Enhancement	Procedure	ICD-10-CM

Appendix E. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
HZ48ZZZ	Group Counseling for Substance Abuse Treatment, Confrontational	Procedure	ICD-10-CM
HZ49ZZZ	Group Counseling for Substance Abuse Treatment, Continuing Care	Procedure	ICD-10-CM
HZ4BZZZ	Group Counseling for Substance Abuse Treatment, Spiritual	Procedure	ICD-10-CM
HZ50ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Cognitive	Procedure	ICD-10-CM
HZ51ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Behavioral	Procedure	ICD-10-CM
HZ52ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Cognitive-Behavioral	Procedure	ICD-10-CM
HZ53ZZZ	Individual Psychotherapy for Substance Abuse Treatment, 12-Step	Procedure	ICD-10-CM
HZ54ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Interpersonal	Procedure	ICD-10-CM
HZ55ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Interactive	Procedure	ICD-10-CM
HZ56ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Psychoeducation	Procedure	ICD-10-CM
HZ57ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Motivational Enhancement	Procedure	ICD-10-CM
HZ58ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Confrontational	Procedure	ICD-10-CM
HZ59ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Supportive	Procedure	ICD-10-CM
HZ5BZZZ	Individual Psychotherapy for Substance Abuse Treatment, Psychoanalysis	Procedure	ICD-10-CM
HZ5CZZZ	Individual Psychotherapy for Substance Abuse Treatment, Psychodynamic	Procedure	ICD-10-CM
HZ5DZZZ	Individual Psychotherapy for Substance Abuse Treatment, Psychophysiological	Procedure	ICD-10-CM
HZ63ZZZ	Family Counseling for Substance Abuse Treatment	Procedure	ICD-10-CM
HZ83ZZZ	Medication Management for Substance Abuse Treatment, Antabuse	Procedure	ICD-10-CM
HZ86ZZZ	Medication Management for Substance Abuse Treatment, Clonidine	Procedure	ICD-10-CM
HZ88ZZZ	Medication Management for Substance Abuse Treatment, Psychiatric Medication	Procedure	ICD-10-CM
HZ89ZZZ	Medication Management for Substance Abuse Treatment, Other Replacement Medication	Procedure	ICD-10-CM
HZ93ZZZ	Pharmacotherapy for Substance Abuse Treatment, Antabuse	Procedure	ICD-10-CM
HZ96ZZZ	Pharmacotherapy for Substance Abuse Treatment, Clonidine	Procedure	ICD-10-CM
HZ98ZZZ	Pharmacotherapy for Substance Abuse Treatment, Psychiatric Medication	Procedure	ICD-10-CM
HZ99ZZZ	Pharmacotherapy for Substance Abuse Treatment, Other Replacement Medication	Procedure	ICD-10-CM
I42.6	Alcoholic cardiomyopathy	Diagnosis	ICD-10-CM
K29.20	Alcoholic gastritis without bleeding	Diagnosis	ICD-10-CM
K29.21	Alcoholic gastritis with bleeding	Diagnosis	ICD-10-CM
K70.0	Alcoholic fatty liver	Diagnosis	ICD-10-CM
K70.10	Alcoholic hepatitis without ascites	Diagnosis	ICD-10-CM
K70.11	Alcoholic hepatitis with ascites	Diagnosis	ICD-10-CM
K70.2	Alcoholic fibrosis and sclerosis of liver	Diagnosis	ICD-10-CM
K70.30	Alcoholic cirrhosis of liver without ascites	Diagnosis	ICD-10-CM
K70.31	Alcoholic cirrhosis of liver with ascites	Diagnosis	ICD-10-CM
K70.40	Alcoholic hepatic failure without coma	Diagnosis	ICD-10-CM
K70.41	Alcoholic hepatic failure with coma	Diagnosis	ICD-10-CM
K70.9	Alcoholic liver disease, unspecified	Diagnosis	ICD-10-CM
O99.320	Drug use complicating pregnancy, unspecified trimester	Diagnosis	ICD-10-CM
O99.321	Drug use complicating pregnancy, first trimester	Diagnosis	ICD-10-CM
O99.322	Drug use complicating pregnancy, second trimester	Diagnosis	ICD-10-CM
O99.323	Drug use complicating pregnancy, third trimester	Diagnosis	ICD-10-CM
O99.324	Drug use complicating childbirth	Diagnosis	ICD-10-CM
O99.325	Drug use complicating the puerperium	Diagnosis	ICD-10-CM
R78.0	Finding of alcohol in blood	Diagnosis	ICD-10-CM
V11.3	Personal history of alcoholism	Diagnosis	ICD-09-CM
Z65.8	Other specified problems related to psychosocial circumstances	Diagnosis	ICD-10-CM

Appendix F. List of Generic and Brand Names for Medical Products Used to Define Baseline Characteristics in this Request

Generic Name	Brand Name
Nicotine	
varenicline tartrate	Chantix Starting Month Box
varenicline tartrate	Chantix Starting Month Pak
bupropion HCl	Zyban
bupropion HCl	bupropion HCl (smoking deter)
bupropion HCl	Buproban
varenicline tartrate	Chantix
varenicline tartrate	Chantix Continuing Month Box
varenicline tartrate	Chantix Continuing Month Pak
nicotine	Nicotrol NS
nicotine polacrilex	nicotine polacrilex (bulk)
nicotine bitartrate	Nicotine Tartrate
nicotine	nicotine
nicotine	Nicoderm CQ
nicotine	NTS Step 1
nicotine polacrilex	nicotine (polacrilex)
nicotine polacrilex	Nicorette
nicotine polacrilex	Quit 4
nicotine polacrilex	Nicorelief
nicotine polacrilex	Quit 2
nicotine polacrilex	Stop Smoking Aid
nicotine polacrilex	Thrive Nicotine
nicotine	Nicotrol
Obesity	
phentermine HCl	Suprenza
lorcaserin HCl	Belviq XR
diethylpropion HCl	diethylpropion
diethylpropion HCl	Tenuate Dospan
diethylpropion HCl	Dipro
benzphetamine HCl	benzphetamine
phendimetrazine tartrate	phendimetrazine tartrate
phentermine HCl	phentermine
phendimetrazine tartrate	Phenzone
phentermine HCl	Supramine
benzphetamine HCl	Didrex
phendimetrazine tartrate	Bontril PDM
phentermine HCl	Adipex-P
phendimetrazine tartrate	Statobex
phentermine HCl	Pro-Fast SA
phentermine HCl	Termene
lorcaserin HCl	Belviq
phendimetrazine tartrate	Obezine
diethylpropion HCl	Tenuate
phendimetrazine tartrate	Weightril
phentermine HCl	Panshape M
phentermine HCl	Lomaira
benzphetamine HCl	Regimex

Appendix F. List of Generic and Brand Names for Medical Products Used to Define Baseline Characteristics in this Request

Generic Name	Brand Name
phentermine HCl	phentermine HCl (bulk)
diethylpropion HCl	diethylpropion HCl (bulk)
phentermine resin	Ionamin
phendimetrazine tartrate	Bontril Slow-Release
phentermine resin	Ionamin-30
phendimetrazine tartrate	X-Troazine LA
phentermine resin	Ionamin-15
phendimetrazine tartrate	Bontril SR
phendimetrazine tartrate	Prelu-2 TR
phendimetrazine tartrate	Adipost
phendimetrazine tartrate	Phendiet-105 SA
phendimetrazine tartrate	Pt-105
phendimetrazine tartrate	Melfiat CR
phendimetrazine tartrate	Neocurb-Td
phentermine HCl/topiramate	Qsymia
sibutramine HCl m-hydrate	Meridia
orlistat	Xenical
phentermine HCl	Obenix
phentermine HCl	Fastin (phentermine)
phentermine HCl	Oby-Trim
orlistat	Alli
phentermine HCl	Pro-Fast SR
phentermine HCl	Phentride
phentermine HCl	Zantryl
phentermine HCl	Tara-30 #1
phendimetrazine tartrate	Phendiet
phentermine HCl	Oby-Cap
phentermine HCl	Pro-Fast HS

Appendix G. List of Generic and Brand Names of Medical Products Used to Define Comedications in this Request

Generic Name	Brand Name
MAS ER	
dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Adderall XR
dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	Mydayis
dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate	dextroamphetamine-amphetamine
Other CNS Stimulants	
amphetamine sulfate	Evekeo ODT
amphetamine	Adzenys XR-ODT
amphetamine sulfate	amphetamine sulfate
dextroamphetamine sulfate	dextroamphetamine
methamphetamine HCl	Desoxyn
amphetamine sulfate	Evekeo
dextroamphetamine sulfate	Zenzedi
methamphetamine HCl	methamphetamine
dextroamphetamine sulfate	Dexedrine
amphetamine	Adzenys ER
amphetamine	amphetamine
amphetamine	Dyanavel XR
dextroamphetamine sulfate	ProCentra
dextroamphetamine sulfate	Dexedrine Spansule
Wake Promoting Agents	
methylphenidate HCl	methylphenidate HCl
methylphenidate HCl	Methylin
methylphenidate HCl	Ritalin
armodafinil	armodafinil
modafinil	modafinil
dextroamphetamine sulfate	dextroamphetamine
modafinil	Provigil
armodafinil	Nuvigil
solriamfetol HCl	Sunosi
Sodium Oxybate	
sodium oxybate	Xyrem
Atomoxetine	
atomoxetine HCl	Strattera
atomoxetine HCl	atomoxetine
Clonidine	
clonidine HCl	clonidine HCl
clonidine HCl	Kapvay
clonidine HCl	Kapvay Dose Pack
clonidine HCl/chlorthalidone	Clorpres
clonidine HCl	Catapres
ropivacaine HCl/clonidine HCl/ketorolac tromethamine	ropivacaine-clonidin-ketorolac
ropivacaine HCl/epinephrine/clonidine HCl/ketorolac trometh	ropivacaine-epi-clonid-ketorol
clonidine HCl/PF	clonidine (PF)
clonidine HCl/PF	Duraclon (PF)
clonidine	clonidine

Appendix G. List of Generic and Brand Names of Medical Products Used to Define Comedications in this Request

Generic Name	Brand Name
clonidine	Catapres-TTS-1
clonidine	Catapres-TTS-2
clonidine	Catapres-TTS-3
Guanfacine	
guanfacine HCl	guanfacine
guanfacine HCl	Intuniv ER
guanfacine HCl	Tenex
Antidepressant (Any)	
vilazodone HCl	Viibryd
milnacipran HCl	Savella
mirtazapine	mirtazapine
mirtazapine	Remeron SolTab
bupropion HCl	bupropion HCl
bupropion HCl	Wellbutrin SR
bupropion HCl	Budeprion SR
venlafaxine HCl	venlafaxine
desvenlafaxine fumarate	desvenlafaxine fumarate
desvenlafaxine	Khedezla
desvenlafaxine	desvenlafaxine
bupropion HCl	Wellbutrin XL
paroxetine HCl	paroxetine HCl
paroxetine HCl	Paxil CR
desvenlafaxine succinate	Pristiq
desvenlafaxine succinate	desvenlafaxine succinate
bupropion HCl	Budeprion XL
bupropion HBr	Aplenzin
trazodone HCl	Oleptro ER
bupropion HCl	Forfivo XL
escitalopram oxalate	escitalopram oxalate
imipramine HCl	imipramine HCl
nefazodone HCl	nefazodone
amitriptyline HCl	amitriptyline
sertraline HCl	sertraline
protriptyline HCl	Vivactil
paroxetine HCl	Paxil
trazodone HCl	trazodone
citalopram hydrobromide	citalopram
mirtazapine	Remeron
desipramine HCl	Norpramin
doxepin HCl	Silenor
escitalopram oxalate	Lexapro
fluoxetine HCl	fluoxetine
sertraline HCl	Zoloft
fluvoxamine maleate	fluvoxamine
imipramine HCl	Tofranil

Appendix G. List of Generic and Brand Names of Medical Products Used to Define Comedications in this Request

Generic Name	Brand Name
protriptyline HCl	protriptyline
vortioxetine hydrobromide	Trintellix
perphenazine/amitriptyline HCl	perphenazine-amitriptyline
doxepin HCl	doxepin
citalopram hydrobromide	Celexa
vortioxetine hydrobromide	Brintellix
amoxapine	amoxapine
tranylcypromine sulfate	tranylcypromine
paroxetine mesylate	Pexeva
isocarboxazid	Marplan
phenelzine sulfate	phenelzine
amitriptyline HCl/chlordiazepoxide	amitriptyline-chlordiazepoxide
fluoxetine HCl	Sarafem
maprotiline HCl	maprotiline
phenelzine sulfate	Nardil
bupropion HCl	Wellbutrin
tranylcypromine sulfate	Parnate
esketamine HCl	Spravato
nortriptyline HCl	nortriptyline
brexanolone	Zulresso
doxepin HCl	doxepin HCl (bulk)
nortriptyline HCl	nortriptyline (bulk)
fluoxetine	fluoxetine (bulk)
clomipramine HCl	clomipramine (bulk)
sertraline HCl	sertraline (bulk)
mirtazapine	mirtazapine (bulk)
serotonin HCl	serotonin HCl (bulk)
duloxetine HCl	duloxetine HCl (bulk)
bupropion HCl	bupropion HCl (bulk)
tryptophan	tryptophan (bulk)
trazodone HCl	trazodone (bulk)
phenelzine sulfate	phenelzine (bulk)
benactyzine HCl	benactyzine HCl (bulk)
desipramine HCl	desipramine HCl (bulk)
amitriptyline HCl	amitriptyline (bulk)
imipramine HCl	imipramine (bulk)
selegiline	Emsam
venlafaxine HCl	Effexor XR
fluvoxamine maleate	Luvox CR
levomilnacipran HCl	Fetzima
duloxetine HCl	Cymbalta
duloxetine HCl	duloxetine
fluoxetine HCl	Prozac Weekly
duloxetine HCl	Irenka
duloxetine HCl	Drizalma Sprinkle

Appendix G. List of Generic and Brand Names of Medical Products Used to Define Comedications in this Request

Generic Name	Brand Name
olanzapine/fluoxetine HCl	olanzapine-fluoxetine
clomipramine HCl	clomipramine
fluoxetine HCl	Prozac
imipramine pamoate	Tofranil-PM
trimipramine maleate	trimipramine
olanzapine/fluoxetine HCl	Symbyax
clomipramine HCl	Anafranil
imipramine pamoate	imipramine pamoate
nortriptyline HCl	Pamelor
paroxetine mesylate	Brisdelle
paroxetine mesylate	paroxetine mesylate(menop.sym)
trimipramine maleate	Surmontil
desipramine HCl	desipramine
Antidepressant (off label)	
amitriptyline HCl	amitriptyline
amitriptyline HCl	amitriptyline (bulk)
amitriptyline HCl/chlordiazepoxide	amitriptyline-chlordiazepoxide
amoxapine	amoxapine
bupropion HBr	Aplenzin
bupropion HCl	Budeprion XL
bupropion HCl	Budeprion SR
bupropion HCl	bupropion HCl
bupropion HCl	Wellbutrin SR
bupropion HCl	Wellbutrin
bupropion HCl	Wellbutrin XL
bupropion HCl	bupropion HCl (bulk)
bupropion HCl	Forfivo XL
clomipramine HCl	clomipramine
clomipramine HCl	clomipramine (bulk)
clomipramine HCl	Anafranil
desipramine HCl	desipramine
desipramine HCl	Norpramin
desipramine HCl	desipramine HCl (bulk)
doxepin HCl	doxepin
doxepin HCl	doxepin HCl (bulk)
doxepin HCl	Silenor
imipramine HCl	Tofranil
imipramine HCl	imipramine HCl
imipramine HCl	imipramine (bulk)
imipramine pamoate	imipramine pamoate
imipramine pamoate	Tofranil-PM
nortriptyline HCl	nortriptyline
nortriptyline HCl	Pamelor
nortriptyline HCl	nortriptyline (bulk)
perphenazine/amitriptyline HCl	perphenazine-amitriptyline

Appendix G. List of Generic and Brand Names of Medical Products Used to Define Comedications in this Request

Generic Name	Brand Name
protriptyline HCl	protriptyline
protriptyline HCl	Vivactil
trimipramine maleate	Surmontil
trimipramine maleate	trimipramine
venlafaxine HCl	Effexor XR
venlafaxine HCl	venlafaxine
Anxiolytics	
alprazolam	alprazolam
alprazolam	Niravam
clonazepam	clonazepam
alprazolam	Xanax XR
bupirone HCl	bupirone
diazepam	diazepam
lorazepam	lorazepam
hydroxyzine HCl	hydroxyzine HCl
clorazepate dipotassium	clorazepate dipotassium
diazepam	Valium
clorazepate dipotassium	Tranxene T-Tab
clonazepam	Klonopin
alprazolam	Xanax
lorazepam	Ativan
meprobamate	meprobamate
bupirone HCl	bupirone (bulk)
lorazepam	lorazepam (bulk)
diazepam	diazepam (bulk)
hydroxyzine HCl	hydroxyzine HCl (bulk)
alprazolam	alprazolam (bulk)
hydroxyzine pamoate	hydroxyzine pamoate (bulk)
clonazepam	clonazepam (bulk)
lorazepam	Lorazepam Intensol
diazepam	Diazepam Intensol
alprazolam	Alprazolam Intensol
hydroxyzine pamoate	hydroxyzine pamoate
oxazepam	oxazepam
chlordiazepoxide HCl	chlordiazepoxide HCl
hydroxyzine pamoate	Vistaril
Antipsychotics	
iloperidone	Fanapt
olanzapine	olanzapine
risperidone	risperidone
aripiprazole	aripiprazole
olanzapine	Zyprexa Zydis
clozapine	clozapine
risperidone	Risperdal M-TAB
clozapine	FazaClo

Appendix G. List of Generic and Brand Names of Medical Products Used to Define Comedications in this Request

Generic Name	Brand Name
aripiprazole	Abilify Discmelt
asenapine maleate	Saphris
asenapine maleate	Saphris (black cherry)
quetiapine fumarate	Seroquel XR
aripiprazole	Abilify MyCite
paliperidone	paliperidone
paliperidone	Invega
quetiapine fumarate	quetiapine
risperidone	Risperdal
aripiprazole	Abilify
quetiapine fumarate	Seroquel
olanzapine	Zyprexa
perphenazine	perphenazine
trifluoperazine HCl	trifluoperazine
prochlorperazine maleate	prochlorperazine maleate
haloperidol	haloperidol
pimozide	Orap
chlorpromazine HCl	chlorpromazine
fluphenazine HCl	fluphenazine HCl
thioridazine HCl	thioridazine
clozapine	Clozaril
brexpiprazole	Rexulti
molindone HCl	Moban
molindone HCl	molindone
lurasidone HCl	Latuda
prochlorperazine maleate	Compazine
pimozide	pimozide
pimavanserin tartrate	Nuplazid
paliperidone palmitate	Invega Trinza
paliperidone palmitate	Invega Sustenna
haloperidol lactate	haloperidol lactate
aripiprazole lauroxil	Aristada
aripiprazole	Abilify Maintena
aripiprazole lauroxil, submicronized	Aristada Initio
risperidone microspheres	Risperdal Consta
risperidone	Perseris
olanzapine pamoate	Zyprexa Relprevv
clozapine	Versacloz
haloperidol decanoate	haloperidol decanoate
haloperidol decanoate	Haldol Decanoate
fluphenazine decanoate	fluphenazine decanoate
haloperidol lactate	Haldol
ziprasidone mesylate	Geodon
ziprasidone mesylate	ziprasidone mesylate
loxapine succinate	loxapine succinate (bulk)

Appendix G. List of Generic and Brand Names of Medical Products Used to Define Comedications in this Request

Generic Name	Brand Name
acepromazine maleate	acepromazine maleate (bulk)
haloperidol decanoate	haloperidol decanoate (bulk)
thioridazine HCl	thioridazine (bulk)
perphenazine	perphenazine (bulk)
haloperidol	haloperidol (bulk)
chlorpromazine HCl	chlorpromazine (bulk)
asenapine	Secuado
fluphenazine decanoate	fluphenazine decanoate (bulk)
cariprazine HCl	Vraylar
ziprasidone HCl	ziprasidone HCl
ziprasidone HCl	Geodon
thiothixene	thiothixene
loxapine succinate	loxapine succinate
loxapine succinate	Loxitane
lumateperone tosylate	Caplyta
loxapine	Adasuve

Appendix H. Specifications for Utilization in this Request

The Center for Drug Evaluation and Research (CDER) has requested execution of the Cohort Identification and Descriptive Analysis (CIDA) tool version 10.3.2 to examine switching between mixed amphetamine salt (MAS) products among patients with attention deficit hyperactivity disorder (ADHD) and narcolepsy in the Sentinel Distributed Database (SDD).

Query period: 01/01/2013- 12/31/2019
Coverage requirement: Medical & Drug
Pre-index enrollment req 183 days
Post-index enrollment require 0 days
Enrollment gap: 45 days
Age groups: 15-24, 25-34, 35-44, 45-54, 55-64
Stratifications: Sex, age group, year
Restrictions: Males & Females
Envelope macro: Reclassify encounters during inpatient stay as inpatient
Freeze data: No

Switching Groups					Inclusion/Exclusion Criteria								
Group	Exposure Group	Cohort definition	Washout period	Episode Gap and Type	Censoring Criteria	Inclusion/Exclusion	Criteria	Care setting	Principal diagnosis position	Evaluation period start	Evaluation period end	Exclude evidence of days supply if inclusion/exclusion includes dispensings	Minimum number of instances the criteria should be found in evaluation period
1	anda_2 02424	ANDA 202424	0 days	7 days	Death; Data Partner End Date; Query End Date; Disenrollment; Product discontinuation	ADHD or Narcolepsy	Inclusion	Any care setting	Any	-183	0	NA	1
2	anda_0 40440	ANDA 040440	0 days	7 days	Death; Data Partner End Date; Query End Date; Disenrollment; Product discontinuation	ADHD or Narcolepsy	Inclusion	Any care setting	Any	-183	0	NA	1
3	anda_0 40422	ANDA 040422	0 days	7 days	Death; Data Partner End Date; Query End Date; Disenrollment; Product discontinuation	ADHD or Narcolepsy	Inclusion	Any care setting	Any	-183	0	NA	1

Appendix H. Specifications for Utilization in this Request													
Switching Groups						Inclusion/Exclusion Criteria							
Group	Exposure Group	Cohort definition	Washout period	Episode Gap and Type	Censoring Criteria	Inclusion/Exclusion	Criteria	Care setting	Principal diagnosis position	Evaluation period start	Evaluation period end	Exclude evidence of days supply if inclusion/exclusion includes dispensings	Minimum number of instances the criteria should be found in evaluation period
4	anda_040439	02: Cohort includes all valid exposure episodes during the query period	0 days	7 days	Death; Data Partner End Date; Query End Date; Disenrollment; Product discontinuation	ADHD or Narcolepsy	Inclusion	Any care setting	Any	-183	0	NA	1
5	anda_040480	02: Cohort includes all valid exposure episodes during the query period	0 days	7 days	Death; Data Partner End Date; Query End Date; Disenrollment; Product discontinuation	ADHD or Narcolepsy	Inclusion	Any care setting	Any	-183	0	NA	1
6	non_202424	02: Cohort includes all valid exposure episodes during the query period	0 days	7 days	Death; Data Partner End Date; Query End Date; Disenrollment; Product discontinuation	ADHD or Narcolepsy	Inclusion	Any care setting	Any	-183	0	NA	1
7	non_040440	02: Cohort includes all valid exposure episodes during the query period	0 days	7 days	Death; Data Partner End Date; Query End Date; Disenrollment; Product discontinuation	ADHD or Narcolepsy	Inclusion	Any care setting	Any	-183	0	NA	1

Appendix H. Specifications for Utilization in this Request

Switching Groups						Inclusion/Exclusion Criteria							
Group	Exposure Group	Cohort definition	Washout period	Episode Gap and Type	Censoring Criteria	Inclusion/Exclusion	Criteria	Care setting	Principal diagnosis position	Evaluation period start	Evaluation period end	Exclude evidence of days supply if inclusion/exclusion period includes dispensings	Minimum number of instances the criteria should be found in evaluation period
8	non_04 0422	Non-040422	0 days	7 days	Death; Data Partner End Date; Query End Date; Disenrollment; Product discontinuation	ADHD or Narcolepsy	Inclusion	Any care setting	Any	-183	0	NA	1
9	non_04 0439	Non-040439	0 days	7 days	Death; Data Partner End Date; Query End Date; Disenrollment; Product discontinuation	ADHD or Narcolepsy	Inclusion	Any care setting	Any	-183	0	NA	1
10	non_04 0480	Non-040480	0 days	7 days	Death; Data Partner End Date; Query End Date; Disenrollment; Product discontinuation	ADHD or Narcolepsy	Inclusion	Any care setting	Any	-183	0	NA	1

ICD-9, ICD-10, HCPCS, and CPT codes are provided by Optum360. NDC codes are checked against First Data Bank's "National Drug Data File (NDDF®) Plus."

IR= Immediate release

"Non"= all other generic MAS IR products

Appendix I. Specifications for Switching in this Request

The Center for Drug Evaluation and Research (CDER) has requested execution of the Cohort Identification and Descriptive Analysis (CIDA) tool version 10.3.2 to examine switching between mixed amphetamine salt (MAS) products among patients with attention deficit hyperactivity disorder (ADHD) and narcolepsy in the Sentinel Distributed Database (SDD).

Query period: 01/01/2013- 12/31/2019
Coverage requirement: Medical & Drug
Pre-index enrollment requirement: 183 days
Post-index enrollment requirement: 0 days
Enrollment gap: 45 days
Age groups: 15-24, 25-34, 35-44, 45-54, 55-64
Stratifications: Sex, age group, year
Restrictions: Males & Females
Envelope macro: Reclassify encounters during inpatient stay as inpatient
Freeze data: No

Switch Pattern Group ¹	Treatment Pathways							Inclusion/Exclusion Criteria								
	Switch Evaluation Step Value	Switch Groups	Pre-Index Enrollment Criteria in Switch Episodes	Post-Index Enrollment Criteria in Switch Episodes	Switch Cohort Definition	Minimum Days Supplied	Gap Tolerance	Overlap Tolerance and Type	Switch Gap Inclusion Indicator	Inclusion/Exclusion	Criteria	Care setting	Principal diagnosis position	Evaluation period start	Evaluation period end	Minimum number of instances the criteria should be found in evaluation period
1 anda_202424_n_202424	0	anda_202424_4	183 days	0 days	02: All switch pattern episodes during the query period	60 days	0 days	Yes, gaps between episodes will be counted as part of the overall switch pattern duration.	ADHD or Narcolepsy	Inclusion	Any care setting	Any	-183	0	1	
	1	non_202424				1 day	7 days									99%
	2	anda_202424_4				1 day	7 days									99%
2 anda_040440_n_040440	0	anda_040440_0	183 days	0 days	02: All switch pattern episodes during the query period	60 days	0 days	Yes, gaps between episodes will be counted as part of the overall switch pattern duration.	ADHD or Narcolepsy	Inclusion	Any care setting	Any	-183	0	1	
	1	non_040440				1 day	7 days									99%
	2	anda_040440_0				1 day	7 days									99%
3 anda_040422_n_040422	0	anda_040422_2	183 days	0 days	02: All switch pattern episodes during the query period	60 days	0 days	Yes, gaps between episodes will be counted as part of the overall switch pattern duration.	ADHD or Narcolepsy	Inclusion	Any care setting	Any	-183	0	1	
	1	non_040422				1 day	7 days									99%
	2	anda_040422_2				1 day	7 days									99%
4 anda_040439_n_040439	0	anda_040439_9	183 days	0 days	02: All switch pattern episodes during the query period	60 days	0 days	Yes, gaps between episodes will be counted as part of the overall switch pattern duration.	ADHD or Narcolepsy	Inclusion	Any care setting	Any	-183	0	1	
	1	non_040439				1 day	7 days									99%
	2	anda_040439_9				1 day	7 days									99%

Appendix I. Specifications for Switching in this Request																
Switch Pattern Group ¹	Treatment Pathways									Inclusion/Exclusion Criteria						
	Switch Evaluation Step Value	Switch Groups	Pre-Index Enrollment Criteria in Switch Episodes	Post-Index Enrollment Criteria in Switch Episodes	Switch Cohort Definition	Minimum Days Supplied	Gap Tolerance	Overlap Tolerance and Type	Switch Gap Inclusion Indicator	Inclusion/Exclusion	Criteria	Care setting	Principal diagnosis position	Evaluation period start	Evaluation period end	Minimum number of instances the criteria should be found in evaluation period
5 anda_040480_n_040480	0	anda_040480	183 days	0 days	O2: All switch pattern episodes during the query period	60 days	0 days	99%	Yes, gaps between episodes will be counted as part of the overall switch pattern duration.	ADHD or Narcolepsy	Inclusion	Any care setting	Any	-183	0	1
	1	non_040480				1 day	7 days									
	2	anda_040480				1 day	7 days									
6 non_202424_non	0	non_202424	183 days	0 days	O2: All switch pattern episodes during the query period	60 days	0 days	99%	Yes, gaps between episodes will be counted as part of the overall switch pattern duration.	ADHD or Narcolepsy	Inclusion	Any care setting	Any	-183	0	1
	1	anda_202424				1 day	7 days									
	2	non_202424				1 day	7 days									
7 non_040440_non	0	non_040440	183 days	0 days	O2: All switch pattern episodes during the query period	60 days	0 days	99%	Yes, gaps between episodes will be counted as part of the overall switch pattern duration.	ADHD or Narcolepsy	Inclusion	Any care setting	Any	-183	0	1
	1	anda_040440				1 day	7 days									
	2	non_040440				1 day	7 days									
8 non_040422_non	0	non_040422	183 days	0 days	O2: All switch pattern episodes during the query period	60 days	0 days	99%	Yes, gaps between episodes will be counted as part of the overall switch pattern duration.	ADHD or Narcolepsy	Inclusion	Any care setting	Any	-183	0	1
	1	anda_040422				1 day	7 days									
	2	non_040422				1 day	7 days									
9 non_040439_non	0	non_040439	183 days	0 days	O2: All switch pattern episodes during the query period	60 days	0 days	99%	Yes, gaps between episodes will be counted as part of the overall switch pattern duration.	ADHD or Narcolepsy	Inclusion	Any care setting	Any	-183	0	1
	1	anda_040439				1 day	7 days									
	2	non_040439				1 day	7 days									
10 non_040480_non	0	non_040480	183 days	0 days	O2: All switch pattern episodes during the query period	60 days	0 days	99%	Yes, gaps between episodes will be counted as part of the overall switch pattern duration.	ADHD or Narcolepsy	Inclusion	Any care setting	Any	-183	0	1
	1	anda_040480				1 day	7 days									
	2	non_040480				1 day	7 days									

Appendix I. Specifications for Switching in this Request																
Switch Pattern Group ¹	Treatment Pathways										Inclusion/Exclusion Criteria					
	Switch Evaluation Step Value	Switch Groups	Pre-Index Enrollment Criteria in Switch Episodes	Post-Index Enrollment Criteria in Switch Episodes	Switch Cohort Definition	Minimum Days Supplied	Gap Tolerance	Overlap Tolerance and Type	Switch Gap Inclusion Indicator	Inclusion/Exclusion	Criteria	Care setting	Principal diagnosis position	Evaluation period start	Evaluation period end	Minimum number of instances the criteria should be found in evaluation period
11 non_202424_sam_e	0	non_202424				60 days	0 days									
	1	anda_202424	183 days	0 days	02: All switch pattern episodes during the query period	1 day	7 days	99%	Yes, gaps between episodes will be counted as part of the overall switch pattern duration.	ADHD or Narcolepsy	Inclusion	Any care setting	Any	-183	0	1
	2	non_202424_1				1 day	7 days	99%								
12 non_040440_sam_e	0	non_040440				60 days	0 days									
	1	anda_040440	183 days	0 days	02: All switch pattern episodes during the query period	1 day	7 days	99%	Yes, gaps between episodes will be counted as part of the overall switch pattern duration.	ADHD or Narcolepsy	Inclusion	Any care setting	Any	-183	0	1
	2	non_040440_1				1 day	7 days	99%								
13 non_040422_sam_e	0	non_040422				60 days	0 days									
	1	anda_040422	183 days	0 days	02: All switch pattern episodes during the query period	1 day	7 days	99%	Yes, gaps between episodes will be counted as part of the overall switch pattern duration.	ADHD or Narcolepsy	Inclusion	Any care setting	Any	-183	0	1
	2	non_040422_1				1 day	7 days	99%								
14 non_040439_sam_e	0	non_040439				60 days	0 days									
	1	anda_040439	183 days	0 days	02: All switch pattern episodes during the query period	1 day	7 days	99%	Yes, gaps between episodes will be counted as part of the overall switch pattern duration.	ADHD or Narcolepsy	Inclusion	Any care setting	Any	-183	0	1
	2	non_040439_1				1 day	7 days	99%								
15 non_040480_sam_e	0	non_040480				60 days	0 days									
	1	anda_040480	183 days	0 days	02: All switch pattern episodes during the query period	1 day	7 days	99%	Yes, gaps between episodes will be counted as part of the overall switch pattern duration.	ADHD or Narcolepsy	Inclusion	Any care setting	Any	-183	0	1
	2	non_040480_1				1 day	7 days	99%								

ICD-9, ICD-10, HCPCS, and CPT codes are provided by Optum360. NDC codes are checked against First Data Bank's "National Drug Data File (NDDF®) Plus."

¹Custom programming will be used to assess switching back to the same ANDA

Appendix J. Specifications for Covariates in this Request

Covariates							
Covariate	Care setting	Principal diagnosis position	Evaluation period start	Evaluation period end	Exclude evidence of days supply if covariate includes dispensings	Minimum number of instances the covariate should be found in evaluation period	Forced supply to attach to dispensings
ADHD	Any care setting	Any	-183	0	NA	1	NA
Narcolepsy	Any care setting	Any	-183	0	NA	1	NA
ADHD and Narcolepsy	Any care setting	Any	-183	0	NA	1	NA
ADHD only (ADHD and not Narcolepsy)	Any care setting	Any	-183	0	NA	1	NA
Narcolepsy only (Narcolepsy and not ADHD)	Any care setting	Any	-183	0	NA	1	NA
Sleep disorders other than narcolepsy	Any care setting	Any	-183	0	NA	1	NA
Mood disorders	Any care setting	Any	-183	0	NA	1	NA
Anxiety disorders	Any care setting	Any	-183	0	NA	1	NA
Schizophrenia	Any care setting	Any	-183	0	NA	1	NA
Other psychotic disorders	Any care setting	Any	-183	0	NA	1	NA
Personality disorders	Any care setting	Any	-183	0	NA	1	NA
Substance use disorders (alcohol/drug abuse/dependence)	Any care setting	Any	-183	0	Evaluation period should search for only evidence of a dispensing date	1	NA
Nicotine use (including tobacco)	Any care setting	Any	-183	0	Evaluation period should search for only evidence of a dispensing date	1	NA
Obesity	Any care setting	Any	-183	0	Evaluation period should search for only evidence of a dispensing date	1	NA
MAS ER	Any care setting	Any	-183	0	Evaluation period should search for only evidence of a dispensing date	1	NA
Other CNS stimulants	Any care setting	Any	-183	0	Evaluation period should search for only evidence of a dispensing date	1	NA
Wake-promoting agents	Any care setting	Any	-183	0	Evaluation period should search for only evidence of a dispensing date	1	NA
Sodium oxybate	Any care setting	Any	-183	0	Evaluation period should search for only evidence of a dispensing date	1	NA
Atomoxetine	Any care setting	Any	-183	0	Evaluation period should search for only evidence of a dispensing date	1	NA
Clonidine	Any care setting	Any	-183	0	Evaluation period should search for only evidence of a dispensing date	1	NA
Guanfacine	Any care setting	Any	-183	0	Evaluation period should search for only evidence of a dispensing date	1	NA
Any antidepressants	Any care setting	Any	-183	0	Evaluation period should search for only evidence of a dispensing date	1	NA
Antidepressants used off-label to treat ADHD (bupropion, venlafaxine, tricyclic antidepressants)	Any care setting	Any	-183	0	Evaluation period should search for only evidence of a dispensing date	1	NA
Anxiolytics	Any care setting	Any	-183	0	Evaluation period should search for only evidence of a dispensing date	1	NA
Antipsychotics	Any care setting	Any	-183	0	Evaluation period should search for only evidence of a dispensing date	1	NA
MAS ER -30	Any care setting	Any	-30	-1	Evaluation period should search for evidence of days supply	1	NA
Other CNS stimulants -30	Any care setting	Any	-30	-1	Evaluation period should search for evidence of days supply	1	NA
Wake-promoting agents -30	Any care setting	Any	-30	-1	Evaluation period should search for evidence of days supply	1	NA
Sodium oxybate -30	Any care setting	Any	-30	-1	Evaluation period should search for evidence of days supply	1	NA
Atomoxetine -30	Any care setting	Any	-30	-1	Evaluation period should search for evidence of days supply	1	NA

Appendix J. Specifications for Covariates in this Request

Covariates							
Covariate	Care setting	Principal diagnosis position	Evaluation period start	Evaluation period end	Exclude evidence of days supply if covariate includes dispensings	Minimum number of instances the covariate should be found in evaluation period	Forced supply to attach to dispensings
Clonidine -30	Any care setting	Any	-30	-1	Evaluation period should search for evidence of days supply	1	NA
Guanfacine -30	Any care setting	Any	-30	-1	Evaluation period should search for evidence of days supply	1	NA
Any antidepressants -30	Any care setting	Any	-30	-1	Evaluation period should search for evidence of days supply	1	NA
Antidepressants used off-label to treat ADHD (bupropion, venlafaxine, tricyclic antidepressants) -30	Any care setting	Any	-30	-1	Evaluation period should search for evidence of days supply	1	NA
Anxiolytics -30	Any care setting	Any	-30	-1	Evaluation period should search for evidence of days supply	1	NA
Antipsychotics -30	Any care setting	Any	-30	-1	Evaluation period should search for evidence of days supply	1	NA
MAS ER +30	Any care setting	Any	1	30	Evaluation period should search for evidence of days supply	1	NA
Other CNS stimulants +30	Any care setting	Any	1	30	Evaluation period should search for evidence of days supply	1	NA
Wake-promoting agents +30	Any care setting	Any	1	30	Evaluation period should search for evidence of days supply	1	NA
Sodium oxybate +30	Any care setting	Any	1	30	Evaluation period should search for evidence of days supply	1	NA
Atomoxetine +30	Any care setting	Any	1	30	Evaluation period should search for evidence of days supply	1	NA
Clonidine +30	Any care setting	Any	1	30	Evaluation period should search for evidence of days supply	1	NA
Guanfacine +30	Any care setting	Any	1	30	Evaluation period should search for evidence of days supply	1	NA
Any antidepressants +30	Any care setting	Any	1	30	Evaluation period should search for evidence of days supply	1	NA
Antidepressants used off-label to treat ADHD (bupropion, venlafaxine, tricyclic antidepressants) +30	Any care setting	Any	1	30	Evaluation period should search for evidence of days supply	1	NA
Anxiolytics +30	Any care setting	Any	1	30	Evaluation period should search for evidence of days supply	1	NA
Antipsychotics +30	Any care setting	Any	1	30	Evaluation period should search for evidence of days supply	1	NA
MAS ER overlap (-30 and +30)					Evaluation period should search for evidence of days supply	1	NA
Other CNS stimulants overlap (-30 and +30)					Evaluation period should search for evidence of days supply	1	NA
Wake-promoting agents overlap (-30 and +30)					Evaluation period should search for evidence of days supply	1	NA
Sodium oxybate overlap (-30 and +30)					Evaluation period should search for evidence of days supply	1	NA
Atomoxetine overlap (-30 and +30)					Evaluation period should search for evidence of days supply	1	NA
Clonidine overlap (-30 and +30)					Evaluation period should search for evidence of days supply	1	NA
Guanfacine overlap (-30 and +30)					Evaluation period should search for evidence of days supply	1	NA
Any antidepressants overlap (-30 and +30)					Evaluation period should search for evidence of days supply	1	NA

Appendix J. Specifications for Covariates in this Request

Covariates							
Covariate	Care setting	Principal diagnosis position	Evaluation period start	Evaluation period end	Exclude evidence of days supply if covariate includes dispensings	Minimum number of instances the covariate should be found in evaluation period	Forced supply to attach to dispensings
Antidepressants used off-label to treat ADHD (bupropion, venlafaxine, tricyclic antidepressants) overlap (-30 and +30)					Evaluation period should search for evidence of days supply	1	NA
Anxiolytics overlap (-30 and +30)					Evaluation period should search for evidence of days supply	1	NA
Antipsychotics overlap (-30 and +30)					Evaluation period should search for evidence of days supply	1	NA
Daily dose of index dispensing*							

All Other Generic MAS IR= All manufacturers other than Aurolife, SpecGx, Barr, NorthstarRx, Sandoz

*Daily dose will be calculated using custom programming